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ABSTRACT 
Dumaual, Carmen, Michelle Ph.D., Purdue University, December 2012.  
Expression and Function of the PRL Family of Protein Tyrosine Phosphatase.  
Major Professor: Stephen K. Randall. 
 
 
The PRL family of enzymes constitutes a unique class of protein tyrosine 
phosphatase, consisting of three highly homologous members (PRL-1, PRL-2, 
and PRL-3).  Family member PRL-3 is highly expressed in a number of tumor 
types and has recently gained much interest as a potential prognostic indicator of 
increased disease aggressiveness and poor clinical outcome for multiple human 
cancers.  PRL-1 and PRL-2 are also known to promote a malignant phenotype in 
vitro, however, prior to the present study, little was known about their expression 
in human normal or tumor tissues.  In addition, the biological function of all three 
PRL enzymes remains elusive and the underlying mechanisms by which they 
exert their effects are poorly understood.  The current project was undertaken to 
expand our knowledge surrounding the normal cellular function of the PRL 
enzymes, the signaling pathways in which they operate, and the roles they play 
in the progression of human disease.  We first characterized the tissue 
distribution and cell-type specific localization of PRL-1 and PRL-2 transcripts in a 
variety of normal and diseased human tissues using in situ hybridization.  In 
normal, adult human tissues we found that PRL-1 and PRL-2 messages were
xix 
 
 
 
 
almost ubiquitously expressed.  Only highly specialized cell types, such as 
fibrocartilage cells, the taste buds of the tongue, and select neural cells displayed 
little to no expression of either transcript.  In almost every other tissue and cell 
type examined, PRL-2 was expressed strongly while PRL-1 expression levels 
were variable.  Each transcript was widely expressed in both proliferating and 
quiescent cells indicating that different tissues or cell types may display a unique 
physiological response to these genes.  In support of this idea, we found 
alterations of PRL-1 and PRL-2 transcript levels in tumor samples to be highly 
tissue-type specific.  PRL-1 expression was significantly increased in 100% of 
hepatocellular and gastric carcinomas, but significantly decreased in 100% of 
ovarian, 80% of breast, and 75% of lung tumors as compared to matched normal 
tissues from the same subjects.  Likewise, PRL-2 expression was significantly 
higher in 100% of hepatocellular carcinomas, yet significantly lower in 54% of 
kidney carcinomas compared to matched normal specimens.  PRL-1 expression 
was found to be associated with tumor grade in the prostate, ovary, and uterus, 
with patient gender in the bladder, and with patient age in the brain and skeletal 
muscle.  These results suggest an important, but pleiotropic role for PRL-1 and 
PRL-2 in both normal tissue function and in the neoplastic process.  These 
molecules may have a tumor promoting effect in some tissue types, but inhibit 
tumor formation or growth in others.  To further elucidate the signaling pathways 
in which the PRLs operate, we focused on PRL-1 and used microarray and 
microRNA gene expression profiling to examine the global molecular changes 
that occur in response to stable PRL-1 overexpression in HEK293 cells.  This 
xx 
 
 
 
 
analysis led to identification of several molecules not previously associated with 
PRL signaling, but whose expression was significantly altered by exogenous 
PRL-1 expression.  In particular, Filamin A, RhoGDIα, and SPARC are attractive 
targets for novel mediators of PRL-1 function.  We also found that PRL-1 has the 
capacity to indirectly influence the expression of target genes through regulation 
of microRNA levels and we provide evidence supporting previous observations 
suggesting that PRL-1 promotes cell proliferation, survival, migration, invasion, 
and metastasis by influencing multi-functional molecules, such as the Rho 
GTPases, that have essential roles in regulation of the cell cycle, cytoskeletal 
reorganization, and transcription factor function.  The combined results of these 
studies have expanded our current understanding of the expression and function 
of the PRL family of enzymes as well as of the role these important signaling 
molecules play in the progression of human disease. 
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ARTICLE
Cellular Localization of PRL-1 and PRL-2 Gene Expression in
Normal Adult Human Tissues
Carmen M. Dumaual, George E. Sandusky, Pamela L. Crowell, and Stephen K. Randall
Department of Biology, Indiana University–Purdue University Indianapolis, Indianapolis, Indiana (CMD,PLC,SKR), and
Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana (GES)
SUMMARY Recent evidence suggests that the PRL-1 and -2 phosphatases may be multi-
functional enzymes with diverse roles in a variety of tissue and cell types. Northern blotting has
previously shown widespread expression of both transcripts; however, little is known about
the cell type-specific expression of either gene, especially in human tissues. Therefore, we
investigated expression patterns for PRL-1 and -2 genes inmultiple normal, adult human tissues
using in situ hybridization. Although both transcripts were ubiquitously expressed, they ex-
hibited strikingly different patterns of expression. PRL-2 was expressed heavily in almost every
tissue and cell type examined, whereas PRL-1 expression levels varied considerably both be-
tween tissue types and between individuals. Widespread expression of PRL-1 and -2 in multiple
organ systems suggests an important functional role for these enzymes in normal tissue
homeostasis. In addition, the variable patterns of expression for these genes may provide
distinct activities in each tissue or cell type. (J Histochem Cytochem 54:1401–1412, 2006)
KEY WORDS
PRL-1
PRL-2
normal human tissues
in situ hybridization
mRNA
differential expression
cellular localization
THE PRL FAMILY of phosphatases constitutes a distinct
class of protein tyrosine phosphatase (PTP), consisting
of three members (PRL-1, -2, and -3). These three closely
related enzymes are distinctive in that they are among
the smallest of the PTPs consisting primarily of a cata-
lytic domain, and their amino acid sequences contain a
carboxy terminal CAAX motif that is posttranslation-
ally isoprenylated. This posttranslational modification,
unique among PTPs, is critical to the subcellular lo-
calization and biological activity of the PRL enzymes
(Cates et al. 1996; Zeng et al. 2000; Si et al. 2001).
Specific substrates and cellular roles of the PRLs remain
to be defined; however, their high degree of conservation
(Cates et al. 1996; Zeng et al. 1998), as well as their
similarity to several dual-specificity phosphatases (DSPs)
involved in cell cycle and cell growth control (Zeng et al.
1998; Kozlov et al. 2004; Sun et al. 2005), suggests a
critical role for these PTPs in cellular regulation. Recent
evidence suggests that these may be pleiotropic-signaling
molecules that play diverse roles in various tissue and cell
types (Diamond et al. 1996; Rundle and Kappen 1999).
PRL-1, the first identified PRL family member, was
initially characterized and named for its expression in
a number of proliferating cell types including rat liver
during hepatic regeneration (Mohn et al. 1991; Diamond
et al. 1994), mouse liver cells and NIH3T3 mouse
fibroblasts stimulated by a primary mitogen (Diamond
et al. 1996; Columbano et al. 1997), rat cerebral cortex
following transient forebrain ischemia (Takano et al.
1996), and multiple human tumor cell lines (Diamond
et al. 1994; Wang et al. 2002a). Further indicating a role
for PRL-1 in cellular growth andproliferation, it has been
found that PRL-1 phosphatase activity is required for
progression of cells through mitosis (Wang et al. 2002a),
and that overexpression of either PRL-1 or -2 in cells
leads to accelerated entry into S phase (Werner et al.
2003). Additionally, all three PRL enzymes have been
linked to cellular transformation and tumorigenesis
(Cates et al. 1996; Wang et al. 2002b; Bardelli et al.
2003; Zeng et al. 2003; Wu et al. 2004).
Although these results are all consistent with a role
for the PRL enzymes in cell growth, analysis of the
normal tissue expression of PRL transcripts revealed
all three genes to be predominantly expressed in ter-
minally differentiated tissues such as skeletal muscle
(Diamond et al. 1994; Zeng et al. 1998; Matter et al.
2001), brain (PRL-1) (Diamond et al. 1994), and
cardiac muscle (PRL-3) (Matter et al. 2001). Consistent
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with this pattern of PRL expression, Diamond et al.
(1996) noted high levels of PRL-1 protein in the
differentiated villus but not in the proliferating crypt
enterocytes of rat intestine and high levels of PRL-1
mRNA in confluent differentiated CaCo2 cells, but
little to no expression in proliferating CaCo2 cells. Guo
et al. (2003) found the PRL-1 gene to be significantly
overexpressed in more differentiated parous breast
tissues as compared with proliferative nulliparous
breast tissues. Scarlato et al. (2000) found that PRL-1
mRNA is upregulated in oligodendroglial progenitor
cells that are capable of terminal differentiation in
comparison to immature oligodendroglial progenitors,
which do not terminally differentiate.
Together these results suggest a dual role for the PRL
gene family in regulation of both cellular proliferation
and differentiation. Consistent with this notion, PRL-1
mRNA was predominantly expressed in proliferating
chondrocytes in early development of mouse embryos
but was localized primarily to differentiated, hyper-
trophic chondrocytes in later stages of development
(Rundle and Kappen 1999). PRLs have also been im-
plicated in more complex biological processes including
embryonic development (Rundle and Kappen 1999;
Kong et al. 2000), angiogenesis (Guo et al. 2004),
cardiomyopathy (Matter et al. 2001), cell movement
(Zeng et al. 2003), and sexual differentiation in the
brain (Carter 1998).
Whereas multi-tissue analysis has revealed PRL-3
expression to be largely confined to heart and skeletal
muscle in normal tissues (Zeng et al. 1998; Matter et al.
2001), PRL-1 and -2 are reported to be more widely
expressed (Montagna et al. 1995; Zeng et al. 1998;
Rundle and Kappen 1999; Kong et al. 2000). Given that
the biological effects of the PRL enzymes may be tissue
specific, characterization of the tissues and cell types that
express PRL-1 and -2 is important to elucidating the
physiological function of the normal genes and to un-
derstanding their roles in the pathogenesis of disease.
However, studies of normal PRL-1 or -2 expression, to
date, have been limited largely to animal systems and
to human cell line or tissue Northern blots. To our
knowledge, no study has yet described the cell type-
specific expression patterns of any of the PRL genes in a
diverse panel of human tissues. Therefore, we sought to
characterize the cellular localization and tissue distribu-
tion of PRL-1 and -2 mRNA in a broad range of normal
adult human tissues using in situ hybridization (ISH).
With non-radioactive ISH, we detected some level of
PRL-1 and -2message in nearly all human tissues studied,
confirming reports of their ubiquitous expression. Our
results also show that the two genes display distinct
expression levels and patterns from one another, as well
as distinct patterns of expression among different tissues,
supporting a potential multi-functional role for these
genes in normal cellular regulation.
Materials and Methods
Tissue Procurement
Samples of normal human tissues consisting of postmortem
tissue specimens, surgical biopsy samples, and surgically re-
sected organs were obtained from the Cooperative Human
Tissue Network, National Disease Research Interchange, and
Indiana University School of Medicine, Department of Pathol-
ogy. Samples were collected in accordance with the guidelines
of Indiana University with approval from the Indiana Uni-
versity–Purdue University Indianapolis Institutional Review
Board. Specimenswere fixed in 10%neutral-buffered formalin,
processed, and embedded in paraffin. Five-mm-thick serial sec-
tions were cut and mounted on Fisherbrand Superfrost/Plus
slides (Fisher Scientific; Pittsburgh, PA). Tissues included
adrenal gland (n53), appendix (n53), bladder (n55), brain
(n57), breast (n518), cervix (n55), colon (n56), eye (n53),
gallbladder (n51), heart (n55), kidney (n518), liver (n56),
lung (n510), lymph node (n56), ovary (n512), pancreas
(n520), parathyroid (n51), placenta (n52), prostate (n520),
skeletal muscle (n59), skin (n53), duodenum (n54), jejunum
(n54), spleen (n510), stomach (n57), testis (n55), thyroid
(n54), tongue (n52), and uterus (n58).
Oligonucleotide Probes
Specific 45-mer oligonucleotide probes for PRL-1 and -2
mRNA were designed using Oligo Primer Analysis Software
(Molecular Biology Insights; Cascade, CO). Oligonucleotide
sequences were verified using a BLAST search of EMBL and
GenBank databases to ensure that there was no significant
homology with other mRNA species. Probes were custom
synthesized by Midland Certified Reagent Company Inc.
(Midland, TX) and were labeled with fluorescein isothiocya-
nate (FITC) at both the 59 and 39 ends. PRL-1 (59-GGC CAA
CAG AAA AGA AGT GCA CTG AGG TTT ACC CCA TCC
AGG TCA-39) and PRL-2 (59-TGG CAA ATA AAA AGT
GTG AGC GTG CGT GTG AGT GTG ATG GGG AAA-39)
antisense probes are complementary to nucleotides 150–194
and 19–63 of the human PRL-1 (GenBank U48296) and PRL-
2 (GenBank U48297) mRNA sequences, respectively. Corre-
sponding control, sense oligonucleotides for PRL-1 and -2,
were also generated. PRL probes were chosen from a region
covering all known transcript variants.
Slot-blot Hybridization
Slot-blot hybridization was performed to verify specificity of
the oligonucleotide probes. PRL-1 cDNA and PRL-2 cDNA,
both cloned in pUC19 vectors (Cates et al. 1996), and PRL-3
cDNA, cloned in a pET-15b vector (a gift from Millenium
Pharmaceuticals; Cambridge, MA), were linearized with
BamHI. Linearized DNA samples of 100, 50, 10, and 5 ng
each were denatured by the addition of 0.4 M NaOH and
10 mM EDTA and by heating for 10 min at 100C. Samples
were then neutralized with an equal volume of cold 2 M am-
monium acetate, pH 7.0. Two hundred ml of each denatured
DNA solution was spotted on a nitrocellulose membrane
(Protran; Schleicher and Schuell Bioscience, Keene, NH) using
a Bio-Dot SF Microfiltration Apparatus (Bio-Rad; Hercules,
CA) according to the manufacturer’s instructions. Samples
were immobilized on the membrane using a Stratalinker UV
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Crosslinker 1800 (Stratagene; La Jolla, CA). Slot-blots were
prehybridized for 30 min at 37C in prewarmed PerfectHyb
Plus hybridization buffer (Sigma; St Louis, MO), followed by
hybridization with FITC-labeled oligonucleotide antisense
probes for PRL-1 and -2, diluted to 100 ng/ml in prewarmed
PerfectHyb Plus buffer. Hybridization was allowed to pro-
ceed overnight at 37C. Posthybridization, membranes were
washed two times for 5 min each in 2X SSC 1 0.1% SDS at
room temperature, followed by one 20-min wash in 0.5X
SSC 1 0.1% SDS at 37C, and a 5-min wash at room tem-
perature in TBST (50 mM Tris–HCl, 150 mM NaCl, pH 7.6,
plus 0.05% Tween-20). Prior to detection, membranes were
blocked for 2 hr with 3% BSA in TBST and additionally for
30 min with Serum Free Protein Block (Dako; Carpinteria,
CA). FITC-labeled probes were detected for 30 min using a
mouse anti-FITC primary antibody (Dako) diluted 1:1000 in
Dako Antibody Diluent, followed by Dako LSAB2 Peroxidase
Link and Peroxidase Conjugated Streptavidin Label (10 min
each). Reactions were visualized using the Dako DAB sub-
strate chromogen system. Development was allowed to oc-
cur for 5 min, and the reactions were stopped by rinsing
membranes in TBST followed by distilled water. Membranes
were washed three times, 5 min each, in TBST, between each
step of the procedure.
Non-radioactive ISH
Paraffin sections were dewaxed in xylene and rehydrated
through a graded series of ethanol (100%, 95%, and 75%) to
water. Sections were permeabilized with 200 ml of 10 mg/ml,
nuclease-free Proteinase K (Sigma). Optimal length of time for
Proteinase K digestion was determined empirically for each
tissue type (data not shown). Deproteination reaction was
stopped by washing slides two times, 3 min each, in Nanopure
(Chesterland, OH) ultrapure water. Slides were subsequently
dehydrated by sequential washes in 95% ethanol and 100%
ethanol and allowed to air dry for 1 hr at room temperature.
Tissue sections were hybridized with 750 ng/ml PRL-1, -2,
or control probe in PerfectHyb Plus (Sigma) hybridization
buffer, sealed with parafilm, and hybridized 12–14 hr at
37C in a humidity chamber. Coverslips were dislodged and
nonspecifically bound probe was removed by soaking slides
for 5 min each in two changes of 2X SSC plus 0.1% SDS at
room temperature. Slides were then washed stringently in
prewarmed 0.5X SSC 1 0.1% SDS at 37C for 20 min,
followed by a 10-min rinse in TBS (50 mM Tris–HCl,
150 mM NaCl, pH 7.6) 1 0.1% SDS at room temperature.
Histochemical Detection
Detection of hybridized probe was performed by standard
immunohistochemical techniques using a catalyzed signal-
amplification procedure. All staining steps were performed on
a Dako Autostainer at room temperature, and slides were
rinsed for 5 min in TBST 1 0.05% Tween-20 between each
step of the procedure. Nonspecific background staining was
blocked by incubation with Dako Serum-Free Protein Block
for 30 min, followed by a 30-min incubation with mouse anti-
FITC primary antibody (Dako), and diluted to 22 mg/ml in
Dako Antibody Diluent. Bound primary antibody was
detected using the labeled streptavidin–biotin method
(LSAB2; Dako) combined with the Renaissance Tyramide
Signal Amplification (TSA Biotin; PerkinElmer Life Sciences,
Boston, MA) kit. Briefly, slides were incubated sequentially
with Dako LSAB2 Peroxidase Link for 30 min, Dako LSAB2
Label for 10 min, biotinyl tyramide (TSA Biotin System)
diluted 1:50 in 13 amplification diluent for 10 min, and Dako
LSAB2 Label again for 10 min. Antibody complexes were
visualized using 3,39-DAB substrate (Chromogen System;
Dako) as the chromogenic substrate. Development was al-
lowed to proceed for 2 to 5 min and was stopped by rinsing
the slides in distilled water. Following immunohistochemi-
cal detection, sections were counterstained briefly with 1X
Lerner’s hematoxylin, dehydrated through graded alcohols,
cleared in xylene, and coverslipped with permanent mounting
media (Fisher).
Controls
Several positive and negative controls were used to confirm
the specificity of the ISH signal. All controls were performed
on serial sections of the same tissues as hybridized with the
labeled PRL-1 and -2 probe, following the ISH procedures
described above. Positive controls included (a) verification of
the hybridization and detection procedure by hybridization of
the PRL-1 and -2 antisense probes to a normal pancreas tissue
(case #032,098) known to be positive for PRL-1 and -2
mRNA and (b) hybridization of tissues with a fluorescein-
conjugated Poly d(T) probe (Novocastra Laboratories; New
Castle upon Tyne, UK) to assess the preservation and integrity
of the mRNA in each sample. Negative controls consisted of
(a) omission of the oligonucleotide probes from the hybridi-
zation mixture, (b) substitution of the specific antisense probe
with an equivalent concentration of labeled sense probe, (c)
hybridization using a cocktail of randomly generated, FITC-
conjugated, oligonucleotide sequences (NCL-CONTROL;
Novocastra) to assess binding of nonspecific sequences, and
(d) RNase pretreatment of tissue sections to demonstrate
specificity of the signal for single-stranded RNA. For RNase
pretreatment, RNase solution was prepared by diluting
RNase A (RNase A; Sigma) in TE buffer (20 mM Tris, pH
7.5, 1 mM EDTA) to a final concentration of 250 mg/ml.
Control sections were incubated with 200 ml RNase solution
or TE buffer only for 2 hr at 37C and were subsequently
washed three times for 5 min each in ultrapure water, imme-
diately prior to tissue dehydration and probe hybridization.
Analysis of ISH Results
Evaluation of all slides was performed under brightfield mi-
croscopy. All sections of a particular tissue type were stained
and analyzed in a single run and are therefore directly com-
parable. Tissue distribution, localization pattern, intensity of
staining, and percentage of positive cells were evaluated by
two investigators (GES and CMD) in a blinded fashion.
Localization pattern was evaluated as cytoplasmic, nuclear,
or perinuclear. Staining intensity was classified according to
the following scale: (2) absent, (1/2) barely detectable, (1)
weak, (11) moderate, and (111) strong. In cases of het-
erogeneous staining, the average intensity across the section
was taken as the score. Also, in a few cases where a patient
sample was stained twice, the case was given a mean score
based on evaluation of the two sections. Percentage of positive
cells was estimated as the number of stained cells per total
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number of cells counted. To confirm reproducibility of the
analysis, 25% of the slides were randomly chosen and scored
twice. Duplicate slides gave similar results.
Results
Specificity of Oligonucleotide Probes
To verify that the PRL-1 and -2 oligonucleotide probes
were specific for their complementary sequences, a
BLAST search was performed against the EMBL and
GenBank databases. Neither sequence displayed signif-
icant similarity to any other known mRNA species. For
confirmation that the labeled PRL-1 and -2 probes were
not cross-hybridizing with sequences from closely re-
lated family members, slot-blot hybridization was
carried out on PRL-1, -2, and -3 cDNA targets. Both
antisense probes displayed a high degree of specificity
for their target mRNA sequences (Figure 1) with min-
imal cross-reactivity. In addition, variable ISH expres-
sion patterns of PRL-1 and -2 and reduced levels of
both transcripts in tissues known to heavily express
PRL-3 (heart) suggested specificity of the probes for
their respective targets. Therefore, we concluded that
the probes were of sufficient specificity to accurately
detect their appropriate PRL-1 or -2 transcripts.
ISH Controls
Several controls were used to confirm specificity of the
staining signal and viability of the tissue mRNA. No
specific hybridization was detected when tissue sections
were hybridized with a control sense probe specific to
PRL-1 or -2, a randomly generated ‘‘nonsense’’ oligonu-
cleotide sequence, or in the absence of probe. In addition,
pretreatment of slides with RNase A abolished the hy-
bridization signals, indicating that staining was specific
to RNA. A positive signal using a poly d(T) probe was
detected in all cases, demonstrating the presence of
mRNA in each sample (control data not shown).
Expression Patterns of PRL-1 and -2 in Normal
Human Tissues
Cellular localization and tissue distribution of PRL-1
and -2 mRNA were examined in zinc formalin-fixed,
paraffin-embedded human tissues using non-isotopic
ISH. ISH revealed widespread nuclear expression of
both transcripts in histologically normal tissues. PRL-2
was generally expressed at higher levels than PRL-1. In
addition, whereas PRL-2 was expressed at moderate to
high levels in all tissues and most cell types examined,
expression of PRL-1 was much more variable. Distri-
bution and expression levels of PRL-1 and -2 in various
tissues are described below and are further summarized
in Table 1.
Skin
Intense and widespread expression of PRL-2 mRNA
was observed throughout the epidermis (Figure 2B) and
in the skin appendages. All epithelial cells in the coiled
secretory portion of the eccrine sweat glands and within
the hair follicles demonstrated heavy staining for this
transcript (not pictured). Abundant expression was also
observed in the fibroblasts of the dermis (Figure 2B)
and in the endothelial cell layer of the tissue microvas-
culature. Expression of PRL-1, however, was more var-
iable. One patient case expressed PRL-1 transcripts at
similar levels to those observed for PRL-2, whereas in
two of three cases, PRL-1 was expressed at a lower
intensity. In these cases, PRL-1 transcripts were lo-
calized to all epithelial cells of the dermal appendages
(not shown) but to a smaller percentage of cells within
the epidermis and dermis (Figure 2A).
Gastrointestinal Tract
Moderate expression of PRL-1 and strong expression
of PRL-2 were noted in the stratified squamous epi-
thelium of the tongue, whereas neither transcript was
detected in the taste buds of the circumvallate papillae.
PRL-1 message was also absent from the sublingual
salivary glands, but scattered staining at a moderate
intensity was observed for PRL-2. In the stomach, PRL-
1 expression varied from mild to heavy, depending on
the region analyzed. Staining for PRL-1 was generally
weak to absent in the mucous producing cells of the
cardiac and body (Figure 2C) mucosa, but moderate
to heavy in the pyloric mucosa (Figure 2D). PRL-1
expression in the parietal and chief cells varied from
Figure 1 Specificity of the PRL-1 and -2 oligonucleotide probes.
Denatured PRL-1, -2, and -3 cDNA were spotted onto a nitrocellulose
membrane in various amounts and hybridized with PRL-1 or -2 FITC-
labeled oligonucleotide probes. Clockwise from the upper left of
each panel are 100, 50, 5, and 10 ng of spotted cDNA. Hybridized
probe was detected using standard immunohistochemical tech-
niques. Both probes displayed a high degree of specificity for their
respective targets.
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patient to patient with expression limited to a small
number of cells in some cases (5–10%) and more
widespread expression in others (90–95%). Expression
in these cell types tended to be both nuclear and cy-
toplasmic, with the most frequent expression occur-
ring closer to the base of the gastric glands. PRL-2 was
heavily expressed in all regions of the stomach. As with
PRL-1, the strongest expression of PRL-2 occurred
toward the base of the gastric glands (Figure 2E), and
both cytoplasmic and nuclear staining were noted in the
parietal and chief cells (Figure 2F).
Both PRL-1 and -2 transcripts were expressed at a
high intensity in the small intestine (Figure 2G). Equiv-
alent levels of expression were noted in the villous
epithelium, crypt epithelium, and muscularis mucosae
of the duodenum and jejunum and in the Brunner’s
glands of the duodenum. PRL-2 was also heavily ex-
pressed in the muscularis and the vasculature. PRL-1,
however, was found at slightly lower levels in these
structures. PRL-2 expression in the colon mirrored that
of the small intestine with heavy expression noted
throughout the organ. PRL-1 expression was moderate
and, as in the stomach, the percentage of stained cells
was case dependent, ranging from 30% in one case to
95–100% in others. Similar patterns of expression were
seen in the appendix where PRL-1 was moderately ex-
pressed and PRL-2 was heavily expressed in the muco-
sal epithelium and submucosa.
Exocrine and endocrine portions of the pancreas
both stained strongly for PRL-1 and -2 mRNA ex-
pression. PRL-1 staining was mixed, withz20–25% of
acinar and islet cells displaying heavy expression and
75–80% cells expressing more moderate levels in each
case. Ductal epithelial cells, on the other hand, always
displayed high levels of PRL-1 transcript. The pancre-
atic vasculature also stained strongly for PRL-2 and at
a slightly lower intensity for PRL-1. Expression in the
pancreas was noted to be both nuclear and cytoplasmic
for both markers. In normal liver, a large degree of
interindividual variation was again noted for PRL-1.
Hepatocytes in four of six cases examined were neg-
ative for PRL-1 message (Figure 2H). In the remaining
cases, 25–50% of the hepatocyte nuclei were strongly
positive. In most cases, PRL-1 expression was low to
undetectable in the bile duct epithelia and varied from
weak to moderate in the vasculature. PRL-2 message
was expressed strongly in z50% of hepatocyte nuclei,
whereas the hepatocyte cytoplasm revealed only weak
or mild expression. Bile duct epithelia displayed mod-
erate to strong hybridization for PRL-2, and blood
vessels stained intensely (Figure 2I). Gallbladder mu-
cosa and microvasculature were highly positive for
both PRL-1 and -2 mRNA. Lymphocytes throughout
gut-associated lymphoid tissue also hybridized strongly
for both transcripts. A large degree of interindividual
variability was seen in the staining intensity and
number of positive lymphocytes for PRL-1.
Central Nervous System
Expression of PRL-1 and -2 in the brain was heaviest in
the granular layer of the cerebellum followed by cell
bodies within the molecular layer. Purkinje cells
displayed faint cytoplasmic expression for PRL-1 and
mild cytoplasmic expression of PRL-2 (Figures 2J and
2K). PRL-1 was absent from the neurons outside the
cerebellum in most cases (Figure 2L), whereas PRL-2
expression in the neurons of the cerebral cortex varied
from absent or weak to strong expression, depending
on the sample and region analyzed (Figures 2M and
2N). Expression in glial cells and capillary endothelial
Table 1 Average PRL-1 and -2 mRNA expression in normal
human tissuesa
Tissue PRL-1 PRL-2 Tissue PRL-1 PRL-2
Skin 11 111 Heart 2 11
Tongue Coronary arteries 2 11
Epithelia 11 111 Cerebral cortex
Taste buds 2 2 Neurons 2 1
Salivary glands 2 11 Neuroglia 2 1
Stomach 11 111 Cerebellum
Small intestine 111 111 Molecular layer 1/2 11
Large intestine 11 111 Granular layer 11 111
Appendix 11 111 Purkinje cells 1/2 1
Pancreas Thyroid
Endocrine 11 111 C cells 1 1
Exocrine 11 111 Follicular cells 11 111
Liver Parathyroid
Hepatocytes 1/2 11 Chief cells 11 111
Ductal cells 1/2 111 Oxyphil cells 1 11
Gallbladder 111 111 Adrenal gland
Oviduct 111 111 Cortex 1 1
Ovary Medulla 11 11
Epithelia 111 111 B-lymphocytes 11 11
Granulosa 11 111 T-lymphocytes 111 111
Cervix 111 111 Spleen 1 11
Uterus Connective tissue
Endometrium 111 111 Adipocytes 111 111
Myometrium 1 11 Fibrocartilage 2 2
Placenta 11 111 Hyaline cartilage 2 111
Breast 11 111 Stromal fibroblasts 11 111
Prostate 11 111 Eye
Testis 111 111 Cornea 11 111
Bladder 11 111 Sclera 11 111
Kidney Choroid 11 111
Glomeruli 1 111 Retinab
Proximal tubules 11 111 GCL 1 111
Distal tubules 1/2 111 IPL 2 2
Collecting tubules 11 111 INL 11 111
Interstitium 1 111 OPL 2 2
Lung 111 111 ONL 1 111
Skeletal muscle 1/2 111 Rods/cones 2 2
aResults represent the average staining intensity across multiple samples.
Degree of staining: 2, undetectable; 1/2, faint or barely detectable; 1, weak
expression; 11, moderate expression; 111, strong expression.
bGCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer;
OPL, outer plexiform layer; ONL, outer nuclear layer.
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cells was also generally absent for PRL-1 and varied
for PRL-2.
Sense Organs
In the eye, PRL-1 and -2 messages were localized to the
outer nuclear, inner nuclear, and ganglion cell layers
of the retina. Whereas PRL-2 was expressed heavily
throughout the nuclei and cell bodies in each of these
layers, PRL-1 expression was mild to moderate and
found in only a limited number of cell bodies and nu-
clei, with predominantly nuclear expression (Figure 2O).
Both transcripts were also present in the vascular
endothelial cells, fibroblasts, and lymphocytes of the
choroids, in the corneal epithelium and endothelium,
and in the fibroblasts of the cornea and sclera. In the
corneal epithelium, PRL-1 predominantly stained the
more apical layers of cells. PRL-2 was expressed heavily
in each of the named structures, whereas PRL-1 ex-
pression was generally mild to moderate and more dif-
fuse. Only the endothelial cell layer of the cornea
strongly expressed the PRL-1 transcript.
Female and Male Reproductive Tracts
In the ovary, PRL-1 expressionwas highest in the surface
epithelium and oviduct. Hybridizationwasmild to heavy
in the stroma, follicular cells, corpus luteum, and vas-
culature, each varying considerably on a case-by-case
basis. PRL-2 expression was consistently heavy in all
structures of the ovary but slightly less intense in the
stromal cell nuclei and vascular endothelium than in the
epithelial cells. PRL-1 and -2 showed parallel patterns of
expression in the cervix. Both were expressed highly in
the epithelial and stromal components of the ectocervix
and endocervix as well as in the tissue vasculature.
Placental chorionic villi also demonstrated abundant
expression of both messages, with moderate staining
observed for PRL-1 and heavy staining for PRL-2. Glan-
dular epithelium of the uterus exhibited pronounced
expression of PRL-1 and -2. Myometrial smooth muscle
and endometrial stroma also displayed consistently
moderate to high expression of PRL-2 mRNA, whereas
variable levels of PRL-1 mRNA were observed. In 50%
of the cases, no PRL-1 expression was observed in the
myometrium, whereas in the other half of cases, PRL-1
myometrial expression was moderate to intense. Endo-
thelial cells within the uterine vasculature strongly ex-
pressed both PRL-1 and -2.
Both transcripts were also abundant in the glandular
epithelium and the vasculature of the breast. Whereas
PRL-1 expression in the mammary duct varied slightly
among individuals, mRNA was generally expressed at
moderate to high levels. Within the stroma of the breast,
tissues hybridized with PRL-1 displayed a more scat-
tered and variable staining. Here expression varied from
absent to heavy, depending on the individual. PRL-2was
always expressed heavily in both the mammary ducts
and stromal fibroblasts. A similar trend was observed in
the prostate, where PRL-1 expression in both the
prostatic glands and stroma displayed a large degree of
interindividual variation. Positive staining for PRL-1
was apparent in all cases studied, but the staining
intensity varied from barely detectable to strongly posi-
tive. On average, staining of the glandular epithelium
was moderate, whereas staining of stromal fibroblasts
was mild and more diffuse (Figure 3A). PRL-2 expres-
sion was heavy in both the epithelium and fibroblasts
of all cases examined (Figure 3B). In the testis, expres-
sion of each transcript was heavy in the seminiferous
tubules with staining of the Sertoli cells, primary sper-
matogonia, andmature spermatocytes. Leydig cells in the
interstitium also expressed both transcripts strongly.
Stromal fibroblasts and the vasculature of the testes
stained moderately for PRL-1 and heavily for PRL-2
mRNA expression.
Urinary System
In the urinary system, PRL-2 was again found to be
consistently and heavily expressed, whereas PRL-1 ex-
pression varied in amount and intensity. In the uri-
nary bladder, PRL-1 mRNA was expressed at weak to
moderate levels in the urothelium, with the strongest
expression occurring in the intermediate and basal cell
layers (Figure 3C). Weak to moderate expression of
PRL-1 was also noted in the stromal fibroblasts,
smooth muscle nuclei, and vasculature of the bladder.
Hybridization of PRL-1 in the kidney was extremely
’
Figure 2 Moderate and diffuse expression of PRL-1 mRNA (A) and strong expression of PRL-2 mRNA (B) in the stratified epithelia and
elastocollagenous stroma of the skin. In the stomach, PRL-1 expression was mild in the body mucosa (C) but heavy in the pyloric mucosa (D).
PRL-2 expression in the body of the stomach tended to be localized toward the base of the gastric glands (E) where both cytoplasmic and
nuclear staining of the acid (arrow 1 in F) and enzyme (arrow 2 in F) producing cells was noted. PRL-1 expression in the jejunumwas strong and
mirrored the expression level of PRL-2 (G). PRL-1 transcripts were absent in the majority of liver tissues analyzed (H), whereas PRL-2 message
was expressed strongly but not in all hepatocyte nuclei (I). High expression of PRL-2 was also noted in the bile duct epithelium (arrow 1 in I) and
vascular endothelium (arrow 2 in I) of the liver. PRL-1 (J) and PRL-2 (K) were both highly expressed in the granular layer of the cerebellum.
Purkinje cells displayed faint expression for PRL-1 and mild expression for PRL-2 (arrows). PRL-1 was generally not expressed in neurons or glial
cells of the cerebral cortex (L). Two different sections taken from the same patient demonstrate that PRL-2 expression in the cerebral cortex
was dependent on the location sectioned (M,N). Scattered PRL-1 expression was observed in the ganglion cell layer (GCL), inner nuclear layer
(INL), and outer nuclear layer (ONL) of the retina (O). Bar 5 100 mm.
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variable, with expression ranging from weak to strong
in different patient samples. Some level of PRL-1 ex-
pression was detected in the proximal convoluted
tubules, collecting tubules, glomeruli, interstitial cells,
and vascular elements in all patient cases (Figure 3E).
The percentage of PRL-1 positive cells, in each case,
varied from as low as 30% to as high as 95%. In all but
two cases, PRL-1 was also expressed in the distal
convoluted tubules. Generally, expression was highest
in the proximal tubules and collecting tubules followed
by the interstitium, glomeruli, and distal tubules. In
contrast to PRL-1, PRL-2 was expressed at high levels
in all components of the urinary bladder (Figure 3D)
and kidney (Figure 3F).
Respiratory System
Heavy nuclear staining of PRL-1 and -2 was observed
in the alveolar and bronchiolar epithelia with PRL-1
expression in pneumocytes being slightly less intense
than its expression in the bronchiolar epithelium. En-
dothelial cells within the lung vasculature also dis-
played heavy expression of both transcripts.
Skeletal Muscle and Heart
Skeletal muscle nuclei stained weakly, if at all, for PRL-1
message, whereas cells of the endomysium, perimy-
sium, and vasculature stained heavily for the transcript
(Figure 3G). PRL-2 expression, on the other hand, was
high in the skeletal muscle nuclei and muscle fibers, in
addition to the surrounding support tissue and vascula-
ture (Figure 3H). The epicardium, myocardium, and
endocardium of normal heart were all generally negative
for PRL-1 gene expression. Likewise, in the coronary
arteries, faint PRL-1 expression was found in only one of
five cases. PRL-2 expression in the heart was stronger
than PRL-1 but much less intense than the PRL-2 ex-
pression levels observed in other organs. Cardiac cell
nuclei stained moderately for PRL-2, whereas epicardial
and endocardial components stained only lightly. All lay-
ers of the coronary arteries moderately expressed PRL-2.
Endocrine Tissues
Follicular epithelial cells in the thyroid expressed mod-
erate levels of PRL-1 and high levels of PRL-2 tran-
scripts. C-cells expressed both transcripts mildly. The
oxyphilic and chief cells of the parathyroid were both
positive for PRL-1 and -2 expression, with slightly
higher expression occurring in the chief cells and with
stronger expression of PRL-2 than of PRL-1. It was
noted that staining for both transcripts in the oxyphilic
cells was nuclear, whereas expression in chief cells
was mostly cytoplasmic. Adipocytes within the gland
stained intensely for both transcripts. Mild to moderate
expression of both PRL-1 and -2 were noted in the
adrenal cortex and medulla.
Lymphoid Tissues
Both B- and T-cell areas of the lymph node strongly
expressed PRL-1 and -2 transcripts, with moderate
staining of B cells and heavy expression in T cells. In
the spleen, PRL-1 expression was less intense and more
variable. Three of ten samples tested were negative for
PRL-1, whereas the remaining seven samples expressed
mRNA mildly and diffusely in the splenic cords, venous
sinuses, and lymphoid follicles. The fibrocollagenous
capsule and microvasculature of the organ expressed
PRL-1 message at more moderate levels. PRL-2 was
expressed in all samples and generally displayed a mod-
erate staining intensity in the red and white pulp areas of
the spleen and strong intensity within the capsule.
Connective Tissues
In general, adipocytes stained heavily for both PRL-1 and
-2 transcripts. Tendon fibrocartilage, on the other hand,
was negative for each. Hyaline cartilage was commonly
negative for PRL-1, whereas chondroblast and chondro-
cyte nuclei and the territorial matrix of the lacuna were
strongly positive for PRL-2. Fibroblasts in all tissues
stained heavily for PRL-2, whereas PRL-1 expression in
fibroblasts variedwidely among tissue types and between
individual samples within a tissue type.
Discussion
A detailed knowledge of the cellular distribution of
PRL-1 and -2 gene expression in different human
tissues and cell types is essential to understanding both
the role of these proteins in normal tissues and their
potential involvement in the pathogenesis of disease.
The present study is the first report describing the cell-
specific pattern of expression for either PRL-1 or -2 in a
variety of human tissues. Previous studies have shown
preferential expression of PRL-3 in the heart and
skeletal muscle of normal tissues (Zeng et al. 1998;
Matter et al. 2001); thus, PRL-3 transcripts were not
examined here.
Results obtained show widespread distribution of
PRL-1 and -2 in tissues from the major organ systems.
’
Figure 3 Moderate expression of PRL-1 mRNA and strong expression of PRL-2 mRNA in the glandular epithelia of the prostate (A,B), urothelia
of the bladder (C,D), and glomeruli and tubules of the kidney (E,F). In the urinary bladder (C), a lack of staining for PRL-1 was noted in most
luminal surface (LS) cells. Skeletal muscle cell fibers and nuclei were generally negative for PRL-1 (arrow 1 in G), although the surrounding
support tissue was strongly positive for the transcript (arrow 2 in G). Skeletal muscle cell fibers and nuclei, as well as the surrounding support
tissue, displayed strong expression of PRL-2 (H). Bar 5 50 mm.
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PRL-1 expression was more variable and generally less
intense than the level of PRL-2 expression in the same
tissue or cell types. Only in the pyloric region of the
stomach, small intestine, gallbladder, oviduct, testis,
lung, and adipose tissue were levels of PRL-1 expression
equivalent to PRL-2 in both intensity and total number of
positive cells. PRL-1 expression was most abundant in
the duodenum, jejunum, gallbladder, testis, lung, adi-
pose, skin appendages, lymph node, oviduct, cervix,
surface epithelium of the ovary, and endometrial glands
of the uterus. Moderate expression of PRL-1 was seen in
several other tissues and cell types including the skin and
tongue epithelium, colon, appendix, pancreas, breast,
placenta, prostate, bladder, and the eye. Lowest levels of
PRL-1 expression were found in the liver and skeletal
muscle, and no PRL-1 message could be detected in the
taste buds, salivary glands, heart, coronary arteries, ce-
rebral cortex, or cartilage.
In the urinary bladder, PRL-1 appeared to be
localized to the more immature, intermediate, and
basal cell layers of the uroepithelium and not to the
more differentiated and highly specialized superficial
cell layer. It would be interesting to examine the colo-
calization of PRL-1 with the cytokeratins (CKs) and/or
uroplakins, which can serve as markers of urothelial
cell proliferation and differentiation. For example,
CK20 is restricted mainly to the superficial layer of
the urothelium, whereas CK13 is present only in the
basal and intermediate layers (Mallofre et al. 2003;
Varley et al. 2004). Such studies could help to elucidate
a specific role for PRL-1 in this tissue type.
A large degree of interindividual variation was noted
for PRL-1 in some tissues, most notably skin, stomach,
liver, pancreas, breast, prostate, bladder, and kidney.
Such differences could be attributed to allelic variants,
environmental factors, lifestyle factors, and/or homeo-
static control mechanisms. Differential expression in
the breast, for example, could be a factor of the donor’s
reproductive history because Guo et al. (2004) found
that PRL-1 is significantly overexpressed in parous
breast tissue, which has been stimulated to differentiate
during pregnancy.
In contrast to PRL-1, PRL-2 mRNA was found in
almost every cell type examined, and the majority of
tissues exhibited intense expression of the transcript.
More moderate levels of PRL-2 were observed in the
salivary glands, heart, coronary arteries, adrenal gland,
spleen, and uterine smooth muscle. Purkinje cells of the
cerebellum and C-cells of the thyroid demonstrated
weak expression of the PRL-2 transcript. Only the taste
buds of the tongue, fibrocartilage of the tendon, and
photoreceptors and cell processes of cells within the
retina were negative for PRL-2 expression. In the liver,
PRL-2 was heavily expressed in the hepatocytes, but
only 40–50% of hepatocyte nuclei were positive for
expression. In comparison, 95–100% of cells were
generally positive for expression in other tissues. In the
cerebral cortex, PRL-2 expression in neurons and glial
cells varied from specimen to specimen and between
different sections within the same specimen. When
expressed, PRL-2 levels in the cortex varied from weak
to moderate. A more extensive analysis of PRL-2 ex-
pression in various areas of the brain and cerebral cor-
tex may reveal region-specific localization patterns.
These results are generally consistent with previous
reports on PRL-1 or -2 mRNA expression in human
tissues. In a panel of cDNA libraries from adult he-
matopoietic tissues, Gjorloff-Wingren et al. (2000)
noted ubiquitous expression of both transcripts with
PRL-1 always expressed at equivalent or lower levels
than PRL-2. Using multiple tissue Northern blots,
Montagna et al. (1995) and Zhao et al. (1996) also
reported widespread PRL-2 expression with moderate
to high levels of PRL-2 transcripts in all tissue types
examined. Additionally, Zhao et al. reported compar-
atively low levels of three PRL-2 variants in the liver.
Our data both confirm and expand on this finding by
suggesting that the lower levels of PRL-2 observed in
the liver are not due to reduced PRL-2 expression
across all cells, but rather to a smaller percentage of
cells actually expressing the gene.
Comparison of our results with patterns of PRL-1 and
-2 expression in other species reveals further similarities.
The current study showed PRL-1 transcripts to be barely
detectable in normal adult human liver or skeletal muscle
and completely undetectable in the heart. In agreement
with these findings, several researchers have reported a
virtual absence of PRL-1 gene transcription in the liver of
normal adult rats (Diamond et al. 1994,1996; Peng et al.
1999). In addition, Northern analysis, ISH, and immu-
nohistochemistry have all consistently shown an absence
of both PRL-1 mRNA and protein in murine heart tissue
(Diamond et al. 1994; Rundle and Kappen 1999; Kong
et al. 2000). Studies using ISH have also indicated an
absence of PRL-1 in mouse skeletal muscle (Rundle and
Kappen 1999). Northern analysis, on the other hand, has
shown heavy expression of PRL-1 in rat skeletal muscle
tissue (Diamond et al. 1994). Our analysis in human
skeletal muscle tissues agrees with both findings, re-
vealing a strong reactivity of the connective tissue
and vasculature directly surrounding the muscle cells,
whereas the muscle fibers and nuclei themselves were
generally negative. PRL-2 was heavily expressed in hu-
man skeletal muscle, but weakly expressed in the brain
cerebral cortex. In accordance with these results, Zeng
et al. (1998) found heavy expression of PRL-2 in mouse
skeletal muscle and comparatively low expression in the
mouse brain.
In several cases, patterns of PRL-1mRNA expression
also appear to correlate well with reports of PRL-1
protein expression. For example, we found that PRL-1
mRNA expression in the regions of the stomach closest
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to the esophagus was weak, whereas expression in
regions more distal to the esophagus was high. Further,
our analysis showed decreased levels of PRL-1 mRNA
in the colon as compared with the duodenum and jeju-
num. Kong et al. (2000) noted a lack of PRL-1 pro-
tein expression in the esophagus of the adult rat and
found a gradient of PRL-1 protein expression within
the small intestine, with highest levels of expression
observed in the proximal intestine (duodenum and je-
junum) and lower levels evident in themore distal ileum.
Together these results suggest that PRL-1 may be dif-
ferentially expressed along the longitudinal axis of the
digestive tract, increasing from esophagus and cardiac
stomach to pyloric stomach and proximal small in-
testine, then decreasing again in the distal intestine and
the colon. Such spatial differences in PRL-1 expression
suggest a specialized role for the enzyme within the
digestive tract.
Variable expression of PRL-1 protein has also been
observed along the crypt–villus axis of the intestine.
Diamond et al. (1996) and Kong et al. (2000) each
reported significantly greater expression of PRL-1
protein in villus enterocytes than in crypt enterocytes.
In the current study, however, we observed heavy ex-
pression of PRL-1 mRNA throughout both villus and
crypt enterocytes. Although some of these observations
could be explained by species-specific patterns of ex-
pression, such differences between mRNA and protein
levels also raise the possibility that PRL-1 expressionmay
be regulated posttranscriptionally.
In conclusion, the present results help to define the
basal gene expression of the PRL-1 and -2 phosphatases
in adult human tissues and provide a foundation for the
recognition and interpretation of the changes in these
patterns that may be associated with cancer or other
disease states. Widespread tissue distribution of PRL-1
and -2 mRNA suggests a fundamental biological
function for these enzymes. Whereas PRL-2 was highly
expressed in the majority of tissues examined, PRL-1
expression was highly variable. PRL-1, therefore, ap-
pears to be regulated spatially in a cell type- and tissue-
specific manner in the adult. Both transcripts showed
widespread expression in both proliferating and quies-
cent normal cells, indicating that each tissue or cell type
may display a unique physiological response to these
genes. Further studies aimed at elucidating the specific
substrates and other interacting molecules for the PRL
enzymes will help clarify the specific cellular functions
of PRL-1 and -2 and provide insight into their varied
expression patterns in human tissues.
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Introduction 
 
The PRL family of phosphatases has gained 
much attention in recent years as potential tar-
gets for therapeutic intervention in a variety of 
tumor types. The family consists of three closely 
related members (PRL-1, PRL-2, and PRL-3), 
which constitute a novel class of protein tyro-
sine phosphatase (PTP). The PRLs are among 
the smallest of the PTPs, having molecular 
masses of 20-22kDa and consisting primarily of 
a catalytic domain. In addition, the PRL en-
zymes are the only PTPs known to be post-
translationally isoprenylated. This post-
translational modification is critical to their sub-
cellular localization and biological activity [1-3].  
Accumulating evidence points to a role for the 
PRL family in tumor formation, invasion, and 
metastasis. Functional studies have shown that 
overexpression of PRL-1, -2, or -3 in non-
tumorigenic rodent cells leads to rapid cellular 
growth and a transformed phenotype in culture 
and to tumor formation in athymic, nude mice 
[1, 4-7]. Moreover, PRL-3 overexpression en-
hances the growth of human embryonic kidney 
fibroblasts in culture [5] and can transform a 
low metastatic potential melanoma cell line into 
a highly metastatic line both in vitro and in vivo 
[6]. Stable expression of PRL-1 or PRL-3 leads 
to enhanced cell motility and invasive ability, 
whereas downregulation of either of these mole-
cules causes a significant reduction in migratory 
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ability in vitro and suppression of metastatic 
tumor formation in vivo [7-14]. The most well 
studied PRL family member, in relation to hu-
man cancer, is PRL-3. Widespread interest in 
this gene was generated after Saha et al. [15] 
identified 144 gene transcripts with increased 
expression in liver metastases compared to 
their primary colorectal tumors and demon-
strated that PRL-3 was the only gene consis-
tently overexpressed in all 18 of the metastatic 
cases examined. A gradient in PRL-3 expression 
was also noted, with low levels of PRL-3 mes-
sage in normal colorectal epithelium, intermedi-
ate levels in the primary tumors, and high ex-
pression in each of the liver metastases. 
Bardelli et al. [16] later showed that PRL-3 
mRNA overexpression was not limited to liver 
metastases, but that PRL-3 was expressed 
more highly in all colorectal carcinoma metasta-
ses examined, regardless of the site of metasta-
sis. PRL-3 overexpression has since been linked 
to such clinical parameters as disease progres-
sion, tumor aggressiveness, lymphatic invasion, 
venous invasion, presence and extent of metas-
tasis, or poor patient prognosis in colon/
colorectal [17-20], cervical [21], ovarian [22, 
23], breast [24-26], gastric [27-35], non-small 
cell lung [36], esophageal [37], nasopharyngeal 
[12], brain [38], hepatocellular [39] and bile 
duct [40] cancers. These data suggest PRL-3 as 
a potential prognostic indicator of disease ag-
gressiveness and clinical outcome for multiple 
tumor types. 
 
In contrast to PRL-3, little data is currently avail-
able on the expression of PRL-1 or PRL-2 in hu-
man malignancies, yet it is clear from cell line 
and murine studies that these genes also play 
important roles in tumor formation, invasion, 
and metastasis [1, 7, 41-43]. In the current 
study, we provide further insight into the role 
that both PRL-1 and PRL-2 play in the develop-
ment and progression of human disease by per-
forming a retrospective analysis on 342 human 
tissue specimens from 243 individual subjects. 
The expression of PRL-1 and PRL-2 mRNA was 
assessed in a variety of normal and tumor tis-
sues of diverse tissue origin using in situ hy-
bridization. Where possible, correlations be-
tween PRL-1 or -2 mRNA expression and several 
clinicopathological features, including patient 
age and gender, tumor type and grade, and 
presence or absence of local or distant metasta-
ses were investigated. A comparison between 
mRNA and protein expression levels was also 
made in a subset of these tissues. In addition, 
because PRL-3 overexpression in mouse mod-
els has previously been linked to cardiovascular 
disease [5] and PTPs in general have been im-
plicated in the progression of several cardiovas-
cular, neurological, metabolic, and autoimmune 
diseases [44-47], we also examined the rela-
tionship between PRL-1 and PRL-2 expression 
and a variety of disease states other than can-
cer. 
 
Materials and methods 
 
Tissue procurement 
 
Formalin-fixed, paraffin-embedded tissue sam-
ples were obtained from archival paraffin 
blocks. Tissues were acquired from the Coop-
erative Human Tissue Network (CHTN), National 
Disease Research Interchange (NDRI), or Indi-
ana University School of Medicine, Department 
of Pathology, collected in accordance with the 
guidelines of Indiana University and with ap-
proval from the IUPUI Institutional Review 
Board. Tissue sections of each specimen were 
stained with Hematoxylin and Eosin (H&E) and 
were examined by a pathologist, with no prior 
knowledge of the available patient data, to con-
firm histopathologic diagnosis and tumor grad-
ing. For all cases, representative tissue sections 
were chosen for in situ hybridization (ISH) and/
or immunohistochemical (IHC) analysis. 
 
In situ hybridization 
 
Non-isotopic ISH was performed using FITC-
labeled oligonucleotide probes specific for PRL-
1 or PRL-2 mRNA, as previously described [48]. 
Briefly, 5ƫm thick tissue sections were deparaf-
finized, rehydrated through graded alcohols to 
distilled water and permeabilized with 200ƫl of 
10ƫg/mL proteinase K for 5-20 minutes de-
pending on tissue type. The deproteination reac-
tion was stopped by washing slides two times, 
three minutes each in Nanopure ultrapure wa-
ter, followed by sequential washes in 95% and 
100% ethanol for three minutes each. Slides 
were allowed to air dry for one hour at room 
temperature (RT), prior to hybridization. Tissue 
sections were then incubated in a humidified 
chamber overnight (12-14 hours) at 37ºC with 
50ƫL of PRL-1, PRL-2, or control probe diluted 
to a final concentration of 750 ng/mL in Perfec-
tHyb™ Plus hybridization buffer (Sigma-Aldrich, 
St. Louis, MO, USA). Following hybridization, non
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-specifically bound probe was removed by wash-
ing slides two times in 2X SSC (300mM NaCl, 
30mM Sodium Citrate, pH 7.0) plus 0.1% SDS 
for five minutes RT, one time in pre-warmed 
0.5X SSC (75mM NaCl, 7.5mM Sodium Citrate, 
pH 7.0) + 0.1% SDS at 37ºC for 20 minutes, 
and one time in tris-buffered saline (TBS; 50mM 
Tris-HCL, 150mM NaCl, pH 7.6) + 0.1% SDS at 
RT for 10 minutes. Detection of hybridized 
probe was performed by standard immunohisto-
chemical techniques using a catalyzed signal 
amplification procedure. Non-specific back-
ground staining was blocked by incubation with 
DAKO Serum-Free Protein Block (DAKO Corpora-
tion, Carpenteria, CA, USA) for 30 minutes, fol-
lowed by 30 minutes incubation with a mouse 
anti-FITC primary antibody (DAKO), diluted to 
22ƫg/mL in DAKO Antibody Diluent. Bound pri-
mary antibody was detected using the labeled 
streptavidin-biotin method (LSAB2, DAKO) com-
bined with the Renaissance® Tyramide Signal 
Amplification kit (TSA™ Biotin, PerkinElmer Life 
Sciences, Inc., Boston, MA, USA). Peroxidase 
bound, antibody complexes were visualized us-
ing DAB (DAB Substrate/Chromogen System, 
DAKO) as the chromogenic substrate. Develop-
ment was allowed to proceed for 2-5 minutes 
and was stopped by rinsing the slides in distilled 
water for five minutes. Sections were counter-
stained briefly with 1X Lerner’s hematoxylin, 
dehydrated through graded alcohols, cleared in 
xylene, and coverslipped with permanent 
mounting media (ThermoFisher Scientific, Inc., 
Waltham, MA, USA). All staining steps were per-
formed on a DAKO Autostainer at room tem-
perature and slides were rinsed for five minutes 
in TBS + 0.05% Tween-20 between each step of 
the procedure. Normal adjacent and tumor tis-
sue sections from one organ type were always 
processed simultaneously.  
 
Immunohistochemistry 
 
Rabbit antibodies against peptides correspond-
ing to amino acids 50-65 of human PRL-1 and 
47-62 of human PRL-2 were generated by 
Genemed Synthesis, Inc (San Antonio, TX, USA). 
The antibodies were affinity purified against E. 
coli expressed PRL proteins. Slides containing 
5ƫm tissue sections were deparaffinized for 9 
minutes in xylene then rehydrated through a 
series of 100%, 80%, and 70% ethanol for 5 
minutes each, followed by a 5 minute rinse in 
PBS. Antigen retrieval was performed by heating 
in a microwave for 5 minutes in 5mM Sodium 
Citrate. Following retrieval, slides were allowed 
to cool at room temperature for 15 minutes. 
Endogenous peroxidase activity was quenched 
by incubation in 3% H2O2 for 5 minutes. Sec-
tions were blocked for 15 minutes in 3% non-fat 
dry milk, 1% BSA, then incubated 90 minutes at 
37°C with primary antibody diluted 1:200 in 
blocking solution. This was followed by a 30 
minute incubation with biotinylated secondary, 
anti-rabbit antibody (Biogenex Laboratories, 
Inc., Fremont, CA, USA) diluted 1:20 in blocking 
buffer and a 30 minute incubation with strepta-
vidin peroxidase (Biogenex). A 5 minute phos-
phate buffered saline (PBS) rinse was incorpo-
rated after each step in the immunostaining 
procedure. Colorimetric detection was carried 
out using AEC and allowed to proceed until color 
was detected in the tissues by microscopic ex-
amination at which point the reaction was 
quenched by rinsing the slides in distilled water. 
Sections were counterstained in Hematoxylin for 
30 seconds and again rinsed with water.  
 
Controls 
 
Several positive and negative controls were 
used, concurrently, to confirm the specificity of 
the ISH or IHC signal. All controls were per-
formed on serial sections of the same tissues 
as examined with the PRL-1 and PRL-2 probes 
or antibodies, utilizing the ISH and IHC proce-
dures described above. For the ISH experi-
ments, positive controls included: (a) verifica-
tion of the hybridization and detection proce-
dure by hybridization of the PRL-1 and PRL-2 
antisense probes to a normal pancreas tissue 
(case # 032098), known to be positive for PRL-
1 and PRL-2 mRNA and (b) hybridization of tis-
sues with a fluorescein-conjugated Poly d(T) 
probe (Novocastra Laboratories, New Castle 
upon Tyne, UK) to assess the preservation and 
integrity of the mRNA in each sample. Negative 
controls consisted of: (a) omission of the oli-
gonucleotide probes from the hybridization mix-
ture and incubation of the tissue specimens 
with only PerfectHyb™ hybridization buffer, (b) 
substitution of the specific antisense probe with 
an equivalent concentration of labeled sense 
probe to examine the stringency of the assay, 
(c) hybridization using a cocktail of randomly 
generated, FITC-conjugated, oligonucleotide 
sequences (NCL-CONTROL, Novocastra), to as-
sess binding of nonspecific sequences, and (d) 
Pretreatment of tissue sections with 250ƫg/mL 
RNase A (Sigma-Aldrich) for 2 hours at 37ºC to 
PRL-1 and PRL-2 expression in cancer 
 
 
86                                                                                                                Am J Transl Res 2012;4(1):83-101 
demonstrate the specificity of the signal for sin-
gle stranded RNA. Probe specificity was also 
verified by slot-blotting and shown previously 
[48]. As negative controls for IHC, tissue sec-
tions were incubated either in the presence of 
no primary antibody, no secondary antibody, or 
primary antibody blocked with the peptide used 
to generate the anti-PRL-1 or anti-PRL-2.  
 
Staining interpretation 
 
Evaluation of all slides was performed under 
bright-field microscopy. The intensity of staining 
and the percentage of positive normal and tu-
mor cells for the ISH studies were evaluated 
with the aid of a single, experienced pathologist, 
in a blinded fashion. For the IHC experiments, 
scoring of images was performed independently 
by three separate individuals and the mean 
reading was taken for each tissue section. The 
appearance of a brownish-red stain over the 
cells was used to indicate probe hybridization or 
antibody binding and thus reflect the cellular 
levels of PRL-1 and PRL-2 mRNA or protein. Im-
munostaining was scored using established 
methods [49, 50]. Briefly, staining intensity was 
classified according to the following scale: (-) 
absent, (+/-) barely detectable, (+) weak, (++) 
moderate, and (+++) strong. In cases of hetero-
geneous staining, the average intensity across 
the tissue was taken as the score. Also, in a few 
cases where a patient sample was stained 
twice, the case was given a mean score, based 
on evaluation of the two sections. The percent-
age of positive cells was estimated as the num-
ber of stained cells, per total number of cells 
counted. The localization of staining within the 
cells of each tissue was also examined and 
noted as nuclear, cytoplasmic, membranous, or 
a combination of these. For semiquantitative 
analysis of the results, the staining intensity was 
assigned an arbitrary value, on a scale of 0-3, 
as follows: (-) = 0, (+/-) = 0.5, (+) =1, (++) = 2, 
(+++) = 3. An overall staining score (SS) was 
calculated for each sample, by multiplying the 
staining intensity times the percentage of posi-
tive cells. After multiplication of both values, 
results were graded from 0 (negative) to 300 
(all cells display strong staining intensity). To 
confirm the reproducibility of the analysis, 25% 
of the slides were randomly chosen and scored 
twice. Duplicate readings gave similar results. 
Images were acquired using a SPOT digital cam-
era and imaging software (Diagnostic Instru-
ments, Inc., Sterling Heights, MI, USA).  
Statistical analysis 
 
Statistical calculations were executed using 
Statistical Analysis System software (SAS ver-
sion 8.2, SAS Institute, Inc., Cary, NC). Analyses 
of differences in PRL expression between can-
cerous and noncancerous tissues were per-
formed using a Student’s paired t-test. Results 
are expressed as mean ± standard error of the 
mean (SEM) and P < 0.05 was considered sta-
tistically significant. For most samples, the 
medical histories of the patients and pathologi-
cal reports for each specimen were also avail-
able. These were reviewed and correlations be-
tween PRL expression and patient clinicopa-
thological features such as patient age and gen-
der; tumor type, subtype, and grade; and pres-
ence of local or distant metastasis were calcu-
lated using a mixed model analysis of variance. 
Again, P < 0.05 was deemed statistically signifi-
cant. 
 
Results 
 
PRL-1 and PRL-2 transcripts are expressed in a 
broad variety of normal and tumor tissues 
 
A total of 285 normal, benign, and malignant 
human tissue samples of diverse origin were 
obtained from archival paraffin blocks and sub-
jected to ISH, in order to examine expression of 
PRL-1 and PRL-2 mRNA transcripts (Table 1). 
PRL-2 message was found to be expressed at 
moderate to high levels in almost all (279/285) 
of the normal and tumor tissues examined. Low 
levels of PRL-2 were noted only in a single case 
of renal cell carcinoma, one normal lymph node, 
one ovarian carcinoma, and three normal speci-
mens from the spleen. PRL-1 mRNA was also 
expressed in the vast majority of tissues exam-
ined, however the degree and intensity of PRL-1 
staining varied considerably between tissue 
types and between individual cases within a 
single tissue type. This transcript was expressed 
at detectable levels in 97% (133/137) of his-
tologically normal tissues examined, as well as 
in 93% (14/15) of breast carcinomas, 83% 
(5/6) of endometrial adenocarcinomas, 78% 
(14/18) of ovarian tumors, 77% (10/13) of re-
nal cell carcinomas, and in 100% of primary 
tumors derived from the bladder (n=9), cervix (n 
= 1), colon (n = 5), liver (n = 4), lung (n = 8), 
pancreas (n = 14), prostate (n = 28), skin (n = 
1), stomach (n = 5), and testis (n = 4). PRL-1 
was also expressed in all cases examined of B-
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 Table 1. Expression of PRL-1 and PRL-2 in various tumors and diseased tissues 
Tissue Type/Histopathology # Samples 
PRL-1   PRL-2 
Weak 
(%) 
Moderate 
(%) 
Strong 
(%)   
Weak 
(%) 
Moderate 
(%) 
Strong 
(%) 
Bladder                 
   Transitional Cell Carcinoma 7 0 71 29   0 0 100 
   Sarcomatoid Carcinoma 1 100 0 0   0 0 100 
   Undifferentiated Carcinoma 1 100 0 0   0 0 100 
   Hyperplastic Lesion 1 100 0 0   0 0 100 
Brain                 
   Alzheimer's 4 25 75 0   25 0 75 
   Multiple Sclerosis 2 0 0 0   100 0 0 
Breast                 
   Invasive Ductal Carcinoma 15 13 40 40   0 7 93 
   Benign Lesions 2 0 100 0   0 0 100 
Cervix                 
   Squamous Cell (LCK) 1 0 100 0   0 0 100 
Colon                 
   Adenocarcinoma 5 20 40 40   0 0 100 
   Metastatic Lesions in Liver 3 0 33 67   0 0 100 
   Crohn's Disease 2 0 0 100   0 0 100 
Coronary Arteries                 
   30-60% Occlusion 3 33 0 0   0 33 33 
   60-90% Occlusion 2 0 0 0   0 50 0 
Heart                 
   Heart Disease 7 43 0 0   14 86 0 
Kidney                 
   Renal Cell Carcinoma 13 38 31 8   8 8 84 
Liver                 
   Hepatocellular Carcinoma 4 0 100 0   0 0 100 
   Hepatitis 2 100 0 0   0 50 50 
   Steatosis 2 50 50 0   0 50 50 
Lung                 
  Non Small Cell Lung Cancer 8 0 37 63   0 12 88 
Lymph Node                 
   B-Cell Lymphoma 4 0 0 100   0 0 100 
   Hodgkin Lymphoma 1 0 0 100   0 0 100 
   Metastatic Lymphoma in Testes 1 0 0 100   0 0 100 
Ovary                 
   Epithelial Tumor 17 41 35 0   6 12 82 
   Dysgerminoma 1 0 100 0   0 0 100 
Pancreas                 
   Exocrine Tumor 12 0 8 92   0 0 100 
   Endocrine Tumor 2 0 0 100   0 0 100 
   Diabetic 8 0 0 100   0 0 100 
Prostate                 
   Adenocarcinoma 28 25 25 50   0 0 100 
Skeletal Muscle                 
   Diabetic 4 0 50 0   0 25 75 
Skin                 
   Basal Cell Carcinoma 1 100 0 0   0 0 100 
Spleen                 
   Chronic Lymphocytic Leukemia 1 100 0 0   0 100 0 
   Chronic Myelogenous Leukemia 1 0 0 100   0 0 100 
   Diabetic 3 0 67 0   0 33 67 
Stomach                 
   Adenocarcinoma 4 0 0 100   0 0 100 
   Leiomyosarcoma 1 0 0 100   0 0 100 
Testis                 
     Germ Cell Tumor 4 0 50 50   0 0 100 
Uterus                 
   Adenocarcinoma 6 33 50 0   0 17 83 
   Sarcoma (MMMT) 1 0 0 100   0 0 100 
Vasculature (Multi Tumor Tissues) 38 21 32 45   0 5 95 
Stroma (Multi Tumor Tissues) 90 41 29 17   0 12 88 
Abbreviations: LCK = Large Cell Keratinizing; MMMT = Malignant Mixed Mullerian Tumor 
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cell lymphoma (n = 5, including one metastatic 
lesion in the testes), Hodgkin lymphoma (n = 1), 
chronic lymphocytic leukemia (CLL; n = 1), 
chronic myelogenous leukemia (CML; n = 1), 
colon metastases to the liver (n = 3), uterine 
sarcoma (n = 1), and benign lesions of the 
breast (n = 2). In the vast majority of cases 
(both normal and tumor), localization of PRL-1 
and PRL-2 staining appeared to be nuclear, 
however in tissues of the breast, liver, pancreas, 
stomach, and uterus, both nuclear and cytoplas-
mic staining were observed. 
 
Dysregulation of PRL-1 and PRL-2 mRNA ex-
pression in tumors is highly tissue specific 
 
To provide further insight into the role of the 
PRL genes in cancer development, PRL-1 and 
PRL-2 mRNA expression were directly compared 
between the tumor and normal tissues exam-
ined by ISH. In both the normal and tumor tis-
sues, a large degree of inter-individual variability 
was observed, particularly in PRL-1 expression, 
suggesting that comparisons between normal 
and diseased tissue from different patients 
could be misleading. To account for this, only 
case matched tumor and normal adjacent tis-
sue (NAT) specimens from the same patient 
were utilized in this analysis. Of the tissues ex-
amined, there were 94 cases where both tumor 
and normal samples were available (188 total 
tissue specimens). These included case 
matched specimens from the bladder (n = 5), 
breast (n = 15), colon (n = 5), kidney (n = 13), 
liver (n = 4), lung (n = 8), ovary (n = 6), pan-
creas (n = 10), prostate (n = 13), spleen (n = 1), 
stomach (n = 5), testis (n = 4), and uterus (n = 
5). 
 
Direct comparison between normal and tumor 
samples revealed several significant, yet highly 
tissue specific differences in PRL-1 and PRL-2 
mRNA expression (Figures 1 and 2). PRL-1 ex-
pression was significantly higher in 100% of the 
gastric carcinomas examined as compared to 
adjacent normal gastric tissue, with an almost 2
-fold higher mean staining score in the cancer-
ous tissue than in the noncancerous tissue (P = 
0.01, Stomach, Figures 1 and 3). PRL-1 was 
also significantly overexpressed in 100% of 
hepatocellular carcinomas (HCC) compared to 
the matched normal tissues examined (P = 
0.0052) with 4-fold higher expression occurring 
in the tumor tissues in this instance. PRL-2 mes-
sage was also found to be upregulated in 100% 
of the hepatocellular carcinomas examined (P = 
0.0152, Liver, Figure 1) with levels of PRL-2 
expression in the HCC tissues, on average, ap-
proximately 2-fold higher than in normal hepato-
cytes (P = 0.0152). 
 
Given the evidence for a role of the PRL en-
Figure 1. Levels of PRL-1 transcript in matched tumor and adjacent normal tissue pairs. The mean staining scores 
(SS) ± the SEM are shown. An asterisk indicates a statistically significant difference between the matched normal 
versus tumor tissue, as determined by paired t-tests (P < 0.05). A statistically significant increase in PRL-1 mRNA 
expression was found in hepatocellular carcinomas (P = 0.0052, n = 4), and carcinomas of the stomach (P = 0.01, n 
= 5), compared to matched normal tissues. A significant decrease in PRL-1 mRNA expression was found in breast 
tumor tissue (P = 0.0058, n = 15), lung tumors (P = 0.015, n = 8), and ovarian carcinomas (P = 0.0007, n = 6) com-
pared to matched normal tissues. 
PRL-1 and PRL-2 expression in cancer 
 
 
89                                                                                                                Am J Transl Res 2012;4(1):83-101 
zymes in tumor development and metastasis, it 
was not surprising to find PRL-1 and PRL-2 ex-
pression increased in a variety of tumor tissues. 
Unexpectedly however, expression of both 
genes was also found to be lower, relative to the 
normal adjacent tissues, in a number of tumor 
types. PRL-1 transcript levels were significantly 
decreased in 100% of ovarian carcinomas (P = 
0.0007, Ovary, Figure 1), twelve (80%) of 15 
benign and malignant breast tumors (P = 
0.0058, Figures 1 and 4), and 6 (75%) of 8 lung 
carcinomas (P = 0.0148) with respect to the 
paired normal tissues for each. A similar down-
ward trend appeared to occur for 80% of the 
colon carcinomas, 69% of the renal cell carcino-
mas, 80% of the testicular carcinomas, and 
80% of the uterine carcinomas examined, how-
ever the differences in these tissues did not 
reach statistical significance. For PRL-2, seven 
(54%) out of 13 renal cell carcinomas showed a 
Figure 2. Levels of PRL-2 transcript in matched tumor and adjacent normal tissue pairs. The mean staining scores 
(SS) ± the SEM are shown. An asterisk indicates a statistically significant difference between the matched normal 
versus tumor tissue, as determined by paired t-tests (P < 0.05). Only hepatocellular carcinomas exhibited a statisti-
cally significant difference, with an approximately 2-fold increase in PRL-2 mRNA expression (P = 0.015, n = 4) in the 
tumors compared to normal liver tissue from the same subjects. 
Figure 3. Increased levels of PRL-1 mRNA in carcinomas of the stomach. A representative example shows that PRL-1 
message is expressed at significantly higher levels in a gastric adenocarcinoma (A) than in the normal gastric tissue 
from the same individual (B). Counterstained with hematoxylin. Magnification x 400. 
PRL-1 and PRL-2 expression in cancer 
 
 
90                                                                                                                Am J Transl Res 2012;4(1):83-101 
slight decrease in PRL-2 expression compared 
to the matched normal tissues (P = 0.049). 
Likewise, 38% of lung carcinomas, 40% of ovar-
ian and 60% of uterine carcinomas showed a 
small decrease in PRL-2 mRNA levels compared 
to corresponding normal tissues, but these 
changes were not found to be statistically sig-
nificant. Both PRL-1 and PRL-2 were also down-
regulated almost 2-fold in a single case of 
chronic lymphocytic leukemia compared to nor-
mal splenic B cells from the same patient, but, 
with only one tumor and matched normal sam-
ple in this case, statistical comparisons for this 
tumor type could not be made. No significant 
changes or trends in either PRL-1 or PRL-2 were 
observed in the overall mRNA expression be-
tween bladder, pancreatic, or prostate tumors 
and their respective matched normal adjacent 
tissues. 
 
PRL-1 and PRL-2 mRNA expression in tumor 
stroma and vasculature 
 
In addition to analyzing PRL-1 and PRL-2 ex-
pression patterns in multiple tumors and their 
normal cellular counterparts, expression of 
these transcripts was also compared between 
the stroma and vasculature of each subject’s 
tumor (Table 1) and normal tissue. PRL-1 mes-
sage was expressed in the vasculature of 100% 
of the normal tissues and 98% of the tumor 
tissues examined, with highly variable degree 
Figure 4. Decreased levels of PRL-1 mRNA in benign and malignant tumors of the breast. PRL-1 mRNA expression in 
(A) normal breast tissue and (B) a case matched, invasive ductal carcinoma of the breast. Counterstained with hema-
toxylin. Magnification x200. (C) Semi-quantitative analysis of PRL-1 mRNA expression in breast tumors (n = 15) and 
their matched normal adjacent tissues (n = 15). Horizontal lines represent the mean values for each group. Differ-
ences between the groups were found to be statistically significant by paired t-test (P = 0.0058). (D) PRL-1 mRNA 
expression in individual cases of matched tumor and adjacent normal tissue of the breast, showing a decrease in 
PRL-1 mRNA transcripts in 12/15 (80%) tumor tissues compared to their matched normal counterparts. Vertical lines 
connect matched tissue pairs from the same patient. 
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and intensity of staining. Only one specimen, a 
uterine adenocarcinoma, did not display PRL-1 
staining in the tumor vasculature, although very 
low levels of PRL-1 message were detectable in 
the glandular tissue of this tumor. In the stroma, 
PRL-1 was expressed in 95% of both the normal 
and tumor tissue sections examined, again with 
highly variable levels of expression from tissue 
to tissue. In most of the cases where an ab-
sence of PRL-1 staining was observed in the 
stroma, staining of all other structures within 
the tissue was also weak to absent. However, in 
2/4 normal breast tissues where PRL-1 mRNA 
expression was not detected in the stroma, PRL-
1 was expressed at moderate to high levels in 
the ductal epithelium. Likewise, in one 
squamous cell carcinoma of the lung which 
lacked PRL-1 expression in the stroma, PRL-1 
was expressed at moderate levels in the tumor 
epithelium. PRL-2 was expressed at moderate 
to high levels in the vasculature and stroma of 
all 190 cases examined. 
 
Similar to its upregulation in adenocarcinomas 
of the stomach, PRL-1 was also overexpressed 
in the stroma of each stomach tumor tissue 
examined (Figure 3), compared to the stroma of 
the corresponding normal adjacent tissues (P = 
0.0382). In the bladder, although no clear dif-
ferences in PRL expression existed between the 
normal and malignant urothelial cells, a signifi-
cant decrease in PRL-1 expression was ob-
served in both the bladder tumor vasculature (P 
= 0.0199) and the stroma surrounding the tu-
mor (P = 0.0182), as compared to these struc-
tures in the normal adjacent tissue samples. 
PRL-2 expression was also significantly de-
creased in the stroma of bladder carcinomas (P 
< 0.0001). Unlike PRL-1, PRL-2 expression was 
not significantly altered in the bladder tumor 
vasculature and displayed high levels of expres-
sion in all normal and tumor tissues. Levels of 
PRL-1 and PRL-2 message in the stroma and 
vasculature were not significantly different be-
tween the normal and tumor tissue pairs of any 
other tissue type. 
 
Expression of PRL-1 and PRL-2 transcripts in 
other human diseases 
 
In addition to carcinogenesis, protein tyrosine 
phosphatases have also been implicated in sus-
ceptibility to, or progression of, various other 
diseases, such as inflammatory and autoim-
mune diseases, neurodegenerative diseases, 
and cardiovascular disease. The PRL family 
member PRL-3 itself has been linked to a role in 
heart disease [5]. Therefore, in an attempt to 
analyze the relationship between PRL expres-
sion and various other disease states, PRL-1 
and PRL-2 mRNA expression were examined in 
the affected organs from patients with Alz-
heimer’s disease (n = 4), multiple sclerosis (n = 
2), crohn’s disease (n = 2), heart disease (n = 
7), coronary artery disease (n = 5), hepatitis (n = 
2), liver steatosis (n = 2), insulin-dependent 
diabetes mellitus (n = 6), and noninsulin-
dependent diabetes (n = 2). A student’s t-test 
was used to compare the mean staining scores 
between each set of diseased tissues and a set 
of histologically normal samples of the same 
tissue type, from different subjects.  
 
PRL-1 expression was again highly variable in all 
tissue types examined. PRL-2 message was 
expressed at moderate to high levels in all tis-
sues examined, with the exception of the brain 
and heart where, like PRL-1, its expression was 
quite variable (Table 1). In the small sample set 
analyzed here, no significant correlations were 
found between either PRL-1 or PRL-2 gene ex-
pression and any of the disease states exam-
ined. There did appear to be a trend toward in-
creased expression of PRL-1 in the brains of 
Alzheimer’s disease patients, where 75% of 
subjects had a SS > 150 in sections from the 
cerebral cortex and hippocampus, while 60% of 
normal subjects displayed SS < 50 in the same 
regions. However, considering the correlations 
with patient age discussed below, this trend is 
unlikely to be significant.  
 
Correlation between PRL-1 and PRL-2 mRNA 
expression and patient clinicopathological pa-
rameters 
 
To evaluate the clinical relevance of PRL-1 and 
PRL-2 expression in each tissue type examined, 
where possible (sufficient sample size and avail-
able patient data), a mixed model analysis of 
variance was used to analyze the relationship 
between the PRL staining scores and several 
clinicopathological features, including patient 
age, patient gender, tumor type, tumor subtype, 
tumor grade, and evidence of tumor metastasis 
(Tables 1 and 2). The intensity of PRL staining 
was also compared to the localization of the 
staining (whether nuclear, cytoplasmic, mem-
branous, or a combination of these) to examine 
any correlations between the two and the stain-
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Table 2. Patient and sample characteristics 
 
Tissue Type 
Total Number Gender Age (years) Tumor Grade Metastasis 
Samples Subjects Tumors M F Unk Mean Range High Intermediate Low Unk Y N Unk 
Bladder 16 10 9 4 6 0 71 60-81 6 3 0 0 1 8 0 
Brain 16 11 0 7 4 0 68 50-87 0 0 0 0 0 0 0 
Breast 35 20 17 0 20 0 58 38-85 12 4 1 0 7 6 4 
Cervix 6 6 1 0 6 0 40 30-44 0 1 0 0 0 1 0 
Colon 16 11 8 7 3 1 69 29-94 2 4 2 0 7 1 0 
Coronary Artery 5 5 0 4 1 0 57 37-78 0 0 0 0 0 0 0 
Heart 11 11 0 7 4 0 45 9-73 0 0 0 0 0 0 0 
Kidney 26 13 13 8 5 0 64 8-81 3 9 1 0 4 9 0 
Liver 16 12 4 5 7 0 54 1-75 0 0 4 0 0 0 4 
Lung 16 8 8 6 2 0 66 57-76 6 2 0 0 5 3 0 
Lymph Node 11 11 5 7 4 0 44 7-82 3 0 2 0 1 0 4 
Ovary 29 24 18 0 24 0 47 17-74 9 6 3 0 4 2 12 
Pancreas 38 28 14 10 9 9 47 3-79 8 5 0 1 6 0 8 
Prostate 41 28 28 28 0 0 63 51-75 14 10 4 0 2 3 23 
Skeletal Muscle 9 9 0 5 3 1 55 16-90 0 0 0 0 0 0 0 
Skin 4 4 1 1 1 2 52 51-52 0 0 1 0 0 1 0 
Spleen 12 11 2 8 3 0 41 13-71 0 0 1 1 0 0 2 
Stomach 10 5 5 4 1 0 72 46-85 4 1 0 0 4 0 1 
Testis 10 5 4 5 0 0 45 28-82 2 1 1 0 0 1 3 
Uterus 16 11 7 0 11 0 47 20-68 2 5 0 0 1 1 5 
Abbreviations: M = male; F = Female; Unk = Unknown; Y = Yes; N = No 
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ing localization was also individually compared 
to each of the various clinicopathological pa-
rameters. 
 
Levels of PRL-1 expression were found to be 
correlated with patient gender in neoplasms of 
the bladder (P = 0.006), where the male sub-
jects all exhibited significantly higher PRL levels 
than the female subjects (Figure 5). Expression 
levels of PRL-1 were also correlated with age in 
some tissue types. PRL-1 staining scores signifi-
cantly decreased with patient age in the skeletal 
muscle (P = 0.0031, Figure 6A) with very low 
expression levels attained after ages greater 
than 75 years. In contrast, PRL-1 strongly in-
creased with patient age in the brain (P = 
0.0252, Figure 6B) with sharp increases ob-
served in patients over the age of 60 years. In 
several tumor tissues, expression of PRL-1 and -
2 was significantly correlated with increasing 
tumor grade (increasing severity). In the ovary 
(Figure 7A), well-differentiated tumors ex-
pressed little to no PRL-1, while the less organ-
ized moderately-differentiated and poorly differ-
entiated tumors tended to express higher levels 
of the transcript (P = <0.0001). There were no 
well-differentiated carcinomas of the uterus in 
this study, however the poorly differentiated 
carcinomas expressed PRL-1 to a significantly 
higher degree than the moderately differenti-
ated uterine tumors (P = 0.0441). In the pros-
tate (Figure 7B), mean PRL-1 staining scores 
once more increased from the low grade, more 
differentiated tumors (Gleason grades 1-4) to 
the moderate grade tumors (Grades 5-7). How-
ever, the mean staining score again decreased 
in the more poorly differentiated, high grade 
(Grades 8-10) prostate tumors (P = 0.0126). In 
the testes, little to no PRL-2 expression was 
Figure 5. Gender specific expression of PRL-1 in the 
bladder. Semi-quantitative analysis of PRL-1 mRNA 
expression in male (n = 4) and female (n = 6) bladder 
tissues. Horizontal lines represent the mean values 
for each group. Differences between the two groups 
were found to be statistically significant by paired t-
test (P = 0.006). 
Figure 6. PRL-1 levels correlate with age in the skele-
tal muscle and brain. Semi-quantitative analysis 
showed that PRL-1 mRNA expression is negatively 
correlated with patient age in the skeletal muscle (A) 
and positively correlated with patient age in the brain 
(B). In both cases, mixed model analysis found the 
results to be statistically significant (P < 0.05). Brain 
specimens included tissue sections from the cere-
brum, hippocampus, substantia nigra, and cerebel-
lum. Different regions of the brain within the same 
individual displayed similar staining scores. The aver-
ages of these are represented. 
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observed in a well-differentiated germ cell tu-
mor, but high levels of PRL-2 were noted in both 
the moderately and poorly differentiated tu-
mors. In this tissue type, however, the number 
of samples in each category was too small to 
make any statistical comparisons. No clear as-
sociations were found between the intensity of 
PRL-1 or PRL-2 staining and the localization of 
the staining, nor between the localization of 
staining and any of the clinicopathological pa-
rameters examined. There were also no correla-
tions found, in this data set, between PRL-1 or -
2 expression and histologic subtype (e.g. clear 
cell vs. chromophobe cell type renal cell carcino-
mas of the kidney; adenocarcinoma vs. 
squamous cell non-small cell cancer of the lung, 
etc.) or with the presence or absence of local or 
distant metastases in any tumor type.  
 
Correlation of PRL mRNA and protein expres-
sion 
 
To examine the relationship between PRL-1 and 
PRL-2 expression at the mRNA and protein lev-
els, select cases from various tissue types and 
representing a wide range of expression levels 
via ISH (RNA) were also examined by IHC 
(protein). The degree of expression for each was 
scored, in a blinded fashion, by different indi-
viduals than those who scored the ISH results 
and the general levels of expression (high, me-
dium, or low) for the mRNA and protein were 
then compared. Using this approach it is not 
possible to compare absolute levels of RNA and 
protein, however, the relative changes seen in 
comparing various tissues and in comparing 
tumor and normal adjacent tissue can be use-
ful. In the majority of the 30 individual cases 
examined, PRL-1 mRNA and protein were ex-
pressed at similar relative levels (Figure 8A). In 
cases where the relative levels differed, staining 
was always more intense for PRL-1 mRNA than 
for the protein. In half of the same 30 tissue 
sections, PRL-2 mRNA staining intensity was 
also higher than that for PRL-2 protein (Figure 
8B). In the remaining half of cases, PRL-2 mRNA 
and protein appeared to be expressed at similar 
levels (37%) or the staining intensity for the pro-
tein was higher than that for the mRNA (13%).  
 
Within the 30 tissues probed by both ISH and 
IHC, there were 10 cases of paired tumor and 
normal adjacent tissue. Examination of these 
tissue pairs revealed that 6 of 10 cases for PRL-
1 (concordance = 60%) and 8 of 10 cases for 
PRL-2 (concordance = 80%) displayed the same 
Figure 7. Correlation of PRL-1 expression with tumor grade in the ovary and prostate. (A) Expression levels, in arbi-
trary units, of PRL-1 mRNA in human ovarian carcinomas (n = 18) of varying histologic grade. WD = well-
differentiated; MD = moderately differentiated; PD = poorly differentiated. (B) Expression levels, in arbitrary units, of 
PRL-1 mRNA in human prostate carcinomas (n = 28) of varying histologic grade. Horizontal lines represent the mean 
values for each group. In both tissue types, mixed model analysis found the results to be statistically significant (P < 
0.05). 
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trends of expression between the RNA and pro-
tein (e.g. both increased from the normal adja-
cent to the tumor tissue; both decreased from 
the normal adjacent to the tumor tissue; or nei-
ther changed). This suggested that there was 
good overall concordance between the RNA and 
protein results and that, in general, changes 
occurring at the mRNA level here are reflective 
of those occurring at the protein level. 
 
Discussion 
 
Accumulating evidence has implicated the PRL 
family of phosphatases as having an oncogenic 
role in human cancers [1, 4-7]. For example, it 
is now well known that PRL-3 expression is gen-
erally absent from normal adult human tissues, 
but frequently elevated in a variety of benign 
and malignant human neoplasms, where it may 
serve as a marker for tumor aggressiveness, 
increased tumor angiogenesis, and/or poor 
prognosis [9, 10, 12, 18, 21-27, 31, 35-37, 51]. 
Here, we used in situ hybridization to examine 
the expression of PRL-1 and PRL-2 in human 
malignancies with the aim of providing further 
insight into the role these two PRL family mem-
Figure 8. Comparison between mRNA and protein expression levels. PRL-1 (A) and PRL-2 (B) mRNA and protein ex-
pression levels were compared in a selection of 30 normal and tumor tissues from a variety of tissue types. Brackets 
indicate matched normal adjacent and tumor tissue pairs from the same individual. The plus sign in (A) denotes a 
sample for which no expression of PRL-1 protein was detected; however a small arbitrary value was assigned so that 
this sample would appear on the graph.  
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bers play in disease pathogenesis. 
 
PRL-1 and PRL-2 transcript levels were evalu-
ated across 285 normal, benign, and malignant 
tumor tissues, where both transcripts were 
found to be ubiquitously expressed. While PRL-2 
transcripts were consistently abundant across 
almost all specimens, PRL-1 expression was 
highly variable, not only between tissue types, 
but also from individual to individual within a 
given tissue type. Since such a high degree of 
patient-to-patient variability in PRL-1 expression 
could confound results when making compari-
sons between groups of unmatched normal and 
tumor tissues from different subjects, only 
matched tumor and normal adjacent tissue 
(NAT) samples taken from the same individuals 
were used to evaluate changes in PRL gene 
expression that might occur as a result of neo-
plastic transformation. Given current knowledge 
of the role that the PRL enzymes play in promot-
ing tumor development and progression, we 
hypothesized that PRL-1 and PRL-2 gene ex-
pression would each be upregulated in a num-
ber of tumor types relative to their matched nor-
mal tissue specimens. In accordance with this 
theory, PRL-1 and PRL-2 transcripts were each 
found to be significantly overexpressed in 100% 
of hepatocellular carcinomas (n = 4; p = 0.0052 
and 0.0152 respectively) and PRL-1 message 
was also significantly overexpressed in both the 
tumor (p = 0.01) and stroma (p = 0.0382) of 
100% of carcinomas from the stomach (n = 5). 
Increased levels of PRL-3 expression have previ-
ously been associated with the progression and 
metastasis of gastric and liver carcinomas [27, 
29-31, 34, 35, 39]. The current report is the 
first to suggest that PRL-1 and PRL-2 may also 
play an important role in the development and/
or progression of these tumor types. 
 
Surprisingly however, in other tissue types, a 
very different result was seen. In 100% of ovar-
ian (n=6; p = 0.0007), 80% of breast (n = 15; p 
= 0.0058), and 75% of lung (n = 8; p = 0.0148) 
tumors, PRL-1 levels were found to be signifi-
cantly lower in the neoplastic cells than in their 
matched, unaffected counterparts. Likewise, 
PRL-2 levels were significantly decreased in 
54% of carcinomas from the kidney (n = 13; p = 
0.049) relative to the matched normal controls. 
These results suggest that dysregulation of PRL-
1 and PRL-2 is a highly tissue specific event. 
This is consistent with observations of normal 
tissues, which have suggested that the PRL en-
zymes may be pleiotropic signaling molecules 
with a diversity of roles in different tissues and 
cell types [52, 53].  
 
In addition to a role in cancer, PTPs have been 
implicated in a growing number of human pa-
thologies, including cardiovascular, immunologi-
cal, infectious, neurological, and metabolic dis-
eases [44-47]. Therefore, we also sought to 
examine PRL-1 and PRL-2 mRNA expression in 
a small cohort of available samples from pa-
tients with various pathological conditions. In 
the panel of tissues examined here, PRL-1 and -
2 were widely expressed, however no significant 
correlations were found between PRL-1 or PRL-
2 expression levels and Alzheimer’s disease, 
multiple sclerosis, Crohn’s disease, coronary 
artery disease, heart disease, liver steatosis, 
hepatitis, or diabetes. 
 
To evaluate the extent to which deregulation of 
PRL expression might be related to known pa-
tient characteristics and clinicopathological vari-
ables, where possible, PRL-1 and -2 mRNA ex-
pression levels in each tissue type were corre-
lated to such features as patient age, patient 
gender, tumor histologic subtype, tumor grade, 
and presence/absence of tumor metastasis. In 
neoplasms of the bladder, expression levels of 
PRL-1 were found to be correlated to patient 
gender (p = 0.006), with male subjects display-
ing significantly higher PRL-1 transcript levels 
than female subjects. A similar trend toward 
increased expression in male subjects was also 
noted for PRL-2 in the lung (data not shown). 
Carter et al. [54] previously observed gender 
based differences of PRL-2 expression in rat 
brains, where PRL-2 mRNA was expressed at 3-
fold higher levels in the anterior pituitaries of 
male rats than in female rats. The current data 
thus support these prior observations that the 
PRL enzymes may play a sexually dimorphic role 
in select tissue types. Increased PRL-1 expres-
sion also correlated positively with patient age 
in the brain (p = 0.0252), yet negatively with 
patient age in the skeletal muscle (p = 0.0031). 
Advancing age of both the brain and skeletal 
muscle is associated with a decline in function 
as well as with several common accompanying 
changes in gene expression [55-57]. Interest-
ingly, in one transcriptional profiling study, 
aimed at identifying gene signatures for human 
aging in the frontal cortex [55], PRL-2 appeared 
on the list of genes which are significantly 
upregulated in the aging human brain. These 
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data suggest that both PRL-1 and PRL-2 may be 
putative players in, or be heavily influenced by, 
the aging process. Taken together, these results 
suggest that age and gender should be taken 
into account when evaluating sample to sample 
variations in PRL abundance and further under-
score the importance of using appropriately 
matched case controls in comparisons of PRL 
expression. 
 
PRL-1 or -2 mRNA levels were found to be asso-
ciated with tumor grade in some tissue types. 
Levels of PRL-1 in ovarian tumors increased 
significantly (p < 0.0001) in the moderate and 
poor grade tumors, relative to the low grade 
specimens, although this increase was to levels 
that remained appreciably lower than that seen 
in the NAT/normal specimens. A similar pattern 
of expression was observed for PRL-1 in the 
uterus and for PRL-2 in the testes. In the pros-
tate, a wide range of PRL-1 expression levels 
were observed across the histologically normal 
tissue specimens, as well as across cases of 
prostatic intraepithelial neoplasia (PIN) and be-
nign prostatic hyperplasia (BPH). However, in 
the prostate tumor specimens there was a sig-
nificant increase in PRL-1 expression going from 
the lower grade to the more moderate grade 
tumors (p = 0.0126), followed by a subsequent 
decrease in the higher grade tumors. These 
data suggest that alterations in PRL expression 
are an early event of carcinogenesis in many 
organ systems and that PRL-1 and/or PRL-2 
may serve as useful biomarkers for detection of 
tumorigenic lesions or for assessment of tumor 
aggressiveness in select tissue types. No corre-
lations were found between PRL-1 or -2 expres-
sion and any of the clinicopathological features 
examined in the breast, heart, kidney, liver, pan-
creas, spleen, or stomach. Nor was any associa-
tion seen between PRL expression and his-
tologic subtype or tumor metastasis in any of 
the tumor types examined. There were also no 
significant correlations between PRL-1 or PRL-2 
mRNA expression and clinical features related 
to colon cancer progression or metastasis, con-
sistent with a previous report examining PRL-1 
and PRL-2 protein in this tissue type [19].  
 
To determine whether changes seen at the RNA 
level are reflective of what is occurring in these 
tissues at the protein level, immunostaining 
results from anti-peptide, affinity-purified poly-
clonal antibodies specific to PRL-1 and PRL-2 
were directly compared to the ISH results in a 
subset of tissues from different tissue origin 
and demonstrating varied levels of PRL mRNA 
expression. Despite the presence of some varia-
tion between the absolute levels of PRL-1 or -2 
mRNA and protein in the analysis of individual 
cases, there was a clear correlation between 
the two with respect to the changes occurring 
during tumorigenesis. In comparisons of 
matched normal and tumor samples from the 
same patient, the mRNA and protein both exhib-
ited the same change (or conversely, lack of 
change) in expression 60% of the time for PRL-1 
and 80% of the time for PRL-2. When differ-
ences in the general expression levels (high, 
medium, low) between mRNA and protein oc-
curred, the mRNA was most often detected at 
higher levels than the protein. It is possible that, 
in each of these cases, changes occurring at the 
RNA level had not yet been reflected at the pro-
tein level. Alternatively, this could indicate post-
transcriptional control of these molecules, per-
haps through translational repression by PolyC-
RNA-binding protein 1 (PCBP1) or a similar 
molecule, as was recently described for PRL-3 
[58].  
 
Only a handful of studies have yet examined 
PRL-1 or PRL-2 expression in human malignan-
cies and even fewer have evaluated PRL-1 or 
PRL-2 in case matched normal and tumor sam-
ples. However, in general, the current results 
are in good agreement with previously pub-
lished reports. In the present study, PRL-1 and 
PRL-2 levels were consistently lower in primary 
tumors from the ovary, compared to paired nor-
mal tissues, suggesting that higher levels of PRL
-1 and -2 may be advantageous in this sample 
type. This is consistent with the observations of 
Reich et al. who showed that higher expression 
of PRL-1 or PRL-2 in ovarian cancer effusions 
correlated with better overall patient survival 
[59]. In contrast, the present data also show a 
relationship between increasing PRL-1 expres-
sion in ovarian carcinomas and advanced tumor 
grade. It is currently unclear how PRL-1 expres-
sion can be consistently downregulated in tu-
mor specimens and positively correlated with 
improved patient outcome, yet also show posi-
tive correlation to increased tumor aggressive-
ness. However, with respect to outcome, Reich 
et al. did not observe the same beneficial effect 
of PRL-1 and -2 on patient survival when the 
molecules were expressed in solid tumors. It is 
possible then that, in solid ovarian tumors, an 
initial knockdown of PRL-1 expression is re-
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quired for neoplastic transformation, following 
which enhanced levels of PRL-1 have no effect. 
Or PRL-1 could have an inhibitory effect on tu-
mor formation in the early stages of ovarian 
carcinogenesis, but play a tumor-promoting role 
in the latter stages. A similar dual, opposing role 
has previously been reported for other mole-
cules including Notch1 [60], MIC-1 [61], and for 
TGFơ [62], which has been shown to be an up-
stream regulator of PRL-3 [63]. In breast tissue, 
Hardy et al. [43] used real-time PCR to examine 
PRL-2 expression and found elevated levels of 
PRL-2 mRNA in primary breast tumors relative 
to matched normal tissue. The present data 
indicate a lack of change in PRL-2 expression 
between normal and neoplastic breast tissues, 
but PRL-2 levels in most breast tissues were 
extremely high and quite possibly at the limits of 
detection for the ISH system. In the pancreas, 
Stephens et al. [64] showed upregulation of 
PRL-1 and PRL-2 protein in 33% and 26% re-
spectively of pancreatic tumors in relation to 
matched NAT specimens. In the current study, 
similar results were noted for PRL-1 mRNA with 
increased expression of PRL-1 seen in 46% of 
pancreatic tumor specimens with respect to 
matched normal controls. However, in 36% of 
samples, the opposite effect was seen, with an 
increase of PRL-1 expression in the NAT tissue 
relative to tumor. And, in 18% of samples, no 
differences were seen between the two. In the 
current data for PRL-2, staining was always 
heavy and no detectable differences between 
PRL-2 expression in the tumor and NAT samples 
were observed.  
 
The results presented here show that, as with 
family member PRL-3, alterations in expression 
of PRL-1 and PRL-2 are a common event in hu-
man cancers; however, the nature of these al-
terations is highly tissue specific. In some tissue 
types, such as the stomach and liver, PRL-1 or -
2 expression associates with tumor promotion, 
whereas in other tissue types, like the ovary and 
lung, expression of these molecules may nor-
mally serve a protective function. The frequent 
deregulation of these molecules in human neo-
plasms suggests that they may be useful mark-
ers for cancer diagnosis. They may also serve as 
valuable therapeutic targets and/or indicators 
of increasing tumor severity in select tissue 
types. The mechanisms of PRL action and regu-
lation are currently poorly understood and the 
exact biological function of these molecules is 
unknown. Identifying the means by which their 
expression is regulated or the signaling path-
ways in which they act will be an important next 
step to provide insight into the pleiotropic role 
these molecules play in the carcinogenic proc-
ess. Characterization of the PRL signaling path-
ways may also enhance our understanding of 
the observed gender and age related variations 
in PRL-1 expression. The present results help to 
expand our current understanding of the differ-
ences that exist between PRL-1 and PRL-2 lev-
els in normal tissues and human malignancies 
and should facilitate larger scale retrospective 
or prospective studies examining the relevance 
of PRL-1 or PRL-2 in clinical cancer as well as in 
other human pathologies. 
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CHAPTER 1.  INTRODUCTION 
1.1 Phosphorylation in Signal Transduction 
Modification of proteins through reversible phosphorylation is the most 
common form of post-translational modification, with a majority of the proteins in 
a mammalian cell being subject to phosphorylation at one or more sites (Khoury, 
Baliban, & Floudas, 2011; Olsen et al., 2006).  Addition and removal of 
phosphate groups regulates protein function through modulation of enzymatic 
activity, protein stability, cellular localization, and/or protein-protein interactions 
(Johnson, 2009; Varedi, Ventura, Merajver, & Lin, 2010).  It plays critical roles in 
controlling cellular responses to diverse signals and directs such fundamental 
biological processes as cell growth, differentiation, metabolism, adhesion, 
migration, cell cycle regulation, cell-to-cell communication, gene transcription and 
translation, apoptosis, ion channel activity, neural function, and immune 
response (Reviewed in:  Cans, Mangano, Barila, Neubauer, & Superti-Furga, 
2000; den Hertog, 2003; Hunter, 1998; Julien, Dube, Hardy, & Tremblay, 2011).  
The phosphorylation state of cellular proteins is governed by the interplay 
between protein kinase (PK) and protein phosphatase enzymes that, respectively, 
attach or remove phosphate groups from their target proteins.  Initially, it was 
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believed that protein kinases were the key regulators of phosphorylation-
dependent signaling and that protein phosphatases constituted a small group of 
non-specific scavenger enzymes, which simply functioned as “off” switches to 
counteract PK effects.  It is now appreciated, however, that protein phosphatases 
are a highly regulated and functionally diverse, multi-member family of enzymes, 
which carry out specific and active roles in cell signaling.  Moreover, members of 
the protein phosphatase family can, not only, negatively regulate the actions of 
the PKs, but also potentiate PK signaling, depending on the cellular context.  
Also, while aberrant phosphorylation due to PK malfunction plays a well 
established role in the pathogenesis of many human diseases, most notably 
human cancers, it has become apparent that deregulation of phosphatase 
function can also lead to disease development and progression.  Abnormal 
protein phosphatase activity has now been linked to a variety of human afflictions, 
including cancer, diabetes, metabolic syndromes, immune dysfunction, 
cardiovascular disease, Alzheimer’s and Parkinson’s diseases (Reviewed by:  
Braithwaite, Voronkov, Stock, & Mouradian, 2012; Cheng, Uetani, Lampron, & 
Tremblay, 2005; Ducruet, Vogt, Wipf, & Lazo, 2005; Julien et al., 2011; Tautz, 
Pellecchia, & Mustelin, 2006). 
 
1.2 The Phosphatase Superfamilies 
Proteins can be phosphorylated on nine amino acid residues (serine, 
threonine, tyrosine, cysteine, arginine, lysine, aspartate, glutamate, and histidine) 
(Hunter, 2004), but in eukaryotic cells, serine, threonine, and tyrosine 
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phosphorylation predominate (Olsen et al., 2006).  The enzymes that 
dephosphorylate these (serine, threonine, and tyrosine) residues can be broadly 
classified into three major families (Table 1.1), based on structure, substrate 
preference, catalytic mechanism, and active site sequence (Moorhead, Trinkle-
Mulcahy, & Ulke-Lemee, 2007; Mustelin, 2007).  The first family consists of the 
protein serine/threonine phosphatases; a group of metalloenzymes that require 
metal ion cofactors for catalytic function and specifically dephosphorylate 
phosphoserine (pSer) and phosphothreonine (pThr) residues.  The second major 
group is the protein tyrosine phosphatase (PTP) superfamily, which is defined by 
the active site sequence signature motif C(X)5R (using one letter amino acid 
code with X representing any amino acid).  This family includes enzymes with 
substrate preferences for phosphotyrosine (pTyr) alone (“classical PTPs”), as 
well as a unique class of enzymes, termed dual specificity phosphatases (DSPs), 
with the ability to dephosphorylate pTyr, pSer, pThr and/or non-proteinaceous 
substrates.  The third family is made up of the Asp-based phosphatases, which 
are characterized by a catalytic motif containing two aspartate residues 
(DXDXT/V).  This is the most newly identified and recently classified family of 
phosphatase.  Some of the molecules in this group, such as FCP1 [TFIIF-
associating C-terminal domain (CTD) phosphatase] and SCP1 (Small CTD 
Phosphatase) exclusively dephosphorylate phosphoserine and are often 
classified with the serine/threonine phosphatase family, while others, like the 
Eyes absent transcription factors (Eya1-4) exhibit tyrosine-specific phosphatase 
activity and are frequently categorized within the PTP family. 
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1.2.1 The Serine/Threonine Phosphatase Superfamily 
As the family name implies, the protein serine/threonine phosphatases 
specifically catalyze cleavage of phosphate from serine and threonine residues.  
All members of this superfamily appear to be metalloenzymes whose catalytic 
mechanism requires the presence of a dinuclear metal ion cofactor at the active 
site (Cohen, 2004; W. P. Taylor & Widlanski, 1995).  The family can be divided 
into two further groups known as the PPP (phosphoprotein phosphatase) and 
PPM (protein phosphatase, Mg2+/Mn2+-dependent) families. 
The PPP family consists of the prototypic member Protein Phosphatase 1 
(PP1), as well as six other members named PP2A, PP2B (Calcineurin), and PP4-
7.  All family members share high sequence homology within a ~280 residue 
stretch of amino acids that contains a conserved catalytic domain and three 
characteristic sequence motifs (-GDXHG-, -GDXVDRG-, and -GNHE-) (Barford, 
1996; Moorhead, De Wever, Templeton, & Kerk, 2009).  Each PPP represents a 
unique catalytic subunit capable of forming diverse multimeric holoenzyme 
complexes with a wide variety of regulatory, scaffolding, targeting, and inhibitory 
proteins.  It is these interacting partners, rather than the catalytic phosphatase 
subunits themselves, that drive the subcellular localization and substrate 
specificity of the PPP enzymes (Hubbard & Cohen, 1993; Pawson & Scott, 1997; 
Virshup & Shenolikar, 2009). 
The PPM family includes PP2C, pyruvate dehydrogenase phosphatase 
(PDP), and other “PP2C-like” proteins (Cohen, 2004).  Although no sequence 
homology exists between the PPM and PPP family members, structural 
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comparisons indicate an analogous catalytic mechanism, but with the PPM 
members specifically requiring Mg2+ or Mn2+ as their metal ion cofactors (Barford, 
1996).  The PPM phosphatases are thought to act as monomers and do not have 
known regulatory subunits.  Instead, their protein sequences display a variety of 
domains that may confer added specificity and function. 
 
1.2.2 The Protein Tyrosine Phosphatase Superfamily 
The defining characteristic for members of the protein tyrosine 
phosphatase (PTP) superfamily, is the presence of a conserved active site 
signature sequence, C(X)5R, in the catalytic domain, referred to as the PTP 
Signature Motif.  An invariant cysteine residue within the signature motif resides 
at the bottom of a catalytic pocket and is absolutely required for PTP 
phosphatase activity (Yuvaniyama, Denu, Dixon, & Saper, 1996).  Due to the 
unique environment of the PTP active site, this cysteine has an unusually low 
pKa (between 4.5 and 5.5, compared to a pKa of ~8.5 for a typical cysteine 
residue) (Z. Y. Zhang & Dixon, 1993).  This low dissociation constant favors the 
function of the cysteine as a nucleophile, initiating attack on its phosphosubstrate 
targets.  Other essential residues in the PTP sequence include an aspartic acid 
residue, outside the signature motif, that acts as a general acid/base (proton 
donor/proton acceptor) during the enzymatic reaction and an invariant arginine, 
in the active site motif, that functions in substrate binding and stabilization of the  
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transition state during phosphoryl displacement (Denu & Dixon, 1998).  Unlike 
the serine/threonine phosphatases, the PTPs do not require metal ions for 
catalysis. 
The general structures of the PTP catalytic domains are highly conserved; 
therefore specificity of PTP function is often gained through the presence of 
additional regulatory sequences or domains in the regions flanking the catalytic 
core.  PTP regulatory domains can either directly modify catalytic activity or 
indirectly influence activity, by targeting the enzymes to particular subcellular 
locations, substrates, or interacting partners.  Some examples of regulatory 
sequences/domains associated with particular PTP subgroups are listed in Table 
1.1.  Such domains include, but are not limited to:  SH2 domains, which target 
molecules to phosphotyrosine containing proteins; SH3 domains which bind 
proline-rich sequences in other proteins; 14-3-3 domains for binding 
phosphoserine residues in other molecules; nuclear localization signals (NLS) 
and nuclear export signals (NES) to direct import into and export from the 
nucleus; and N-terminal myristoylation sequences, CAAX isoprenylation motifs, 
FERM, C2, and pleckstrin homology (PH) domains for targeting molecules to 
intracellular membranes or the plasma membrane (Alonso et al., 2004; Hunter, 
1998).  PTPs can also be modified and regulated post-translationally via a variety 
of other mechanisms, including phosphorylation, proteolysis, sumoylation, 
dimerization, and oxidation (den Hertog, Ostman, & Bohmer, 2008; Ostman, 
Frijhoff, Sandin, & Bohmer, 2011; Soulsby & Bennett, 2009). 
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Based on sequence and structure, the PTP enzymes are divided into 
three distinct classes (Table 1.1).  The Class I PTPs comprise the so called 
“classical PTPs”, which exclusively dephosphorylate phosphotyrosine residues.  
This same class also includes the dual specificity phosphatase (DSP) enzymes, 
whose family members vary considerably in substrate specificity.  The Class II 
PTP family is represented by the small low molecular weight protein tyrosine 
phosphatases (LMPTP).  And Class III is made up of three important cell cycle 
regulators (CDC25A, CDC25B, CDC25C).  Between these three classes, more 
than 100 human PTPs have now been identified and several of them have 
demonstrated crucial roles in normal cellular homeostasis, as well as in 
pathogenesis of a variety of diseases (Cheng et al., 2005; Ducruet et al., 2005; 
Goldstein, 2002; Julien et al., 2011; Ostman, Hellberg, & Bohmer, 2006; Pulido & 
Hooft van Huijsduijnen, 2008; Tautz et al., 2006).  Despite this, many of the PTP 
enzymes are largely uncharacterized and their function and biological substrates 
remain unknown.  Further efforts toward defining PTP function will be crucial to 
understanding the biology of these enzymes and could ultimately lead to the 
development of novel therapies for disease treatment.
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Table 1.1 The Phosphatase Superfamilies and Subfamilies 
 
1Abbreviations:  BRCT, Breast Cancer gene 1 (BRCA1) C-Terminus; C2, Protein kinase C, conserved region 2; CA, Carbonic Anhydrase-like; CAAX, Cysteine-Aliphatic-Aliphatic-Any amino acid 
(Isoprenylation motif); CBD, Carbohydrate Binding Domain; CH2, Cdc25 Homology region 2; ColBD, Collagen Binding Domain; F-actin, Filamentous actin binding domain; FERM, Band 
4.1/Ezrin/Radixin/Moesin Homology; FN, Fibronectin-like; FYVE, Fab1/Yotb/Vac1p/Early endosomal antigen-1 homology;  Ig, Immunoglobulin-like; KIM, Kinase Interaction Motif; MAM, meprin, 
A2, RPTPµ homology; NLS, Nuclear Export Signal; PDZ, Postsynaptic density-95/Discs large/ZO1 homology; PH, Pleckstrin Homology; SH2, Src Homology 2; SH3, Src Homology 3; SH4, Src 
Homology 4 (myristoylation signal).  *Although this is a large superfamily of enzymes, so far only chronophin and Eya1-4 have been demonstrated to have protein phosphatase activity. 
Information included in this table was gathered from the references cited in the text for each phosphatase family..
Phosphatase Family/Subgroup 
Number of 
Members   Example Members Substrate Specificity 
Example 
Regulatory Domains1 
I.  Ser/Thr Phosphatase Superfamily 31    
     A.  PPP Family 13   PP1, PP2A, PP2B   pSer, pThr      Multi Regulatory Subunits 
     B.  PPM Family 18   PP2C   pSer, pThr      ColBD 
     
II.  PTP Superfamily 104    
     A.  Class I Cys-based PTPs 99    
           1.  Classical PTPs 38    
                 a.  RPTPs 21   CD45, PTPα, LAR   pTyr      FN, CA, Ig, MAM 
                 b.  NRPTPs 17   PTP1B, TCPTP, SHP1   pTyr      SH2, FERM, PDZ 
           2.  DSPs 61    
                 a.  MKPs 11   MKP1-5, MKP7, PAC-1   pTyr, pThr      CH2, KIM 
                 b.  Slingshots 3   SSH1, SSH2, SSH3   pSer      14-3-3, F-actin, SH3 
                 c.  PRLs 3   PRL-1, PRL-2, PRL-3   pTyr, Phosphoinositides      CAAX Box 
                 d.  Atypical DSPs 19   VHR, PIR1, STYX   pTyr, pThr, mRNA      SH4, CBD 
                 e.  CDC14s  4   CDC14A, CDC14B, KAP   pSer, PThr      NES 
                 f.   PTENs 5   PTEN, TPIP, Tensin   D3-Phosphoinositides      C2, PDZ 
                 g.  Myotubularins 16   MTM1, MTMR1-15   D3-Phosphoinositides      C2, PH, FYVE, PDZ 
     B.  Class II Cys-based PTPs 2   LMPTP, SSU72   pTyr, pSer  
     C.  Class III Cys-based PTPs          3   CDC25A, CDC25B,  CDC25C   pTyr, pThr  
     
III.  Asp-based Phosphatases 13    
     A.  FCP/SCP Family 8    
           1.  FCP1 1   FCP1   pSer      BRCT 
           2.  SCP 3   SCP1-3   pSer  
           3.  FCP/SCP-like 4   TIMM50, Dullard   pSer, pThr  
     B.  HAD Family   5*   EYA1-4, Chronophin   pTyr, pSer  
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1.2.2.1 The Class I Cysteine-Based PTPs:  Classical PTPs 
The Class I cysteine (Cys)-based PTP family, at 99 members, is by far the 
largest class of PTP.  Class I members are divided into two groups:  The 
classical PTPs and the DSPs.  These are then further divided into several 
subgroups on the basis of sequence homology, overall structure, and substrate 
specificity (Alonso et al., 2004; Moorhead et al., 2007). 
The 38 classical PTPs share extensive sequence similarity over an 
approximately 240-280 amino acid catalytic domain.  They are strictly specific for 
hydrolysis of pTyr residues in protein substrates, due to the presence of a deep 
(9Å) substrate binding pocket that selectively accommodates the longer 
phosphotyrosine sidechains.  Unlike pTyr, the pSer and pThr side chains are too 
short to reach the catalytic residues at the base of the pocket (Tonks & Neel, 
2001).  CD45 and PTP1B are the prototypic examples of the two types of 
classical PTPs, which include transmembrane, receptor-like PTPs (RPTPs) and 
non-membrane spanning, cytoplasmic enzymes, referred to as intracellular PTPs 
or non-receptor PTPs (NRPTPs). 
The 21 RPTP enzymes are all type I, membrane spanning proteins, 
consisting of a variable extracellular domain, a single membrane spanning region, 
and an intracellular segment containing one or two catalytic domains.  In most 
cases, where two catalytic domains exist, the membrane proximal domain is 
responsible for the majority of catalytic activity, while the membrane distal 
domain is either inactive or only weakly active.  The function of the low activity 
domain is unknown, but it has been postulated to play a role in recruitment of 
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interacting molecules or in regulation of the more active domain (Blanchetot, 
Tertoolen, Overvoorde, & den Hertog, 2002; Krueger et al., 2003).  The 
extracellular regions of RPTPs vary greatly in length and composition and can be 
used to further separate the RPTPs into eight smaller groups.  Though the 
specific features of the extracellular segments differ between subgroups, almost 
all resemble the extracellular domains of cell adhesion molecules and include 
adhesion-type domains, such as meprin/A5/PTPmu (MAM) domains, fibronectin 
type-III-like repeats, and immunoglobulin-like domains (Paul & Lombroso, 2003; 
Tonks, 2006).  The functional significance of these domains in the context of the 
PTPs remains an area of active study, but it appears that they may serve to 
promote homophilic interactions with identical molecules on adjacent cells 
(Aricescu et al., 2006; Cismasiu, Denes, Reilander, Michel, & Szedlacsek, 2004).  
Such interactions would allow the RPTPs to serve as bifunctional molecules, 
directly linking cell adhesion to intracellular signaling pathways. 
The 17 NRPTPs all contain a single catalytic domain and are localized 
intracellularly.  As with the RPTPs, the regions flanking the catalytic domain of 
NRPTPs are highly variable and contain sequences that, in this case, serve to 
regulate enzymatic activity, enhance interactions with other proteins, or direct the 
molecules to specific subcellular locations.  For example, PTP1B and T-Cell PTP 
(TC-PTP) are NRPTPs that each contains a 20 amino acid hydrophobic 
sequence at their C-termini, which directs them to the cytoplasmic surface of the 
endoplasmic reticulum (Bourdeau, Dube, & Tremblay, 2005; Simoncic, McGlade, 
& Tremblay, 2006).  This specific localization of the intracellular PTP enzymes 
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serves a regulatory function, either bringing the phosphatases in contact with or 
restricting them from their cellular substrates. 
 
1.2.2.2 The Class I Cysteine-based PTPs:  DSPs 
In addition to the classical PTPs, the Class I family of Cys-based PTPs 
also contains a heterogeneous group of enzymes referred to as dual specificity 
phosphatases (DSPs), because the founding members of this class had the 
capability of dephosphorylating both pTyr and pSer/pThr residues.  DSPs have 
now been identified that can also target non-proteinaceous substrates, including 
phosphatidylinositol phosphates (Maehama & Dixon, 1998; G. S. Taylor, 
Maehama, & Dixon, 2000) and mRNA (Deshpande, Takagi, Hao, Buratowski, & 
Charbonneau, 1999), making this the most diverse class of phosphatase 
enzymes in terms of substrate specificity.  The ability of the DSPs to 
accommodate phospho-substrates other than pTyr lies in the presence of a 
shallower and often wider active site cleft for the DSPs than for the Tyr-specific 
PTPs.  These structural differences permit, for example, the shorter side chains 
of Ser/Thr residues or the bulkier structure of the inositol ring, to access the DSP 
catalytic core (J. O. Lee et al., 1999; Yuvaniyama et al., 1996). 
DSP enzymes are intracellular phosphatases containing a single catalytic 
domain that is smaller than the conserved domain of the classical tyrosine 
phosphatases, but includes the PTP signature motif.  Outside the catalytic 
domain, DSP subfamilies bear little resemblance to one another or to any other 
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PTPs.  Even so, all DSPs maintain similar secondary and tertiary structures and 
utilize the same basic catalytic mechanism as the tyrosine-specific PTPs (Denu & 
Dixon, 1998).  There are a total of 61 DSP family members and these can be 
further divided into 7 subfamilies on the basis of sequence similarity as well as 
the presence of specific non-catalytic domain motifs (Alonso et al., 2004; 
Moorhead et al., 2007).  The DSP family members include:  11 MPKs (Bermudez, 
Pages, & Gimond, 2010), 3 Slingshots (Y. Wang, Shibasaki, & Mizuno, 2005), 3 
PRLs (Bessette, Qiu, & Pallen, 2008), 4 CDC14s (Mocciaro & Schiebel, 2010; 
Poon & Hunter, 1995), 19 Atypical DSPs (Bayon & Alonso, 2010), 5 PTENs (J. O. 
Lee et al., 1999; Leslie & Downes, 2004), and 16 Myotubularins (Kerk & 
Moorhead, 2010).  The DSP phosphatase family is nicely reviewed by Alonso et 
al. (Alonso et al., 2004) and Patterson et al. (Patterson, Brummer, O'Brien, & 
Daly, 2009). 
 
1.2.2.3 The Class II Cysteine-based PTPs 
The Class II enzymes are low molecular weight molecules (~18kDa) that 
contain a minimal PTP signature sequence, which is uniquely found in the 
extreme N-terminus of the molecule.  Aside from the PTP signature motif, these 
enzymes have little recognizable homology to other PTPs and share some 
resemblance with bacterial arsenate reductase enzymes (Alonso et al., 2004; 
Mustelin et al., 1999).  Until recently, the Class II PTP family contained only one 
human member, known as low molecular weight PTP (LMPTP).  However, a 
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second low molecular weight PTP (Ssu72) has recently been identified and, 
based on overall structure and location of the catalytic domain, was proposed to 
belong to the LMPTP class (Y. Zhang & Zhang, 2011).  While LMPTP displays 
specificity for pTyr residues, this new, structurally related, family member 
preferentially dephosphorylates phosphoserine residues.  These also exhibit 
highly distinct roles from one another.  LMPTP is involved in control of 
cytoskeletal rearrangements and cell adhesion (Chiarugi et al., 2000), whereas 
Ssu72 is a transcriptional regulator that physically interacts with transcription 
initiation and termination complexes and dephosphorylates the C-terminal 
domain of RNA polymerase II (Ganem et al., 2003; Y. Zhang & Zhang, 2011). 
 
1.2.2.4 The Class III Cysteine-based PTPs 
The Class III family of PTP consists of three cell cycle regulators, CDC25A, 
CDC25B, and CDC25C.  These have dual specificity for pTyr and pThr residues 
and are responsible for removing inhibitory phosphates from Threonine-Tyrosine 
motifs at the N-termini of cyclin dependent kinase (Cdk) enzymes.  The CDC25s 
thus act as positive regulators of cell division by dephosphorylating and activating 
the Cdks, favoring cell cycle progression.  The CDC25 enzymes share sequence 
similarity to bacterial rhodanese enzymes and are thought to have evolved from 
rhodanese-like proteins (Alonso et al., 2004; Hofmann, Bucher, & Kajava, 1998). 
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1.2.3 The Asp-based Phosphatase Superfamily 
The Asp-based phosphatases carry out dephosphorylation through an 
unusual mechanism that involves the use of conserved aspartic acid residues in 
the active site motif (DXDXT/V) to catalyze nucleophilic attack of the phosphate 
group in a metal-dependent fashion (Moorhead et al., 2007; Rayapureddi et al., 
2003).  The family is often further divided into the FCP/SCP and HAD (haloacid 
dehalogenase) families, but both groups share the same conserved active site 
sequence and catalytic mechanism.  The HAD superfamily is actually a much 
larger family of enzymes, which includes dehalogenases, ATPases, 
phosphomutases, and phosphonatases (Burroughs, Allen, Dunaway-Mariano, & 
Aravind, 2006) but, thus far, only five members have been demonstrated to have 
phosphatase activity.  These include four Eyes absent (Eya) proteins which also 
serve as transcription factors with major roles in development (Rayapureddi et al., 
2003) and chronophin which dephosphorylates and activates cofilin, an actin 
depolymerizing factor essential for cytoskeletal reorganization (Gohla, Birkenfeld, 
& Bokoch, 2005). 
 
1.3 The PRL Family of Dual Specificity Phosphatase 
There are three PRL phosphatases, PRL-1 (also known as PTP4A1 and 
PTPCAAX1), PRL-2 (also known as PTP4A, PTP4A2, PTPCAAX2, HH13, and OV-1), 
and PRL-3 (also known as PTP4A3) that constitute a unique DSP subfamily of 
unknown biological function.  They were initially characterized and named, 
Phosphatase of Regenerating Liver, for the identification of PRL-1 as an 
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immediate early gene induced in proliferating rat liver during hepatic regeneration 
(Diamond, Cressman, Laz, Abrams, & Taub, 1994; Mohn et al., 1991).  Each 
PRL enzyme is encoded by a different gene, with the PRL-1 gene found on 
chromosome 6q12, the PRL-2 gene on chromosome 1p35, and the PRL-3 gene 
mapping to chromosome 8q24.3 (Montagna, Serova, Sylla, Mattei, & Lenoir, 
1996; Y. Peng, Genin, Spinner, Diamond, & Taub, 1998; B. J. Stephens, Han, 
Gokhale, & Von Hoff, 2005).  This family of enzymes is distinctive in that they are 
among the smallest of the PTPs, having apparent molecular masses of 20-22kDa 
and consisting primarily of a centrally located catalytic domain that contains the 
canonical C(X)5R PTP active site signature sequence (Diamond et al., 1994; 
Matter et al., 2001; Sun et al., 2005).  The PRL family members are further 
characterized by the presence of a C-terminal CAAX consensus motif, which 
targets them for post-translational modification by farnesylation (Cates et al., 
1996).  This post-translational modification is unprecedented among PTPs and is 
critical to the subcellular localization and biological activity of the PRL enzymes 
(Si, Zeng, Ng, Hong, & Pallen, 2001; J. Wang, Kirby, & Herbst, 2002; Zeng et al., 
2000).  The CAAX box is immediately preceded by a polybasic stretch of amino 
acids, which resembles a bipartite nuclear localization signal, but may instead 
serve in facilitating membrane interactions (Pascaru et al., 2009; Sun et al., 
2007). 
Also unique among PTPs is the ability of PRL-1 and PRL-3 to 
homotrimerize within the cell (Sun et al., 2007; Sun et al., 2005).  PRL trimers are 
structured such that the active sites are facing outward and the C-terminal 
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farnesylation sites are clustered together on one face, ideally positioned to allow 
cooperative membrane binding (Jeong et al., 2005).  This structure is likely to 
augment membrane attachment and may also represent a novel mechanism of 
PTP regulation, given that disruption of trimer formation was found to inhibit the 
effects of PRL-1 signaling (Sun et al., 2007). 
Aside from these hallmarks and a few predicted protein phosphorylation 
sites (Diamond et al., 1994; Zeng, Hong, & Tan, 1998), the PRL enzymes lack 
any other apparent regulatory sequences or domains.  A schematic 
representation of the PRL primary structure is displayed in Figure 1.1. 
 
 
Figure 1.1.  Schematic Diagram of Mammalian PRL Protein Primary 
Structure 
The catalytic domain is responsible for the enzymatic activity of the PTPs and 
contains invariant cysteine (C), arginine (R), and aspartate (D) residues.  The 
polybasic and prenylation motifs are important determinants of the intracellular 
localization of the proteins.  The CAAX box sequence is CCIQ for PRL-1, 
CCVQ for PRL-2, and CCVM for PRL-3.  This figure was created using 
information from the various references cited in this section of the text. 
 
The full length PRL-1 and PRL-3 proteins are each 173 amino acids in 
length, while the PRL-2 sequence is slightly shorter at 167 amino acids (Kozlov 
et al., 2004).  All three molecules share a high degree of amino acid sequence 
similarity with 87% identity between PRL-1 and PRL-2, 76% identity between 
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PRL-1 and PRL-3, and 75% identity between PRL-2 and PRL-3 (Zeng et al., 
1998).  In addition, the enzymes are well conserved between species with 
virtually 100% homology across all characterized mammalian proteins for each 
PRL (Yarovinsky et al., 2000; Yuan, Chen, Lin, Zhang, & Zhang, 2007).  The 
mammalian enzymes also share at least 50% identity with PRLs found in the fruit 
fly, Drosophila melanogaster; the nematode Caenorhabditis elegans; and the 
protozoan parasite Trypanosoma cruzi.  In all organisms, the active site 
sequence is 100% identical and the C-terminal prenylation motif is highly 
conserved (Cuevas, Rohloff, Sanchez, & Docampo, 2005; Kozlov et al., 2004; Y. 
Peng et al., 1998).  Such remarkable conservation across species suggests an 
important evolutionary function for this family of enzymes. 
Although the three PRL family members are highly similar to one another, 
they bear very little resemblance to other known PTPs.  Sequence alignment 
suggest their closest relatives to be two DSPs; the cell cycle regulator CDC14 
and the lipid phosphatase/tumor suppressor PTEN, each with which the PRLs 
share less than 30% sequence identity (Kim et al., 2004; Zeng et al., 1998).  In 
contrast, structural alignments show the closest PRL relatives to be VHR (an 
atypical DSP), MKP, KAP (a member of the CDC14 family), and PTEN (Jeong et 
al., 2005; Kozlov et al., 2004).  Little is currently known about the specific 
functions of the PRL enzymes and the signal transduction pathways in which 
they operate, however, their high degree of conservation, as well as their 
similarity to several DSPs involved in cell cycle and cell growth control, suggests 
a key role for these PTPs in cellular regulation. 
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1.3.1 Biological Function of the PRL Enzymes 
Little is currently known about the specific functions of the PRL enzymes 
or the signal transduction pathways in which they participate.  Recent evidence, 
however, suggests that these may be multifaceted molecules involved in a 
number of diverse biological processes. 
The first identified PRL family member, PRL-1, was initially described as 
an immediate early gene induced as part of the proliferative response in 
regenerating rat liver after partial hepatectomy (Diamond et al., 1994; Mohn et al., 
1991).  PRL-1 expression has since been associated with a number of other 
proliferating cell types, including mitogen stimulated NIH 3T3 mouse fibroblasts 
(Diamond et al., 1994), mitogen or hepatocarcinogen treated mouse liver 
(Columbano et al., 1997), cytokine-stimulated human myeloma cells (Fagerli et 
al., 2008), hormone treated rat reproductive tissues (McLean, Friel, Pouchnik, & 
Griswold, 2002; Schmidt, de Avila, & McLean, 2006), rat cerebral cortex following 
transient forebrain ischemia (Takano et al., 1996), developing tissues of diverse 
origin (Diamond et al., 1996; Haber, Naji, Cressman, & Taub, 1995; W. Kong, 
Swain, Li, & Diamond, 2000; Rundle & Kappen, 1999), and multiple human tumor 
cell lines (Diamond et al., 1994; Fagerli et al., 2008; Hardy, Wong, Muller, Park, 
& Tremblay, 2010; Rouleau et al., 2006; Schwering et al., 2003; J. Wang et al., 
2002).  The up-regulation of PRL-1 in these instances suggested that it may have 
a positive role in the growth response.  Reinforcing this notion, Wang et al. (2002) 
found that PRL-1 phosphatase activity is required for normal progression of cells 
through mitosis and Werner et al. (2003) showed that overexpression of either 
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PRL-1 or PRL-2 in D27 pancreatic ductal epithelial cells leads to accelerated 
entry into S phase.  Similar results have since been shown for PRL-3 in mouse 
embryonic fibroblasts (MEFs; Basak et al., 2008) and SW480 colon carcinoma 
cells (Semba, Mizuuchi, & Yokozaki, 2010).   
Further supporting a role for the PRL enzymes in promotion of cell growth 
and survival, researchers have shown that overexpression of any of the three 
PRL enzymes in non-tumorigenic cells can lead to enhanced cell growth, altered 
morphology concomitant with cellular transformation, and tumor formation upon 
injection of transformed cells into athymic nude mice (Cates et al., 1996; 
Diamond et al., 1994; Liang et al., 2007; Matter et al., 2001; Semba et al., 2010; 
X. Wu et al., 2004).  Overexpression of either PRL-1 in HeLa cells (Min et al., 
2009) or of PRL-3 in an esophageal squamous cell carcinoma (ESCC) cell line 
(Ooki et al., 2010) also causes inhibition of 5-Fluorouracil treatment-induced 
apoptosis.  In addition, cells overexpressing PRL-2 exhibit reduced requirements 
for the growth factors erythropoietin and interleukin-3 (Akiyama, Dhavan, & Yi, 
2010). 
Although all of these results support a positive role for the PRL 
phosphatases in cell growth regulation, surprisingly, initial analysis of the normal 
tissue expression of PRL transcripts revealed that all three genes were 
predominantly expressed in skeletal muscle, a terminally differentiated tissue 
characterized by permanent withdrawal from the cell cycle (Diamond et al., 1994; 
Zeng et al., 1998).  In addition, further analysis revealed an abundance of PRL 
transcripts in the brain (PRL-1) (Diamond et al., 1994; Takano et al., 1996) and 
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cardiac muscle (PRL-3) (Matter et al., 2001) and high levels of PRL-1 protein in 
the zymogen cells of the stomach and surface enterocytes of the gastrointestinal 
tract (W. Kong et al., 2000), all tissues/cell types that are considered to have little 
to no capacity for proliferation.  In intestinal epithelium, which contains both 
proliferating and terminally differentiated cells, PRL-1 and PRL-3 were found only 
in the differentiated enterocyte villi and not in the proliferating crypt cells 
(Diamond et al., 1996; Zeng et al., 2000).  Consistent with this pattern of 
expression, PRL-1 mRNA was also exclusively expressed in Caco-2 cells when 
they were in a differentiated state, but not when they were in a proliferative state 
(Diamond et al., 1996).  Furthermore, Guo et al. (2003) found the PRL-1 gene to 
be significantly overexpressed in more differentiated parous breast tissues as 
compared to proliferative nulliparous breast tissues.  Finally, Scarloto et al. (2000) 
demonstrated up-regulation of PRL-1 mRNA in oligodendroglial progenitor cells 
that are capable of terminal differentiation in comparison to immature 
oligodendroglial progenitors, which do not terminally differentiate.  Taken 
together, these results suggest a dual role for the PRL enzymes, where they 
could have growth-associated functions under some circumstances and 
differentiation-associated functions in others.  In keeping with this notion, PRL-1 
mRNA was found to be expressed predominantly in proliferating chondrocytes 
during early development of mouse embryos, but was localized primarily to 
differentiated, hypertrophic chondrocytes in later stages of mouse development 
(Rundle & Kappen, 1999). 
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It is possible that cellular responses to PRL signaling may differ depending 
on the cell or tissue type.  Another possibility is that the amplitude and duration of 
the PRL signal may govern its action.  Along these lines, Diamond et al. reported 
that small levels of PRL-1 overexpression in NIH 3T3 cells resulted in a 
transformed phenotype, while higher levels of PRL-1 caused growth cessation 
(Diamond et al., 1994; Diamond et al., 1996).  Similarly, Basak et al. (2008) 
found that basal expression of PRL-3 in mouse embryonic fibroblasts enhanced 
cell survival signaling through the PI3K/Akt pathway, whereas high levels of PRL-
3 overexpression in the same cell line decreased PI3K/Akt activity and resulted in 
cell cycle arrest.  These results were the first to demonstrate the critical dose-
sensitive effects of PRL expression on cell cycle progression and to highlight the 
importance of properly maintaining basal PRL levels in order to ensure normal 
cell cycle control. 
Overall, the specific actions of the PRLs in various cell types require 
further clarification.  An enhanced understanding of the specific tissue expression 
patterns of the PRL genes and analysis of the signaling pathways in which they 
operate may help to further elucidate their natural biological functions. 
 
1.3.2 Subcellular Localization of the PRL Proteins 
The subcellular localization of a protein can sometimes provide clues 
regarding its biological function; however, reports on the intracellular localization 
of the PRL enzymes have been quite varied.  PRL-1 was originally described as 
a nuclear protein by Diamond et al. (1994) who showed that NIH 3T3 cells 
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transiently or stably transfected with the enzyme displayed PRL-1 
immunoreactivity in both the nucleus and cytoplasm, with the most predominant 
staining in the nucleus.  The same authors found almost exclusively nuclear 
PRL-1 staining in proliferating rat liver and rat small intestine (Diamond et al., 
1996).  Subsequent studies, on the other hand, have largely described the PRLs 
as membrane associated proteins.  In transiently transfected CHO cells and 
stably transfected NIH 3T3 cells, Zeng et al. (2000) found all three PRLs to 
localize to the plasma membrane and the early endosome.  They later extended 
their study to show that, in stably transfected CHO cells, plasma membrane 
associated PRL-3 is concentrated at membrane structures such as ruffles, 
protrusions, and vacuolar-like membrane extensions (Zeng et al., 2003).  All of 
these structures have been affiliated with cell movement and invasion, thus 
supporting a role for the PRL phosphatases in those processes. 
PRL localization to membrane structures, whether it be the plasma 
membrane, early endosome membrane, nuclear membrane, or the surface of the 
endoplasmic reticulum, has also been observed in transiently transfected 
HEK293 cells, HeLa cells, SW480 colon adenocarcinoma cells, HCT-116 
colorectal cancer cells, COS-7 cells, and mouse embryonic fibroblasts (Bardelli 
et al., 2003; Basak et al., 2008; Fiordalisi, Keller, & Cox, 2006; Jeong et al., 2005; 
Sun et al., 2007; Sun et al., 2005; J. Wang et al., 2002; X. Wu et al., 2004).  Each 
of these studies, though, used overexpression systems, which have the 
possibility to result in non-physiological localization of a protein.  For this reason, 
J. Wang et al. (2002) decided to examine the subcellular localization of 
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endogenously expressed PRL-1.  In this analysis, they found the cellular 
distribution of PRL-1 to be cell-cycle dependent, with localization to the ER in 
non-mitotic HeLa cells and localization to the centrosomes and spindle apparatus 
in mitotic HeLa cells.  Fagerli et al. (2008) also showed a cell-cycle dependent 
shuttling of endogenous PRL-3 between cellular compartments.  In the OH-2 
multiple myeloma cell line, PRL-3 was localized in the nucleus during G0/G1 
phase, but then partially redistributed to the cytoplasm throughout the S and G2M 
phases.  In addition, Wu et al. (2004) noted that, in PRL-3 overexpressing COS-7 
cells, PRL-3 was concentrated in the perinuclear region during interphase and 
became enriched at the metaphase plate during mitosis.  Such data support a 
role for the PRL enzymes in cell cycle regulation.  
Reports of endogenous PRL expression in other cell lines and in tissue 
sections have been highly incongruous, with some cell or tissue types displaying 
exclusively or primarily cytoplasmic expression (Dai, Lu, Shou, & Li, 2009; 
Fagerli et al., 2008; L. Kong, Li, Wang, Liu, & Sun, 2007; B. Stephens, Han, 
Hostetter, Demeure, & Von Hoff, 2008; Yarovinsky et al., 2000), some showing 
only membrane localization (Ooki et al., 2010), and others exhibiting a 
combination of these (J. Li et al., 2005; Ruan et al., 2010; Y. Wang et al., 2007).  
These data seem to suggest that PRL subcellular localization may be cell or 
tissue type specific; however, reports within a single tissue type also vary.  In a 
single study, PRL-3 expression was predominantly cytoplasmic in 64% of 
cervical cancer cases and mostly nuclear in another 36% of cervical cancer 
specimens.  Interestingly, the number of cases exhibiting cytoplasmic staining 
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was increased in lymph node metastases from these same tumors (Ma & Li, 
2011).  Also, in a study of developing and adult rat tissues, a number of tissues 
that showed evidence of cytoplasmic PRL-1 staining early in tissue development 
(e.g. lung) displayed more highly nuclear patterns of PRL-1 localization in the 
mature tissues (W. Kong et al., 2000). 
Taken together, these data indicate that PRL distribution inside the cell 
may be influenced by a number of different factors, including cell cycle phase, 
tissue or cell type, tumor grade, and/or developmental stage.  Post-translational 
modification also appears to be a factor, because treatment of cells with FTIs or 
expression of farnesylation site mutants in non-mitotic cells causes PRLs to 
dissociate from membrane structures and redistribute to the cytoplasm and/or 
nucleus (Fiordalisi et al., 2006; Jeong et al., 2005; Pascaru et al., 2009; Si et al., 
2001; Sun et al., 2005; J. Wang et al., 2002; Zeng et al., 2000).  Additional 
investigation will be required to further understand the dynamics of PRL 
subcellular localization and to elucidate the mechanisms by which the PRLs are 
translocated within the cell. 
 
1.3.3 PRL Expression in Normal Tissues 
As with the subcellular localization of a protein, the tissue and cell type 
specificity of a molecule can sometimes provide clues that contribute to 
understanding gene function.  Multi-tissue analysis has revealed PRL-3 
expression in normal tissues to be somewhat restricted, whereas PRL-1 and 
PRL-2 appear to be more widely distributed.  The various normal tissues where 
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either positive or negative PRL expression has been observed are listed in 
Appendix A, Tables A.1 and A.2 respectively. 
In normal human and rodent tissues, PRL-3 is preferentially enriched in 
the heart and skeletal muscle, although it is also expressed at moderate levels in 
the pancreas and at low levels in various other organs (K. Guo et al., 2006; 
Matter et al., 2001; X. Wu et al., 2004; Zeng et al., 1998; Zeng et al., 2000).  
PRL-1 expression has been found at differing levels in the bulk of tissues 
examined to date with heaviest expression noted in the rat brain, rat skeletal 
muscle (Diamond et al., 1994; Takano et al., 1996) and human reproductive 
tissue, small intestine, lung, (Dumaual, Sandusky, Crowell, & Randall, 2006) and 
developing liver (Gjorloff-Wingren et al., 2000; K. Guo et al., 2006).  Tissues with 
the lowest PRL-1 expression levels include human thyroid and kidney, as well as 
adult liver tissues from both human and rat (Diamond et al., 1994; Dumaual et al., 
2006; K. Guo et al., 2006).  Like PRL-1, the tissue distribution of PRL-2 is nearly 
ubiquitous.  The heaviest expression of PRL-2 has been noted in rodent skeletal 
muscle and heart (Carter, 1998; Zeng et al., 1998) and in human skeletal muscle 
and thymus (Dumaual et al., 2006; K. Guo et al., 2006; Montagna, Serova, Sylla, 
Feunteun, & Lenoir, 1995; Z. Zhao et al., 1996).  Most tissues express PRL-2 at 
moderate to high levels, but lower levels of PRL-2 have been observed in human 
adrenal tissues (Dumaual et al., 2006; K. Guo et al., 2006) and in human and 
mouse spleen and cerebral cortex (Dumaual et al., 2006; K. Guo et al., 2006; 
Zeng et al., 1998).  Expression of each of the PRLs in normal tissues seems to 
correlate most often with a differentiated state. 
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Although widely expressed, PRL-1 and PRL-2 do display very specific 
patterns of expression.  For example, despite the fact that PRL-1 is expressed 
heavily in regenerating liver tissue, its expression is low to undetectable in most 
normal, quiescent liver samples (Diamond et al., 1994; Diamond et al., 1996; 
Dumaual et al., 2006; K. Guo et al., 2006; Haber et al., 1995; W. Kong et al., 
2000).  Additionally, PRL-1 expression in the primate retina exhibits selectivity in 
cone-type expression, with PRL-1 protein levels restricted to the red and green 
light-sensitive photoreceptors and no PRL-1 expression in the blue light-sensitive 
photoreceptors (Yarovinsky et al., 2000).  In the human and rat gastrointestinal 
tract, PRL-1 exhibits a horizontal gradient of expression with highest levels noted 
in the proximal small intestine and lower levels in the more distal small intestine 
and colon (Dumaual et al., 2006; W. Kong et al., 2000).  There is also a gradient 
of PRL expression along the crypt-villus axis of the small intestine, where 
significantly greater expression of PRL-1 and PRL-3 protein is present in the 
apical villus enterocytes than in the basal crypt enterocytes.  Moreover, PRL-2 is 
expressed at significantly higher levels in the anterior pituitary glands of male 
Sprague-Dawley rats than in female rats, possibly suggesting a sexually 
dimorphic role for PRL-2 in anterior pituitary function (Carter, 1998).  In a related 
manner, increased expression of PRL-1 mRNA was detected in rat Sertoli cells 
responding to follicule stimulating hormone (FSH) and in rat ovary upon 
stimulation with FSH and luteinizing hormone (McLean et al., 2002; Schmidt et 
al., 2006), raising the possibility that PRL expression may be influenced by the 
levels of specific hormones in particular organs or tissues. 
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Overall, while the mechanisms behind differential expression of the PRLs 
remain unclear, the near ubiquitous expression of PRL-1 and PRL-2 in both 
developing and adult tissues confirms an important cellular role for these 
molecules and indicates that they may function in regulation of basic 
physiological processes that are common to many tissues and cell types.  The 
differential expression patterns seen between the three PRL molecules implies 
that, although the PRL family members are highly homologous, they are likely to 
be differentially regulated and may even serve divergent functions from one 
another. 
 
1.3.4 PRL Expression and Cancer 
Recent interest in the PRL family members relates to their relationship 
with cellular proliferation, as accumulating evidence points to a role for these 
proteins in the promotion of tumorigenesis and metastasis.  Functional studies 
have shown that overexpression of PRL-1, -2, or -3 in varied cell types can lead 
to rapid cellular growth and a transformed phenotype, as evidenced by altered 
cell morphology, loss of contact inhibition, and gain of anchorage-independent 
growth, in culture (Cates et al., 1996; Diamond et al., 1994; Hwang et al., 2012; 
Matter et al., 2001; Werner et al., 2003).  In addition, ectopic expression of any of 
the PRL phosphatases leads to enhanced cell motility and invasiveness and the 
ability to induce metastatic tumor formation in athymic nude mice (Akiyama et al., 
2010; Fiordalisi et al., 2006; K. Guo et al., 2004; Hardy et al., 2010; Luo, Liang, & 
Zhang, 2009; Mizuuchi, Semba, Kodama, & Yokozaki, 2009; Nakashima & Lazo, 
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2010; Sun et al., 2007; Y. Wang & Lazo, 2012; X. Wu et al., 2004; Zeng et al., 
2003).  Conversely, down-regulation of endogenous PRL by RNA interference 
(shRNA, siRNA, miRNA) or blockage of PRL activity with small molecule 
inhibitors or PRL-specific antibodies has the opposite effect, reducing cell growth, 
abolishing cell invasion, and migration in vitro, and suppressing metastatic tumor 
formation in vivo (Achiwa & Lazo, 2007; Ahn et al., 2006; Daouti et al., 2008; 
Fiordalisi et al., 2006; K. Guo, Tang, Tan, Wang, & Zeng, 2008; Hardy et al., 
2010; Kato et al., 2004; Z. Li et al., 2006; Matsukawa et al., 2010; Ming, Liu, Gu, 
Qiu, & Wang, 2009; Mizuuchi et al., 2009; Nakashima & Lazo, 2010; Ooki et al., 
2010; Polato et al., 2005; Qian et al., 2007; B. Stephens et al., 2008; Sun et al., 
2007; L. Wang et al., 2009; Y. Wang & Lazo, 2012; Z. Wang et al., 2008; X. Wu 
et al., 2004; Zhou, Wang, Lu, Li, & Ding, 2009).  Expression of a catalytically 
inactive PRL mutant, a CAAX domain mutant, or a polybasic domain mutant also 
inhibits the ability of PRL expressing cells to undergo cellular transformation and 
acquisition of metastatic properties (Fiordalisi et al., 2006; K. Guo et al., 2004; 
Matter et al., 2001; McParland et al., 2011; Nakashima & Lazo, 2010; Sun et al., 
2007; Y. Wang & Lazo, 2012; X. Wu et al., 2004; Zeng et al., 2003).  Collectively, 
these data suggest that PRL expression plays a causal role in tumor cell growth 
and metastatic progression, rather than simply being a consequence of these 
events.  Moreover, the phosphatase activity and membrane-binding properties of 
the PRLs are each required for this functionality. 
The most well studied PRL family member, in relation to human cancer, is 
PRL-3.  Widespread interest in this gene was generated after Saha et al. (2001) 
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identified 144 gene transcripts which were up-regulated in liver metastases 
compared to their matched primary colorectal tumors and discovered that, of 38 
transcripts chosen for further analysis, PRL-3 was the only one consistently 
overexpressed in all 18 metastatic lesions examined.  Bardelli et al. (2003) later 
found that PRL-3 mRNA overexpression was not limited to colorectal cancer 
(CRC) metastases to the liver, but that PRL-3 is expressed highly in all 
metastatic lesions derived from CRCs, regardless of the metastatic site (liver, 
lung, brain, or ovary).  A gradient in PRL-3 expression was noted, with low levels 
of PRL-3 message in normal colorectal epithelium, intermediate levels in the 
primary CRC tumors, and high expression in each of the liver metastases.  A 
similar trend of increasing PRL-3 expression with increased tumor 
aggressiveness has since been observed for a number of different tumor types 
(Fagerli et al., 2008; Guzinska-Ustymowicz, Pryczynicz, & Kemona, 2009; Hao et 
al., 2010; L. Kong et al., 2007; Z. Li et al., 2006; Lou, Liu, Guo, Lei, & Li, 2012; 
Ma & Li, 2011; Miskad et al., 2007; Miskad, Semba, Kato, & Yokozaki, 2004; 
Ooki et al., 2009; Radke et al., 2006; Schwering et al., 2003; Y. Wang et al., 
2007; Y. Xu et al., 2010; Zhou et al., 2009).  In addition, PRL-3 up-regulation has 
now been linked to such clinical parameters as tumor size, tumor grade/stage, 
lymphatic invasion, venous invasion, presence and extent of metastasis, and/or 
poor patient prognosis, not only in colon/colorectal carcinomas (Hatate et al., 
2008; Kato et al., 2004; Mollevi et al., 2008; L. Peng, Ning, Meng, & Shou, 2004; 
Semba et al., 2010; Y. Wang et al., 2007; Xing et al., 2009), but also in cervical 
(Ma & Li, 2011), ovarian (Polato et al., 2005; T. Ren et al., 2009), breast (Hao et 
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al., 2010; Radke et al., 2006; L. Wang et al., 2006), gastric (Dai et al., 2009; Z. R. 
Li et al., 2007; Miskad et al., 2007; Ooki et al., 2011; Ooki et al., 2009; Pryczynicz, 
Guzinska-Ustymowicz, Chang, Kisluk, & Kemona, 2010; Z. Wang et al., 2009), 
non-small cell lung (Ming et al., 2009) esophageal (Y. Q. Liu, Li, Lou, & Lei, 2008; 
Ooki et al., 2010), nasopharyngeal (Zhou et al., 2009), hepatocellular (W. B. 
Zhao, Li, Liu, Zhang, & Wang, 2008) and bile duct (Y. Xu et al., 2010) cancers.  
These data suggest up-regulated PRL-3 expression as a potential prognostic 
indicator of disease aggressiveness and clinical outcome for multiple tumor types. 
Several lines of evidence also point to a role for PRL-3 in angiogenesis, a 
key process that is required for invasive tumor growth and metastasis. For 
instance, PRL-3 expression is found in the endothelial cells of multiple tumor 
types and, in many cases, its expression is up-regulated in tumor endothelium 
with respect to the endothelium of histologically normal tissues (Bardelli et al., 
2003; L. Kong et al., 2007; Miskad et al., 2007; Radke et al., 2006; St Croix et al., 
2000).  High PRL-3 expression is significantly correlated with increased venous 
and/or lymphatic invasion in human colorectal (Hatate et al., 2008; Kato et al., 
2004; Mollevi et al., 2008; Semba et al., 2010), gastric (Z. R. Li et al., 2007; 
Miskad et al., 2007; Ooki et al., 2009), cervical (Ma & Li, 2011), bile duct (Y. Xu 
et al., 2010), and hepatocellular (W. B. Zhao et al., 2008) carcinomas.  PRL-3 is 
capable of enhancing endothelial cell migration in vitro (Parker et al., 2004) and 
of recruiting endothelial cells and promoting vascular formation both in vitro and 
in vivo (K. Guo et al., 2006; Parker et al., 2004; Rouleau et al., 2006).  In contrast, 
disruption of PRL-3 activity or expression suppresses vascular formation (J. Xu 
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et al., 2011).  PRL-3 expressing cells injected into the tail veins of nude mice can 
form highly vascularized micro and macrometastatic solid tumors which can 
invade already established, host organ blood vessels (K. Guo et al., 2004).  
Furthermore, PRL-3 expression is positively associated with the expression of 
several pro-angiogenic factors, such as VEGF, VEGF-C, and ETAR (Ming et al., 
2009; Radke et al., 2006) and negatively associated with anti-angiogenic factors 
like IL-4 (K. Guo et al., 2006).  Finally, in human umbilical vein endothelial cells 
(HUVECs), VEGF signaling can directly induce PRL-3 transcription (J. Xu et al., 
2011).  These results have led to speculation that PRL-3 could facilitate the 
spread of cancer cells by promoting establishment of tumor microvasculature, a 
requirement for tumor cell expansion.  In this capacity, PRL-3 overexpression 
may be a prerequisite for the development of both local and distant metastatic 
lesions. 
In contrast to PRL-3, PRL-1 and PRL-2 are much less well studied in 
human malignancies, however there is also evidence linking these two family 
members to malignant transformation and disease progression.  High PRL-1 
mRNA levels are found in a variety of tumor cell lines and expression levels in 
these tumor lines are often higher than those in the respective, non-tumorigenic 
lines.  PRL-1 mRNA is associated with advancing disease in esophageal 
squamous cell carcinoma (ESCC) patient samples, where it is found at higher 
levels in ESCC tumor samples than in normal esophageal mucosa and is 
expressed more frequently in ESCC cases with lymph node metastasis than in 
those without (Y. Q. Liu et al., 2008).  PRL-1 is also more highly expressed in 
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carcinomas of the stomach and liver than in the matching normal tissues 
(Dumaual et al., 2011).  As with PRL-3, PRL-1 and PRL-2 are both expressed 
heavily in lymph node metastases from colonic adenocarcinomas, but expressed 
at lower levels in the primary adenocarcinomas, and often undetectable in 
colonic adenomas or normal colon sections (Y. Wang et al., 2007).  Both PRL-1 
and PRL-2, but not PRL-3 are up-regulated in pancreatic cancer cell lines and 
pancreatic tumor tissues as compared to normal pancreatic tissue (B. Stephens 
et al., 2008).  Moreover, PRL-2 has been associated with tumor progression in 
breast (Hardy et al., 2010), lung (Hwang et al., 2012), liver (Dumaual et al., 2011) 
and prostate (Q. Wang, Holmes, Powell, Lu, & Waxman, 2002) carcinomas. 
The potential pathogenic role of all three PRLs in the progression of 
human malignancies makes these enzymes attractive targets for development of 
novel anti-cancer therapeutics.  However, little is currently known about the 
specific functions of these enzymes or the signal transduction pathways in which 
they participate.  Identification of the signaling pathways in which the PRLs act is 
an important next step to understanding the biology of these proteins and the role 
they play in the carcinogenic process. 
 
1.3.5 PRL Substrates and Signaling Pathways 
Researchers are just beginning to learn about some of the cellular players 
with which the PRL phosphatases interact.  Nevertheless, there is a lot of work 
remaining to be done in this arena before the cellular functions of the PRL 
enzymes are fully understood.  The following sections summarize our current 
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knowledge of the signaling pathways, substrates, and interacting partners of 
each of the PRL family members.  In combination, an overwhelming amount of 
evidence suggests that the PRL molecules leverage multiple signaling pathways, 
which exert effects mainly on the cell cycle, cytoskeleton, and cellular adhesions 
to promote cell proliferation and cell survival and favor the acquisition of invasive 
and metastatic properties. 
 
1.3.5.1 PRL-1 Substrates and Signaling Pathways 
No true in vivo substrates for PRL-1 have yet been identified; however 
PRL-1 does exhibit tyrosine phosphatase activity in vitro (Diamond et al., 1994; 
Yu et al., 2007).  To date, it shows strongest activity as an autophosphatase, but 
it can also slightly dephosphorylate the proto-oncogenic kinase c-Src (Diamond 
et al., 1994) and the transcription factor ATF-7 (Peters et al., 2001).  Although 
immunoprecipitation experiments have failed to find a direct interaction between 
PRL-1 and c-Src (Luo et al., 2009), a physical association between PRL-1 and 
ATF-7 has been confirmed (Peters et al., 2001).  ATF-7 (activating transcription 
factor-7; also called ATF-5 or ATF-X) is a basic leucine zipper transcription factor 
which can bind cAMP-response (CRE) elements in DNA and functions as a pro-
survival factor.  Though PRL-1 may, in part, exert its effects through this 
molecule, the nature of the PRL-1/ATF-7 relationship has not been further 
characterized. 
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A number of other PRL-1 binding partners have also been identified.  
PRL-1 and PRL-3, but not PRL-2 can directly interact with α-tubulin, one of the 
major components of cytoskeletal microtubules (J. Wang et al., 2002).  This 
association may be required for localization of PRL-1 to the spindle apparatus 
during mitosis, as suggested by J. Wang et al. (2002).  Alternatively, it could be 
involved in the trafficking of PRL-1 from the ER to the plasma membrane, as has 
been proposed for K-Ras4B, which, like PRL-1, contains both a post-translational 
farnesylation motif and a C-terminal polybasic domain (Fu & Casey, 1999; Silvius, 
2002).  An association between the C-terminal polybasic domain of PRL-1 and 
several phosphoinositides has also been discovered and may contribute to PRL-
1 membrane targeting (Sun et al., 2007).  This relationship is completely non-
enzymatic as, unlike PRL-3, PRL-1 does not demonstrate any lipid phosphatase 
activity (Sun et al., 2007; Yu et al., 2007).  Other binding partners identified for 
PRL-1 include PRL-2 (Ewing et al., 2007); TNFα-induced protein 8 (TNFAIP8), a 
suppressor of TNF-mediated apoptosis (Ewing et al., 2007); the Rho GTPase 
activating protein (GAP) p115 RhoGAP (Bai et al., 2011); and FKBP38 (peptidyl 
prolyl cis/trans isomerase FK506-binding protein 38), a molecule which may 
promote proteosomal degradation of the PRL enzymes (M. S. Choi et al., 2011). 
Among these PRL-1 interacting partners, p115 RhoGap (gene symbol 
ARHGAP4) was the most recently identified (Bai et al., 2011).  This molecule is a 
member of the Slit-Robo (Sr) GAP family of molecules and normally functions to 
inhibit cell motility through the down-regulation of RhoA and MEKK1, two 
important mediators of actin cytoskeleton reorganization and cell migration.  Bai 
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et al. (2011) have proposed that a direct physical interaction between PRL-1 and 
p115 RhoGAP may augment cell motility by both preventing p115 RhoGAP from 
promoting RhoA deactivation and blocking its inhibitory binding of MEKK1.  Not 
only does PRL-1 co-immunoprecipitate with p115 RhoGAP, but it also co-
immunoprecipitates with all other SrGAP family members, with which it interacts 
through their SH3 domains (Bai et al., 2011). 
PRL-1 has also been implicated in a number of other signaling pathways 
which may contribute to its role in malignant transformation.  Several studies 
indicate that PRL-1 may enhance proliferation by coordinately decreasing 
expression of negative cell cycle regulators and increasing expression of positive 
cell cycle regulators.  For instance, overexpression of PRL-1 leads to down-
regulation of the Cdk inhibitor p21cip1/waf1 and up-regulation of the S phase cyclin, 
Cyclin A, resulting in increased activation of Cdk2 and stimulating early entry into 
S phase (Hwang et al., 2012; Werner et al., 2003).  PRL-1 also participates as 
part of a negative feedback loop, whereby the tumor suppressor p53 can directly 
activate transcription of PRL-1, which in turn negatively regulates p53 protein 
stability through two independent pathways.  Upon up-regulation by p53, PRL-1 
signaling induces transcription of the early growth response (Egr-1 and Egr-2) 
transcription factors, which subsequently induce expression of the p53 induced 
protein with a RING-H2 domain (PIRH2) ubiquitin ligase.  PRL-1 also leverages 
the PI3K/Akt signaling pathway to mediate activation of the mouse double minute 
2 (Mdm2) ubiquitin ligase.  These events culminate in the ubiquitination and 
proteosomal degradation of p53 and the inhibition of p53-mediated apoptosis 
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(Min et al., 2010; Min et al., 2009).  Additionally, this causes suppression of the 
ability of p53 to transactivate both its own promoter and the p21 promoter, 
providing a potential mechanism for the independently observed PRL-1-mediated 
reductions in p21cip1/waf1 levels (Hwang et al., 2012; Min et al., 2009; Werner et al., 
2003). 
Recent studies have identified a relationship between the PRLs and 
various components of the integrin-mediated cell signaling pathways.  In 
response to extracellular matrix proteins, cell surface receptors, known as 
integrins, use multiple cytoplasmic signaling pathways to regulate G1 phase 
cyclins and Cdks and to initiate re-arrangements in the actin cytoskeleton.  This 
dynamic remodeling of the cytoskeleton is central to cell motility, invasion, and 
metastasis (Assoian, 1997; Reddig & Juliano, 2005; Schwartz & Assoian, 2001).  
Some of the most well known players in the integrin-mediated cell adhesion 
signaling pathways include members of the Src family of tyrosine kinases (SFKs), 
Rho family small GTPases, and focal adhesion complex-related proteins 
(Huveneers & Danen, 2009).  Several independent researchers have now 
identified a relationship between PRL-1 and a variety of these integrin-responsive 
players.  For example, up-regulation of PRL-1 leads to phosphorylation and 
activation of Src kinase and focal adhesion kinase (FAK), which results in 
phosphorylation/activation of the focal adhesion adaptor protein p130Cas and the 
mitogen activated protein kinase (MAPK) known as extracellular signal-regulated 
kinase (ERK).  Src-induced ERK activation, in turn, can cause AP-1 and Sp1 
mediated transcriptional up-regulation of the MMP2 and MMP9 
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metalloproteinases, which are able to facilitate invasion by degrading the 
basement membrane and extracellular matrix (Luo et al., 2009).  Overexpression 
of PRL-1 can also lead to increased RhoA and RhoC activity (Fiordalisi et al., 
2006; Nakashima & Lazo, 2010) and decreased expression of the adhesion 
molecules E-cadherin and vinculin (Nakashima & Lazo, 2010).  In contrast, 
down-regulation of PRL-1 has been shown to cause a decrease in c-Src and 
p130Cas protein levels, a decrease in levels of the focal adhesion component 
paxillin, and decreased activation of the Rho family proteins Rac1 and Cdc42 
(Achiwa & Lazo, 2007).  Taken together, these data suggest that PRL-1 may, at 
least in part, regulate cell proliferation, invasion, motility, and metastasis through 
downstream effects on both the cell cycle and on mediators of actin cytoskeleton 
organization and cell adhesion. 
 
1.3.5.2 PRL-2 Substrates and Signaling Pathways 
To date, only one confirmed PRL-2 binding partner has been found.  PRL-
2 and not PRL-1 or PRL-3, can directly interact with the beta subunit of the Rab 
geranylgeranyltransferase GGTII (βGGTII) in a manner that is dependent both on 
PRL-2 farnesylation and on a region just upstream of the C-terminal CAAX box 
that differs in sequence from other PRL family members (Hardy et al., 2010; Si et 
al., 2001).  GGTII functions as an α/β heterodimer and binding of αGGTII and 
PRL-2 to the β subunit are mutually exclusive events.  PRL-2 binding causes 
displacement of the α subunit and decreases GGTII activity, suggesting that 
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GGTII function may be regulated by alterations in intracellular αGGTII/PRL-2 
ratios (Si et al., 2001).  Although PRL-2 can be weakly geranylgeranylated in 
vitro, it is normally farnesylated in vivo and is not a substrate of GGTII (Cates et 
al., 1996; Si et al., 2001).  The only known GGTII substrates are the Rab proteins, 
monomeric G-proteins that are involved in regulation of membrane trafficking and 
vesicle movement (Stenmark & Olkkonen, 2001), therefore PRL-2 may indirectly 
function in control of Rab protein prenylation.  Given that numerous Rab proteins 
are localized to endocytic pathways (Agola, Jim, Ward, Basuray, & Wandinger-
Ness, 2011; Simpson & Jones, 2005), the presence of PRL-2 in the early 
endosome (Zeng et al., 2000) would position it well for a role in Rab protein 
regulation. 
A large-scale protein-protein interaction mapping study by Ewing et al. 
(2007), used immunoprecipitation combined with mass spectrometry (MS) to 
identify several additional proteins as potential PRL-2 interaction partners.  
These included PRL-1; farnesyltransferase subunits α and β (FNTA, FNTB); 
Ephrin Type B Receptor 2 (EPHB2), a molecule involved in neuronal cell 
signaling; the negative regulator of apoptosis TNFAIP8; upstream transcription 
factor 2 (USF2), a helix-loop-helix transcription factor; cyclin M3 (CNNM3), a 
putative metal transporter; and cyclin M4 (CNNM4), another putative metal 
transporter, with a possible role in sensory neuron function or retinal function.  
The interaction of PRL-2 with a molecule thought to be involved in cell signaling  
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within the retina is especially intriguing given that the expression patterns of PRL-
1 have also implicated it with a role in retinal cell signaling (Yarovinsky et al., 
2000; Yu et al., 2007). 
Various cellular changes that occur downstream, following alterations in 
PRL-2 expression, support the role for this family member in promoting cellular 
proliferation, cell survival and cell movement.  Similar to PRL-1, PRL-2 is 
involved in cell cycle regulation by promoting the G1 to S transition through down-
regulation of p21cip1/waf1, which subsequently results in up-regulation of Cdk2.  
However, unlike PRL-1, overexpression of PRL-2 does not influence expression 
of Cyclin A (Werner et al., 2003).  Ectopic expression of PRL-2 in a murine pre-B-
cell line (Baf3ER) increases expression of Bmi-1, a stem cell marker and 
promoter of cell survival and proliferation.  In the same cell line, ectopic 
expression of PRL-2 augments phosphorylation of Stat5 in response to growth 
factor stimulation, suggesting that PRL-2 might provide cells with a heightened 
sensitivity to growth factors, thus allowing for a more rapid proliferative response 
(Akiyama et al., 2010).  In HeLa and A549 cells, knockdown of PRL-2, using 
siRNA, causes down-regulation of total and phosphorylated p130Cas.  This also 
leads to cleavage of p130Cas, generating a small fragment of the molecule that 
is capable of translocating to the nucleus where it functions as a transcriptional 
repressor and induces cell death (Daouti et al., 2008; Y. Wang & Lazo, 2012).  In 
addition, knockdown of PRL-2 results in cleavage of FAK (Daouti et al., 2008), 
reduces expression of the focal adhesion component, vinculin, and increases 
phosphorylation (on Tyr146) of Ezrin, a cytoskeleton/plasma membrane linker 
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molecule with important roles in cell adhesion and migration (Y. Wang & Lazo, 
2012).  PRL-2 knockdown also leads to decreased phosphorylation, hence, 
activation of ERK, whereas ectopic overexpression of PRL-2 induces ERK 
activation and translocation of ERK to the nucleus where it can up-regulate 
transcription of target genes (Hardy et al., 2010; Y. Wang & Lazo, 2012).  These 
data suggest a number of potential signaling pathways where PRL-2 may exert 
its effects; however no physiological substrates for PRL-2 have yet been 
identified. 
 
1.3.5.3 PRL-3 Substrates and Signaling Pathways 
There are several commonalities between the signaling pathways of PRL-
3 and PRL-1/PRL-2, indicating at least some functional redundancy between 
family members.  As with PRL-1, PRL-3 associates with α-tubulin (J. Wang et al., 
2002), and also with FKBP38 (M. S. Choi et al., 2011).  In addition, PRL-3 
participates in a similar p53-driven negative feedback loop to PRL-1, where PRL-
3 up-regulation by p53 ultimately results in p53 degradation, followed by down-
regulation of p21 and culminating in enhanced cell proliferation and cell survival 
(Basak et al., 2008; Hwang et al., 2012; Min et al., 2010).  Studies examining 
ectopic overexpression of PRL-3 (Basak et al., 2008) or down-regulation of PRL-
3 using either RNAi (Jiang et al., 2011) or small molecule inhibitors (L. Wang et 
al., 2009) have revealed that PRL-3 mediated effects on the cell cycle can also 
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involve alterations in Akt, Cdk2, Cyclin D, p38 MAPK, the Cdk inhibitor p27, and 
Foxo3a, a transcriptional activator of p21 and p27. 
As with PRL-1, PRL-3 appears to signal through several molecules 
involved in integrin-mediated cell adhesion signaling and cytoskeletal 
reorganization, including c-Src, FAK, paxillin, the Rho family GTPases, and the 
integrins themselves (Daouti et al., 2008; Fiordalisi et al., 2006; Ming et al., 2009; 
Mizuuchi et al., 2009; L. Wang et al., 2009; X. Wu et al., 2004).  PRL-3 can 
interact directly with the α1 integrin subunit (ITGA1) and, possibly through this 
interaction, can decrease the tyrosine phosphorylation level of the integrin β1 
(ITGB1) subunit (L. Peng et al., 2009).  Dephosphorylation of ITGB1 enhances 
its ability to bind its effector molecules and leads to activation of downstream 
signal transduction pathways.  For example, PRL-3 mediated dephosphorylation 
of ITGB1 leads to downstream activation of ERK, which promotes the increased 
expression and hydrolytic activity of MMP2.  At the same time, PRL-3 
overexpression and ITGB1 dephosphorylation leads to down-regulation of TIMP2, 
a negative regulator of MMP2 (L. Peng et al., 2009).  Overexpression of PRL-3 
also causes activation of Src kinase, leading to the phosphorylation and 
activation of ERK, p130Cas, and Stat3, all alterations which lead to promotion of 
cell proliferation and migration (Liang et al., 2007).  Strikingly, PRL-3 up-
regulates Src through an eIF2 (eukaryotic initiation factor 2)-mediated down-
regulation of the negative Src regulator, Csk, leading to decreased Src 
phosphorylation at Tyr527, an inhibitory site (Liang et al., 2008).  In contrast, 
PRL-1 activates Src by enhancing its phosphorylation at Tyr416, an activating 
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site (Luo et al., 2009), suggesting that, although the PRL family members might 
target similar molecules/pathways, the mechanisms they employ to control their 
targets may differ. 
Similarities between the PRL-3 and PRL-2 signaling pathways can also be 
found.  As with PRL-2, Ewing et al. (2007) found a direct interaction between 
PRL-3 and the farnesyltransferase subunits FNTA and FNTB, as well as with the 
metal transporters CNNM3 and CNNM4.  Also, like PRL-2, the expression of 
PRL-3 is inversely correlated with the phosphorylation level of the cytoskeletal-
membrane linker protein Ezrin (Forte et al., 2008; Orsatti, Forte, et al., 2009; Y. 
Wang & Lazo, 2012).  Although a direct interaction between the two molecules 
has not yet been demonstrated, immunoprecipitated PRL-3 could effectively 
dephosphorylate immunoprecipitated Ezrin at its Thr567 residue (Forte et al., 
2008), indicating that Ezrin may be a direct PRL-3 substrate.  Ezrin is a member 
of the ERM (Ezrin, Radixin, Moesin) family of proteins whose primary role is to 
serve as an intracellular scaffold between the cell surface receptors and the actin 
cytoskeleton.  ERM family members are capable of recruiting, among other 
molecules, RhoGEFs (positive Rho regulators) and RhoGDIs (negative Rho 
regulators) and thus are involved in control of Rho signaling.  Phosphorylation of 
Ezrin at Thr567 is necessary for its activity, suggesting that dephosphorylation at 
this site by PRL-3 would have an inhibitory effect.  Given this, it has been 
postulated that PRL-3-mediated down-regulation of Ezrin might ultimately lead to 
promotion of tumor progression through the deregulation of Rho signaling (Forte 
et al., 2008). 
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Other molecules which interact with PRL-3 and have been suggested as 
potential substrates include KRT8, Stathmin, nucleolin, and PI(4,5)P2 (also 
known as PIP2).  KRT8 (Keratin 8) is a cytoskeletal intermediate filament protein 
whose phosphorylation level at specific serine residues is inversely correlated to 
PRL-3 expression (Mizuuchi et al., 2009).  Stathmin is a microtubule destabilizing 
protein that can promote cell proliferation and migration and whose expression is 
positively influenced by PRL-3 (Zheng et al., 2010).  Nucleolin (NCL) is a major 
nucleolar protein involved in a variety of functions, including ribosome assembly, 
packaging of ribosomal RNA, and organization of nucleolar chromatin.  PRL-3 
overexpression leads to decreased NCL phosphorylation levels and promotes 
translocation of NCL to the nucleus where it participates in assembly of the 
nucleolus (Semba et al., 2010), a structure that is required for cell survival 
(Hernandez-Verdun, Roussel, & Gebrane-Younes, 2002). 
Although direct dephosphorylation of KRT8, Stathmin, and NCL by PRL-3 
has not been shown, the phosphatidylinositol phosphate PIP2 is a confirmed 
PRL-3 substrate.  Evidence suggests that PRL-3 is a 5-phosphatase, responsible 
for removing the phosphate at the 5 position of the inositol ring in PI(4,5)P2 and, 
to a lesser extent, PI(3,4,5)P3 (McParland et al., 2011).  Interestingly, Ezrin 
requires PIP2 binding to become active at the plasma membrane (Yonemura, 
Matsui, & Tsukita, 2002) and depletion of PIP2 increases cell motility (McParland 
et al., 2011), suggesting that PRL-3 also promotes metastatic effects through its 
lipid phosphatase activity. 
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A number of other PRL-3 interacting proteins, including CDH22, HDAC4, 
and EF2 have also been found.  CDH22 is a member of the cadherin superfamily 
of proteins, which promote cell adhesion.  PRL-3 overexpression reduces levels 
of CDH22, while knockdown of PRL-3 results in increased CDH22 levels (Y. Liu 
et al., 2009).  HDAC4 is a histone deacetylase which functions as a negative 
regulator of transcriptional activity.  PRL-3 specifically interacts with HDAC4 and 
not with other HDAC family members (Zhou et al., 2011), but the result of this 
interaction has not been studied.  EF2 (elongation factor 2) is an actin-binding 
protein that is part of the translational machinery.  Dephosphorylation of EF2, 
which can occur downstream of PRL-3, is required for its activation (Orsatti, 
Innocenti, Lo Surdo, Talamo, & Barbato, 2009; Zheng et al., 2010). 
PRL-3 also exerts its influence on a diverse array of other signaling 
molecules.  PRL-3 inhibits mobilization of intracellular calcium transients induced 
by angiotensin II (AngII) and may block AngII-mediated phosphorylation of 
p130Cas (Matter et al., 2001).  PRL-3 overexpression up-regulates the Ca2++ 
activated K+ channel KCNN4 in an NFKB-dependent manner, leading to KCNN4-
regulated changes that support cellular proliferation (Lai et al., 2011).  PRL-3 
promotes vascular and lymphatic vessel formation by up-regulating pro-
angiogenic factors such as VEGF and VEGF-C (Ming et al., 2009) and down-
regulating anti-angiogenic factors like IL-4 (K. Guo et al., 2006).  Furthermore, 
PRL-3 exerts its anti-apoptotic effects through alterations in expression of a 
number of pro-survival factors including Akt, mcl-1, cIAP1, and xIAP (Jiang et al., 
2011; Min et al., 2010; Zhou et al., 2011). 
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Epithelial-mesenchymal transition (EMT) is an important process, during 
tumor progression, by which epithelial cells acquire mesenchymal fibroblast-like 
properties, exhibit reduced cell-cell adhesion, and display increased motility 
(Sipos & Galamb, 2012).  The recognition that the phenotypic changes induced 
by stable expression of any of the three PRL molecules in non-tumorigenic 
epithelial cells are characteristic of EMT led to the theory that the PRL molecules 
may be major drivers of epithelial to mesenchymal transition.  In support of this 
theory, overexpression of PRL-3 was found to initiate a chain of events involving 
down-regulation of PTEN, activation of PI3K/Akt signaling, and deactivation of 
GSK3β (glycogen synthase kinase 3β), leading to accumulation of the 
mesenchymal marker and transcription factor Snail concomitant with 
transcriptional repression of epithelial markers such as E-Cadherin, γ-catenin, 
cytokeratin, and integrin β3.  Further supporting a role for PRL-3 in the initiation 
of EMT, PRL-3 overexpression also causes down-regulation of specific cell 
adhesion markers (e.g. paxillin and vinculin) and up-regulation of other 
mesenchymal markers (e.g. fibronectin and vimentin) in addition to Snail (Y. Liu 
et al., 2009; Mizuuchi et al., 2009; H. Wang et al., 2007). 
Upstream effectors/regulators of PRL-3 signaling include FKBP38 (M. S. 
Choi et al., 2011), p53 (Fontemaggi et al., 2002; Min et al., 2010), and the PRL-3 
family member p73α (Fontemaggi et al., 2002).  Additionally, VEGF can promote 
the transcription of PRL-3 through the transcription factor MEF2C (J. Xu et al., 
2011).  Snail can also bind the PRL-3 promoter and up-regulate its activity 
(Zheng et al., 2011).  TGFβ signaling promotes binding of Smad3 and Smad4 to 
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the PRL-3 promoter, suppressing PRL-3 promoter activity (Jiang et al., 2011).  
Lastly, poly(C)-RNA-binding protein 1 (PCBP1) was recently identified as a 
negative regulator of PRL-3 expression that can bind the 5’ UTR of PRL-3 mRNA 
and partially block protein translation (H. Wang et al., 2011). 
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CHAPTER 2.  RESEARCH GOALS AND DISSERTATION FORMAT 
An overwhelming amount of evidence suggests that the PRL 
phosphatases are multi-functional enzymes capable of signaling through a 
diverse number of interconnected pathways to trigger events that promote 
cellular proliferation, survival, and metastatic transformation.  However, despite 
many recent advances in our understanding of the molecular players with which 
the PRL phosphatases interact, the specific functional roles of these enzymes 
and the underlying mechanisms by which they exert their effects are still poorly 
understood.  This is true, in particular for PRL-1 and PRL-2, which have been 
much less studied than PRL-3.  Therefore, I undertook the present study with the 
goal of expanding our knowledge about the cellular functions of the PRL family 
and the roles these enzymes play in the progression of human disease.  Toward 
this goal, the specific aims of my dissertation research were to 1.) Characterize 
the tissue distribution and cell-type specific localization of PRL-1 and PRL-2 gene 
expression in normal human tissues, 2.) Compare the gene expression patterns 
of PRL-1 and PRL-2 between normal and diseased human tissues, and 3.) 
Globally identify and analyze possible signaling pathways in which the PRL-1 
phosphatase may operate. 
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This dissertation includes three manuscripts that support each of my 
research goals.  Two of these manuscripts are published and can be found in the 
‘Publications’ section immediately preceding the introduction with supplementary 
material that supports these publications found in Chapter 4.  The remaining 
manuscript, which is currently in preparation, can be found in its entirety in 
Chapter 7 with supporting information included in Chapters 5-6 and 8. 
 
Goal 1:  Examination of PRL Expression in Normal Human Tissues 
The correlation of PRL expression with growth in some cellular systems 
and differentiation in others suggests that the PRL enzymes may have different 
roles depending on the tissue or cell type.  Given this, characterization of the 
tissues and cell types that express the PRL genes is important to elucidating their 
physiological function and to providing a baseline for understanding their roles in 
the pathogenesis of disease. 
While multi-tissue analysis revealed normal PRL-3 expression in humans 
to be largely confined to the heart and skeletal muscle (Matter et al., 2001; Zeng 
et al., 1998), PRL-1 and PRL-2 were reported to be more widely expressed 
(Diamond et al., 1994; K. Guo et al., 2006; Montagna et al., 1995).  However, 
when I began my research, studies of normal PRL-1 or PRL-2 expression were 
largely limited to rodent tissues or to human cell lines and tissue northern blots 
(See Appendix Tables A.1 and A.2), which lack information on expression in 
specific microanatomical structures.  Therefore, I sought to characterize the 
cellular localization and tissue distribution of PRL-1 and PRL-2 mRNA in a broad 
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range of normal adult human tissues using in situ hybridization (ISH).  This 
technique provided the ability to pinpoint the exact cell-types which contribute to 
PRL-1 and -2 normal tissue expression 
The results of this analysis were reported in a publication entitled:  Cellular 
localization of PRL-1 and PRL-2 gene expression in normal adult human tissues.  
In addition, Chapter 4 of this dissertation contains supplemental information to 
support the reported work. 
 
Goal 2:  Comparison of PRL Expression in Normal and Diseased Tissues 
There is clear evidence demonstrating that all three PRL enzymes can 
promote tumor progression in vitro and the literature now abounds with 
information regarding PRL-3 expression in human tumors and its positive 
correlation to increasing tumor aggressiveness and poor patient prognosis 
(Reviewed in:  Bessette et al., 2008).  Few studies, however, have examined the 
expression of PRL-1 or PRL-2 in human malignancies.  In fact, at the onset of my 
research, there was only one other report examining either of these family 
members in human tumor samples (PRL-2; Q. Wang et al., 2002).  Therefore, I 
sought to provide further insight into the role that PRL-1 and PRL-2 play in the 
development and progression of human disease by using ISH to examine 
expression of these molecules in a large panel (342 specimens) of human 
tissues of diverse tissue origin and to compare their expression profiles in normal 
versus diseased samples. 
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Provided that cell line and murine studies show an important role for PRL-
1 and PRL-2 in tumor formation, invasion, and metastasis and given the 
abundant evidence linking PRL-3 to disease progression in multiple tumor types, 
I hypothesized that, like PRL-3, PRL-1 and PRL-2 expression would be up-
regulated in a majority of human tumor tissues and might correlate with 
advanced stages of disease.  Moreover, because PTPs, in general, have been 
connected to a variety of diseases other than cancer and PRL-3 over-expression 
in mouse models has been linked to cardiovascular disease, I hypothesized that 
aberrant expression of PRL-1 and PRL-2 may also be detected in human 
diseases other than cancer. 
The results of this research were published in a manuscript entitled:  
Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.  Additional 
supporting information is included in Chapter 4 of this dissertation. 
 
Goal 3:  Perform an Unbiased Examination of PRL Signaling Pathways 
The normal physiological role of the PRL phosphatases remains an 
important, unanswered question.  Their association with differentiation in some 
contexts and with proliferation in others raises the possibility that these enzymes 
may serve multiple functions within the cell.  Their variable subcellular 
localization and the diverse array of signaling molecules to which they have now 
been connected seem to support this notion.  An increased understanding of the 
signaling pathways in which the PRLs are involved and the substrates on which 
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they act will be required in order to elucidate both their normal functions and the 
processes by which they promote tumorigenesis and metastasis. 
While knowledge surrounding PRL-mediated signaling events has been 
greatly enhanced through focused investigations on individual genes and isolated 
pathways, there is an increasing appreciation that cellular processes are 
governed by a complex interplay between multiple signaling networks.  Moreover, 
what is known about PRL signaling to date suggests that we are unlikely to be 
successful in assigning these molecules to any single target pathway.  “Omics” 
techniques offer the advantage of obtaining an unbiased and more global view of 
the changes that are occurring, as well as the opportunity to identify previously 
unforeseen players that are responding, with respect to a particular stimulus.  
Therefore, I used microarray gene expression profiling (transcriptomics) to more 
broadly examine the alterations that occur in response to PRL overexpression in 
HEK293 cells and to attempt to identify pathways and transcripts that might be 
responsive to changes in PRL levels.  Additionally, because microRNAs 
(miRNAs) are emerging as key regulators of gene expression (Carthew, 2006), I 
also employed miRNA expression profiling to examine the effects of PRL 
overexpression on the miRNAome. 
My primary interest for this portion of my studies was in the PRL-1 
pathway, because this molecule displayed highly variable expression patterns in 
the ISH analysis of both normal and tumor tissues, while PRL-2 tended to be 
ubiquitously and heavily expressed in almost every tissue type examined and 
PRL-3 is known to have a limited expression profile.  Therefore, I focused the 
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majority of my efforts on the transcriptional and miRNA profiling of PRL-1; 
however, because of its well known role in cancer progression, PRL-3 was also 
examined.  Given prior knowledge of the PRL signaling pathways, I hypothesized 
that genes directly involved in cell movement, cell adhesion, and cell cycle 
regulation would be the primary targets influenced by PRL overexpression and 
that the use of Omics techniques would uncover previously undiscovered players 
involved in PRL-mediated signaling. 
The analysis results for the PRL-1 expression profiling are included in a 
draft manuscript which is found in Chapter 7, with additional, supporting 
information included in Chapters 5-6 and 8 of this dissertation.  The PRL-1 
microRNA results are included in Chapter 9 and the PRL-3 results are presented 
in Chapters 10-11. 
 
The potential involvement of all 3 PRLs in the progression of human 
malignancies makes them attractive targets for generation of novel anti-cancer 
therapeutics.  The work described in this dissertation will contribute to the 
understanding of the biological functions of the PRL phosphatases and to the 
role they play in the development and progression of human disease. 
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CHAPTER 3.  MATERIALS AND METHODS 
3.1 Tissue Procurement 
Human tissue samples were obtained from the Cooperative Human 
Tissue Network, National Disease Research Interchange, and Indiana University 
School of Medicine, Department of Pathology.  Samples were collected in 
accordance with the guidelines of Indiana University with approval from the 
IUPUI Institutional Review Board.  Specimens were fixed in 10% neutral buffered 
formalin, processed, and embedded in paraffin.  Serial sections, 5µm thick, were 
cut and mounted on Fisherbrand Superfrost/Plus slides (Fisher Scientific, 
Pittsburgh, PA).  Where available, the medical histories of the patients and 
pathological reports for each specimen were reviewed.  Tissue sections of each 
specimen were then stained with Hematoxylin and Eosin and were examined by 
a pathologist (Dr. George E. Sandusky), with no prior knowledge of the available 
patient data, to confirm histopathologic diagnosis and tumor grading.  For all 
cases, representative tissue sections were chosen for in situ hybridization (ISH). 
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3.2 Generation of Oligonucleotide Probes 
Specific 45-mer, oligonucleotide probes for PRL-1 and PRL-2 mRNA were 
designed using the Hybridization Probes Search option of Oligo Primer Analysis 
Software (Molecular Biology Insights, Cascade, CO).  The oligonucleotide 
sequences were verified using a BLAST search of EMBL and GenBank 
databases to ensure that there was no significant homology with other mRNA 
species.  All chosen sequences showed a 100% homology with the target PRL-1 
or PRL-2 sequence and no significant homology with any other known 
sequences.  The PRL-1 probe mapped to PRL-1 with 100% identity over the full 
probe sequence (E = 4 x 10-17), while the first non-target sequence showed 100% 
identity over only 17 of the 45 nucleotides with an e-value of 8.3.  The PRL-2 
probe mapped to PRL-2 with 100% identity over the full probe sequence (E = 4 x 
10-17) and the first non-target sequence displayed 95% identity over 20 
nucleotides (E = 2.1). 
Probes were custom synthesized by Midland Certified Reagent Company 
Inc. (Midland, TX) using cyanoethyl phosporamidite chemistry. Probes were 
labeled with fluorescein isothiocyanate (FITC) at both the 5’ and 3’ ends and 
were purified by Reversed Phase HPLC.  The PRL-1 (5'-GGC CAA CAG AAA 
AGA AGT GCA CTG AGG TTT ACC CCA TCC AGG TCA-3') and PRL-2 (5'-
TGG CAA ATA AAA AGT GTG AGC GTG CGT GTG AGT GTG ATG GGG AAA-
3') antisense probes are complementary to nucleotides 150-194 and 19-63 of the 
human PRL-1 (GenBank U48296) and PRL-2 (GenBank U48297) mRNA 
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sequences, respectively.  Corresponding control, sense oligonucleotides for 
PRL-1 and PRL-2 were also generated. 
 
3.3 Slot Blot Hybridization 
Slot blot hybridization was performed to verify the specificity of the 
oligonucleotide probes.  PRL-1 cDNA and PRL-2 cDNA, both cloned in pUC19 
vectors (Cates et al., 1996) and PRL-3 cDNA, in a pET-15b vector (a gift from 
Millenium Pharmaceuticals, Inc., Cambridge, MA), were linearized with BamHI 
(New England Biolabs, Beverly, MA).  The resulting restriction fragments were 
analyzed on a 1% agarose gel, run at 75V (constant voltage) for 45-60 min in 1X 
TAE buffer (40mM Tris Acetate, pH 8.3, 10mM EDTA).  Density profiling of the 
gel image was carried out with Scion Image Acquisition and Analysis Software, 
Beta 4.02 for Windows (Scion Corporation, Frederick, MD) and was used to 
estimate the amount of DNA in each lane for sample normalization. 
Linearized DNA samples of 100ng, 50ng, 10ng, and 5ng each, were 
denatured by the addition of 0.4M NaOH and 10mM EDTA and by heating for 10 
min at 100°C.  Samples were then neutralized with an equal volume of cold 2M 
ammonium acetate, pH 7.0.  Two-hundred microliters of each denatured DNA 
solution was spotted on a nitrocellulose membrane (Protran, Schleicher & 
Schuell Bioscience, Keene, NH) using a Bio-Dot SF Microfiltration Apparatus 
(BIO-RAD, Hercules, CA), according to the manufacturer’s instructions.  Samples 
were immobilized on the membrane using a Stratalinker Ultraviolet (UV) 
Crosslinker 1800 (Stratagene, La Jolla, CA).  Slot-blots were prehybridized for 30 
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min at 37°C in pre-warmed Sigma PerfectHyb Plus hybridization buffer (Sigma-
Aldrich, St. Louis, MO), followed by hybridization with FITC-labeled 
oligonucleotide antisense probes for PRL-1 and PRL-2, diluted to 100ng/ml in 
pre-warmed PerfectHyb Plus buffer.  Hybridization was allowed to proceed 
overnight (16hr) at 37°C in a rotating hybridization oven (Hybridization Oven 640, 
Affymetrix, Santa Clara, CA).  Post hybridization, membranes were washed two 
times for five minutes each in 2 X SSC (300mM NaCl, 30mM Sodium Citrate, pH 
7.0) + 0.1% SDS at room temperature (RT), followed by one 20 min wash in 0.5X 
SSC (75mM NaCl, 7.5mM Sodium Citrate, pH 7.0) + 0.1% SDS at 37°C, and a 
five minute wash at RT in TBST (50mM Tris-HCL, 150mM NaCl, pH 7.6 plus 0.05% 
Tween-20).  Prior to detection, membranes were blocked for two hours with 3% 
BSA in TBST and additionally, for 30 min with Serum Free Protein Block (DAKO 
Corporation, Carpenteria, CA).  FITC-labeled probes were detected for 30 min 
using a mouse, anti-FITC primary antibody (DAKO) diluted 1:1000 in DAKO 
Antibody Diluent, followed by Peroxidase Link and Peroxidase-Conjugated 
Streptavidin Label (10 min each) from the DAKO Labeled Streptavidin-Biotin 2 
(LSAB2) kit.  Reactions were visualized using the DAKO 3, 3’-diaminobenzadine 
(DAB) substrate chromogen system.  Development was allowed to occur for five 
minutes and the reactions were stopped by rinsing membranes in TBST, followed 
by distilled water.  Membranes were washed three times, five minutes each, in 
TBST, between each step of the procedure. 
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3.4 Non-radioactive In Situ Hybridization 
Paraffin sections were baked in a 60°C oven for four hours and 
subsequently dewaxed in xylene and rehydrated through a graded series of 
ethanol (100%, 95%, and 75%; two changes, five minutes each) to water.  Slides 
were placed in an OmniSlide Slide Rack (ThermoHybaid, Ashford, Middlesex, UK) 
and tissue sections were encircled with a ImmEdge hydrophobic barrier pen 
(Vector Laboratories, Burlingame, CA), then covered with 1X PBS (D-PBS, Gibco 
BRL, Gaithersburg, MD). 
Sections were permeabilized with 200µl of 10µg/ml, nuclease-free 
Proteinase K (Sigma-Aldrich) in 1X PBS at 37°C using an OmniSlide Thermal 
Cycler and Humidity Chamber (ThermoHybaid).  The optimal length of time for 
Proteinase K digestion was determined empirically for each tissue type (see 
Chapter 4 for results).  The deproteination reaction was stopped by washing 
slides two times, three minutes each in Nanopure (Chesterland, OH) ultrapure 
water.  Slides were subsequently dehydrated by sequential washes in 95% and 
100% ethanol (three minutes each) and allowed to air dry for one hour RT.  
Tissue sections were hybridized with 50µl of 750 ng/ml PRL-1, PRL-2, or control 
probe in PerfectHyb Plus hybridization buffer, sealed with parafilm, and 
hybridized 12-14 hr at 37°C in a humidity chamber.  Coverslips were dislodged 
and non-specifically bound probe was removed by soaking slides for 5 min each 
in two changes of 2X SSC + 0.1% SDS at RT with gentle agitation.  Slides were 
then washed stringently in pre-warmed 0.5X SSC + 0.1% SDS at 37°C for 20 min, 
followed by a 10 min rinse in TBS + 0.1% SDS at RT. 
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3.5 Histochemical Detection of Hybridized Probes 
Detection of hybridized probe was performed by standard 
immunohistochemical techniques, using a catalyzed signal amplification 
procedure.  All staining steps were performed on a DAKO Autostainer at room 
temperature and slides were rinsed for five minutes in TBST between each step 
of the procedure.  Normal and diseased tissue sections from one organ type 
were always processed simultaneously. 
Non-specific background staining was blocked by incubation with DAKO 
Serum-Free Protein Block for 30 min, followed by a 30 min incubation with 
mouse anti-FITC primary antibody (DAKO), diluted to 22 µg/ml in DAKO Antibody 
Diluent.  Bound primary antibody was detected using the LSAB2 method 
combined with the Renaissance Tyramide Signal Amplification (TSA Biotin, 
PerkinElmer Life Sciences, Inc., Boston, MA) kit.  Briefly, slides were incubated 
sequentially with DAKO LSAB2 Peroxidase Link for 30 min, DAKO LSAB2 Label 
for 10 min, Biotinyl Tyramide (TSA Biotin System) diluted 1:50 in the kit provided 
1X Amplification Diluent for 10 min, and DAKO LSAB2 Label again for 10 min.  
The antibody complexes were visualized using DAB as the chromogenic 
substrate.  Development was allowed to proceed for 2-5 minutes and was 
stopped by rinsing the slides in distilled water.  Following immunohistochemical 
detection, sections were counterstained briefly with 1X Lerner’s hematoxylin, 
dehydrated through graded alcohols (95%, 100%, two changes, one minute 
each), cleared in xylene (two changes, two minutes each), and coverslipped with 
permanent mounting media (Fisher Scientific). 
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3.6 Analysis of ISH Results 
Evaluation of slides was performed under brightfield microscopy.  All 
sections of a particular tissue type were stained and analyzed in a single run and 
are therefore directly comparable.  The tissue distribution, localization pattern, 
intensity of staining, and the percentage of positive cells were evaluated with the 
aid of an experienced pathologist (Dr. George E. Sandusky), in a blinded fashion.  
The appearance of a brownish-red stain over the cells was used to indicate 
probe hybridization and thus reflect the cellular levels of PRL-1 and PRL-2 
mRNA.  The localization pattern was evaluated as cytoplasmic, nuclear, 
membranous, or a combination of these.  Immunostaining was scored using 
established methods (Jackel, Mitteldorf, Schweyer, & Fuzesi, 2001; Nitadori et al., 
2006).  Briefly, staining intensity was classified according to the following scale:  
(-) absent, (+/-) barely detectable, (+) weak, (++) moderate, and (+++) strong.  In 
cases of heterogeneous staining, the average intensity across the tissue was 
taken as the score.  Also, in a few cases where a patient sample was stained 
twice, the case was given a mean score, based on evaluation of the two sections.  
The percentage of positive cells was estimated as the number of stained cells, 
per total number of cells counted.  For semiquantitative analysis, the staining 
intensity was assigned an arbitrary value, on a scale of 0-3, as follows:  (-) = 0, 
(+/-) = 0.5, (+) =1, (++) = 2, (+++) = 3.  An overall staining score (SS) was 
calculated for each sample, by multiplying the staining intensity times the 
percentage of positive cells.  After multiplication of both values, results were 
graded from 0 (negative) to 300 (almost all cells display strong staining). 
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To confirm the reproducibility of the analysis, 25% of the slides were 
randomly chosen and scored twice.  Duplicate slides gave similar results.  
Images were acquired using a SPOT digital camera and imaging software 
(Diagnostic Instruments, Inc., Sterling Heights, MI).   
Statistical calculations were executed by a qualified statistician (Dr. Han 
Weng Soo) using Statistical Analysis System software (SAS version 8.2, SAS 
Institute, Inc., Cary, NC).  Analyses of differences in PRL expression between 
cancerous and noncancerous tissues were performed using a Student’s paired t-
test.  Results are expressed as mean ± standard error of the mean (SEM) and p 
< 0.05 was considered statistically significant.  For most samples, the medical 
histories of the patients and pathological reports for each specimen were also 
available.  These were reviewed and correlations between PRL expression and 
patient clinicopathological features such as patient age and gender; tumor type, 
subtype, and grade; and presence of local or distant metastasis were calculated 
using a mixed model analysis of variance.  Again, p < 0.05 was deemed 
statistically significant.  GraphPad PRISM, version 5.0 (GraphPad Software Inc., 
La Jolla, CA) was used, by me, for visual representation of the results. 
 
3.7 Cell Lines and Cell Culture 
Human embryonic kidney 293 (HEK293) cells stably overexpressing PRL-
1, PRL-3, empty pcDNA4 vector (PRL-1 control), or empty pcDNA3 vector (PRL-
3 control) were generously provided by Dr. Zhong-Yin Zhang’s laboratory 
(Department of Biochemistry and Molecular Biology, Indiana University School of 
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Medicine, Indianapolis, IN).  Cells were grown in 100 mm plates in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(Thermo Scientific HyClone, Logan, UT), 50units/ml penicillin (Mediatech, Inc., 
Manassas, VA), and 50µg/ml streptomycin (Mediatech). 
H1299 human non-small cell lung carcinoma cells transiently transfected 
with PRL-3 or empty pcDNA3 vector were generated with the help of Dr. Martin L. 
Smith’s laboratory at the Indiana University Melvin and Bren Simon Cancer 
Center (Indianapolis, IN).  Plasmid DNA used for the transfections was provided 
by Dr. Zhong-Yin Zhang.  H1299 cells were grown to 10-15% confluency in 
DMEM supplemented with 10% fetal bovine serum.  Transfections were 
performed using FuGENE HD Transfection Reagent (Roche Diagnostics, 
Mannheim, Germany) as per the manufacturer’s instructions.  After 48hrs the 
media was removed, TRIzol reagent was added, and samples were stored frozen 
at -80°C until ready for RNA extraction. 
 
3.8 RNA Extraction and RNA Quality Assessment 
Total RNA was extracted from HEK293 cells stably transfected with PRL-1 
(HEK293-PRL-1), PRL-3 (HEK293-PRL-3), or their respective empty vector 
controls (HEK293-vector), using the TRIzol reagent (Invitrogen Life Technologies, 
Carlsbad, CA).  For microarray analysis and RT-PCR, the RNA was further 
purified with an RNeasy Mini Kit (Qiagen Inc., Valencia, CA), following 
manufacturer’s instructions.  For microRNA analysis, this column purification step 
was omitted.  RNA integrity and yield were assessed by determining sample 
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absorbance at 260 and 280 nm on a DU640B spectrophotometer (Beckman 
Coulter, Brea, CA) and by subjecting samples to the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Inc., Santa Clara, CA), using the Agilent RNA 6000 Nano 
LabChip Kit as directed. 
 
3.9 Gene Expression Microarray 
Gene expression profiling was carried out according to the protocol 
described in the Affymetrix GeneChip Expression Analysis Technical Manual.  
Briefly, 5µg of each cleaned, total RNA extracted from cultured HEK293-PRL-1, 
HEK293-PRL-3, and HEK293-vector control cells was used to generate double-
stranded cDNA, by reverse transcription, using a Superscript Double-Stranded 
cDNA Synthesis Kit (Invitrogen Life Technologies) and a GeneChip T7-Oligo(dT) 
Promoter Primer Kit (Affymetrix).  Following second-strand synthesis, cDNA was 
cleaned with a GeneChip Sample Cleanup Module (Affymetrix), and then used 
as a template for synthesis of biotinylated cRNA with the Enzo BioArray 
HighYield RNA Transcript Labeling Kit (Enzo Life Sciences, Farmingdale, NY).  
Labeled cRNA was cleaned with a GeneChip Sample Cleanup Module, 
fragmented, and hybridized overnight to HG-U133 Plus 2.0 GeneChip Human 
Genome Arrays (Affymetrix).  Following hybridization, GeneChips were washed, 
stained with streptavidin phycoerythrin (Molecular Probes, a subsidiary of Life 
Technologies, Carlsbad, CA), and scanned using the Affymetrix GeneChip 
Scanner 3000 7G.  Raw image (CEL file) generation and analysis was performed 
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using the Affymetrix GeneChip Operating System (GCOS).  All RNA samples 
and arrays met Affymetrix recommendations for standard quality control metrics. 
Microarray data analysis for the PRL-1 stable transfectants was performed 
by a bioinformatician (Dr. Boyd A. Steere).  Data files were processed with R-
project software (http://www.r-project.org/), version 2.13.1 through the RStudio 
interface version 0.94.92 (http://www.rstudio.org).  The intensity values were read 
using the “affy” library of the Bioconductor package (Gentleman et al., 2004), 
version 2.8.  Normalization and calls were made using the mas5 procedure under 
default parameters.  After transformation into a log2 scale, mean normalized 
expression values were calculated for both of the experimental comparison 
groups (HEK293-PRL-1 and HEK293-vector).  Differential expression between 
the two groups was determined for each probeset and assessed for significance 
in terms of p-value by the Student’s t-test.  Multiple-testing false discovery rate 
(FDR) correction values were calculated using the Benjamini-Hochberg 
procedure. 
Data analysis for all other samples was carried out by myself, using 
multiple methods, including Bioconductor, as described above, Partek Genomics 
Suite version 6.11.1115 (Partek Inc., St. Louis, MO), and the MultiExperiment 
Viewer (MeV) data analysis application (Dana Farber Cancer Institute, Boston, 
MA).  In all cases, raw data image files were normalized using the Robust 
Multichip Average (RMA) method and a student’s paired t-test was performed to 
look for significant differences between groups.  FDR correction values were 
calculated using both the Benjamini-Hochberg and the Bonferroni procedures.  
64 
 
 
 
The lists of significantly differentially expressed genes that were generated by 
each of the analysis tools were scrutinized for consistent changes. 
 
3.10 Functional Profiling of Significantly Changing Transcripts 
Functional/pathway profiling was performed to gain an understanding of 
the biological context behind genes whose mRNA expression was measured, by 
microarray, to be significantly altered with PRL-1 overexpression.  This analysis 
was performed by Dr. Boyd A. Steere, using the significant gene lists from the 
microarray and miRNA analysis, in the following manner: 
Two input data sets of the mRNA microarray results were prepared by 
applying significance cutoffs of q ≤ 0.20 and q ≤ 0.50 to the detected 
differentially-expressed probesets.  These data sets, consisting of 58 and 2263 
probesets respectively, included each probeset’s Affymetrix ID, associated gene 
Entrez ID, fold change, and the p-value and FDR-corrected q-value of that 
change.  Using both input data sets, enriched biological functions and pathways 
were determined using three systems: Ingenuity Pathway Analysis (IPA; 
Ingenuity Systems; www.ingenuity.com) core analysis, application build version 
162820, content version 12710793 with default settings; the Enrichment and 
Interactome workflows of MetaCore from GeneGo, Inc. 
(www.genego.com/metacore.php) version 6.8 with default settings; and the 
Database for Annotation, Visualization, and Integrated Discovery (DAVID) 
functional annotation and gene function classification tools, version 6.7 (Dennis 
et al., 2003). 
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3.11 Quantitative RT-PCR for Selection of Endogenous Controls 
Selection of endogenous controls for quantitative, real time, reverse 
transcription PCR (qRT-PCR) data analysis was performed using a TaqMan Low 
Density Endogenous Control Panel (Applied Biosystems, a subsidiary of Life 
Technologies, Carlsbad, CA), which contains 16 human control genes.  Total 
RNA isolated from HEK293-PRL-1, HEK293-PRL-3, and HEK293-vector 
samples was treated with DNase I, using the Ambion TURBO DNA-free kit from 
Invitrogen Life Technologies and 1.5µg of each sample was reverse transcribed 
into cDNA with the SuperScript III First-Strand Synthesis System and random 
hexamer primers (Invitrogen Life Technologies), in accordance with the 
manufacturer’s guidelines.  The resulting cDNAs were combined with TaqMan 
Gene Expression Master Mix (Applied Biosystems) and 100ng cDNA was added 
to each well of a TaqMan Endogenous Control Array following the manufacturer’s 
protocol.  Samples were amplified by PCR on an Applied Biosystems 7900HT 
Fast Real-Time PCR System using universal cycling conditions (2 min at 50ºC, 
10 min at 95°C and 40 cycles of 15 sec at 95°C for denaturation and 1 min at 
60°C for annealing/extension).  Raw threshold cycle (Ct) values were obtained 
using Sequence Detection System (SDS) Software v2.4 (Applied Biosystems; will 
be referred to in this document as SDSS to avoid confusion with Sodium Dodecyl 
Phosphate).  Ct values ≥ 40 were set to 40 and were considered not detectable.  
DataAssist Software, v2.0 (Applied Biosystems) was used to examine the 
stability of the candidate endogenous controls across all samples.  Microsoft 
Excel 2007 (Microsoft Corporation, Redmond, WA) was also used to calculate 
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the standard deviation across all measurements for each gene.  The genes with 
the best stability scores and lowest standard deviation were selected as 
candidate endogenous controls for further qRT-PCR analysis.  Data analysis for 
this section was performed fully by me. 
 
3.12 Quantitative RT-PCR for detection of PRL-1 and PRL-3 
Total RNA isolated from HEK293-PRL-1, HEK293-PRL-3, and HEK293-
vector samples was treated with DNase I, using the Ambion TURBO DNA-free kit 
and 4µg of each sample was reverse transcribed into cDNA with the SuperScript 
III First-Strand Synthesis System and random hexamer primers, in accordance 
with the manufacturer’s guidelines.  The resulting cDNA was used as template 
for qRT-PCR using commercially available TaqMan Gene Expression Assays 
(Applied Biosystems,) for PRL-1 (Assay ID:  Hs01109144_m1), PRL-3 
(Hs02341134_m1), 18S (Hs99999901_s1), and UBC (Hs00824723_m1).  For 
PRL-1 and UBC only, a pre-amplification step was performed using the TaqMan 
PreAmp Master Mix Kit (Applied Biosystems) according to the manufacturer’s 
protocol.  Briefly, 250ng of each cDNA was combined with 2X Taqman PreAmp 
Master Mix and a pooled mix of the PRL-1 and UBC TaqMan assays, each at 
0.2X.  Samples were pre-amplified using a GeneAmp PCR System 9700 
(Applied Biosystems) and the following cycling conditions:  95°C for 10min, 
followed by 10 cycles of 95°C for 15 sec and 60°C for 4 min.  Pre-amplified 
products were diluted 1:5 in 1X TE.  Twenty-five microliters of diluted, pre-
amplified product (for PRL-1 and UBC) or 100ng of non-amplified cDNA (for 
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PRL-3 and 18S) was combined with 2X TaqMan Gene Expression Master Mix 
and the corresponding 20X TaqMan Gene Expression Assay in triplicate wells of 
a 96-well PCR plate.  PCR amplification and detection were carried out on an 
Applied Biosystems 7900HT Fast Real-Time PCR System under the universal 
cycling conditions.  Raw Ct values were obtained using SDSS v2.4.  Ct values ≥ 
40 were set to 40 and were considered not detectable.  DataAssist Software, 
v2.0 was used, by me, to verify the stability of the selected endogenous controls.  
Microsoft Excel 2007 was used to calculate relative fold change (FC) using the 
comparative Ct method (∆∆Ct) and either UBC (PRL-1) or 18S (PRL-3) as the 
endogenous control.  GraphPad PRISM, version 5.0 was used for visual 
representation of the results. 
 
3.13 Quantitative RT-PCR Custom Arrays 
A set of 184 genes, identified by microarray as differentially regulated or 
associated in the literature with signaling pathways involved in integrin-mediated 
cell signaling, cytoskeletal remodeling, and/or cell motility, was chosen for 
validation of gene expression changes using qRT-PCR.  Total RNA from 
HEK293-PRL-1 and HEK293-vector cell lines was treated with DNase I, using 
the Ambion TURBO DNA-free kit and 1µg of each sample was reverse 
transcribed into cDNA with the SuperScript III First-Strand Synthesis System and 
random hexamer primers, in accordance with the manufacturer’s guidelines.  The 
resulting cDNA was used as template for qRT-PCR using commercially available 
TaqMan Gene Expression Assays (Applied Biosystems) custom arrayed on 96-
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well plates (92 experimental genes and 4 candidate endogenous controls:  
GAPDH, UBC, 18S, B2M per plate).  See Chapter 7 for a full gene list and 
associated Assay IDs.  As per the manufacturer’s protocol, cDNAs were 
combined with TaqMan Gene Expression Master Mix and 100ng cDNA was 
added to each well of the custom TaqMan Array Plate and amplified by PCR on 
an Applied Biosystems 7900HT Fast Real-Time PCR System under the universal 
cycling conditions.  Raw Ct values were obtained using SDSS v2.4.  Ct values ≥ 
40 were set to 40 and were considered not detectable.  DataAssist Software, 
v2.0 was used to examine the stability of the candidate endogenous controls and 
the gene with the lowest stability score across all tested samples was chosen for 
use in data normalization. 
Mean normalized Ct values for each assay over all biological replicates 
were calculated by Dr. Boyd A. Steere using Partek Genomics Suite version 
6.11.1115 under default parameters.  Differential expression between the two 
comparison groups was determined for each assay using the ∆∆Ct method and 
was calculated by me, using Microsoft Excel.  Comparative statistical analysis 
was then performed by Dr. Boyd A. Steere, in Partek Genomics Suite using the 
Student’s t-test. 
 
3.14 MicroRNA Profiling 
MicroRNA (also called miRNA) expression was evaluated using TaqMan 
Array Human microRNA cards A and B, version 2.0 (Applied Biosystems), which 
measure the expression levels of 664 microRNAs.  One thousand nanograms 
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each of total RNA from cultured HEK293-PRL-1, HEK293-PRL-3, and HEK293-
vector control lines was subjected to reverse transcription using a TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems) with Megaplex 
Reverse Transcription Primers (Human Pools A and B v2.0; Applied Biosystems) 
following the manufacturer’s protocol.  Reverse transcription was carried out on 
an Applied Biosystems GeneAmp PCR System 9700 thermal cycler with the 
following conditions:  40 cycles of 16°C for 2 min, 42ºC for 1 min, and 50ºC for 1 
sec, followed by an incubation at 85°C for 5 min to inactivate the reverse 
transcriptase.  The resulting products were diluted with RNase-free water and 
combined with TaqMan Universal PCR Master Mix (Applied Biosystems), after 
which 100µl of each sample was loaded onto TaqMan Array Human MicroRNA 
Card Sets A and B v2.0 (Applied Biosystems).  Per manufacturer’s instructions, 
qRT-PCR was carried out on an Applied Biosystems 7900HT Fast Real-Time 
PCR System using the default thermal-cycling conditions for 384-well TaqMan 
Low Density Arrays.  Raw Ct values were obtained using SDSS v2.4.  Ct values 
≥ 40 were set to 40 and were considered not detectable. 
Raw miRNA data files were processed using Partek Genomics Suite 
version 6.11.1115 under default parameters.  Expression levels of the small 
nuclear RNA MammU6 were used as the endogenous control for data 
normalization.  Mean normalized Ct values for each of the 664 assays over all 
biological replicates for each of the experimental comparison groups were 
calculated.  Differential expression between the two comparison groups was 
determined for each assay and assessed for significance in terms of p-value by 
70 
 
 
 
the Student’s t-test.  Multiple-testing FDR correction values were calculated using 
the Benjamini-Hochberg procedure.  PRL-1 data analysis was carried out by Dr. 
Boyd A. Steere and PRL-3 data analysis was carried out by me. 
 
3.15 miRNA Target Prediction 
Prediction of mRNA targets for the assayed miRNAs was performed 
through the use of IPA and through use of the MiROR database (Friedman, 
Naamati, & Linial, 2010).  Target prediction and analysis for the PRL-1 
associated samples was performed by Dr. Boyd A. Steere and target prediction 
for the PRL-3 associated samples was performed by me. 
 
3.16 Functional Profiling of miRNA Targets 
The full list of predicted mRNA targets for each significantly differentially 
expressed miRNA was used as input for functional/pathway analysis using a 
combination of four systems:  IPA software core analysis, application build 
version 162820, content version 12710793 with default settings; the Enrichment 
and Interactome workflows of MetaCore, version 6.8 with default settings; the 
PathWay Express tool from Wayne State University’s Onto-Tools (Khatri, 
Draghici, Ostermeier, & Krawetz, 2002); and the DAVID Functional Annotation 
and Gene Function Classification tools version 6.7 (Dennis et al., 2003).  These 
analyses were performed by both Dr. Boyd A. Steere and me. 
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3.17 miRNA/mRNA Data Integration 
For the PRL-1 samples, integration of significant results from the mRNA 
and miRNA expression profiling studies was performed by Dr. Boyd A. Steere 
using the expression pairing function of the IPA software.  For the PRL-3 
samples, I used both IPA and Partek Genomics Suite Software to perform this 
analysis.  Each data set was scrutinized to look for significantly changing mRNAs 
whose expression was inversely correlated to significantly changing miRNAs that 
are predicted to target them. 
 
3.18 Western Blotting 
HEK293-PRL-1 and HEK293-vector cells were grown to 80% confluency 
then rinsed with 1X PBS and lysed in RIPA Buffer (Thermo Scientific, Rockford, 
IL) plus 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific).  
Cell lysates were sonicated for 5min at 4°C in a Branson 2510 sonicator  
(Thomas Scientific, Swedesboro, NJ), then centrifuged at 21,000 x g for 20 min 
at 4 C.  Supernatant protein concentrations were determined using the Pierce 
BCA Protein Assay Kit (Thermo Scientific) and a SpectraMax Plus Microplate 
Spectrophotometer (Molecular Devices, Sunnyvale, CA), both according to the 
manufacturer’s protocols.  Samples were mixed 1:1 with 6X Laemmli reducing 
sample buffer (Boston Bioproducts, Ashland, MA) and 15µg of each sample was 
resolved using NuPAGE 4-12% Bis-Tris gels and NuPAGE 1X MOPS Running 
Buffer (Invitrogen Life Technologies).  Samples were electro-transferred to 
nitrocellulose membranes using the iBlot Western Blotting System (Invitrogen 
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Life Technologies) and membranes were blocked for 1 hr in either 5% BSA or 5% 
nonfat dry milk (according to the manufacturer’s instructions for each antibody) in 
1X TBST.  Blots were incubated in primary antibody at 4°C overnight, washed 4X, 
2-3 min in TBST, incubated in secondary antibody for 1 hr at room temperature, 
and rinsed 4X, 2-3 min each in TBST again.  Membranes were developed using 
the Pierce SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific) or Pierce SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific) depending on the primary antibody used.  Images were 
captured using an ImageQuant LAS-4000 imager (GE Healthcare, Uppsala, 
Sweden).  GAPDH was used as a loading control.  Stripping of blots was 
performed using Pierce, Restore Western Blot Stripping Buffer (Thermo Scientific) 
according to the manufacturer’s recommendations. 
Antibodies (and the dilution used) included:  RhoA (1:1000); Src (1:1000); 
Phospho-Src (Tyr527) (1:1000); Phospho-Src (Tyr416) (1:1000); Non-phospho-
Src (Tyr527) (1:1000); Non-phospho-Src (Tyr416) (1:1000); p44/42 MAPK 
(ERK1/2, 1:1000); Phospho-p44/42 MAPK (Thr202/Tyr204) (1:1000); SAPK/JNK 
(1:1000); Phospho-SAPK/JNK (Thr183/Tyr185) (1:1000); PAK1 (1:1000); 
Phospho-PAK1 (Ser144)/PAK2 (Ser141) (1:1000); Anti-rabbit IgG, HRP-linked 
(1:1000); Anti-mouse IgG, HRP-linked (1:1000); GAPDH, HRP-linked (1:1000).  
All antibodies were purchased from Cell Signaling Technology (Danvers, MA).  
All primary antibodies have specificity for human sequences.
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CHAPTER 4.  IN SITU HYBRIDIZATON PROTOCOL OPTIMIZATION AND 
CONTROLS 
4.1 Introduction 
Most studies examining the tissue distribution of PRL-1 and PRL-2 have 
been conducted on rodent tissues, while reports on human samples have been 
largely limited to tissue northern blots.  Tissue analysis performed at this level 
does distinguish between functionally different cell types in the tissue and, further, 
the results could reflect gene expression in contaminating cell types (e.g. stromal 
fibroblasts, inflammatory cells, or vascular cells) rather than the tissue proper.  
Therefore, I sought to characterize the cellular localization and tissue distribution 
of PRL-1 and PRL-2 in a large panel of normal and diseased human tissues of 
diverse origin using in situ hybridization.  The results of this analysis are 
presented in my publications entitled Cellular localization of PRL-1 and PRL-2 
gene expression in normal adult human tissues and Tissue-specific alterations of 
PRL-1 and PRL-2 expression in cancer.  Additional information to support these 
two publications is included here. 
Before beginning the ISH analysis, it was important to establish the 
appropriate assay conditions for each individual tissue type.  Tissue samples 
used in this study were all obtained from archival, formalin-fixed, paraffin-
embedded (FFPE) tissue blocks.  While the process of formalin-fixation serves to
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preserve tissue architecture, it leads to formation of biomolecular cross-links that 
can chemically mask proteins and nucleic acids (Gilbert et al., 2007).  Due to this 
cross-linking, proteolytic digestion by an enzyme such as Proteinase K is often 
required to permeabilize the tissue and allow access of ISH probes and detection 
reagents to their target sites.  Some tissue types are more sensitive to protease 
digestion than others; therefore, the appropriate Proteinase K digestion time for 
each tissue must be determined empirically such that a proper balance can be 
found to allow for increased permeability and signal enhancement without 
causing loss of tissue morphology.  To determine the optimal Proteinase K 
incubation time for each tissue type, a time course of Proteinase K exposure was 
performed on two purchased multi-tissue arrays (Normal Tissue Checkerboard 
and Normal Sausage) from Biogenex (Fremont, CA) along with several self made 
tissue arrays (generated using the tissue samples described in the methods 
section).  Protease treated samples were hybridized with the PRL-2 
oligonucleotide probe or a poly d(T) probe (Novocastra Laboratories, New Castle 
upon Tyne, UK), detected using standard immunohistochemical procedures, and 
examined under brightfield microscopy to compare staining intensity and tissue 
integrity. 
Besides assay optimization, it was also important to define suitable 
controls that could be used to verify the functionality and specificity of the assay.  
Therefore, a number of controls were selected and their performance was 
examined across multiple tissue types. 
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4.2 Results 
As expected, different tissue types showed a large amount of variability in 
their susceptibility to Proteinase K digestion.  Tissues such as lung, prostate, and 
gall bladder were particularly sensitive to proteolysis, while tissues such as 
uterus, ovary, brain, and cervix required the longest incubation times.  Table 4.1 
summarizes the optimal Proteinase K incubation times determined for each 
tissue type. 
A variety of different tissues were examined to locate a sample that could 
be used as a good positive control for both PRL-1 and PRL-2 expression.  While 
many tissues displayed variable expression patterns from specimen to specimen, 
particularly for PRL-1, the majority of normal and tumor tissues from the 
pancreas stained heavily for both markers.  Therefore, select cases from this 
tissue type were chosen as positive controls to be run with each sample set and 
used in verification of the hybridization and detection procedure.  Representative 
examples are shown in Figure 4.1A and B. 
To verify the presence and examine the integrity of mRNA in each sample, 
a second positive control was used.  This consisted of a fluorescein-conjugated 
poly d(T) probe, purchased from Novocastra Laboratories for the detection of 
total mRNA poly A tails.  A weak or absent signal from this probe is an indication 
that the tissue RNA is heavily degraded.  An example of this is shown in Figure 
4.2. 
A number of negative assay controls were also selected.  These included:  
(a) omission of the oligonucleotide probes from the hybridization mixture and 
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incubation of the tissue specimens with hybridization buffer alone (Figure 4.1D), 
(b) substitution of the specific antisense probe with an equivalent concentration 
of labeled sense probe to examine the stringency of the assay (Figure 4.3), (c) 
hybridization using a cocktail of randomly generated, FITC-conjugated, 
oligonucleotide sequences (NCL-CONTROL, Novocastra), to assess binding of 
nonspecific sequences (Figure 4.1C), and (d) Pretreatment of tissue sections 
with 250µg/ml RNase A to demonstrate the specificity of the signal for single 
stranded RNA (Figure 4.4). 
Throughout the remainder of the study, selected controls were run on 
serial sections of the same tissues as examined with the PRL-1 and PRL-2 
probes, using the same detection procedures. 
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Table 4.1 Optimal incubation times for ISH tissue permeabilization 
Incubation times were determined by performing a time course of 
Proteinase K exposure on several multi-tissue arrays then probing for 
PRL-2 and poly d(T) expression. 
 
    Tissue Type Incubation Time (min) 
     Adrenal Gland 20 
     Appendix 7 
     Bladder 10 
     Brain 20 
     Breast 10 
     Cervix 20 
     Colon 10 
     Coronary Artery 15 
     Eye 5 
     Gall Bladder 5 
     Heart 7 
     Kidney 10 
     Liver 15 
     Lung 5 
     Lymph Node 20 
     Ovary 20 
     Pancreas 7 
     Parathyroid 20 
    Placenta 20 
    Prostate 5 
    Skeletal Muscle 5 
    Skin 10 
    Small Intestine 10 
    Spleen 10 
    Stomach 10 
    Testis 10 
    Thyroid 20 
    Tongue 20 
    Uterus 20 
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Figure 4.1 Positive and negative ISH controls 
Serial sections of a normal human pancreas tissue (Case No. 2141) were 
hybridized with (A) PRL-1 antisense probe, (B) PRL-2 antisense probe, (C) 
random oligonucleotide sequences (NCL-CONTROL, Novocastra), or (D) 
hybridization buffer in the absence of any probe. 
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Figure 4.2 Poly d(T) control 
(A) Hybridization of a poly d(T) probe to a normal ovarian tissue specimen 
(Case No. 9912C004) verifies the presence of mRNA in the sample.  (B)  
Hybridization of the same poly d(T) probe to a normal ovarian tissue sample 
from another subject (Case No. 2242002) indicates that the RNA in this 
sample has been completely degraded, thus, this tissue would not be suitable 
for ISH analysis. 
 
 
 
 
Figure 4.3 Sense and antisense hybridization probes 
A pancreatic ductal adenocarcinoma tumor specimen (Case No. 2979B) was 
hybridized with (A) sense or (B) antisense oligonucleotide probe for PRL-1. 
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Figure 4.4 RNase pre-treatment 
Pre-treatment of tissue samples with RNase A prior to hybridization of specific 
antisense probe results in near to complete abolishment of the hybridization 
signal.  Serial sections taken from normal human cerebellum (Case No. 3011) 
are shown. 
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4.3 Discussion 
Assay optimization and selection of appropriate assay controls are both 
central to establishing the validity of the in situ hybridization results.  Here, we 
determined the optimal Proteinase K digestion time for each tissue type used in 
this study, in order to ensure maximum assay sensitivity with minimal disruption 
to tissue morphology.  We also defined several positive and negative assay 
controls.  Hybridization of a poly d(T) control probe confirmed the presence of 
mRNA in each sample, while pre-treatment of tissue sections with RNase A 
verified the specificity of the probes for RNA.  The use of several negative 
controls, such as omission of probe, hybridization with a sense probe, or use of a 
random sequence “nonsense” probe, with each run further established the 
specificity of the staining results.  Finally, inclusion of a positive control specimen 
that was known to be positive for PRL-1 and PRL-2 expression demonstrated 
that the assay and reagents were functioning as expected.  In addition to the 
data shown here, slot blot hybridization on PRL-1, PRL-2, and PRL-3 cDNA 
targets was also carried out to ensure that the PRL-1 and PRL-2 probes were not 
cross-hybridizing with sequences from closely related family members (Dumaual 
et al., 2006).  In combination, each of these factors helped to validate the 
specificity of the assay and increase our confidence in the staining results. 
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CHAPTER 5.  QUALITY ASSESSMENT OF SAMPLES TO BE USED FOR 
MICROARRAY BASED TRANSCRIPTIONAL PROFILING 
5.1 Introduction 
In situ hybridization was used to examine the cellular localization and 
tissue distribution of PRL-1 and PRL-2 mRNA in a broad range of normal and 
diseased human tissues.  This analysis revealed several significant, and highly 
tissue specific, differences in PRL-1 and PRL-2 expression between tumor 
tissues and their normal adjacent counterparts.  Given that we already had an 
idea of the PRL-1 and -2 expression levels in the tissues analyzed by ISH, I was 
interested in learning what other genes were up- or down-regulated in 
concordance with the PRLs in these same tissues. 
It is well known that thousands of genes in the body function through 
complex, combinatorial and interactive networks.  However, traditional methods 
for quantitation of gene expression allow for interrogation of only a single or 
limited number of genes at a time, leading to low throughput and making the 
whole picture of gene function difficult to obtain.  Techniques for multiplex gene 
expression analysis, such as DNA microarrays, have become increasingly 
widespread and provide an opportunity to simultaneously interrogate thousands 
of genes in a sample to provide a more global picture of transcriptional activity.  
Such investigations enable researchers, not only to better assess the behavior
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and relationship of genes previously implicated in a given process, but also to 
identify novel, similarly regulated genes and complex interacting pathways.  
Given this, I felt that DNA microarrays would provide a powerful tool for 
examining the transcriptional profiles of some of the same matched normal and 
tumor tissues used in the ISH analysis.  My primary interest was in the PRL-1 
pathway, because it displayed the most highly variable expression patterns via 
ISH, while PRL-2 tended to be ubiquitously and heavily expressed and PRL-3 
has previously been shown to have a limited expression profile.  Based on 
information emerging in the literature, I hypothesized that PRL-1 expression in 
this sample set would correlate strongly with the expression of genes directly 
involved in cell movement, cell adhesion, and cell cycle regulation. 
To begin the analysis, I first attempted to optimize a procedure for the 
isolation of RNA from microdissected, formalin-fixed, paraffin-embedded (FFPE) 
tissue sections.  Microdissection provides an efficient method of extracting tissue 
samples from FFPE tissues for microarray analysis, because it enables the 
dissection of pure cell populations from a heterogeneous tissue specimen and 
allows for the screening of gene expression changes in the specific cell types of 
interest.  However, efficient extraction and isolation of RNA from FFPE blocks is 
often limited by an inability to extract high quality and quantity genetic material 
from these samples.  Several recent RNA extraction procedures advertise the 
ability to produce sufficient material for microarray profiling from FFPE samples, 
so I began by testing and comparing three different extraction protocols. 
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I first selected two tissue types with relatively high expression of PRL-1 in 
tumor as compared to matched normal tissue (stomach and liver) and two tissue 
types with significantly lower expression of PRL-1 in tumor as compared to 
matched normal tissue (breast and lung).  For each case, 30 slides, each 
containing a single 5µm tissue section, were deparaffinized and rehydrated by 
passing slides through two changes of xylene for 5 minutes each, followed by 
incubation in a graded series of ethanols (100%, 95%, 70%) and two changes of 
nuclease-free water for 30 seconds each.  Following rehydration, slides were 
briefly air dried (~3-5 minutes).  Using a serial H&E stained section as a guide, 
the normal or tumor cells of interest were then scraped from each slide into a 
microfuge tube (10 slides per tube) using a sterile scalpel.  Each tube was 
subjected to one of three different RNA extraction methods:  TRIzol extraction; 
the Ambion RNAqueous Micro Kit (Invitrogen Life Technologies); or the Qiagen 
RNeasy Micro Kit.  Each procedure was carried out according to the 
manufacturer’s protocol.  The quantity and quality of RNA produced by each 
method was then examined using spectrophotometry and the Agilent Bioanalyzer. 
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5.2 Results 
RNA yields and 260/280 ratios from each of the three tested RNA 
extraction procedures are listed in Table 5.1.  From this data, it can be seen that 
the TRIzol procedure provided the best total RNA yields.  All RNA samples, 
though, showed signs of degradation, as evidenced by optical density 260/280 
ratios less than 1.8.  This sample degradation was confirmed by analysis on an 
Agilent Bioanalyzer (Figure 5.1).  The Agilent Bioanalyzer has become the 
standard tool for RNA quality assessment of samples for microarray analysis.  It 
uses electrophoretic separation on a microchip device, along with fluorescence 
detection, to reveal the size distribution of RNA fragments in a sample, 
represented in the form of a virtual gel or a chromatogram.  Intact, 
electrophoretically separated eukaryotic RNA shows two distinct ribosomal peaks 
corresponding to 18S and 28S ribosomal RNA (rRNA), with the 28S band 
approximately twice as intense as the 18S band (2:1 ratio).  As RNA degradation 
proceeds, the RNA begins to take on a smeared appearance in gel images and 
the 28S/18S rRNA ratio decreases.  None of the RNA extracted from FFPE 
tissues in the current analysis displayed clear rRNA bands. 
To ensure that this result was not specific to the four initial tissue samples 
analyzed, the TRIzol procedure was used to extract RNA from all of the FFPE 
tissues that were selected for microarray analysis.  As before, the RNA yields 
were acceptable, but the RNA in each sample was heavily degraded.  As an 
alternate approach, we next decided to examine RNA quality in a set of tissue 
samples that had been flash frozen in liquid nitrogen and stored frozen at -80°C 
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(“fresh frozen”) rather than fixed and embedded in paraffin.  Case matched tumor 
and normal adjacent tissues were obtained for 6 breast and 6 stomach tissue 
specimens and RNA was extracted with TRIzol.  As shown in Figure 5.2, the 
tumor sample RNAs were only partially degraded, but the RNA derived from the 
matched normal specimens was highly degraded and resembled the RNA quality 
obtained from the FFPE samples.  Thus, it was determined that neither the FFPE 
nor the frozen tissue samples produced high enough quality RNA to proceed with 
standard microarray protocols. 
As an alternative, we sought to obtain experimental cell lines that would 
allow the assessment of global changes in gene expression that might correlate 
with PRL-1 overexpression.  Dr. Zhong-Yin Zhang’s laboratory in the Indiana 
University School of Medicine, Department of Biochemistry and Molecular 
Biology, had already established HEK293 cell lines stably overexpressing PRL-1 
(Luo et al., 2009) or PRL-3 (Liang et al., 2007) and graciously harvested and 
provided us cells from each of these lines, along with control HEK293 cells that 
were transfected only with empty vector.  Total RNA was extracted from the cells 
using TRIzol and RNA quality was again assessed using the Agilent Bioanalyzer.  
The extracted RNA was of excellent quantity and quality as determined by the 
presence of clear 18S and 28S rRNA bands with the 28S band being roughly 
twice as intense as the 18S band (Figure 5.3).  Based on these results, the cell 
line samples were selected for transcriptional profiling using Affymetrix 
microarrays.
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Table 5.1 Comparison of methods for RNA extraction from FFPE tissues 
 
Sample 
Number 
Absorbance 260/280 RNA Yield (ng) 
TRIzol RNAqueous RNeasy TRIzol RNAqueous RNeasy 
Tissue 1 1.68 1.71 1.87 259 216 133 
Tissue 2 1.49 1.90 1.79 630 94 163 
Tissue 3 1.53 1.52 1.68 1402 282 226 
Tissue 4 1.52 1.70 1.84 1654 1101 133 
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Figure 5.1 Agilent Bioanalyzer profile of RNA extracted from FFPE tissue 
The virtual gel in (A) shows the poor quality of RNA derived from FFPE tissue 
blocks, as compared to an example gel (B), displaying high quality RNA derived 
from fresh, whole blood samples.  The higher quality RNA in these samples is 
evidenced by the presence of clear 28S and 18S ribosomal RNA bands. 
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Figure 5.2 Representative Agilent Bioanalyzer profile of RNA 
extracted from fresh frozen tissues 
Tumor tissues were only partially degraded and clearly retained 28S and 
18S ribosomal RNA bands, whereas RNA from their matched Normal 
Adjacent Tissues (NAT) was heavily degraded. 
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Figure 5.3 Agilent Bioanalyzer profile of cell line-derived RNA 
RNA derived from HEK293 cells stably overexpressing PRL-1, PRL-
3, or empty vector (control) displayed high quality, intact RNA, as 
indicated by the presence of distinct 28S and 18S ribosomal RNA 
bands on a virtual gel. 
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5.3 Discussion 
The assessment of RNA integrity is a critical first step to obtaining 
meaningful gene expression data.  Traditional microarray protocols rely on cDNA 
synthesized from the poly-A tail of RNA and therefore require well preserved, 
highly intact RNA in order to be successful.  Older FFPE samples tend to yield 
particularly poor quality RNA, largely due to the handling practices that were 
used for collection of these specimens.  In the past, less stringent collection 
procedures, supplying lower quality total RNA, were acceptable, because 
commonly used methods (e.g. ISH, PCR) examined only a small number of 
genes or did not require fully intact RNA.  The advent of microarray analysis has 
led to the development of more stringent procedures for sample collection; 
however, archival FFPE sample blocks were typically not collected under these 
improved conditions.  The tissue blocks used in our ISH experiments are more 
than a decade old at this point and a few years have passed even since they 
were used in the ISH analysis.  Therefore, it is not surprising that the RNA in 
these samples exhibits a significant degree of degradation. 
Due to the recent emergence of a number of protocols and kits that help 
overcome some of the technical limitations associated with microarray-based 
analysis of FFPE samples, it is possible that meaningful expression data could 
still be obtained from our FFPE-derived RNA.  However the combinatorial effects 
of differential RNA degradation and inter-individual variability in PRL-1 
expression between samples are likely to complicate and perhaps confound data 
interpretation, making it difficult to parse out the gene expression changes that 
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are directly correlated to PRL-1.  The use of cell lines stably overexpressing 
PRL-1, on the other hand, will allow more direct analysis of the downstream 
changes related to altered PRL-1 transcript levels.  In addition, use of the PRL-3 
overexpressing lines will allow comparison of the downstream pathways affected 
by both of these genes and examination of any potential overlap in gene function 
between PRL family members. 
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CHAPTER 6.  RT-PCR ENDOGENOUS CONTROL SELECTION AND 
ANALYSIS OF PRL EXPRESSION IN PRL TRANSFECTED HEK293 CELL 
LINES 
6.1 Introduction 
RT-PCR is considered the gold-standard method for quantifying gene 
expression and is often used to validate significant findings from microarray 
based data sets.  Quantitative real-time PCR expression results are generally 
normalized using endogenous control genes to correct for potential biases in 
RNA input or reverse transcription efficiency.  For accurate analysis, it is 
important to find control genes that are expressed at a constant level across all of 
the samples and experimental conditions that will be compared in a study.  
GAPDH and β-actin have historically been used as standard normalization 
controls for a number of RNA and protein assays, but it is now understood that 
levels of both of these genes can be modulated by a variety of conditions (Suzuki, 
Higgins, & Crawford, 2000).  Hence, prior to running any qRT-PCR assay, it is 
important to first validate the selected control or set of controls in the study 
sample set.  To this end, I used a TaqMan Endogenous Control Array to examine 
the stability of 16 candidate endogenous control genes in HEK293 cells 
transfected with PRL-1, PRL-3, or empty vector.
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The HEK293 cell lines stably overexpressing PRL-1 and PRL-3 had 
previously been characterized and shown to exhibit at least two-fold higher levels 
of PRL-1 or PRL-3 expression compared to their respective empty vector-
transfected cell lines (Liang et al., 2007; Luo et al., 2009).  Despite this, using 
microarray analysis we were unable to detect a significant up-regulation of PRL 
expression in the PRL transfectants.  It is not unheard of for cells to compensate 
and down-regulate expression of a transgene over time; therefore, I elected to 
use qRT-PCR to further examine the PRL-1 and PRL-3 expression levels in the 
same set of samples analyzed in the microarray studies, as well as to 
prospectively examine PRL levels in the samples used for other portions of this 
project (e.g. miRNA and RT-PCR custom arrays).  Endogenous control genes 
selected from the above mentioned Endogenous Control Arrays were used for 
normalization of these data sets. 
 
6.2 Results 
The TaqMan DataAssist software was used to identify the most stably 
expressed transcripts on the endogenous control array.  DataAssist is based on 
the GenNorm statistical algorithm (Vandesompele et al., 2002) which calculates 
an expression stability score for each candidate gene using pairwise 
comparisons of variability.  Each gene is compared to every other gene to 
determine which genes display the least amount of variation in the sample set.  
The calculated scores are then used to rank the genes in order of stability.  The 
resulting stability scores for the PRL-1 stable transfectants and controls are 
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displayed in Table 6.1.  This analysis ranked UBC as the most stable gene in the 
PRL-1 sample set, followed closely by 18S. 
In addition to the stability score comparison, the gene expression levels 
(expressed as Ct values) for each of the candidate endogenous controls were 
plotted (Figure 6.1) and a student’s paired t-test was performed between the 
empty vector and PRL-1 transfectant groups.  Expression of all 16 candidate 
genes was fairly consistent across the sample set.  The standard deviation (SD) 
in Ct value across all samples was also examined individually for each gene 
(Figure 6.2).  SD values ranged from 0.16 for UBC to 0.66 for HPRT1.  The 
genes UBC, 18S, and IPO8, which were the top 3 genes ranked by stability score, 
all exhibited less than 0.2 standard deviations across samples. 
In contrast to PRL-1, stable transfection of HEK293 cells with PRL-3 had a 
remarkable effect on the expression of almost all tested endogenous control 
genes.  Genes that are not detected at a cycle threshold of 36-40 or above are 
often considered absent.  From the DataAssist plot in Figure 6.3, it can be seen 
that each of the tested genes is expressed at detectable levels (Ct < 36) in the 
empty vector samples, but the bulk of these dramatically decrease in expression 
(Ct values increase, most to undetectable levels), in each of the PRL-3 
transfectants.  Only 18S displayed any degree of stability across the full sample 
set.  Examination of the standard deviation in Ct values for this sample set 
revealed SD values greater than 3.5 for all genes except 18S, which had a 
standard deviation of 0.32 (Figure 6.4).  A paired t-test comparing the mean Ct 
values between the empty vector and the PRL-3 transfectant groups revealed 
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significant differences between groups for all genes but 18S (p = 0.35), PGK1 (p 
= 0.61), and RPLP0 (p = 0.11).  These results suggest that PRL-3 may exert 
effects on a broad range of signaling pathways and also underscore the 
importance of the endogenous control selection exercise for verifying consistent 
expression of candidate normalization controls.  UBC was selected as a suitable 
normalization control for PRL-1, while 18S was deemed an acceptable control for 
either the PRL-1 or PRL-3 sample sets in this study. 
Following endogenous control selection, qRT-PCR was performed to 
measure the levels of PRL-1 and PRL-3 in the study samples.  Expression of 
PRL-1 in all samples was low and addition of a pre-amplification procedure to the 
qRT-PCR assay was required to measure it in either the HEK293-PRL-1 or 
HEK293-vector cell lines.  This analysis revealed that two of the three stable 
PRL-1 transfectants used in the microarray analysis displayed PRL-1 transcript 
levels that were at least 4-fold higher than in the empty vector controls (Figure 
6.5).  The third PRL-1 transfectant did not exhibit increased levels of PRL-1 
expression and so this sample was excluded from all downstream data analysis.  
A number of additional HEK293 stable transfectants were also examined and 
three of these, where the PRL-1 transfectants exhibited at least a 1.5-fold 
increase in expression over the vector controls (Figure 6.6), were selected for the 
miRNA and custom TaqMan array studies. 
In the case of PRL-3, surprisingly, not only was PRL-3 not found to be 
overexpressed in the PRL-3 stably transfected cell lines, as compared to their 
empty vector controls, but PRL-3 expression was consistently decreased, by 
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greater than 50-fold, in the PRL-3 transfectants (Figure 6.7).  These results are 
suggestive of a potential compensatory mechanism by which the stably 
transfected cells are down-regulating/silencing PRL-3 expression over time. 
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Table 6.1 Stability scores for candidate endogenous control genes in 
the PRL-1 sample set 
The TaqMan DataAssist algorithm was used to calculate a stability value 
for expression of 16 candidate endogenous control genes in the HEK293 
cells stably transfected with PRL-1 or empty vector that were used for 
microarray analysis.  Genes were ranked in order of greatest stability 
(lowest stability score) to least stability (highest stability score).  Using this 
algorithm, UBC was ranked as the most stably expressed gene in the 
PRL-1 sample set. 
 
Rank Gene Symbol Stability Score 
1 UBC 0.3346 
2 18S 0.3356 
3 IPO8 0.3392 
4 POLR2A 0.3397 
5 TBP 0.3686 
6 PGK1 0.3843 
7 HMBS 0.3847 
8 TFRC 0.3913 
9 PPIA 0.3947 
10 B2M 0.4005 
11 RPLP0 0.4145 
12 YWHAZ 0.4392 
13 GUSB 0.4898 
14 GAPDH 0.6672 
15 ACTB 0.6944 
16 HPRT1 0.7111 
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Figure 6.1 Expression levels of candidate endogenous control genes in 
the PRL-1 sample set 
A TaqMan Endogenous Control Array was used to examine the expression of 
16 candidate endogenous controls in the HEK293 cells stably transfected with 
PRL-1 or empty vector that were used for microarray analysis.  Expression 
levels are represented by cycle threshold (Ct) values.  Median Ct values are 
shown as the black line within each box plot and divide the plot into lower and 
upper quartile ranges.  Whiskers illustrate the minimum and maximum sample 
values.  An asterisk indicates a significant difference (p < 0.05) between 
sample groups, as determined by paired t-test. 
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Figure 6.2 Standard deviation of candidate endogenous controls for PRL-1 
A TaqMan Endogenous Control Array was used to examine the expression of 16 candidate endogenous controls in the 
HEK293 cells stably transfected with PRL-1 or empty vector that were used for microarray analysis.  The standard 
deviation between Ct values for all samples was calculated using Microsoft Excel and plotted in GraphPad Prism.  The 
genes UBC, 18S, and IPO8 exhibited the lowest standard deviation in Ct values for this sample set. 
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Figure 6.3 Endogenous control selection for PRL-3 in HEK293 cells 
A TaqMan Endogenous Control Array was used to examine the expression of 
16 candidate endogenous controls in the HEK293 cell lines stably transfected 
with PRL-3 or empty vector that were used for microarray analysis.  Examination 
of the expression values with DataAssist revealed that only the 18S gene is 
expressed at constant levels across all samples.  In contrast, stable transfection 
of PRL-3 leads to a significant decrease in expression of most other candidate 
genes, as evidenced by Ct values that are well within the detection range of the 
assay in the vector control samples, but increase beyond the level of detection 
in the stable PRL-3 transfectants. 
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Figure 6.4 Standard deviation of candidate endogenous controls for PRL-3 
A TaqMan Endogenous Control Array was used to examine the expression of 16 candidate endogenous controls in the 
HEK293 cells stably transfected with PRL-3 or empty vector that were used for microarray analysis.  The standard 
deviation between Ct values for all samples was calculated using Microsoft Excel and plotted in GraphPad Prism.  The 
18S gene exhibited the lowest standard deviation in Ct values for this sample set. 
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Figure 6.5 PRL-1 expression in cell lines used for microarray 
experiments 
The fold change differences in PRL-1 mRNA transcript levels in HEK293 
cells stably transfected with PRL-1 or empty vector were determined by 
qRT-PCR.  A single PRL-1 stable transfectant (St1) did not exhibit 
enhanced levels of PRL-1 compared to the empty vector controls and was 
removed from microarray data analysis. 
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Figure 6.6 PRL-1 expression in samples used for miRNA and RT-PCR 
custom array analysis 
Quantitative RT-PCR analysis confirmed at least a 1.5-fold up-regulation 
of PRL-1 in HEK293 cells stably transfected with PRL-1 compared to cells 
transfected with empty vector.  These samples were utilized to examine 
the effects of PRL-1 overexpression on miRNA expression and on 
expression of a custom array of genes related to cytoskeletal 
rearrangement and cell motility. 
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Figure 6.7 PRL-3 expression in cell lines used for microarray 
experiments 
The fold change differences in PRL-3 mRNA transcript levels in HEK293 
cells stably transfected with PRL-1 or with empty vector were determined 
by qRT-PCR.  All PRL-3 transfected cells, unexpectedly, displayed lower 
levels of PRL-3 than in the respective empty vector controls. 
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6.3 Discussion 
The fact that PRL-1 transcripts are present at such low levels as to require 
pre-amplification, even with the more sensitive method of qRT-PCR, explains 
why changes in PRL-1 mRNA levels could not be detected using microarrays.  
Moreover, this could suggest that maintenance of basal PRL-1 expression levels 
is tightly regulated within the cell.  Expression of PRL-3 also appears to be 
carefully controlled, given that HEK293 cells stably transfected with PRL-3 were 
initially confirmed to overexpress the transgene, but after multiple passages 
exhibit a down-regulation of PRL-3 expression.  It is possible that the cells 
recognize high levels of PRL-3 and undergo a protective mechanism (e.g. gene 
silencing) to compensate.  This would not be entirely surprising as Basak et al. 
(2008) previously reported the effects of PRL-3 expression on cell-cycle 
progression to be highly dose-sensitive. 
The primary goal of my microarray studies was to identify signaling 
pathways and molecules that are responsive to PRL overexpression; however 
there is clearly additional biology that is occurring in the stably transfected PRL-3 
lines that could confound this analysis.  We are unlikely to be able to confidently 
select candidate PRL-3 effectors from transcriptional profiling of the HEK293 
stable cell lines alone.  A number of commonalities between the PRL-1 and PRL-
3 signaling pathways have now been discovered though, so molecular changes  
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occurring in response to PRL-1 overexpression may provide useful clues that 
promote our understanding of PRL-3 signaling and the cellular response to PRL-
3 up-regulation. 
108 
 
 
 
 
CHAPTER 7.  NOVEL INSIGHTS TO PRL-1 SIGNALING GAINED THROUGH 
INTEGRATED ANALYSIS OF mRNA AND PROTEIN EXPRESSION DATA 
7.1 Chapter Introduction 
To improve our understanding of PRL-1-mediated cellular signaling, I 
performed transcriptional profiling via microarray on triplicate biological replicates 
of the HEK293-PRL-1 and HEK293-vector stable transfectants described in 
Chapters 5 and 6.  The results of this analysis were then integrated with a set of 
proteomic (mass spectrometry) data generated and kindly made available to us 
by Chad Walls in Dr. Zhong-Yin Zhang’s laboratory (Department of Biochemistry 
and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN).  
These combined data sets have been incorporated into a manuscript that is 
currently in preparation to be submitted for publication and is included, in its 
entirety below.  An ‘Author Contributions’ section included at the end of the 
manuscript specifies the portions of this work that were completed by me and 
also details the specific contributions of each co-author.
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7.3 Abstract 
 
7.3.1 Background 
The protein tyrosine phosphatase PRL-1 represents a putative oncogene 
with wide-ranging cellular effects.  Overexpression of PRL-1 can promote cell 
proliferation, survival, migration, invasion, and metastasis, but the underlying 
mechanisms by which it influences these processes remain poorly understood. 
 
7.3.2 Methodology 
To increase our comprehension of PRL-1 mediated signaling events, we 
employed transcriptional profiling (DNA microarray) and proteomics (mass 
spectrometry) to perform a thorough characterization of the global molecular 
changes in gene expression that occur in response to stable PRL-1 
overexpression in a relevant model system (HEK293). 
 
7.3.3 Principle Findings 
Overexpression of PRL-1 led to several significant changes in the mRNA 
and protein expression profiles of HEK293 cells.  The differentially expressed 
gene set was highly enriched in genes involved in cytoskeletal remodeling, 
integrin-mediated cell-matrix adhesion, and RNA recognition and splicing.  In 
particular, members of the Rho signaling pathway and molecules that converge 
on this pathway were heavily influenced by PRL-1 overexpression, supporting 
observations from previous studies that link PRL-1 to the Rho GTPase signaling 
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network.  In addition, several genes not previously connected to PRL-1 were 
found to be significantly altered by its expression.  Most notable among these 
were Filamin A, RhoGDIα, SPARC, hnRNPH2, and PRDX2. 
 
7.3.4 Conclusions and Significance 
This systems-level approach sheds new light on the molecular networks 
underlying PRL-1 action and presents several novel directions for future, 
hypothesis-based studies. 
 
7.4 Introduction 
The PRL family of enzymes has recently emerged as potential tumor 
biomarkers and novel anti-cancer therapeutic targets.  Evidence suggests that 
the three PRL family members (PRL-1, PRL-2, and PRL-3) may be multi-faceted 
molecules involved in a number of diverse biological processes [1-5], however 
recent attention to these enzymes revolves around their relationship to cellular 
proliferation and tumor progression. 
PRL-1, the first family member identified, was initially characterized and 
named Phosphatase of Regenerating Liver for its role as an immediate early 
gene induced in mitogen-stimulated cells and in proliferating rat liver during 
hepatic regeneration [6,7].  Accumulating evidence now indicates that up-
regulation of PRL-1 expression may play a causal role in cellular transformation 
and tumor advancement.  Overexpression of PRL-1 in non-tumorigenic cells 
leads to rapid cellular growth and a transformed phenotype [6,8,9].  Moreover, 
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cells that stably overexpress PRL-1 exhibit enhanced cell motility and invasive 
activity and are capable of forming metastatic tumors in nude mice [6,10-13].  
Conversely, knockdown of endogenous PRL-1 in tumor cells has the opposite 
effect, reducing proliferation and suppressing cell migration and invasion 
[10,12,14-16].  An association between PRL-1 expression and tumor promotion 
has also been found in human tumor tissues where we previously showed that 
PRL-1 was significantly up-regulated in 100% of hepatocellular and gastric 
carcinomas compared to matched normal tissues from the same patients [17].  
Collectively, these results suggest that the PRL-1 phosphatase regulates key 
pathways involved in tumorigenesis and metastasis.  However, the mechanisms 
of PRL-1 action and regulation are poorly understood and the exact biological 
function of this molecule remains unknown. 
Examination of individual molecules and pathways reveals that PRL-1 
may be involved in multiple different signaling cascades.  PRL-1 up-regulation 
may enhance cell proliferation by coordinately decreasing expression of negative 
cell cycle regulators (p21cip1/waf1, p53) and increasing expression of positive cell 
cycle regulators (Cyclin A, Cdk2), thus promoting unscheduled entry into S phase 
[9,18].  PRL-1 might also augment cell motility and invasion by signaling through 
the Rho family small GTPases, focal adhesion complex-associated proteins, and 
the ERK1/2 mitogen-activated protein kinase (MAPK) cascade to induce the 
alterations in the actin cytoskeleton required for cell movement and to up-
regulate matrix metalloproteinases capable of breaking down the extracellular 
matrix and permitting cell invasion and migration [10-12,14].  A direct physical 
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interaction between PRL-1 and the Rho GTPase activating protein (GAP), p115 
RhoGAP may promote some of these effects by preventing p115 RhoGAP from 
deactivating RhoA as well as blocking its inhibitory binding of the ERK activator 
MEKK1 [19].  
To date, PRL-1 shows the strongest activity as an autophosphatase [6], 
but it can also bind and partially dephosphorylate the pro-survival transcription 
factor ATF-7 (a.k.a. ATF-5) [20].  PRL-1 interacts directly with several 
phosphoinositide lipids [16], the cytoskeletal component α-tubulin [21], the 
suppressor of TNF-mediated apoptosis TNFAIP8 (tumor necrosis factor alpha-
induced protein 8) [22], and with FKBP38 (peptidylprolyl cis/trans isomerase 
FK506-binding protein 38), whose binding may target PRL-1 for proteosomal 
degradation [23].  PRL-1 induction in mitogen stimulated cells and regenerating 
liver can largely be attributed to its up-regulation by the transcriptional activator 
EGR-1 [24].  Additionally, PRL-1 is subject to redox regulation and has been 
suggested to play a role in the photo-oxidative stress response in the retina, 
where it relies on the glutathione system for constant regeneration of its 
enzymatic activity [5,25]. 
While knowledge surrounding PRL-1-mediated signaling events has been 
greatly enhanced through focused investigations on individual genes and isolated 
pathways, it is clear that PRL-1 signaling is a multi-dimensional process.  
Moreover, there is an increasing appreciation that all cellular processes are 
governed by the complex interplay between multiple signaling networks.  “Omics” 
techniques offer the advantage of an unbiased and global view of the changes 
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that are occurring as well as the opportunity to identify previously unforeseen 
players that are responding with respect to a particular stimulus.  Therefore, in 
the current study, we utilized microarray profiling of gene expression 
(transcriptomics) and mass spectrometry (proteomics) to more broadly examine 
the gene and protein level alterations occurring in human embryonic kidney 293 
(HEK293) cells stably overexpressing PRL-1.  This integrated, systems-level 
approach provides an unprecedented, comprehensive dataset that helps shed 
light on the molecular networks underlying PRL-1 action and also presents new 
possible directions for future, hypothesis-driven research. 
 
7.5 Methods 
 
7.5.1 Stable Cell Lines and Cell Culture 
Human embryonic kidney 293 cells stably overexpressing PRL-1 
(HEK293-PRL-1) or empty pcDNA4 vector (HEK293-vector) were previously 
generated and described [11,16].  Cells were grown in 100 mm plates in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) fetal 
bovine serum (Thermo Scientific HyClone, Logan, UT), 50units/ml penicillin 
(Mediatech, Inc., Manassas, VA), and 50µg/ml streptomycin (Mediatech). 
 
7.5.2 Mass Spectrometry 
Seven 100mm plates each of HEK293-PRL-1 and HEK293-vector cells 
were grown to 95% confluency, the culture medium was aspirated and the cell 
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monolayers were washed once in 1X PBS, then frozen at -80°C until use.  Upon 
thawing the cells, protein samples were prepared and analyzed as previously 
described [26].  Briefly, cells were treated with 100µl of a hypotonic lysis buffer 
containing 8M urea, 10mM DTT and 1mM sodium orthovanadate (Sigma-Alrich, 
St. Louis, MO).  The resulting cell lysates were reduced by triethylphosphine 
(Sigma-Aldrich), alkylated by iodoethanol (Sigma-Aldrich) and subsequently 
digested using trypsin (Promega, Madison, WI).  Peptide concentration was 
determined using the Bradford Protein Assay. 
Mass spectrometry (MS) and MS data analysis were carried out at 
Monarch Life Sciences (Indianapolis, IN) using previously described methods 
[26-29].  Tryptic digests were analyzed using a linear ion-trap mass spectrometer 
(LTQ) coupled to a Surveyor HPLC system (Thermo Scientific, Waltham, MA).  
Tryptic peptides (~20µg/injection) were injected in random order onto a 
microbore, C18 reversed-phase column (Zorbax 300SB0C18, 1mm x 5cm) with a 
flow rate of 50µl/min and eluted with a gradient from 5 to 45% acetonitrile 
(Honeywell Burdick & Jackson, Morristown, NJ) developed over 120 min.  The 
effluent was electrosprayed into the LTQ mass spectrometer and data were 
collected in triple-play mode (MS scan, zoom scan, MS/MS scan).  The acquired 
data were filtered and analyzed using algorithms developed and described by 
Higgs et al. [27-29].  For peptide identification, database searches were carried 
out against the IPI (International Protein Index) human database and the non-
redundant Homo sapiens database using both the X!Tandem and SEQUEST 
algorithms [30,31].  Identified proteins were categorized into tier groups (1-4) 
116 
 
 
 
 
based on the quality of the peptide identification and the number of unique 
peptides identified.  Proteins assigned to Tier 1 had high (>90%) peptide 
confidence and multiple sequences identified; Tier 2 had high peptide confidence 
with only a single sequence identified; Tier 3 had moderate (75-89%) peptide 
confidence and multiple sequences; Tier 4 had moderate peptide confidence and 
a single sequence.  Estimation of confidence levels was based on a random 
forest recursive partition supervised learning algorithm [27].  Peptides assigned 
to proteins with a confidence level of less than 90% (Tier 3 and Tier 4 peptides) 
were filtered out of this study.  For protein quantification, raw files were acquired 
from the LTQ mass spectrometer and all extracted chromatograms (XIC) were 
aligned by retention time.  To be used in the protein quantification procedure, 
each aligned peak must match parent ion, charge state, daughter ions (MS/MS 
data) and retention time (within a one-minute window).  After alignment, the area-
under-the-curve (AUC) for each individually aligned peak from each sample was 
measured, quantile normalized, and compared for relative abundance.  All peak 
intensities were transformed to a log2 scale before quantile normalization.  If 
multiple peptides had the same protein identification, then their quantile 
normalized log2 intensities were averaged to obtain log2 protein intensities.  
Analysis of Variance (ANOVA) was used to detect significant changes in protein 
expression between the HEK293-PRL-1 and HEK293-vector groups.  The p-
value threshold was fixed to control the false discovery rate at 5% (≤ 0.05).  The 
inverse log2 of each sample mean was calculated to determine the fold change 
between samples.  
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IPI identifiers and NCBI (National Center for Biotechnology Information) 
GenInfo Identifiers (GIs) were mapped to NCBI gene symbols using the Biobase 
Biological Database (http://www.biobase-international.com/) and the National 
Center for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/gquery).  This mapping of proteins to their coding 
genes serves as the basis for integrating the protein mass-spectrometry results 
with the mRNA data sets described below. 
 
7.5.3 Gene Expression Microarray 
Total RNA was extracted from three independent cultures each of 
HEK293-PRL-1 and HEK293-vector cells using the TRIzol reagent (Invitrogen 
Life Technologies, Carlsbad, CA) and further purified with an RNeasy Mini Kit 
(Qiagen Inc., Valencia, CA), following manufacturer’s instructions.  RNA integrity 
and yield were assessed by determining sample absorbance at 260 and 280 nm 
on a DU640B spectrophotometer (Beckman Coulter, Brea, CA) and by subjecting 
samples to the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, 
CA), using the Agilent RNA 6000 Nano LabChip Kit as directed.   
Gene expression profiling was carried out according to the protocol 
described in the Affymetrix GeneChip Expression Analysis Technical Manual.  
Briefly, 5µg of each cleaned, total RNA was used to generate double-stranded 
cDNA, by reverse transcription, using a Superscript Double-Stranded cDNA 
Synthesis Kit (Invitrogen Life Technologies) and a GeneChip T7-Oligo(dT) 
Promoter Primer Kit (Affymetrix, Santa Clara, CA).  Following second-strand 
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synthesis, cDNA was cleaned with a GeneChip Sample Cleanup Module 
(Affymetrix), and then used as a template for synthesis of biotinylated cRNA with 
the Enzo BioArray HighYield RNA Transcript Labeling Kit (Enzo Life Sciences, 
Farmingdale, NY).  Labeled cRNA was cleaned with a GeneChip Sample 
Cleanup Module (Affymetrix), fragmented, and hybridized overnight to HG-U133 
Plus 2.0 GeneChip Human Genome Arrays (Affymetrix), which analyze the 
expression level of more than 47,000 RNA transcripts and variants.  Following 
hybridization, GeneChips were washed, stained with streptavidin phycoerythrin 
(Molecular Probes, a subsidiary of Life Technologies, Carlsbad, CA), and 
scanned using the Affymetrix GeneChip Scanner 3000 7G.  Raw image (CEL file) 
generation and analysis was performed using the Affymetrix GeneChip Operating 
System (GCOS).  All RNA samples and arrays met Affymetrix recommendations 
for standard quality control metrics. 
Microarray data files were processed with R-project software 
(http://www.r-project.org/), version 2.13.1 through the RStudio interface version 
0.94.92 (http://www.rstudio.org).  The intensity values were read using the “affy” 
library of the Bioconductor package, version 2.8 [32,33].  Normalization and calls 
were made using the mas5 procedure under default parameters.  Probesets 
were scored for hybridization reliability as “High”, “Medium”, or “Low” by the 
method described in [34].  One of the chips that was hybridized with a HEK293-
PRL-1 sample was removed from the analysis, after quantitative real-time 
reverse transcription PCR (qRT-PCR) confirmation revealed that this sample did 
not express PRL-1 differently from the controls, leaving 2 biological replicates in 
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the PRL-1 overexpressing group and 3 biological replicates in the vector control 
group.  Probesets that were not called as ‘present’ by mas5 in at least four out of 
the five remaining chips were removed from the analysis, save for cases where a 
probeset was present in both members of the PRL-1 overexpressing group but 
absent in all of the vector controls.  15,967 probesets of the original 54,675 
passed this presence filter. 
After transformation into a log2 scale, mean normalized expression values 
were calculated for each of the 15,967 probesets over all biological replicates for 
both of the experimental comparison groups (HEK293-PRL-1 and HEK293-
vector).  Differential expression between the two groups was determined for each 
probeset and assessed for significance in terms of p-value by the Student’s t-test.  
Multiple-testing false discovery rate (FDR) correction values were calculated 
using the Benjamini-Hochberg procedure [35]. 
 
7.5.4 Quantitative RT-PCR 
A set of 184 genes, identified by microarray and/or proteomic analyses as 
differentially regulated or associated in the literature with signaling pathways 
involved in integrin-mediated cell signaling, cytoskeletal remodeling, and/or cell 
motility, was chosen for validation of gene expression changes using qRT-PCR.  
Total RNA was isolated as described for the microarray experiments, but using 
independent biological replicates of HEK293-PRL-1 and HEK293-vector cells.  
Isolated total RNA was treated with DNase I, using the Ambion TURBO DNA-free 
kit from Invitrogen Life Technologies and 1µg of each sample was reverse 
120 
 
 
 
 
transcribed into cDNA with the SuperScript III First-Strand Synthesis System and 
random hexamer primers (Invitrogen Life Technologies), in accordance with the 
manufacturer’s guidelines.  The resulting cDNA was used as template for qRT-
PCR using commercially available TaqMan Gene Expression Assays (Applied 
Biosystems, a subsidiary of Life Technologies, Carlsbad, CA) custom arrayed on 
96-well plates.  Supplemental Table S1 contains the full list of TaqMan assays 
that were examined. 
As per the manufacturer’s protocol, cDNAs were combined with TaqMan 
Gene Expression Master Mix (Applied Biosystems) and 100ng cDNA was added 
to each well of the custom TaqMan Array Plate and amplified by PCR on an 
Applied Biosystems 7900HT Fast Real-Time PCR System under the 
recommended cycling conditions:  2 min at 50°C, 10 min at 95°C and 40 cycles 
of 15 sec at 95°C for denaturation and 1 min at 60°C for annealing/extension.  
Raw threshold cycle (Ct) values were obtained using Sequence Detection 
System (SDS) software v2.4 (Applied Biosystems).  Ct values ≥ 40 were set to 40 
and were considered not detectable.  Among 4 reference genes tested, B2M, 
18S ribosomal RNA, GAPDH, and UBC, 18S was found to be the most stable 
according to analysis with DataAssist Software, v2.0 (Applied Biosystems) and 
therefore was chosen as the reference gene for normalization of all gene 
expression results. 
For comparative statistics, mRNA data files were processed with Partek 
Genomics Suite version 6.11.1115 (http://www.partek.com) using default 
parameters and 18S as the endogenous control.  Mean normalized Ct values for 
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each assay over all biological replicates (n = 2) for both of the experimental 
comparison groups (HEK293-PRL-1 and HEK293-vector) were calculated.  
Differential expression between the two comparison groups was determined for 
each assay using the comparative Ct method (ΔΔCt) and assessed for 
significance in terms of p-value by the Student’s t-test. 
 
7.5.5 Functional, Network, and Pathway Analysis 
Two input data sets for functional and pathway analysis of the protein 
mass-spectrometry results were prepared by applying significance cutoffs of q ≤ 
0.20 and q ≤ 0.50 to the detected Tier-1 differentially-expressed proteins.  These 
data sets, consisting of 81 and 152 proteins respectively, included each protein’s 
Entrez Gene ID, fold change under the experimental conditions described in the 
mass-spectrometry section above, and the p-value and FDR-corrected q-value of 
that change. 
Two input data sets for functional and pathway analysis of the mRNA 
microarray results were prepared by applying significance cutoffs of q ≤ 0.20 and 
q ≤ 0.50 to the detected differentially-expressed probesets.  These data sets, 
consisting of 58 and 2263 probesets respectively, included each probeset’s 
Affymetrix ID, associated gene Entrez ID, fold change under the experimental 
conditions described in the mass-spectrometry section above, and the p-value 
and FDR-corrected q-value of that change. 
For each of the four above input data sets, enriched biological functions 
and pathways were determined using three systems: Ingenuity Pathway Analysis 
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(IPA) software core analysis (Ingenuity Systems, http://www.ingenuity.com), 
application build version 162820, content version 12710793 with default settings; 
the Enrichment and Interactome workflows of MetaCore from GeneGo, Inc. 
version 6.8 with default settings; and the DAVID Functional Annotation and Gene 
Function Classification tools version 6.7 [36,37]. 
 
7.6 Results 
To investigate the signaling pathways through which PRL-1 mediates its 
biological effects, we previously established and characterized a HEK293 cell 
line stably overexpressing PRL-1 and confirmed that both the mRNA and protein 
levels of PRL-1 in this line are at least 2-fold higher than that of endogenous 
PRL-1 in the associated vector control cells [11,16].  The stable overexpression 
of PRL-1 in the HEK293 cells produces significant changes in the patterns of 
expression of mRNA transcripts and proteins.  In the first part of this section, we 
examine these changes at the level of the individual nucleic acid and protein 
experiments.  In the second part, we examine these changes using data sets 
constructed from the integration of the results of nucleic acid and protein 
experiments. 
 
7.6.1 Mass Spectrometry 
To identify proteins whose expression is specifically altered in response to 
PRL-1, protein lysates from seven independent cultures each of HEK293-PRL-1 
and HEK293-vector cells were subjected to MS analysis.  Proteomic analysis 
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resulted in the identification, coding gene annotation, and relative quantification 
of 763 Tier 1 (high peptide confidence; multiple hits) and 571 Tier 2 (high peptide 
confidence; single hit) proteins.  Of these, there were 45 Tier 1 and 15 Tier 2 
proteins that were subtly, but significantly differentially expressed (FDR ≤ 0.05) 
between the HEK293-PRL-1 and HEK293- vector cell lines.  23 Tier 1 and 5 Tier 
2 proteins were up-regulated in the HEK293-PRL-1 lines and 22 Tier 1 and 10 
Tier 2 proteins were down-regulated in these lines with respect to the vector 
controls.  A list of significantly differentially expressed Tier 1 proteins is provided 
in Table 7.1. 
 
7.6.2 Microarray 
Expression changes at the mRNA level were simultaneously analyzed 
using Affymetrix Human Genome U133 Plus 2.0 microarrays on HEK293 cells 
that were cultured independently from those utilized in the proteomic analysis.  
Of the 15,967 microarray probesets that were assayed for mRNA expression and 
found to be present in one or both comparison groups of HEK293 cells, 25 were 
found to show significant (q ≤ 0.10) differential expression between PRL-1 
overproducing and control vector groups after adjustment for FDR.  Of these 
probesets, 11 showed a decrease of expression and 14 showed an increase of 
expression in the presence of overproduced PRL-1.  Table 7.2 lists these 
probesets along with their corresponding genes. 
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7.6.3 Quantitative RT-PCR Validation 
The protein coded by the top up-regulated transcript by microarray, 
SPARC (secreted protein, acidic, cysteine-rich), was not detected in the 
proteomic data, therefore, to further validate the microarray result for this gene, 
SPARC expression was evaluated by quantitative RT-PCR, using two HEK293-
PRL-1 and two HEK293-empty-vector samples that were independent from those 
used for the microarray analysis.  As shown in Table 7.3, qRT-PCR validation 
confirmed that SPARC mRNA is significantly (q-value = 5.83 x 10-03, fold-change 
= 226) up-regulated in response to PRL-1 overexpression. 
Previous studies have shown a relationship between PRL-1 and various 
components of integrin-mediated cell signaling pathways.  These integrin-
responsive players can promote re-arrangements in the actin cytoskeleton that 
are central to promotion of cell motility, invasion, and metastasis.  Therefore, a 
total of 184 genes (including SPARC) known to be associated with integrin-
mediated signaling pathways or cytoskeletal remodeling were arrayed on 
Taqman custom 96-well plates and assayed for differential expression in 
response to PRL-1 up-regulation.  Of the 177 qRT-PCR assays that yielded 
mRNA expression signals, 58 were found to have significant differential 
expression at a Fold Change > 2, p ≤ 0.02, and FDR q-value ≤ 0.05.  Table 7.3 
lists these assays along with their corresponding genes.  The full list of qRT-PCR 
results can be found in Table S1.  Most significantly up-regulated genes 
represented positive regulators of epithelial-mesenchymal transition (EMT), cell 
proliferation, survival, and migration, for example, HIF1A, ZEB1, H-RAS, N-RAS, 
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K-RAS, ROCK 1/2, Arp 2/3 (ACTR2/3) and phosphoinositide 3-kinase (PIK3CA 
and PIK3R1).  Only seven genes were significantly down-regulated.  Among 
these were HNF4A, a suppressor of EMT; IGFBP7, a stimulator of cell adhesion 
and inhibitor of cell growth; and, interestingly, PRL-3 (PTP4A3). 
 
7.6.4 Microarray and protein data integration 
Approximately 825 of the 918 Tier-1 proteins detected by mass 
spectrometry were mapped to a least one probe set on the HG-U133 Plus 2.0 
array by coding gene name matching.  After accounting for multiple protein 
products associated with the same coding gene, the final count of unique Tier 1 
proteins that were mapped to microarray probesets was 763.  Although other 
groups have demonstrated that some microarray probesets can be associated 
with the specific mRNA transcripts of particular protein isoforms [38], all protein-
mRNA mapping in this study was performed at the more conservative level of the 
coding gene.  Of the 1202 probesets mapped to Tier-1 proteins, 1089 (91%) had 
detectable gene expression as defined by their presence or absence in either 
comparison group, demonstrating a high level of co-detection. 
Further evidence of the alignment of the mRNA microarray and protein 
experimental results is provided by a comparison of the distributions of the 
expression signals of those mRNA probesets that were matched to coding genes 
of detected proteins and those that were not.  Figure 7.1 shows that the proteins 
associated with higher mRNA expression levels were preferentially detected in 
the mass-spectrometry experiment in both the empty-vector (EV) and the PRL-1-
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overproducing (P1) groups.  The medians of the distributions for the protein-
matched and non-protein-matched probeset expression values differ by a factor 
of approximately 4-fold, which is consistent with values reported by other paired 
protein and mRNA studies [39].  The median expression level for the mRNA’s 
associated with proteins that were detected under PRL-1-overproducing 
conditions was approximately 5% higher than that observed in the empty vector 
group. 
We also observed a positive directional correlation between the 
expression levels of 63 significantly-changed (q ≤ 0.10) proteins and their 
associated microarray mRNA probesets, as illustrated by the annotated volcano 
plot in Figure 7.2.  Of the 63 proteins with significant differential expression, 52 
were mapped to detected microarray probesets and 30 (48%) had corresponding 
mRNA level changes at a p-value ≤ 0.2.  The total number mRNA transcripts with 
p ≤ 0.2 that mapped to these 30 proteins was 43.  Of these 43 changing 
transcripts, 39 (91%) demonstrated fold changes in the same direction as the 
protein and only 4 (mapped to the genes EEF1A1, ELAVL1, FASN, and HSP1A1) 
changed in the opposite direction. 
 
7.6.5 Functional and Pathway Analysis 
 
7.6.5.1 Functional annotation enrichment 
To address the biological relevance of the significantly differentially 
regulated proteins and mRNA signals under PRL-1 overproducing conditions, we 
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first used functional annotation enrichment analysis to associate the data with 
specific biological themes and canonical pathways.  Three different tool systems 
were used: IPA, MetaCore, and DAVID (see Methods). 
The enrichment results from the protein data set indicated an over-
representation of coding genes related to high-level (more broad) ontology 
database annotations of cellular proliferation, tumorigenesis, regulation of cell 
death, and protein folding (p-value range from 1E-11 to 1E-06).  The most 
enriched low-level (more detailed) annotations were spliceosome components 
and RNA recognition via RRM domains, nucleotide binding and metabolism 
(purines in general and GTP in particular), cytoskeletal remodeling (notably actin 
and intermediate filaments), and integrin-mediated cell-matrix adhesion (p-value 
range from 1E-12 to 1E-05). 
At the mRNA microarray level, the top functional annotation results follow 
those for the protein data set in most of the categories described above, 
including cellular proliferation, tumorigenesis, RNA recognition and splicing, and 
cytoskeletal remodeling (p-value range from 1E-07 to 1E-03).  As an exception, 
the mRNA data indicate an enrichment in transcriptional regulation terms that is 
not seen in the protein data, which follows given the greater sensitivity of nucleic 
acid assays over global protein mass-spectrometry methods when detecting low-
abundance regulatory gene products. 
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7.6.5.2 Pathway analysis 
The interactions among the proteins that were differentially-expressed 
under PRL-1 overexpressing conditions were evaluated in light of previous 
studies that described PRL-1-associated changes in Rho-mediated signaling 
pathways [10,12,14], the direct interaction between PRL-1 and Rho-regulator 
ARHGAP4 [19], and the prominence of Rho-regulating proteins in the mass-
spectrometry results of this study (e.g. ARHGDIA, GDI2). 
We observe broad changes in cytoskeletal remodeling signaling proteins 
in the presence of overexpressed PRL-1.  These changes are illustrated in Error! 
Reference source not found. using a diagram of selected direct influences of 
Rho-regulating proteins on cytoskeleton remodeling that was adapted from the 
Rho-mediated signaling canonical pathways published in the IPA and GeneGo 
MetaCore databases.  Specifically, we observe a decrease in the expression of 
the Tier-1 Rho guanine nucleotide dissociation inhibitor RhoGDIα (ARHGDIA, 
foldchange = -1.17, p = 6.8E-12).  RhoGDIα binds to the ezrin-radixin-moesin 
(ERM) proteins, which regulate membrane-cytoskeletal interactions and maintain 
membrane tension [40].  All three ERM proteins were detected at Tier-1 and 
show a non-significant but co-directional decrease in expression [41].  RhoGDIα 
also binds to RhoA.  This interaction not only blocks nucleotide exchange and 
sequesters RhoA away from its substrates, but additionally protects RhoA from 
proteosomal degradation [42].  Consequently, RhoA protein expression levels 
tend to mimic the expression of RhoGDIα [42,43].  Consistent with this, RhoA 
protein levels were decreased in the PRL-1 transfectants compared to the empty 
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vector controls and this result was confirmed by western blotting (data shown in 
dissertation Chapter 8).  We also observed non-significant, but consistent 
changes in proteins that drive actin polymerization (e.g. actin-related protein 2 or 
ACTR2 and other members of the ARP2/3 complex), actin disassembly (e.g. 
destrin, cofilin-1, and cofilin-2), and myosin light chain components.  The direct 
interaction between PRL-1 (PTP4A1) and ARHGAP4 is shown in Error! 
Reference source not found., but the indirect influences of PRL-1 on the 
pathway components (e.g. via ERK1/2) are not shown here. 
 
7.7 Discussion 
The identification of genes that are affected by PRL-1 up-regulation may 
provide important clues regarding the biology of this protein and shed light on the 
mechanism underlying PRL-1 induced tumorigenesis and metastasis.  However, 
there is an expanding repertoire of genes thought to be under PRL-1 control and 
no single, linear signaling pathway can be attributed to its effects.  Therefore, we 
took a systems level approach to globally characterize the molecular changes in 
expression that occur upon sustained exposure to PRL-1 at the transcriptome 
and proteome levels using DNA microarray and mass spectrometry technology.  
The HEK293 epithelial cell line was chosen to investigate the effects of PRL-1 
overexpression because we had previously characterized the phenotypic 
alterations, including enhanced cell growth and increased migratory and invasive 
capacity, associated with stable PRL-1 overexpression in this system [11,16].  
Through use of these highly complementary technologies, we have identified 
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several new genes as being responsive to PRL-1 signaling and provide evidence 
strengthening the notion that PRL-1 leverages signaling pathways which exert 
effects mainly on the cell cycle, cytoskeleton, and cellular adhesions to promote 
cell proliferation and cell survival and to favor the acquisition of invasive and 
metastatic properties. 
 
7.7.1 Most genes display coordinate regulation at the mRNA and protein levels 
Overall, there was good directional correspondence between the RNA and 
protein data with 91% of mRNA microarray probesets changing in the same 
direction as the significantly differentially expressed proteins to which they map.  
This correspondence implies that the levels of these proteins are driven directly 
by the abundance of their cognate transcripts.  There were also instances, 
however, where the changes at the RNA and protein levels did not parallel one 
another.  There were a small number of instances where one of either the RNA 
or protein, was changing significantly while the other was not.  In addition, there 
were four genes, ELAVL1 (embryonic lethal, abnormal vision, drosophila-like 1), 
HSPA1A (heat shock 70kDa protein 1A), EEF1A1 (eukaryotic translation 
elongation factor 1, alpha 1), and FASN (fatty acid synthase) where the protein 
and RNA showed opposite expression patterns.  A lack of correlation between 
RNA and protein could be due to multiple factors, including differential turnover 
rates or the presence of post-transcriptional or post-translational control 
mechanisms.  The established thresholds or differential sensitivities and biases 
between the microarray and proteomics assays could also be a factor.  For one, 
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proteomics datasets tend to display a systematic bias favoring more abundant 
proteins over low abundant, transiently expressed or unstable molecules [44-46].  
In support of this, an examination of the RNA expression levels revealed that the 
signal distribution was approximately four times higher for genes whose products 
were detected in the proteomic survey as compared to those that were not, 
suggesting that some changes may simply not have been detected due to low 
protein abundance. 
Despite these discrepancies, the combined proteomic and transcriptomic 
data sets are highly complementary to one another and provide a more complete 
picture of PRL-1-mediated signaling events, in HEK293 cells, than could be 
gleaned from either technique in isolation.  These data suggest that, in many 
cases, transcript levels trend the same as protein levels and can be used as a 
general indicator of protein abundance in this system, but that both transcription-
dependent and transcription-independent pathways contribute to PRL-1-induced 
signaling responses. 
 
7.7.2 FLNA, HNRNPH2, and PRDX2 are among the most significantly changing 
gene products in both the microarray and proteomics datasets 
A total of 17 genes were identified (those marked with an asterisk in 
Figure 7.2) that exhibited statistically significant changes in expression at both 
the RNA and protein levels and each of these is revealed here, for the first time, 
to be responsive to alterations in PRL-1 expression.  Three of these genes, 
FLNA, HNRNPH2, and PRDX2 continued to reach significance at both the RNA 
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and protein levels, even after multiple testing correction was applied to both data 
sets and therefore make highly promising candidates for downstream 
components of the PRL-1 signaling pathway. 
FLNA (Filamin A) represents the most robustly and highly up-regulated 
protein in the proteomic analysis.  In addition, all three probesets for FLNA on the 
Affymetrix microarray showed approximately 2-fold up-regulation in response to 
PRL-1 (p < 0.05).  The FLNA gene encodes the most abundant and widely 
expressed member of a family of three filamin proteins (FLNa, FLNb, FLNc) [47].  
It is a large, homodimeric, actin binding protein that plays important roles in 
remodeling the cytoskeleton to influence cell shape and cell motility [47-49].  
Cells deficient in FLNa exhibit defects in both cell spreading and initiation of 
migration [50]. 
Filamin A also serves as a versatile molecular scaffold, connecting and 
coordinating the intracellular signaling partners from a wide variety of cellular 
processes.  It directly interacts with more than 90 different proteins including 
transmembrane receptors, ion channels, intracellular signaling molecules, and 
transcription factors [51].  Among these are several members of the integrin and 
Rho GTPase families which play central roles in actin cytoskeletal reorganization, 
cell adhesion, cell migration, invasion, and control of cell cycle progression [52-
54].  FLNa can bind the Rho GTPases Rho, Rac, and Cdc42, the Rac guanine 
nucleotide exchange factor (GEF) Trio, the RhoGEF Lbc, the Rho GTPase 
activating protein p190RhoGAP, the Rac GAP FilGAP, and the Rho GTPase 
effectors PAK and ROCK [48].  These interactions make FLNa an ideal integrator 
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of the Rho GTPase signaling cascade.  Changes in PRL-1 expression have 
previously been shown to alter the downstream activity (amount bound to GTP) 
of RhoA, RhoC, Rac1, and Cdc42 [10,12].  Moreover, PRL-1 overexpression in 
the current study led to down-regulation of RhoGDIα and RhoA expression levels.  
The strong up-regulation of FLNa in the PRL-1 transfectants, combined with its 
known relationship to the Rho pathways make it an attractive subject for future 
examination as a potential link between PRL-1 and control of Rho GTPase-
mediated signaling. 
Besides having an influence on various mediators of cell cycle and cell 
migration, FLNa has been implicated in regulation of a multitude of other wide-
ranging processes.  Among these, regulation of potassium ion channel function 
[55-57], vascular function and angiogenesis [58-61], TGFβ-mediated signaling 
[62-64], and integrin receptor recycling [65] are particularly intriguing, given that 
PRL family member PRL-3 has previously been linked to each of these 
processes [10,66-69].  Furthermore, FLNa has been found to directly interact 
with and control the surface expression levels of the 2.1 subunit (also known as 
KCNJ2) of the inwardly rectifying K+ 2 (Kir2) subfamily of potassium channel [57].  
In the current study, we did not detect significant changes in Kir2.1 levels, 
however we did find that PRL-1 overexpression led to significantly elevated (1.6 
fold) transcript levels of the Kir2.2 subunit (KCNJ12), which can 
heterotetramerize with Kir2.1 to form active Kir channels [70].  FLNa thus has the 
potential to serve as a link between PRL-1 and a wide variety of downstream 
signaling pathways, which may, in part, overlap with the functions of closely 
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related family member PRL-3.  Interestingly, expression of PRL-3 mRNA was 
decreased in the PRL-1 transfectants. 
HNRNPH2 was also significantly up-regulated at both the mRNA and 
protein levels in response to PRL-1.  This molecule belongs to the heterogenous 
nuclear ribonucleoprotein (hnRNP) family of RNA-binding proteins which heavily 
influence pre-mRNA processing as well as other aspects of mRNA metabolism 
and transport [71,72].  The hnRNPH2 protein is part of a subfamily of hnRNP 
whose members (H1, H2, H3, and F) are best known for their key roles in the 
regulation of alternative splicing.  Splice site selection is controlled by the 
orchestrated effects of multiple splicing factors that bind to specific RNA 
elements and either promote or impede the assembly of the splicing machinery 
[73,74].  In addition to the HNRNP family, other gene families with well known 
roles in alternative splice site selection include the serine/arginine-rich splicing 
factor (SRSF) family [74] and the embryonic lethal, abnormal vision, Drosophila-
like (ELAVL) family [75,76].  Notably, in our study, members of each of these 
three families of splice site regulators (HNRNPH1, HNRNPH2, HNRNPF, 
HNRNPA3, SRSF2, SRSF3, and ELAVL1) exhibited significant changes in 
expression, at least at the protein level, upon PRL-1 overexpression.  Alternative 
splicing increases the functional complexity of gene expression and, in tumors, it 
generates variants that can contribute to multiple aspects of tumor establishment, 
progression, and maintenance.  Observations suggest that genes involved in cell 
morphology, movement, adhesion, growth, proliferation, and cytoskeletal 
organization are particularly prone to alternative splicing events [77].  Genes 
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involved in each of these processes have been shown, both here and in other 
studies, to be modulated by PRL-1 raising the possibility that changing 
alternative splicing patterns may be one mechanism by which PRL-1 contributes 
to cancer cell plasticity. 
In contrast to FLNA and HNRNPH2, the gene products of PRDX2 were 
significantly down-regulated upon PRL-1 overexpression.  PRDX2 is a member 
of the peroxiredoxin (Prdx) family of ubiquitously expressed antioxidant enzymes 
with important functions in maintaining cellular redox homeostasis [78].  
Additional roles have also been found for the Prdx enzymes in signal 
transduction, protection from tissue injury and infection, and tumorigenesis 
[79,80].  Family member Prdx1 (also decreasing with PRL-1 expression in our 
study) has been described as a tumor suppressor, because it binds c-myc, 
suppressing its oncogenic signaling potential [81], binds to the tumor suppressor 
PTEN, protecting it from oxidative inactivation, and suppresses H-Ras and ErbB-
2-induced cellular transformation and tumor formation [82].  Studies have also 
shown that inactivation of Prdx1 or Prdx2 may be necessary for hydrogen 
peroxide mediated cellular signaling in response to growth factor stimulation and 
for cell survival signaling under conditions of oxidative stress [83,84].  However, 
elevated levels of each Prdx family member have been found in a variety of 
cancer cell lines and tissues [79,85-87] and both Prdx1 and Prdx2 can directly 
suppress the activity of several pro-apoptotic factors [79].  Therefore, the 
functional consequences of Prdx activity and/or inhibition remain an active area 
of study. 
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Taken together, the consistent and robust changes between RNA and 
protein for FLNA, HNRNPH2, and PRDX2, provides strong confidence that these 
alterations can be attributed to PRL-1 overexpression and make these attractive 
candidates for further investigation. 
 
7.7.3 The matrix associated gene SPARC (osteonectin) is the most significantly 
up-regulated gene at the mRNA level 
Most PRL-1-induced differences in expression were less than two-fold in 
magnitude, however, SPARC transcripts were shown by the Affymetrix 
microarray to be up-regulated 20-fold (p = 5.86E-05) in the PRL-1 transfectants 
compared to vector control cells.  SPARC (also known as osteonectin) is a non-
structural, extracellular matrix (matricellular) glycoprotein that is involved in 
matrix remodeling and influences a diverse array of biological processes 
[Reviewed in 88,89-91].  SPARC influences cell-cell and cell-matrix interactions; 
promotes extracellular matrix remodeling; regulates integrin expression and 
activity; alters focal adhesions; and modulates the activity of growth factors, cell 
cycle regulators, matrix metalloproteinases, and molecules involved in 
cytoskeletal rearrangement.  It thereby controls a wide range of cellular functions, 
including cell cycle progression, cell proliferation, cell survival, angiogenesis, 
migration, invasion and metastasis.  However its effects on these processes are 
highly context and cell type dependent [88]. 
Although qRT-PCR validation, in an independent sample set, reproducibly 
confirmed the significant up-regulation of SPARC message in the HEK293-PRL-1 
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transfectants, no protein product was detected for this gene in either the PRL-1 
overexpressing or the control cell lines.  However, SPARC is a secreted protein 
and internalized SPARC is thought to be quickly re-released outside the cell [92], 
which could explain our inability to detect SPARC protein in whole cell lysates.  
Differential RNA and protein stability could also play a role given that SPARC 
message has been found to be stable for more than 38 hours [93], while SPARC 
protein has a half-life of less than two hours [94].  Limitations described in the 
previous section, regarding low abundance proteins, could also be a factor.  
Nevertheless, overexpression of PRL-1 in HEK293 cells clearly leads to 
enhanced levels of SPARC mRNA transcripts, which could play a role in 
mediating the signaling events downstream of PRL-1.  Further supporting this 
notion, qRT-PCR analysis revealed that FAK (PTK2), SHC, and the Ras pathway, 
all which lie immediately downstream of SPARC, were also up-regulated in 
response to PRL-1 overexpression.  A proposed diagram of SPARC-mediated 
signaling is included in Figure 7.4. 
Several parallels exist between SPARC and PRL-1 signaling.  When 
overexpressed in epithelial cells, both genes induce morphological and biological 
changes consistent with an EMT-like transition [11,12,95].  Each has pleiotropic 
functions with the capacity to enhance cellular proliferation and metastatic 
potential, but also playing important roles in cellular differentiation [1,96].  Both 
molecules display similar tumor type specific influences on human tumor tissues 
[17,88,89,97-100].  Both can also exert similar effects on downstream signaling 
pathways and molecules such as E-Cadherin [12,101], Src [11,102], FAK 
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[11,101], ERK1/2 [11,103], MMP2 [11,104], Akt, p53, p21cip1/waf1 [18,105,106], 
and the Rho GTPase family members [12,102].  Moreover, both genes have 
been implicated in maintenance of retinal function [5,107,108].  Both display age-
dependent changes in expression with an inverse correlation to age in the 
skeletal muscle [17,109] and a positive correlation to age in structures of the 
brain [17,110].  And finally, both genes exhibit cell cycle dependent localization of 
expression [21,111].  During mitosis, PRL-1 interacts directly with α-tubulin and 
localizes to the centrosomes, where it has been suggested to play a role in 
modulating spindle dynamics [21].  Interestingly, the integrin-linked kinase (ILK), 
which is a SPARC interaction partner and a known effector of SPARC signaling 
[112], also localizes to the centrosome in mitotic cells, where it binds to the 
RuvB-like proteins 1 and 2 (RUVBL1, RUVBL2), which were both significantly up-
regulated in the HEK293-PRL-1 cells.  Together, ILK, RUVBL1, and RUVBL2 
regulate microtubule dynamics and mitotic spindle organization [113].  ILK also 
connects to Filamin A through the Filamin binding protein Migfilin.  These many 
commonalities between the PRL-1 and SPARC signaling pathways, along with 
the up-regulation of SPARC transcripts in response to PRL-1, make SPARC an 
attractive candidate as a mediator of PRL-1 function. 
 
7.7.4 Altered levels of gene products involved in cytoskeletal rearrangements 
are a common theme with PRL-1 overexpression 
Dynamic reorganization of the cytoskeleton is the primary mechanism by 
which cells generate the protrusive structures and contractile forces necessary 
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for cell movement [114-117].  Cytoskeletal changes also play a crucial role in the 
orchestration of cell division [118,119].  In this study, transcriptomic and 
proteomic analysis revealed that stable overexpression of PRL-1 significantly 
alters the RNA and/or protein levels of a number of molecules with roles in the 
assembly, organization, and regulation of each of the three main structural 
components of the cytoskeleton.  PRL-1 overexpression led to significant up-
regulation of actin-binding and cross-linking proteins such as FLNA, transgelin-2 
(TAGLN2), and the alpha-actinin isoforms ACTN1, ACTN2, and ACTN4.  
Conversely, overexpression of PRL-1 caused the significant down-regulation of 
tubulin isoforms (TUBA1A, TUBA4A, TUBA1C, TUBA3C), the microtubule 
regulators RAN and stathmin (STMN1 and STMN2), the intermediate filament 
protein vimentin (VIM), and the regulator of Rho signaling RhoGDIα.  These data 
suggest that PRL-1 can modulate cytoskeletal changes at multiple levels.  
Moreover, the known interaction between PRL-1 and α-tubulin [21] suggests that 
the influence of PRL-1 on the various isoforms of α-tubulin may be direct.  
It deserves mention that up-regulation of vimentin is one of the hallmarks 
of conversion from an epithelial to a mesenchymal phenotype and expression of 
vimentin is typically correlated with enhanced cell migration and invasive activity 
[120].  Thus, we were surprised to find that both vimentin RNA and protein were 
slightly down-regulated in the PRL-1 transfectants, especially considering that 
PRL-1 overexpression visibly alters the morphology of HEK293 cells, causing 
them to elongate and take on a more fibroblast-like appearance and also results 
in a gain of invasive motility, both changes that are consistent with EMT [121].  
140 
 
 
 
 
Vimentin expression levels have also previously been reported to positively 
correlate with the expression of FLNA [122] and SPARC [95], hence the 
mechanisms leading to down-regulation of vimentin in the present study are 
currently unclear.  In some cell types, down-regulation of vimentin has been 
proposed to inhibit apoptosis, contributing to cell survival and resistance to 
various anti-cancer agents [123-125].  Therefore it is plausible that PRL-1-
mediated down-regulation of vimentin could provide HEK293 cells with a survival 
advantage. 
Further supporting the ability of PRL-1 to exert strong influences on the 
cytoskeleton, members of the Rho signaling pathway and molecules that feed 
into this pathway were highly over-represented among both significant and non-
significant differentially expressed gene products.  Alterations in several 
molecules downstream of the Rho GTPases that mediate actin polymerization 
and disassembly are consistent with the occurrence of active cytoskeletal 
remodeling in these cells.  Many other molecules with known or suspected roles 
in the regulation of cytoskeletal reorganization and cell migration also displayed 
significantly altered expression in response to PRL-1, including SPARC [102,126], 
ELAVL1 [127], HSPA1A (Hsp70) [128], EIF6 [129], EEF1A1 [130], IGF2BP1 
[131], NME1 [132], NME2 [133], SEPT11 [134], LGALS3BP [135], SPINT2 [136], 
VCAN [137], MYADM [138], RAB35 [139], FLRT1 [140], and FAM84B [141].  
Accordingly, functional enrichment analysis showed an over-representation of 
genes related to cytoskeletal remodeling and cell adhesion.  Up-regulation of 
gene products involved in nucleotide, nucleic acid, protein, and lipid biosynthesis 
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was also a common theme, consistent with an increased rate of proliferation in 
the PRL-1 overexpressing cells. 
Taken together, all of the above data support a role for PRL-1 in 
modulation of cytoskeletal components and cytoskeletal regulators to influence 
cell proliferation, survival, invasion, and migration.  Given that PRL-1 significantly 
up-regulates Filamin A and down-regulates RhoGDIα and RhoA in this system; 
that Filamin A is known to control the early phases of cell spreading and 
migration initiation [50]; and that an initial inhibition of RhoA is necessary early on 
to allow membrane extension during cell spreading [52]; the current evidence 
may implicate a role for PRL-1 in the very early stages of cell spreading and 
migration, at least in HEK293 cells. 
 
7.8 Conclusions 
The use of two highly complementary technologies (microarray and mass 
spectrometry) has expanded our knowledge of the repertoire of signaling 
molecules and pathways effected by PRL-1 and allowed the identification of 
several novel candidates for downstream mediators of PRL-1 function.  In 
particular, Filamin A, RhoGDIα, and SPARC are attractive subjects of future 
study given their established relationships with a number of signaling molecules 
(e.g. the Rho GTPase family) known to be influenced by PRL-1 expression.  
PRL-1 was also found to significantly alter the expression of multiple other genes 
with roles in regulation of cell shape, adhesion, motility, and the cell cycle, 
supporting prior evidence that PRL-1 may control cytoskeletal dynamics and cell 
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division.  In particular, members of the Rho signaling pathway appear to be 
heavily influenced by PRL-1 overexpression.  PRL-1 also has strong influence on 
the expression of genes involved in alternative splicing, presenting another 
possible mechanism by which PRL-1 may contribute to the acquisition of a 
tumorigenic and/or metastatic phenotype.  This study represents the first 
comprehensive overview of the biological impact of PRL-1 overexpression on 
cellular mRNA or protein levels.  It is clear from these results that the effects of 
PRL-1 are much broader than we currently understand.  Although further studies 
will be required to characterize and examine the consequences of the 
interactions between PRL-1 and the PRL-1 responsive molecules identified here, 
these results provide a rich resource of information that should serve as a 
starting point to open up new lines of investigation into the role of this important 
oncogene. 
 
7.9 Abbreviations Not Defined in Manuscript Text 
ARHGDIA, Rho GDP dissociation inhibitor alpha; ARP, actin-related 
protein; ATF-7, activating transcription factor 7; B2M, beta-2 microglobulin; Cdk2, 
cyclin-dependent kinase 2; cDNA, complementary DNA; DNA, deoxyribonucleic 
acid; DTT, Dithiothreitol; Egr-1, early growth response 1; EIF6, eukaryotic 
translation initiation factor 6; ERK, extracellular signal-regulated kinase; FAK, 
focal adhesion kinase; FAM84B, family with sequence similarity 84, member B; 
FLRT1, fibronectin leucine rich transmembrane protein 1; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; GDP, guanosine 5’-diphosphate; 
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GTP, guanosine 5’-triphosphate; HIF1A, hypoxia inducible factor 1, alpha subunit; 
HNF4A, hepatocyte nuclear factor 4, alpha; HPLC, high-performance liquid 
chromatography; ID, identification; IGFBP7, insulin-like growth factor 2 binding 
protein 7; IGF2BP1, insulin-like growth factor 2 mRNA binding protein 1; KCNJ, 
potassium inwardly rectifying channel, subfamily J; LGALS3BP, lectin, 
galactoside-binding, soluble, 3 binding protein; Mas5, Microarray Analysis Suite 
5.0; MEKK1, mitogen-activated protein kinase kinase kinase 1 (Gene Symbol 
MAP3K1); MMP, matrix metalloproteinase; MYADM, myeloid-associated 
differentiation marker; NME, non-metastatic cells; PAK, p21 protein (Cdc42/Rac)-
activated kinase 1; PBS, phosphate buffered saline; RAB35, ras-related (ras 
analog in brain) protein 35; RAN, ras-related nuclear protein; RAS, Rous 
sarcoma kinase; RNA, ribonucleic acid; ROCK, Rho-associated, coiled-coil 
containing protein kinase; RRM, RNA recognition motif; SEPT, septin; SHC, Src 
homology 2 domain containing transforming protein; SPINT2, serine peptidase 
inhibitor, Kunitz type 2; Src, v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog; TGFβ, transforming growth factor, beta 1; TNF, tumor necrosis factor; 
UBC, ubiquitin C; VCAN, versican; ZEB1, zinc finger E-box binding homeobox 1. 
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Table 7.1 Significant (q ≤ 0.05) differentially-expressed Tier-1 proteins from 
mass-spectrometry analysis of PRL-1-overexpressing HEK293 cells 
Protein ID 
Coding 
Gene 
Symbol 
Entrez 
Gene 
ID 
HEK293-
vector  
Average 
Signal 
HEK293-
PRL-1 
Average 
Signal 
Fold 
Change p-value FDR 
IPI00302592.2 FLNA 2316 14630 18061 1.23 1.28E-15 1.2E-12 
IPI00550363.2 TAGLN2 8407 28555 25728 1.21 2.77E-11 8.5E-09 
IPI00026230.1 HNRNPH2 3188 18665 22688 1.14 2.68E-04 9.8E-03 
IPI00010204.1 SRSF3 6428 36303 24669 1.14 8.64E-04 2.2E-02 
IPI00010105.1 EIF6 3692 13685 19513 1.13 3.36E-04 1.1E-02 
IPI00005978.7 SRSF2 6427 27477 25050 1.13 2.73E-03 4.8E-02 
IPI00465439.4 ALDOA 226 26307 15255 1.12 1.34E-03 2.9E-02 
IPI00021700.3 PCNA 5111 22571 18349 1.11 8.51E-08 8.7E-06 
IPI00029079.5 GMPS 8833 15137 27233 1.11 3.06E-05 1.4E-03 
IPI00009104.6 RUVBL2 10856 19000 20909 1.10 1.17E-05 6.3E-04 
IPI00021187.3 RUVBL1 8607 17014 38789 1.09 4.68E-05 2.0E-03 
28935 ACLY 47 18448 16848 1.09 9.83E-04 2.4E-02 
IPI00017617.1 DDX5 1655 24037 25907 1.08 2.88E-04 1.0E-02 
IPI00011134.1 HSPA6 3310 48728 19488 1.08 8.22E-04 2.2E-02 
IPI00012007.5 AHCY 191 19038 20153 1.08 1.32E-03 2.9E-02 
IPI00014424.1 EEF1A2 1917 31227 21229 1.08 2.53E-03 4.6E-02 
IPI00645907.2 FASN 2194 25369 26014 1.07 3.15E-07 2.6E-05 
IPI00301936.3 ELAVL1 1994 18210 30686 1.07 1.76E-04 6.7E-03 
IPI00304925.3 HSPA1A 3303 35223 20761 1.07 2.16E-03 4.1E-02 
IPI00027442.4 AARS 16 13358 12750 1.06 4.79E-04 1.4E-02 
IPI00186290.5 EEF2 1938 35443 14098 1.06 6.80E-04 1.8E-02 
IPI00013808.1 ACTN4 81 20245 41484 1.05 1.05E-03 2.5E-02 
IPI00013508.5 ACTN1 87 17101 21325 1.04 1.61E-03 3.4E-02 
IPI00003881.5 HNRNPF 3185 25884 24858 -1.04 1.09E-03 2.6E-02 
IPI00645078.1 UBA1 7317 21758 29386 -1.05 3.54E-04 1.2E-02 
IPI00024067.3 CLTC 1213 15241 20481 -1.05 1.28E-03 2.9E-02 
IPI00166768.2 TUBA1C 84790 53528 50481 -1.06 1.88E-03 3.8E-02 
IPI00220644.7 PKM 5315 32867 37698 -1.07 3.80E-04 1.2E-02 
IPI00643041.2 RAN 5901 58484 11372 -1.07 2.53E-03 4.6E-02 
IPI00479997.3 STMN1 3925 24430 18787 -1.09 4.41E-04 1.3E-02 
IPI00329801.11 ANXA5 308 16450 30922 -1.09 1.41E-03 3.0E-02 
438069 PRDX2 7001 21747 42207 -1.09 2.57E-03 4.6E-02 
IPI00015018.1 PPA1 5464 28822 18988 -1.11 8.25E-05 3.4E-03 
IPI00643920.2 TKT 7086 25307 9141 -1.12 8.51E-09 1.1E-06 
IPI00008557.3 IGF2BP1 10642 20573 29331 -1.12 3.51E-06 2.1E-04 
IPI00015947.4 DNAJB1 3337 22598 41893 -1.12 1.24E-04 4.9E-03 
IPI00031461.1 GDI2 2665 21957 36925 -1.13 7.64E-08 8.7E-06 
5822569 GSTP1 2950 17205 27309 -1.13 1.66E-07 1.5E-05 
IPI00012048.1 NME1 4830 43955 35961 -1.13 1.94E-05 9.9E-04 
IPI00291510.3 IMPDH2 3615 18005 14479 -1.13 3.03E-05 1.4E-03 
IPI00019376.5 SEPT11 55752 12830 10236 -1.13 2.05E-03 4.0E-02 
IPI00218667.2 STMN2 11075 14649 31947 -1.15 6.73E-04 1.8E-02 
IPI00217143.2 SDHA 6389 11687 19318 -1.15 1.75E-03 3.6E-02 
IPI00003815.2 ARHGDIA 396 30071 28853 -1.17 6.79E-12 3.1E-09 
IPI00418471.5 VIM 7431 28883 24494 -1.17 9.93E-11 2.3E-08 
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Table 7.2 Significant (q ≤ 0.10) differentially-expressing mRNA signals from 
microarray analysis of PRL-1 overexpressing HEK293 cells 
Probeset ID 
Gene 
Symbol 
Entrez 
Gene ID 
HEK293-
vector 
Average 
Signal 
HEK293-
PRL-1 
Average 
Signal 
Fold 
Change p-value FDR 
200665_s_at SPARC 6678 32 632 20 5.86E-05 0.068 
210715_s_at SPINT2 10653 486 2389 4.9 2.46E-05 0.068 
213746_s_at FLNA 2316 1080 2402 2.2 6.44E-05 0.068 
200859_x_at FLNA 2316 1750 3459 2.0 4.05E-05 0.068 
201132_at HNRPH2 3188 2008 3824 1.9 1.04E-04 0.079 
203689_s_at FMR1 2332 1961 3603 1.8 1.19E-04 0.083 
219569_s_at SLC35G2 80723 868 1556 1.8 4.07E-05 0.068 
206546_at SYCP2 10388 68 114 1.7 4.12E-05 0.068 
232289_at KCNJ12 3768 192 309 1.6 5.39E-05 0.068 
225673_at MYADM 91663 858 1203 1.4 9.79E-05 0.079 
1553122_s_at RBAK 57786 177 232 1.3 4.65E-05 0.068 
215646_s_at VCAN 1462 1538 2007 1.3 9.03E-05 0.079 
219326_s_at B3GNT2 10678 365 455 1.2 1.13E-04 0.082 
200874_s_at NOP56 10528 1352 1617 1.2 1.38E-05 0.068 
223125_s_at C1orf21 81563 1186 1059 -1.1 4.20E-05 0.068 
221194_s_at RNFT1 51136 636 503 -1.3 1.37E-04 0.091 
221819_at RAB35 11021 1098 834 -1.3 9.64E-05 0.079 
211658_at PRDX2 7001 5648 4248 -1.3 1.45E-04 0.092 
217780_at WDR830S 51398 4568 3218 -1.4 3.78E-05 0.068 
227590_at C22orf40 150383 566 375 -1.5 6.00E-05 0.068 
219029_at C5orf28 64417 750 418 -1.8 6.86E-05 0.068 
210414_at FLRT1 23769 232 101 -2.3 3.65E-05 0.068 
208966_x_at IFI16 3428 1317 394 -3.3 6.85E-05 0.068 
239352_at SLC6A15 55117 447 38 -12 6.28E-05 0.068 
225864_at FAM84B 157638 3361 11 -300 1.01E-04 0.079 
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Table 7.3 Genes confirmed by qRT-PCR to be significantly differentially 
expressed in HEK293 cells overexpressing PRL-1 
Significance was defined as Fold Change > 2, p-value ≤ 0.02, and FDR ≤ 0.05 
Assay ID 
Gene 
Symbol 
Entrez 
Gene 
ID 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00234160_m1 SPARC 6678 22.9 15.1 225.7 1.08E-04 5.83E-03 
Hs00181051_m1 APC 324 20.6 15.9 25.2 2.07E-03 9.33E-03 
Hs00153074_m1 ROCK2 9475 19.6 14.9 24.7 6.02E-04 8.12E-03 
Hs00180679_m1 PIK3CA 5290 23.7 19.3 21.0 1.06E-02 1.50E-02 
Hs00232783_m1 ZEB1 6935 21.3 17.0 20.0 4.13E-03 1.24E-02 
Hs00179099_m1 MAP3K2 10746 20.0 15.8 18.6 6.69E-03 1.34E-02 
Hs00936371_m1 HIF1A 3091 19.2 15.1 17.1 5.29E-03 1.19E-02 
Hs00362308_m1 SOS1 6654 20.7 16.6 16.8 5.24E-03 1.23E-02 
Hs00989507_m1 CHUK 1974 20.9 16.9 16.7 1.72E-02 1.69E-02 
Hs00182099_m1 PPP1R12A 4659 19.9 15.9 15.9 1.03E-02 1.50E-02 
Hs00169257_m1 DUSP6 1848 22.8 18.9 15.0 1.70E-02 1.70E-02 
Hs00855199_g1 ACTR2 10097 19.4 15.5 14.5 8.67E-03 1.46E-02 
Hs01110394_m1 ITGB8 3696 24.7 21.0 13.7 4.50E-03 1.21E-02 
Hs00180035_m1 NRAS 4893 17.9 14.1 13.3 9.27E-03 1.43E-02 
Hs01127699_m1 ROCK1 6093 19.5 15.8 13.1 1.07E-02 1.45E-02 
Hs00828586_m1 ACTR3 10096 17.4 13.8 12.7 6.56E-03 1.36E-02 
Hs01039896_m1 MAP3K5 4217 22.1 18.6 11.5 1.91E-03 9.38E-03 
Hs00270666_m1 KRAS 6407 19.4 15.9 11.4 1.82E-02 1.75E-02 
Hs00381459_m1 PIK3R1 5295 20.8 17.3 11.3 7.33E-03 1.41E-02 
Hs00248373_m1 TAB2 23118 18.9 15.4 10.8 1.40E-02 1.54E-02 
Hs00168433_m1 ITGA4 3676 19.1 15.7 10.8 3.65E-03 1.31E-02 
Hs00601957_m1 CSNK2A1 1457 20.0 16.7 10.2 1.17E-02 1.44E-02 
Hs00559595_m1 ITGB1 3688 17.8 14.4 10.2 1.96E-02 1.74E-02 
Hs00243196_m1 RYK 6259 18.6 15.3 10.0 1.53E-02 1.62E-02 
Hs00177373_m1 MAP3K7 6885 18.0 14.7 9.9 3.82E-03 1.29E-02 
Hs01041011_m1 ITGA6 3655 18.7 15.5 9.6 1.84E-02 1.74E-02 
Hs00243115_m1 RASA1 5921 20.1 16.8 9.6 1.44E-02 1.55E-02 
Hs00237216_m1 NCK1 4690 20.9 17.6 9.4 1.21E-03 9.37E-03 
Hs00375042_m1 SHC3 53358 23.4 20.2 8.8 8.88E-03 1.45E-02 
Hs00187614_m1 WASL 8976 19.9 16.8 8.6 1.10E-02 1.45E-02 
Hs00180418_m1 CRK 1398 18.2 15.1 8.6 6.08E-03 1.31E-02 
Hs00235006_m1 ITGA1 3672 20.9 17.9 8.3 1.92E-02 1.72E-02 
Hs00394890_m1 MAP3K1 4214 20.3 17.3 7.9 1.22E-02 1.43E-02 
Hs00377415_m1 MAP4K4 9448 18.1 15.2 7.8 1.37E-02 1.54E-02 
Hs00427259_m1 PPP2CA 5515 16.0 13.0 7.6 1.20E-02 1.44E-02 
Hs00177150_m1 MAP2K6 5608 21.1 18.3 7.2 1.68E-02 1.71E-02 
Hs01047719_m1 GSK3B 2932 17.5 14.7 7.1 1.86E-02 1.71E-02 
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Table 7.3 Cont. 
Assay ID 
Gene 
Symbol 
Entrez 
Gene 
ID 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00387426_m1 MAP2K4 6416 19.6 16.9 6.5 3.96E-03 1.26E-02 
Hs01124081_m1 LAMA2 3908 26.1 23.5 5.8 8.67E-04 7.80E-03 
Hs00169407_m1 RIPK1 8737 21.4 19.0 5.5 1.53E-02 1.59E-02 
Hs00177102_m1 MAPK9 5601 17.2 14.8 5.5 8.44E-03 1.47E-02 
Hs00300550_m1 LAMA1 284217 17.1 14.8 4.8 1.85E-02 1.72E-02 
Hs00560189_m1 PPM1E 22843 18.9 16.7 4.8 1.00E-02 1.50E-02 
Hs00177083_m1 MAPK8 5599 17.8 15.5 4.8 4.22E-03 1.20E-02 
Hs00373461_m1 MAPK10 5602 25.0 22.9 4.4 1.24E-02 1.43E-02 
Hs00183311_m1 SOS2 6655 19.0 16.8 4.4 3.19E-03 1.23E-02 
Hs00180269_m1 BAX 581 12.8 10.8 4.1 2.15E-03 8.91E-03 
Hs00169777_m1 PECAM1 5175 26.0 24.5 3.0 7.53E-03 1.40E-02 
Hs00237119_m1 MMP14 4323 21.2 19.7 2.8 1.16E-02 1.46E-02 
Hs00266332_m1 COL15A1 1306 25.2 23.9 2.4 1.31E-03 8.85E-03 
Hs00610483_m1 HRAS 3265 15.8 14.7 2.1 8.49E-04 9.17E-03 
Hs00365167_m1 COL6A2 1292 14.9 16.1 -2.2 1.14E-02 1.46E-02 
Hs00242448_m1 COL6A1 1291 14.7 16.1 -2.7 8.39E-03 1.51E-02 
Hs00266026_m1 IGFBP7 3490 17.1 18.9 -3.4 1.37E-04 3.71E-03 
Hs00609088_m1 COL5A1 1289 19.5 21.6 -4.2 1.71E-03 9.23E-03 
Hs02341135_m1 PTP4A3 11156 16.3 19.0 -6.4 5.10E-03 1.31E-02 
Hs00174009_m1 ITGB4 3691 19.5 22.5 -8.0 5.86E-04 1.05E-02 
Hs00230853_m1 HNF4A 3172 22.6 25.9 -9.7 1.06E-02 1.47E-02 
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Figure 7.1 Cumulative distributions of mRNA expression levels for 
microarray probesets 
The cumulative distributions of the expression levels of mRNA 
probesets that were associated with the coding genes of detected and 
non-detected proteins are respectively shown in blue and red for the 
empty-vector (EV) group, and in green and yellow for the PRL-1-
overexpressing (P1) group. 
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Figure 7.2 Volcano plot of significant (q ≤ 0.10) differentially-expressed 
proteins integrated with changes in corresponding mRNA signals 
The dot (☻) symbols represent the Tier-1 proteins that were observed to be 
differentially expressed in HEK293-PRL-1 cells.  These protein data are plotted 
along the X- and Y-axes according to the log of the protein expression ratio and 
FDR-corrected significance respectively. A positive log2(protein ratio) value 
indicates an up-regulation of protein expression in the PRL-1 transients as 
compared to controls, while a negative value indicates down-regulation of protein 
expression.  Each protein’s corresponding mRNA data is represented by colored 
circle around that protein’s dot symbol.  Each probeset in the microarray 
experiment that was 1) mapped to a plotted protein’s coding gene and was 2) 
differentially expressed with a significance of p ≤ 0.20 is represented by a colored 
region.  An asterisk (*) indicates an mRNA signal with a significance of p ≤ 0.05.  
In cases where multiple detected probesets were mapped to the same protein’s 
coding gene, the colored circle is divided into sectors according to the relative 
contribution that each probeset had to the total mRNA signal.  Yellow colors 
represent an up-regulation of mRNA expression and blue colors indicate a down-
regulation at the mRNA level.
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Figure 7.3 Protein changes in the Rho-signaling canonical pathway resulting from PRL-1 overexpression in 
HEK293 cells 
Selected proteins that conduct signals to remodel the cytoskeleton through RhoA, Rac1, and CDC42 are represented by 
their coding gene names in a canonical pathway diagram adapted from IPA.  The symbols of proteins that were detected 
in the mass-spectrometry experiment at Tier-1 or Tier-2 levels are colored according to the direction of their expression 
change under PRL-1-overexpressing conditions as compared to the empty vector group, with yellow hues indicating an 
increased quantity of protein and blue hues indicating a decrease.  An asterisk (*) indicates that a protein expression 
change is significant at a level of p ≤ 0.05.  Tier-1 proteins are noted with bold font labels.  Groups of related or complex-
forming proteins are illustrated with double-outlined symbols.  Connecting lines with arrowheads indicate an activating, de-
activating, or translocating influence, and the absence of an arrowhead indicates a protein-protein binding interaction or 
group membership.  Solid connecting lines show direct interactions while dashed lines show indirect interactions.  The 
direct interaction of PRL-1 (PTP4A1) with ARHGAP4 is represented here, but indirect connections between PRL-1 and 
the components of this pathway are not shown. 
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Figure 7.4 SPARC-mediated signaling pathways 
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Table S1 Full list of qRT-PCR assays and results 
A value of Not Applicable (N/A) indicates that the gene was undetectable (Ct ≥ 
40) in all assayed samples. 
Assay ID 
Gene 
Symbol 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00855199_g1 ACTR2 19.4 15.5 14.5 8.67E-03 1.46E-02 
Hs00828586_m1 ACTR3 17.4 13.8 12.7 6.56E-03 1.36E-02 
Hs00178289_m1 AKT1 12.2 12.6 -1.3 1.23E-01 4.80E-02 
Hs00181051_m1 APC 20.6 15.9 25.2 2.07E-03 9.33E-03 
Hs00869394_s1 ARHGAP5 24.5 19.6 29.3 3.53E-02 2.17E-02 
Hs00241801_m1 ARHGAP6 N/A N/A N/A N/A N/A 
Hs00976924_g1 ARHGDIA 9.6 9.6 1.0 9.94E-01 2.83E-01 
Hs00180327_m1 ARHGEF1 15.3 15.4 -1.1 4.11E-01 1.36E-01 
Hs00153179_m1 ATF2 20.1 15.7 20.9 4.38E-02 2.39E-02 
Hs00247172_m1 ATF5 12.3 12.7 -1.3 5.95E-01 1.92E-01 
Hs00180269_m1 BAX 12.8 10.8 4.1 2.15E-03 8.91E-03 
Hs00183953_m1 BCAR1 14.6 13.9 1.6 5.82E-02 2.73E-02 
Hs99999018_m1 BCL2 21.6 16.3 38.4 2.33E-02 1.85E-02 
Hs00197982_m1 BCL2L11 17.5 16.3 2.4 6.73E-02 2.98E-02 
Hs00269944_m1 BRAF 21.6 15.4 75.8 3.00E-01 1.02E-01 
Hs00965092_m1 CAPN2 16.1 13.5 6.0 2.97E-02 1.96E-02 
Hs00174575_m1 CCL5 24.4 24.6 -1.2 5.17E-03 1.27E-02 
Hs00765553_m1 CCND1 15.1 13.1 3.8 2.41E-02 1.83E-02 
Hs00236949_m1 CCND3 14.2 14.1 1.0 5.30E-01 1.74E-01 
Hs00854939_g1 CDC42 18.3 15.7 5.7 2.22E-02 1.85E-02 
Hs01013953_m1 CDH1 19.3 18.9 1.4 2.16E-01 7.54E-02 
Hs00355782_m1 CDKN1A 12.8 13.0 -1.2 9.59E-02 3.95E-02 
Hs00989507_m1 CHUK 20.9 16.9 16.7 1.72E-02 1.69E-02 
Hs01058288_g1 CKB 9.4 9.6 -1.1 2.27E-02 1.86E-02 
Hs00355024_m1 CNTN1 19.9 20.7 -1.7 1.12E-01 4.49E-02 
Hs00266273_m1 COL11A1 N/A N/A N/A N/A N/A 
Hs00189184_m1 COL12A1 22.4 17.8 24.5 4.76E-02 2.50E-02 
Hs00385388_m1 COL14A1 15.9 14.6 2.6 6.22E-02 2.80E-02 
Hs00266332_m1 COL15A1 25.2 23.9 2.4 1.31E-03 8.85E-03 
Hs00156876_m1 COL16A1 N/A N/A N/A N/A N/A 
Hs00164004_m1 COL1A1 21.6 23.2 -3.0 2.70E-02 1.84E-02 
Hs01098873_m1 COL4A2 12.0 12.0 -1.0 9.69E-01 2.78E-01 
Hs00609088_m1 COL5A1 19.5 21.6 -4.2 1.71E-03 9.23E-03 
Hs00242448_m1 COL6A1 14.7 16.1 -2.7 8.39E-03 1.51E-02 
Hs00365167_m1 COL6A2 14.9 16.1 -2.2 1.14E-02 1.46E-02 
Hs00164310_m1 COL7A1 21.1 20.2 1.8 4.88E-02 2.53E-02 
Hs00156669_m1 COL8A1 24.8 24.8 -1.0 9.81E-01 2.80E-01 
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Table S1 Cont. 
Assay ID 
Gene 
Symbol 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00180418_m1 CRK 18.2 15.1 8.6 6.08E-03 1.31E-02 
Hs00177843_m1 CSK 18.1 18.2 -1.1 8.33E-01 2.46E-01 
Hs00601957_m1 CSNK2A1 20.0 16.7 10.2 1.17E-02 1.44E-02 
Hs00176268_m1 CSNK2B 10.4 10.1 1.3 4.24E-02 2.36E-02 
Hs00355045_m1 CTNNB1 15.1 12.4 6.7 2.44E-02 1.80E-02 
Hs00946556_m1 DIAPH1 16.0 14.6 2.6 4.75E-02 2.51E-02 
Hs00169192_m1 DOCK1 18.3 15.3 7.9 2.71E-02 1.83E-02 
Hs00169257_m1 DUSP6 22.8 18.9 15.0 1.70E-02 1.70E-02 
Hs00152928_m1 EGR1 16.0 15.9 1.1 6.47E-01 2.02E-01 
Hs01052961_m1 FLT1 20.4 17.9 5.9 3.18E-02 2.02E-02 
Hs01549976_m1 FN1 16.5 16.6 -1.1 6.88E-01 2.10E-01 
Hs00941600_m1 FYN 14.6 13.7 1.9 9.96E-02 4.05E-02 
Hs00157817_m1 GRB2 15.2 14.2 2.0 2.69E-02 1.86E-02 
Hs00534180_m1 GRLF1 17.6 15.0 6.0 3.38E-02 2.12E-02 
Hs01047719_m1 GSK3B 17.5 14.7 7.1 1.86E-02 1.71E-02 
Hs00356079_m1 GSTM3 18.7 17.5 2.4 9.92E-02 4.06E-02 
Hs00168310_m1 GSTP1 11.0 11.6 -1.5 4.09E-02 2.30E-02 
Hs00936371_m1 HIF1A 19.2 15.1 17.1 5.29E-03 1.19E-02 
Hs00230853_m1 HNF4A 22.6 25.9 -9.7 1.06E-02 1.47E-02 
Hs00610483_m1 HRAS 15.8 14.7 2.1 8.49E-04 9.17E-03 
Hs03044127_g1 HSPB1 10.7 10.3 1.3 2.01E-01 7.06E-02 
Hs00164932_m1 ICAM1 23.8 23.8 1.0 7.44E-01 2.24E-01 
Hs00153126_m1 IGF1 N/A N/A N/A N/A N/A 
Hs00609566_m1 IGF1R 14.4 13.4 2.0 5.81E-02 2.75E-02 
Hs00266026_m1 IGFBP7 17.1 18.9 -3.4 1.37E-04 3.71E-03 
Hs00233287_m1 IKBKB 17.5 16.5 2.0 8.72E-02 3.74E-02 
Hs00415849_m1 IKBKG 15.5 15.7 -1.1 5.01E-01 1.65E-01 
Hs00174092_m1 IL1A 25.7 23.3 5.2 3.65E-02 2.14E-02 
Hs00178563_m1 IRS1 21.4 19.1 4.8 3.78E-02 2.15E-02 
Hs00192713_m1 ISG15 24.8 25.0 -1.1 6.10E-01 1.94E-01 
Hs00235006_m1 ITGA1 20.9 17.9 8.3 1.92E-02 1.72E-02 
Hs00158127_m1 ITGA2 20.9 18.2 6.3 2.57E-02 1.83E-02 
Hs01076873_m1 ITGA3 18.5 19.5 -2.1 3.56E-02 2.16E-02 
Hs00168433_m1 ITGA4 19.1 15.7 10.8 3.65E-03 1.31E-02 
Hs01547673_m1 ITGA5 13.1 13.2 -1.1 6.08E-01 1.94E-01 
Hs01041011_m1 ITGA6 18.7 15.5 9.6 1.84E-02 1.74E-02 
Hs00174397_m1 ITGA7 18.2 19.2 -2.0 1.22E-01 4.82E-02 
Hs00233321_m1 ITGA8 18.7 16.8 3.8 2.46E-02 1.77E-02 
Hs00559595_m1 ITGB1 17.8 14.4 10.2 1.96E-02 1.74E-02 
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Table S1 Cont. 
Assay ID 
Gene 
Symbol 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00164957_m1 ITGB2 24.3 24.9 -1.5 6.71E-01 2.07E-01 
Hs01001478_m1 ITGB3 22.8 23.0 -1.1 8.69E-01 2.54E-01 
Hs00174009_m1 ITGB4 19.5 22.5 -8.0 5.86E-04 1.05E-02 
Hs00174435_m1 ITGB5 16.2 15.7 1.4 1.13E-01 4.50E-02 
Hs01110394_m1 ITGB8 24.7 21.0 13.7 4.50E-03 1.21E-02 
Hs00270666_m1 KRAS 19.4 15.9 11.4 1.82E-02 1.75E-02 
Hs00300550_m1 LAMA1 17.1 14.8 4.8 1.85E-02 1.72E-02 
Hs01124081_m1 LAMA2 26.1 23.5 5.8 8.67E-04 7.80E-03 
Hs00165042_m1 LAMA3 18.7 16.9 3.4 3.00E-02 1.95E-02 
Hs01055971_m1 LAMB1 16.5 14.2 5.1 5.43E-02 2.62E-02 
Hs00165078_m1 LAMB3 22.6 21.2 2.8 3.65E-02 2.16E-02 
Hs00267056_m1 LAMC1 15.6 13.9 3.3 5.04E-02 2.54E-02 
Hs00605615_mH MAP2K1 15.2 13.6 3.1 2.05E-02 1.76E-02 
Hs00360961_m1 MAP2K2 13.8 13.7 1.1 2.88E-01 9.89E-02 
Hs00177127_m1 MAP2K3 13.5 12.9 1.5 5.06E-02 2.53E-02 
Hs00387426_m1 MAP2K4 19.6 16.9 6.5 3.96E-03 1.26E-02 
Hs00177134_m1 MAP2K5 15.2 15.1 1.1 6.77E-01 2.08E-01 
Hs00177150_m1 MAP2K6 21.1 18.3 7.2 1.68E-02 1.71E-02 
Hs00178198_m1 MAP2K7 15.2 15.1 1.0 9.59E-01 2.78E-01 
Hs00394890_m1 MAP3K1 20.3 17.3 7.9 1.22E-02 1.43E-02 
Hs00176759_m1 MAP3K11 14.1 14.0 1.1 8.23E-01 2.44E-01 
Hs01089753_m1 MAP3K14 17.3 16.5 1.7 3.18E-02 2.04E-02 
Hs00179099_m1 MAP3K2 20.0 15.8 18.6 6.69E-03 1.34E-02 
Hs00176747_m1 MAP3K3 15.9 15.8 1.0 6.47E-01 2.01E-01 
Hs00245958_m1 MAP3K4 20.2 17.4 7.0 3.71E-02 2.15E-02 
Hs01039896_m1 MAP3K5 22.1 18.6 11.5 1.91E-03 9.38E-03 
Hs00177373_m1 MAP3K7 18.0 14.7 9.9 3.82E-03 1.29E-02 
Hs00178297_m1 MAP3K8 20.2 19.4 1.7 2.92E-01 9.98E-02 
Hs00377415_m1 MAP4K4 18.1 15.2 7.8 1.37E-02 1.54E-02 
Hs01046830_m1 MAPK1 17.1 14.5 6.1 2.29E-02 1.84E-02 
Hs00373461_m1 MAPK10 25.0 22.9 4.4 1.24E-02 1.43E-02 
Hs00176247_m1 MAPK14 16.3 14.5 3.5 2.60E-02 1.82E-02 
Hs00385075_m1 MAPK3 12.9 12.9 -1.0 7.55E-01 2.25E-01 
Hs00177079_m1 MAPK7 15.5 15.1 1.3 4.52E-02 2.44E-02 
Hs00177083_m1 MAPK8 17.8 15.5 4.8 4.22E-03 1.20E-02 
Hs00177102_m1 MAPK9 17.2 14.8 5.5 8.44E-03 1.47E-02 
Hs00250126_m1 MARK2 15.5 15.2 1.2 1.69E-01 6.29E-02 
Hs00237119_m1 MMP14 21.2 19.7 2.8 1.16E-02 1.46E-02 
Hs01548727_m1 MMP2 19.5 19.2 1.2 8.98E-03 1.43E-02 
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Table S1 Cont. 
Assay ID 
Gene 
Symbol 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs00957555_m1 MMP9 N/A N/A N/A N/A N/A 
Hs00364926_m1 MYLK 21.6 20.0 3.1 6.89E-02 3.03E-02 
Hs00294850_m1 MYLK3 24.1 23.7 1.3 8.39E-01 2.46E-01 
Hs00941830_m1 NCAM1 18.1 16.8 2.4 3.41E-01 1.14E-01 
Hs00237216_m1 NCK1 20.9 17.6 9.4 1.21E-03 9.37E-03 
Hs00765730_m1 NFKB1 18.4 16.7 3.2 5.26E-02 2.56E-02 
Hs00174517_m1 NFKB2 14.6 15.4 -1.9 5.49E-02 2.62E-02 
Hs00180035_m1 NRAS 17.9 14.1 13.3 9.27E-03 1.43E-02 
Hs00176815_m1 PAK1 17.2 16.4 1.7 6.16E-02 2.82E-02 
Hs00605586_m1 PAK2 19.6 16.8 6.8 3.62E-02 2.17E-02 
Hs00176828_m1 PAK3 25.8 23.7 4.3 1.35E-01 5.23E-02 
Hs00178686_m1 PAK4 14.5 14.2 1.2 9.42E-02 3.94E-02 
Hs00205457_m1 PCDH17 22.7 25.4 -6.4 2.45E-02 1.78E-02 
Hs00964426_m1 PDGFA 16.5 16.8 -1.2 1.25E-01 4.85E-02 
Hs00966522_m1 PDGFB 18.6 19.1 -1.4 3.23E-01 1.09E-01 
Hs00998018_m1 PDGFRA 25.1 21.9 9.2 5.93E-02 2.76E-02 
Hs01019589_m1 PDGFRB 22.1 23.2 -2.2 1.39E-01 5.32E-02 
Hs00169777_m1 PECAM1 26.0 24.5 3.0 7.53E-03 1.40E-02 
Hs00180679_m1 PIK3CA 23.7 19.3 21.0 1.06E-02 1.50E-02 
Hs00381459_m1 PIK3R1 20.8 17.3 11.3 7.33E-03 1.41E-02 
Hs00560189_m1 PPM1E 18.9 16.7 4.8 1.00E-02 1.50E-02 
Hs00182099_m1 PPP1R12A 19.9 15.9 15.9 1.03E-02 1.50E-02 
Hs00427259_m1 PPP2CA 16.0 13.0 7.6 1.20E-02 1.44E-02 
Hs00925195_m1 PRKCA 16.0 14.9 2.1 1.08E-01 4.33E-02 
Hs01920652_s1 PTEN 23.6 16.1 171.1 9.46E-02 3.93E-02 
Hs00178587_m1 PTK2 18.6 15.6 8.0 2.42E-02 1.82E-02 
Hs00140)69444_m1 PTK2B 19.5 20.1 -1.5 1.53E-01 5.76E-02 
Hs01109144_m1 PTP4A1** N/A N/A N/A N/A N/A 
Hs00754750_s1 PTP4A2 17.3 14.5 6.6 2.91E-02 1.94E-02 
Hs02341135_m1 PTP4A3 16.3 19.0 -6.4 5.10E-03 1.31E-02 
Hs00236064_m1 PXN 12.1 12.0 1.1 5.35E-01 1.74E-01 
Hs00251654_m1 RAC1 16.0 15.3 1.7 8.00E-02 3.46E-02 
Hs00234119_m1 RAF1 18.5 17.3 2.3 6.16E-02 2.84E-02 
Hs00243115_m1 RASA1 20.1 16.8 9.6 1.44E-02 1.55E-02 
Hs01042010_m1 RELA 12.2 11.4 1.8 5.03E-02 2.56E-02 
Hs00357608_m1 RHOA 11.0 10.8 1.2 1.42E-01 5.39E-02 
Hs00747110_s1 RHOC 14.5 14.4 1.1 6.34E-01 1.99E-01 
Hs00169407_m1 RIPK1 21.4 19.0 5.5 1.53E-02 1.59E-02 
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Table S1 Cont. 
Assay ID 
Gene 
Symbol 
HEK293-
vector 
Average 
ΔCt 
HEK293-
PRL-1 
Average  
ΔCt 
Fold 
Change p-value FDR 
Hs01127699_m1 ROCK1 19.5 15.8 13.1 1.07E-02 1.45E-02 
Hs00153074_m1 ROCK2 19.6 14.9 24.7 6.02E-04 8.12E-03 
Hs00243196_m1 RYK 18.6 15.3 10.0 1.53E-02 1.62E-02 
Hs00174057_m1 SELE N/A N/A N/A N/A N/A 
Hs01384744_m1 SGK1 N/A N/A N/A N/A N/A 
Hs00427539_m1 SHC1 14.5 14.4 1.1 6.28E-01 1.98E-01 
Hs01044374_m1 SHC2 15.3 16.2 -1.9 2.37E-02 1.85E-02 
Hs00375042_m1 SHC3 23.4 20.2 8.8 8.88E-03 1.45E-02 
Hs00950344_m1 SNAI2 25.4 24.8 1.6 6.07E-01 1.95E-01 
Hs00362308_m1 SOS1 20.7 16.6 16.8 5.24E-03 1.23E-02 
Hs00183311_m1 SOS2 19.0 16.8 4.4 3.19E-03 1.23E-02 
Hs00234160_m1 SPARC 22.9 15.1 225.7 1.08E-04 5.83E-03 
Hs00178494_m1 SRC 14.4 14.4 -1.1 7.12E-01 2.16E-01 
Hs01047580_m1 STAT3 16.2 15.2 2.1 6.67E-02 2.98E-02 
Hs00194572_m1 SYT1 20.8 25.3 -23.7 3.40E-02 2.11E-02 
Hs00980604_m1 SYT2 21.1 20.6 1.4 3.78E-01 1.26E-01 
Hs00196143_m1 TAB1 14.4 15.0 -1.5 1.50E-01 5.66E-02 
Hs00248373_m1 TAB2 18.9 15.4 10.8 1.40E-02 1.54E-02 
Hs00194578_m1 TAF12 16.1 14.8 2.4 7.62E-02 3.32E-02 
Hs00234278_m1 TIMP2 14.4 14.1 1.2 5.24E-02 2.60E-02 
Hs00196775_m1 TLN1 13.3 13.0 1.3 2.36E-01 8.17E-02 
Hs00377558_m1 TRAF6 N/A N/A N/A N/A N/A 
Hs01003372_m1 VCAM1 N/A N/A N/A N/A N/A 
Hs00243320_m1 VCL 14.1 12.7 2.8 4.91E-02 2.53E-02 
Hs00900054_m1 VEGFA 15.9 15.9 -1.0 9.63E-01 2.78E-01 
Hs01591751_m1 WASF1 17.6 15.7 3.8 4.74E-02 2.53E-02 
Hs00746309_s1 WASF2 14.9 15.0 -1.0 7.49E-01 2.25E-01 
Hs00187614_m1 WASL 19.9 16.8 8.6 1.10E-02 1.45E-02 
Hs00219183_m1 WNK1 14.9 12.8 4.2 3.73E-02 2.14E-02 
Hs00998537_m1 WNT5A 17.0 15.2 3.5 2.18E-02 1.84E-02 
Hs00232783_m1 ZEB1 21.3 17.0 20.0 4.13E-03 1.24E-02 
 
**Note that no pre-amplification step was performed as part of this analysis and 
pre-amplification is known to be required for PRL-1 (PTP4A1) detection using 
this TaqMan assay.
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CHAPTER 8.  PRL-1 INDUCTION ALTERS RHOA AND PHOSPHO-SRC 
LEVELS 
8.1 Introduction 
The combined analysis of transcript and protein level changes that occur 
in response to stable overexpression of PRL-1 in HEK293 cells identified several 
novel candidates for mediators of PRL-1 function and provided evidence 
strengthening the notion that PRL-1 can leverage signaling pathways which 
regulate cellular adhesions and cytoskeletal rearrangement.  Given that cell 
migration occurs through a multi-step cycle that requires continuous remodeling 
of both the actin cytoskeleton and cell-matrix adhesions (Ridley, Vincente-
Manzanares); the ability of PRL-1 to influence each of these structures likely 
plays a role in its capacity to promote cell motility and metastasis. 
The integration of microarray and proteomics data sets considerably 
expanded our knowledge of the signaling molecules and pathways influenced by 
PRL-1.  Nevertheless, due to mechanisms such as alternative splicing and post-
translational modification, the level of transcription of a protein-coding RNA does 
not always correspond to the level of expression or, moreover, to the level of 
activity of the coded protein.  For example, PRL-1 signaling has previously been 
shown to cause activation of c-Src, through increased phosphorylation at Tyr416, 
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without any change in the levels of total c-Src (Luo et al., 2009).  This 
relationship between c-Src and PRL-1 would not be possible to observe through 
analysis of RNA or protein abundance alone.  Therefore, I used western blotting 
with total and phospho-specific antibodies to further examine the influence of 
PRL-1 on the expression and activity levels of select molecules with crucial roles 
in cell adhesion, cytoskeletal remodeling, cell motility, and cell invasion. 
 
8.2 Results 
Downstream of integrin activation, Src kinase is a crucial mediator of 
adhesion-related signaling and cell motility.  It localizes to cell-matrix adhesions 
where it augments adhesion turnover and regulates activity of the Rho GTPases, 
which are the primary drivers of cytoskeletal reorganization for cell migration 
(Huveneers & Danen, 2009; Parri & Chiarugi, 2010).  Src activity is regulated by 
tyrosine phosphorylation at two sites, each having opposing effects:  
phosphorylation at Tyr416 up-regulates enzyme activity, while phosphorylation at 
Tyr527 has an inhibitory effect (Hunter, 1987).  Luo et al. (2009) previously 
demonstrated that stable overexpression of PRL-1 in HEK293 cells enhances c-
Src activity through increased phosphorylation at its activating Tyr416 residue.  
SPARC, which was determined by microarray to be the mostly highly up-
regulated transcript in response to stable PRL-1 expression in the current study, 
is also known to increase Tyr416 phosphorylation of c-Src (Bhoopathi, Gondi, 
Gujrati, Dinh, & Lakka, 2011).  Based on this evidence, I expected that c-Src 
Tyr416 phosphorylation would be enhanced in the HEK293 lines used for the 
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current study.  To determine if this was the case, I performed western blotting, on 
duplicate biological replicates of HEK293 cells stably transfected with PRL-1 or 
with empty vector, using antibodies against several forms of phosphorylated and 
non-phosporylated-Src.  The National Institute of Health’s ImageJ program 
(Schneider, Rasband, & Eliceiri, 2012) was then used to quantify the blots and 
compare expression levels between samples.  This analysis revealed that, in line 
with previous reports, the level of c-Src phosphorylation at Tyr416 was 
dramatically increased (approximately 5-fold) in response to stable PRL-1 
overexpression in HEK293 cells (Figure 8.1; First row).  Moreover, this increase 
in Tyr416 phosphorylation was accompanied by a concomitant decrease in levels 
of non-phospho-Tyr416 Src (Figure 8.1; Second row).  In contrast, no 
appreciable changes were seen in the levels of phosphorylated or 
unphosphorylated Src at Tyr527 (Figure 8.1; Third and Fourth rows) or in the 
levels of total Src protein (Figure 8.1; Fifth row). 
Rho family GTPases act as molecular switches that cycle between an 
active, GTP-bound state and an inactive, GDP-bound, state.  They are key 
regulators of actin cytoskeletal dynamics associated with cell motility and are 
also important regulators of cell cycle progression, survival, and invasion (Parri & 
Chiarugi, 2010; Ridley, 2004).  Among the best characterized of the Rho proteins 
are RhoA, Rac, and Cdc42.  Rac and Cdc42 regulate the formation of membrane 
protrusions, while RhoA regulates the assembly of the contractile filaments that 
are required to move the cell body forward and retract the trailing edge 
(Raftopoulou & Hall, 2004).  A reciprocal relationship has previously been 
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reported between SPARC and RhoA, where overexpression of RhoA leads to 
repression of SPARC and RhoA silencing by siRNA causes SPARC up-
regulation (Giang Ho et al., 2011).  Given that PRL-1 overexpression led to up-
regulated SPARC expression and SPARC and RhoA are known to be inversely 
correlated, I was interested in determining the effect of increased PRL-1 levels 
on RhoA.  A closer look at the microarray and MS data sets revealed that RhoA 
transcript levels were unaltered with PRL-1 up-regulation.  In contrast, the 
abundance of RhoA protein was lower in the PRL-1 transfectants compared to 
the empty vector lines, though this difference failed to meet the significance 
thresholds set for the MS data analysis.  To further examine the effect of PRL-1 
overexpression on RhoA protein levels, I used western blotting to assess the 
amount of total RhoA in an independent set of HEK293 samples stably 
transfected with PRL-1 or empty vector.  This analysis confirmed that stable 
PRL-1 overexpression in HEK293 leads to decreased expression of RhoA 
protein (Figure 8.2; First row). 
The levels of total and phosphorylated PAK1 (p21-activated kinase 1), 
ERK1/2, and SAPK/JNK (stress-activated protein kinase/c-Jun N-terminal kinase) 
were also measured by western blot.  PAK1 is a downstream effector of Rac1 
and Cdc42 that is activated by the actin crosslinking and Rho GTPase 
scaffolding protein FLNA (Vadlamudi et al., 2002), a molecule which was 
determined by both microarray and MS to be highly up-regulated in response to 
PRL-1.  FLNA also directly interacts with the MAPK kinases MEK1 and MKK4 
which are upstream activators of ERK and SAPK/JNK respectively.  Besides 
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FLNA, several other signaling molecules/pathways that control cell migration 
and/or invasion, including the Rho GTPase and Src signaling pathways ultimately 
converge at ERK or SAPK/JNK.  However, neither the phosphorylation status nor 
total protein level of PAK1 (Figure 8.3), ERK1/2 (Figure 8.2), or SAPK/JNK 
(Figure 8.4) were notably altered in the HEK293 cells stably transfected with 
PRL-1 compared to those transfected with empty vector. 
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Figure 8.1 PRL-1 expression enhances Src phosphorylation at Tyr416 
HEK293 cells stably transfected with PRL-1 or empty vector were subject to 
western blot analysis using antibodies against phospho, non-phospho, and 
total Src.  An approximately 5-fold increase in Tyr416 (Y416) 
phosphorylation, concomitant with a decrease in non-phosphorylated Tyr416 
was observed in PRL-1 transfectants compared to the vector controls.  After 
accounting for differences in sample loading, no appreciable changes were 
seen in phosphorylation of Src at Tyr527 or in the levels of total Src.  
GAPDH was utilized as a loading control. 
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Figure 8.2 PRL-1 expression down-regulates RhoA protein levels 
HEK293 cells stably transfected with PRL-1 or empty vector were subject 
to western blot analysis using antibodies against total RhoA, 
phosphorylated ERK1/2, or total ERK1/2.  Expression of RhoA was heavily 
decreased in the PRL-1 transfectants compared to the vector controls, 
while the expression of total and phospho-ERK was unvaried.  GAPDH 
was used as the loading control. 
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Figure 8.3 PRL-1 expression has no effect on PAK1 expression or 
phosphorylation at serine 144 
HEK293 cells stably transfected with PRL-1 or empty vector were subject to 
western blot analysis using antibodies against total PAK1 or phosphorylated 
PAK1/PAK2 (Ser144/Ser141).  No differences were observed between 
samples in either total PAK1 expression or phosphorylation state.  GAPDH 
was used as a loading control. 
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Figure 8.4 PRL-1 expression does not alter the levels of total or phospho-
SAPK/JNK 
HEK293 cells stably transfected with PRL-1 or empty vector were subject to 
western blot analysis using antibodies against total SAPK/JNK or SAPK/JNK 
phosphorylated at Thr183 (T183) and Tyr185 (Y185).  No apparent 
differences were observed between samples in either total SAPK/JNK 
expression or phosphorylation state.  GAPDH was used as a loading control. 
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8.3 Discussion 
Cell movement is a multistep process that involves turnover of cell-matrix 
adhesions and dynamic reorganization of the actin cytoskeleton.  Through the 
ability to effect the necessary changes in both the actin cytoskeleton and cell 
adhesions, small GTPases of the Rho family, such as RhoA, Cdc42, and Rac, 
have been identified as essential regulators of cell motility.  Rac and Cdc42 both 
stimulate formation of protrusions at the leading edge of the cell, while RhoA 
controls retraction of the rear of the cell (Raftopoulou & Hall, 2004).  Although the 
Rho GTPases work coordinately to influence cell movement, their activity must 
be precisely controlled, both spatially and temporally, for efficient cell migration to 
occur.  For example, while RhoA expression and activity are crucial for tail 
retraction, high levels of RhoA activity can block the formation of membrane 
protrusions and result in inhibition of cell movement (Arthur & Burridge, 2001).  
Studies have suggested that an initial inhibition of RhoA is necessary to relieve 
cytoskeletal tension and allow membrane extension during cell spreading.  As 
spreading ends, RhoA activity then gradually increases, allowing the formation of 
stress fibers and promoting cell contractility.  Finally, RhoA activity decreases to 
a low basal level (Arthur & Burridge, 2001; X. D. Ren, Kiosses, & Schwartz, 
1999). 
The initial, transient down-regulation of RhoA activity during cell spreading 
occurs, at least in part, through the actions of Src, which activates the Rho 
GTPase activating protein p190RhoGAP, leading to Rho GTP hydrolysis and 
inactivation (Arthur, Petch, & Burridge, 2000).  The current results suggest that, 
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in addition to increasing the levels of active c-Src, which has the capacity to 
down-regulate RhoA enzyme activity, ectopic overexpression of PRL-1 in 
HEK293 cells can also down-regulate RhoA protein abundance.  One 
mechanism by which this might occur is through the control of another Rho 
regulator, RhoGDIα (gene symbol ARHGDIA).  Most Rho family proteins are 
post-translationally modified by prenylation, enhancing their interaction with 
membranes.  Rho guanine nucleotide dissociation inhibitors (RhoGDIs) can bind 
Rho proteins via their prenyl group, blocking Rho nucleotide exchange, extracting 
the Rho proteins from the membrane, and sequestering them away from their 
substrates (Dovas & Couchman, 2005).  The interaction between Rho and 
RhoGDI can also protect the Rho proteins from proteosomal degradation (Boulter 
et al., 2010).  Consequently, exogenous expression of RhoGDIα is accompanied 
by increased levels of RhoA protein, while silencing of endogenous RhoGDIα 
corresponds with decreased levels of RhoA protein (Boulter et al., 2010; Giang 
Ho et al., 2011).  In the current study, microarray and mass spectrometry 
analysis revealed that PRL-1 overexpression leads to significantly decreased 
levels of RhoGDIα at both the mRNA and protein levels.  Therefore, it is possible 
that PRL-1 down-regulates RhoA expression by decreasing the amount of 
RhoGDIα available for RhoA protein stabilization.  Such post-translational control 
of Rho protein stability would explain the fact that ectopic overexpression of PRL-
1 leads to decreased expression of RhoA protein without influencing RhoA 
transcript levels.  Collectively, the microarray, mass spectrometry, and western 
blotting results support prior evidence suggesting that PRL-1 regulates focal 
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adhesion turnover and cytoskeletal rearrangement, through control of molecules 
such as Src and the RhoGTPases, to promote cell motility and metastasis. 
An established link also exists between PRL-1 expression and increased 
cell invasion (Achiwa & Lazo, 2007; Fiordalisi et al., 2006; Luo et al., 2009; Zeng 
et al., 2003).  Luo et al. (2009) showed that ectopic overexpression of PRL-1 in 
HEK293 cells leads to increased phosphorylation (hence activation) of ERK1/2 at 
Thr202/Tyr204 and to increased expression of the matrix metalloproteinases 
MMP2 and MMP9.  They proposed that PRL-1-mediated activation of Src 
signaling leads to the downstream phosphorylation/activation of ERK1/2, which in 
turn causes activation of the transcription factors AP-1 and Sp1, leading to up-
regulation of MMP2 and MMP9 expression which can cause degradation of the 
extracellular matrix, contributing to increased invasive activity.  In the current 
analysis, we did not see any notable changes in either the expression or activity 
levels of ERK1/2 in response to PRL-1.  The reasons for this are unclear; 
however alterations in ERK1/2 activity are often rapid and transient in order to 
precisely fine tune the cellular response.  Moreover, RhoA activity may be 
required for establishing sustained ERK activation (Renshaw, Ren, & Schwartz, 
1997; Welsh et al., 2001) and we have shown that RhoA expression in these 
cells is down-regulated.  Given that Rho has been implicated in controlling the 
duration of ERK signaling and that Rho activity is known to fluctuate in a cyclical 
manner, it is likely that the detection of changes in phospho-ERK levels is 
dependent on the time of cell collection.  It would be interesting, in future 
experiments, to generate HEK293 cell lines transiently expressing PRL-1 and to 
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examine the response of ERK, as well as other players involved in integrin-
mediated cell signaling, to PRL-1 expression over a time course.  Regardless, 
the current and previously reported results all suggest that PRL-1 can heavily 
influence Rho GTPase signaling.  Provided that the Rho GTPases have been 
tied to all stages of cancer progression, including cell growth, proliferation, 
migration, invasion, and metastasis, it is possible that many or all of the 
phenotypic effects resulting from aberrant PRL-1 expression could be linked to 
PRL-1-mediated control of the Rho GTPase signaling pathways. 
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CHAPTER 9.  PRL-1 OVEREXPRESSION ALTERS THE MICRORNA 
EXPRESSION PROFILE OF HEK293 CELLS AND LEADS TO DOWN-
REGULATION OF MICRORNAS THAT TARGET PRL-1 AND ITS 
DOWNSTREAM PATHWAYS 
9.1 Introduction 
MicroRNAs (miRNAs; miRs) have recently emerged as central post-
transcriptional regulators of gene expression.  These small, non-coding RNA 
molecules are capable of influencing many biological processes and are 
increasingly recognized as having critical roles in malignant transformation 
(Stahlhut Espinosa & Slack, 2006; E. Wang, 2008).  MicroRNAs bind to 
complementary mRNA targets and, generally, inhibit protein synthesis by 
inducing mRNA degradation or sterically hindering protein translation (Bartel, 
2004; Eulalio, Huntzinger, & Izaurralde, 2008), but translational up-regulation by 
miRNA's has also been observed (Place, Li, Pookot, Noonan, & Dahiya, 2008; 
Vasudevan, 2012).  Interestingly, while examining the effects of the PRL-1 
phosphatase on global gene expression, we found that overexpression of PRL-1 
in HEK293 cells led to up-regulation of the mRNA and/or protein products for 
several genes with important roles in microRNA biogenesis and function (see 
Chapter 7).  Two of these (HNRNPH1 and DDX5) are part of the DGCR8 
recognition complex that directs the RNase III enzyme Drosha to primary miRNA 
targets (pri-miRNAs) to carry out the first step in generation of mature
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 miRNA transcripts (Shiohama, Sasaki, Noda, Minoshima, & Shimizu, 2007).  
Another gene, FMR1, is a component of the microRNA RNA induced silencing 
complex (miRISC) that mediates inhibition of miRNA targets (Ishizuka, Siomi, & 
Siomi, 2002).  Finally, a fourth gene, ELAVL1, can bind mRNA target sequences 
and either facilitate or counteract miRNA-mediated repression in a gene-specific 
manner (Meisner & Filipowicz, 2011). 
Given that PRL-1 signaling can up-regulate the expression of such key 
molecules related to miRNA processing and behavior, I hypothesized that PRL-1 
could, either directly or indirectly, regulate miRNA expression and/or function.  
The relationship between PRL-1 and microRNAs had not previously been 
explored; therefore, I used TaqMan Low Density Human MicroRNA arrays to 
compare the miRNA expression profiles of HEK293 cells stably transfected with 
PRL-1 or with empty vector control.  
 
9.2 Results 
Expression levels of 664 microRNAs were evaluated in triplicate biological 
replicates of HEK293-PRL-1 and HEK293-vector cells using TaqMan Human 
MicroRNA arrays.  The resulting data set was then filtered to retain the 268 
miRNA measurements that had consistent present or not-present calls in all 3 
replicates of each comparison group.  Of these 268 miRNAs, there were 50 that 
displayed differential expression below a p-value threshold of 0.1, but only 5 of 
these retained significance below an FDR of 10% (Table 9.1).  The miRNA's hsa-
miR-154* and hsa-miR-886-5p were significantly up-regulated, while the miRNA's 
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hsa-miR-339-5p, hsa-miR-801, and hsa-miR-616 were significantly down-
regulated in the PRL-1-overexpressing cells compared to the empty vector 
controls. 
A combination of different software tools were used to determine which 
functional categories and signaling pathways were most over-represented by 
those mRNAs that were either experimental proven or predicted with high 
confidence, by at least two prediction algorithms, to be targets of the 5 miRs that 
showed significantly altered expression with increased exposure to PRL-1.  Each 
tool gave similar results.  Figure 9.1 and Figure 9.2 display the top 30 
functions/pathways that are over-represented by mRNA targets of the up-
regulated and down-regulated miRs respectively.  MicroRNA targets were 
commonly involved in cancer, cell adhesion, actin cytoskeletal rearrangement, 
and MAPK signaling, indicating that the miRNAs that change significantly with 
PRL-1 overexpression are influencing many of the same pathways where 
significant changes in mRNA and protein expression were also seen.  Other 
highly over-represented pathways included those related to neuronal signaling, 
Wnt signaling, Jak-STAT signaling, calcium signaling, and immune signaling. 
Given that many of the targets of significantly altered miRNAs were genes 
involved in actin cytoskeletal rearrangement and cell adhesion and that qRT-
PCR analysis confirmed significant changes in mRNA expression of several 
genes involved in these same processes, we choose to perform a direct 
comparison of the qRT-PCR (significantly changing genes only) and miRNA (all 
miRs) data sets.  Since miRNAs are best known as negative regulators of gene 
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expression, the data sets were scrutinized for negative correlations between the 
expression of a particular miRNA and the expression levels of its predicted 
and/or known mRNA targets.  As can be seen in the volcano plot in Figure 9.3, 
most of the transcripts that were significantly up-regulated in the PRL-1 
transfectants corresponded to miRNAs whose expression was down-regulated in 
those same samples.  In contrast, none of the miRs for three of four significantly 
down-regulated mRNAs were differentially expressed between the HEK293-PRL-
1 and HEK293-vector samples.  In addition, we found that the two miRNAs (miR-
339-5p and miR-30-c-5p), which are consistently reported, by all examined 
prediction algorithms, to target PRL-1 were down-regulated in the PRL-1 
overexpressing cells compared to the controls (Figure 9.4).  Therefore, 
overexpression of PRL-1 leads to down-regulation of microRNAs that target PRL-
1 as well as down-regulation of microRNAs that target signaling molecules 
having increased mRNA expression in response to PRL-1. 
 
 
 
 
189 
 
 
 
 
 
 
 
 
 
Table 9.1 MicroRNAs with differential expression in HEK293-PRL-1 cells compared to HEK293-vector cells 
A total of 664 microRNAs were assessed for differential expression using TaqMan Array Human microRNA Cards.  
Significance was determined based on an FDR threshold of 10% (i.e. FDR < 0.10). 
Assay ID 
Associated IPA 
mature RNA ID 
Empty vector 
Average ΔCt 
PRL-1 
transfectant 
Average ΔCt 
Fold 
Change p-value FDR 
hsa-miR-886-5p Vault RNA 2-1 10.2 6.5 12.8 6.8E-04 6.3E-02 
hsa-miR-154* miR-154-3p 22.4 19 10.6 9.5E-04 6.3E-02 
hsa-miR-339-5p miR-339-5p 11.0 11.2 -1.2 7.2E-04 6.3E-02 
hsa-miR-801 RNU11 12.8 14.8 -3.8 1.2E-03 6.3E-02 
hsa-miR-616 miR-616-3p 17.3 20.5 -9.3 8.1E-04 6.3E-02 
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Figure 9.1  Functional categories/pathways over-represented by 
predicted and known targets of the miRNAs that were significantly up-
regulated by PRL-1 
Number of events refers to the number of genes in each category.  
Abbreviations:  ABC, ATP-binding cassette; ECM, extracellular matrix; GnRH, 
gonadotropin-releasing hormone; Jak-STAT, Janus-activated kinase-signal 
transducer and activator of transcription; MAPK, mitogen-activated protein 
kinase; NK, natural killer; Present, presentation; Process, processing; Reg, 
regulation; VEGF, vascular endothelial growth factor. 
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Figure 9.2 Functional categories/pathways over-represented by 
predicted and known targets of the miRNAs that were significantly 
down-regulated by PRL-1 
Number of events refers to the number of genes in each category.  
Abbreviations:  ECM, extracellular matrix; Fc Epsilon R1, fragment 
crystallizable region, epsilon, receptor 1; Jak-STAT, Janus-activated kinase-
signal transducer and activator of transcription; MAPK, mitogen-activated 
protein kinase; NK, natural killer; PPAR, peroxisome proliferator-activated 
receptor; Reg, regulation; VEGF, vascular endothelial growth factor. 
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Figure 9.3 Significantly differentially expressed mRNA transcripts 
integrated with changes in corresponding miRNA signals 
Each black dot represents a gene whose transcripts were confirmed by qRT-
PCR to be differentially expressed between HEK293-PRL-1 and HEK293-vector 
cells.  A positive log2(mRNA expression ratio) value on the x-axis indicates an 
up-regulation of mRNA expression, while a negative value indicates a down-
regulation of mRNA expression.  The –log10 of the p-value for the mRNA 
expression data is plotted on the y-axis such that the higher the number, the 
better the p-value.  Colored circles surrounding the dots represent miRNAs 
known or predicted with moderate- to high-confidence to target each mRNA and 
having expression data from the TaqMan MicroRNA Arrays.  In instances where 
more than one miRNA with expression data targets the same mRNA, the colored 
circle is divided into sectors where each sector represents a single miRNA 
sequence and the size of the sector represents that miRNA’s contribution to the 
total signal for all miRNAs targeting that gene.  The various shades of color 
represent different fold change (FC) thresholds for the miRNA data, as defined in 
the inset legend. 
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Figure 9.4 Expression of miRs targeting PRL-1 
The fold change in expression for each miRNA in HEK293 cells stably 
transfected with PRL-1 is shown relative to the expression of the miR in 
cells transfected with empty vector.  The mean ± SEM for three 
independent biological replicates are shown. 
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9.3 Discussion 
To begin to investigate the role of microRNAs in regulation of gene 
expression downstream of PRL-1, we used TaqMan Low Density Human 
MicroRNA arrays to compare the miRNA expression profiles of PRL-1 
transfected to empty vector transfected HEK293 cells.  In this analysis, five 
miRNAs were identified whose expression was significantly (q ≤ 0.10) altered in 
the PRL-1 transfectants.  Of these, two (miR-886-5p and miR-154*) were 
significantly up-regulated and three (miR-339-5p, miR-801, and miR-616) were 
significantly down-regulated. 
MicroRNA-886-5p was the most significantly up-regulated miRNA (up 13-
fold) in the HEK293-PRL-1 transfectants.  The classification of the miR-886 
sequence as a microRNA is actually a topic of some debate.  In 2009, Nandy et 
al. proposed that, based on structural resemblance and a similar expression 
profile to vault RNAs (vtRNAs), miR-886 might instead be a component of the 
hollow, barrel-shaped ribonucleoprotein complex known as the vault complex.  
Accordingly, miR-886 was officially renamed vtRNA2-1.  More recently, however, 
K. Lee et al. (2011) provided evidence suggesting that 886 is not part of the vault 
complex, nor is it a canonical miRNA.  Instead, this sequence may represent a 
new, as yet uncharacterized, class of non-coding RNA (ncRNA).  The biological 
significance of miR-886/vt2-1 is just beginning to be explored, but it appears to 
have the capacity to both promote and suppress malignant transformation in a 
cell-type dependent manner (Gao, Shen, Liu, Xu, & Shu, 2011; Han et al., 2012; 
K. Lee et al., 2011; J. H. Li et al., 2011; Xiao et al., 2012).  It is predicted to target 
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the genes FLNA, TAGLN2, and EF2, all which were significantly increasing in our 
PRL-1 transfectants, and is also predicted to target RhoGDIα and COL5A1, 
which were both significantly decreasing in the PRL-1 transfectants.  Not enough 
is known yet about the relationship of miR-886/vtRNA2-1 to these molecules to 
say whether its effects on each are normally synergistic or antagonistic. 
Two instances where the effect of miRNA-886/vtRNA2-1 is experimentally 
shown to have an inhibitory effect are on the pro-apoptotic molecule Bax (J. H. Li 
et al., 2011) and the RNA-dependent protein kinase PKR (K. Lee et al., 2011).  
Interestingly, miR-616, which was the most significantly down-regulated miRNA 
(down 9-fold) in the PRL-1 transfectants, is also predicted to target both Bax and 
PKR.  The differential regulation of two ncRNAs with similar targets underscores 
the complexity of both PRL-1 signaling and miRNA regulation and suggests that 
opposing forces may be at work in an attempt to regain balance within in the 
system, following perturbation by PRL-1.  Given that alterations in PKR activity 
can have profound effects on the cell, it is not surprising that the activity of this 
molecule would be tightly controlled.  PKR is a versatile signaling molecule that 
has both pro-survival and pro-apoptotic effects (Cho et al., 2011; Kazemi et al., 
2007; K. Lee et al., 2011; von Roretz & Gallouzi, 2010; Yoon, Miah, Kim, & Bae, 
2010).  It is known to promote increased mRNA expression of HNRNPH1 and 
TAGLN2 (Guerra, Lopez-Fernandez, Garcia, Zaballos, & Esteban, 2006), which 
were both significantly increased in the PRL-1 transfectants.  Nonetheless, PKR 
is best known for its regulation of the eukaryotic translation initiation factor eIF2A.  
In response to cellular stress, active PKR can phosphorylate and inhibit eIF2A, 
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resulting in a shutdown of global protein synthesis (Garcia et al., 2006).  
Sustained inhibition of protein synthesis can lead to cell death, however, more 
transient inhibition can selectively regulate the translation of specific mRNAs that 
have a higher requirement for eIF2A activity.  Notably, Liang et al. (2008) 
previously showed that ectopic expression of PRL-3 in HEK293 cells leads to 
enhanced phosphorylation and inactivation of eIF2A and proposed this as the 
mechanism by which PRL-3 is able to down-regulate the expression of the Src 
inhibitor Csk, leading to increased Src activity.  The current results suggest that, 
as with PRL-3, ectopic expression of PRL-1 in HEK293 can also influence the 
expression of molecules which regulate downstream eIF2A activity. 
In addition to miR-886/vtRNA2-1, miR-154* was also up-regulated (11-fold) 
in the HEK293-PRL-1 lines.  This miR is predicted to target HNRNPH2, ACTN4, 
and ALDOA, all genes whose products were significantly up-regulated in those 
samples.  Up-regulation of miR-154* has also been associated with cancer.  It is 
known to be highly expressed in a subset of acute myeloid leukemia patient 
samples (Dixon-McIver et al., 2008) and in primary Ewing’s sarcoma xenografts 
(Mosakhani et al., 2012); however it is found at lower levels in the associated 
metastatic tumors from the Ewing’s sarcomas. 
MiR-339-5p and miR-801 were significantly down-regulated (1.2- and 3.8-
fold respectively) in the PRL-1 transfectants.  MiR-339-5p is predicted to target 
PRL-1 itself and is also predicted to target Mdm2, a molecule that is known to 
function downstream of PRL-1 promoting p53 degradation and apoptosis 
inhibition (Min et al., 2009).  This miR appears to have a tumor suppressive effect 
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on cells, as it has been found at significantly lower levels in breast cancer tissue 
compared to benign tissue and is capable of decreasing migration and invasion 
of breast cancer cell lines (Z. S. Wu et al., 2010).  As with miR-886, miR-801 is 
another molecule that was originally thought to be a microRNA and was included 
on the Applied Biosystems TaqMan miRNA Arrays, but has recently been 
reclassified.  This molecule was originally identified based on its ability to 
associate with the AIN-1 and AIN-2 proteins that form part of the RNA induced 
silencing complex (RISC) (L. Zhang et al., 2007).  However, the sequence was 
later determined to be a fragment of the small nuclear ribonucleoprotein (snRNP) 
U11 (www.mirbase.org).  The snRNP U11 (a.k.a. RNU11) functions as a 
component of the minor spliceosome (noncanonical splicing pathway) that is 
responsible for catalyzing the removal of a small (~0.1% of all introns) class of 
atypical intron (Tarn & Steitz, 1996).  Known targets of the minor spliceosome 
that are relevant to PRL-1-biology include PTEN and PRDX1 (The U12 Intron 
Database:  genome.crg.es/cgi-bin/u12db/u12db.cgi).  Microarray and proteomic 
analysis revealed that PRL-1 overexpression in HEK293 cells caused alterations 
in the mRNA and protein expression levels of a number of molecules with 
important roles in alternative splicing, including members of the HNRNP, SRSF, 
and ELAVL1 gene families.  The down-regulation of RNU11 in response to PRL-
1 further implicates PRL-1 with a potential role in altering alternative splicing 
patterns to influence downstream gene expression. 
Altogether, the full list of predicted and known targets for all five 
significantly differentiated ncRNAs show an over-representation of genes 
198 
 
 
 
 
involved in cell adhesion and cytoskeletal rearrangement.  This result is in close 
agreement with the mRNA and protein results for this sample set.  Focusing in 
further on these pathways, we found a down-regulation of almost all assayed 
miRs, which target mRNA transcripts that were confirmed by qRT-PCR to be 
significantly up-regulated in response to PRL-1, in the PRL-1 transfectants (i.e. 
expression of these miRs was inversely correlated to the expression of their 
targets).  Moreover, both miRNAs which are thought to directly target PRL-1 
were also down-regulated in the PRL-1 transfectants.  These findings indicate 
that PRL-1 signaling has the capacity to indirectly affect downstream gene 
expression through alteration of microRNA levels.  Moreover, up-regulation of 
PRL-1 may initiate a positive feedback loop leading to inhibition of PRL-1 
targeting miRNA's and thus increased PRL-1 mRNA stability or protein 
translation.  Further characterization will be required to understand the roles of 
each of the differentially expressed miRNAs and other ncRNAs in PRL-1 
signaling and their relationship to PRL-1 induced malignant transformation.  
Nevertheless, this study is the first to show that PRL-1 signaling can lead to 
altered patterns of miRNA expression. 
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CHAPTER 10. STABLE TRANSFECTION OF PRL-3 IN HEK293 CELLS LEADS 
TO DOWN-REGULATION OF GLOBAL TRANSCRIPTION 
10.1 Introduction 
A growing number of studies have implicated PRL-3 in the progression 
and metastasis of a wide array of tumor types (Reviewed in:  Bessette et al., 
2008), calling attention to the PRL family as potential novel targets for cancer 
therapy.  However, despite much emerging evidence surrounding PRL-3 binding 
partners and the downstream consequences of exogenous PRL-3 expression or 
endogenous PRL-3 knockdown by RNAi, the normal biological function of this 
molecule remains unknown and the signaling pathways through which it exerts 
its effects are poorly understood.  Although the primary focus of my research 
project was PRL-1, because we were also able to obtain HEK293 cells stably 
transfected with PRL-3 and because many questions surrounding PRL-3 
signaling events still remain unanswered, I also attempted to examine the global 
transcriptional profiles of HEK293 cells transfected with PRL-3 using microarray 
analysis. 
For this analysis, total RNA was extracted from triplicate biological 
replicates of HEK293 cells stably transfected with PRL-3 and HEK293 cells 
transfected with empty vector.  Transcriptional profiling of each RNA sample was 
performed, using Affymetrix microarrays, as described in the methods section.
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10.2 Results 
The Affymetrix GeneChip Operating System (GCOS) was used to 
generate an “Expression Report” for each sample hybridized to a microarray and 
an initial quality check of each sample was performed by evaluating the 
Expression Report metrics.  Typically, in a given sample, at any one time, 
somewhere between 40-50% of all transcripts represented on the microarray are 
being expressed.  This value is measured by the GCOS Software and is referred 
to as the Percent Present call or %P in the Expression Report.  Although, in 
some tissue types or cell lines, fewer than 40% or greater than 50% of the 
transcripts can be expressed, the %P is almost always consistent between 
samples of the same origin (e.g. same cell type).  Table 10.1 lists the %P calls 
that were reported for all samples examined by microarray in the current study.  
As expected, the % Present calls for the PRL-1 transfected samples and their 
pcDNA4 empty vector control samples ranged from 44-50%.  In addition, all other 
quality control (QC) parameters (e.g. background level, scale factor, 3’/5’ ratios of 
β-actin and GAPDH) for these samples were within normal ranges, suggesting 
high quality RNA as starting material and consistent performance of the assay.  
Likewise, all report values for the PRL-3 empty vector (pcDNA3) controls were 
within expected ranges and these lines displayed %P values ranging from 45 to 
48%.  Unexpectedly, however, in all biological replicates of the HEK293 lines 
stably transfected with PRL-3, the %P values were between 11 and 12%.  
Normally, such a result would suggest poor sample quality, which would also be 
evident in the values of other QC parameters within the report, but in this case, 
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all other report values were normal.  In addition, evaluation of the RNA using the 
Agilent Bioanalyzer had indicated the presence of high quality RNA in these 
samples (see Chapter 5 results).  Since all evidence indicates that the RNA 
sample quality was good and the assay was performing correctly, these data 
suggest that stable overexpression of PRL-3 may lead to down-regulation of 
transcription on a global level. 
To further examine the PRL-3 microarray results, Partek Genomics Suite 
was used to perform a statistical comparison of the genes that were expressed in 
the PRL-3 transfectants compared to those expressed in the corresponding 
empty vector samples.  In this analysis, the large scale alterations in overall gene 
expression caused by stable PRL-3 transfection were even more apparent.  Of 
the 47,400 total RNA transcripts represented on the Affymetrix U133 Plus 2.0 
microarrays, 22,123 (47%) of these displayed more than a 2-fold change in 
expression between the PRL-3 stable cell lines and the empty vector control lines.  
Even when far more stringent cut-off criteria were applied, for example a fold 
change threshold of 10 in combination with a false discovery rate threshold of 
10%, there were still almost 2,300 transcripts exhibiting significant differences in 
expression between the two groups (Figure 10.1).  Interestingly, PRL-3 did not 
appear among the list of genes that displayed significantly increased expression 
in the PRL-3 transfectants.  To confirm this result, we elected to examine PRL-3 
expression in the microarray samples using qRT-PCR.  As shown in Chapter 6 of 
this dissertation, RT-PCR analysis revealed that PRL-3 expression was actually 
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several orders of magnitude lower in the PRL-3 transfectants than in the empty 
vector controls. 
One possible explanation for the large scale alterations in gene 
expression observed in the PRL-3 stable transfectants is that these lines, which 
have a significantly enhanced doubling time compared to the control lines may 
have been overgrown, with a large proportion of cells dead or dying at the time of 
sample collection.  To test this theory, a new batch of cells, which had more 
recently been taken out of frozen storage (had been through fewer passages) 
than the initial set of samples used in the microarray experiments, was grown 
and cells were collected at various stages of growth, ranging from 20% to 90% 
confluency.  RNA was extracted and reverse transcribed, then analyzed by qRT-
PCR using an ABI Endogenous Control Array.  Quantitative RT-PCR analysis 
with the same Endogenous Control Array and the samples from the microarray 
experiments, had already revealed that stable transfection of PRL-3 could 
dramatically reduce the expression of a number of genes typically considered to 
be housekeeping controls (see Chapter 6 results); thus, use of the same array 
with this new batch of samples allowed a direct comparison of the results.  
Despite marked differences in the confluency at which the new cells were 
harvested and careful consideration as to the conditions under which they were 
harvested, the results of this endogenous control experiment were the same as 
with the previous batch of cells.  With the exception of 18S rRNA, the expression 
of all 15 other control genes on the array was down-regulated in the PRL-3 
transfectants compared to the empty vector samples.  As can be seen by plotting 
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the Ct values for the samples using DataAssist (Figure 10.2), genes which were 
expressed at low, moderate, or even high levels in the vector only control lines 
became low to undetectable in the PRL-3 overexpressing cells regardless of the 
confluency at which they were collected.  These data indicate that the observed 
alterations in global gene expression, upon stable PRL-3 transfection in HEK293 
cells are not simply a factor of the conditions under which the cells were 
harvested.  Taken together with Agilent Bioanalyzer results and the quality 
review of the microarrays, these data suggest that the global changes in gene 
expression observed with exogenous expression of PRL-3 in HEK293 cells is a 
real biological phenomenon and not the result of poor sample quality, sample 
handling error, or technical/assay error. 
The expression of PRL-3 itself was also examined by RT-PCR in the 
samples that were collected at various stages of confluency.  As with the 
previous sample set, PRL-3 expression was again lower in the cells stably 
transfected with PRL-3 than in the lines transfected with empty vector (Figure 
10.3).  Compellingly, PRL-3 expression declined as the cells grew more confluent, 
suggesting that PRL-3 transgene expression is influenced by cell density. 
The large scale decreases of PRL-3 expression in the PRL-3 stable 
transfectants compared to the vector controls raised the question of whether 
these stably transfected HEK293 lines may have undergone some sort of 
adaptive response over time, leading to transgene silencing.  This, along with the 
presence of such numerous changes in gene expression that it is difficult to filter 
the microarray data down to a reasonable and meaningful level, is likely to 
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preclude our ability to use these stable HEK293 PRL-3 transfectants to identify 
alterations in gene expression that are directly influenced by PRL-3.  Instead, 
cells transiently transfected with PRL-3 might be more useful in that capacity.  To 
evaluate whether we could successfully generate cell lines transiently 
overexpressing pcDNA3-PRL-3, a human non small cell lung carcinoma cell line 
(H1299) was transiently transfected with either PRL-3 or empty vector (n =1 
each).  RNA was extracted from the cells and was subjected to both RT-PCR 
and microarray analysis.  Quantitation of PRL-3 levels in these samples revealed 
that PRL-3 was expressed at more than 30-fold higher levels in the PRL-3 
transfected H1299 cells than in the cells transfected with empty vector (Figure 
10.4).  Moreover, evaluation of the QC report metrics for these samples after 
hybridization to microarrays revealed %P values for the empty vector and PRL-3 
transfectants of 43.9% and 43.6% respectively.  Based on these results, the 
H1299 transient transfectants may be a viable alternative to the HEK293 stable 
transfectants for use in future examination of the signaling events downstream of 
PRL-3. 
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Table 10.1 Percentage of total transcripts called present (%P) for samples 
assayed by microarray 
RNA derived from HEK293 cells that were stably transfected with PRL-1, PRL-3 
or their respective empty vectors were hybridized to Affymetrix U133A Plus 2.0 
microarrays and the Affymetrix GCOS software was used to determine the 
number of transcripts on the array that were called present in each sample.  
Values between 40-50%, such as seen for the PRL-1 transfectants and all empty 
vector controls are typical.  Transfection of HEK293 cells with PRL-3, on the 
other hand, led to a large scale decrease in global transcription as indicated by 
the unusually low %P values for all biological replicates of these samples on the 
microarray. 
Cell Line Sample %P 
HEK293 Empty Vector 1 (PRL-1) 43.6 
HEK293 Empty Vector 2 (PRL-1) 44.1 
HEK293 Empty Vector 3 (PRL-1) 44.4 
HEK293 PRL-1 Transfectant 1 46.5 
HEK293 PRL-1 Transfectant 2 45.1 
HEK293 PRL-1 Transfectant 3 50.0 
HEK293 Empty Vector 1 (PRL-3) 47.7 
HEK293 Empty Vector 1 (PRL-3) 47.6 
HEK293 Empty Vector 1 (PRL-3) 45.0 
HEK293 PRL-3 Transfectant 1 11.9 
HEK293 PRL-3 Transfectant 2 11.5 
HEK293 PRL-3 Transfectant 3 10.7 
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Figure 10.1 Number of transcripts significantly differentially expressed in 
HEK293 cells stably transfected with PRL-3 
Global gene expression in HEK293 cells stably transfected with PRL-3 or empty 
vector was assessed using Affymetrix microarrays and Partek Genomics Suite 
software was used to identify genes that were significantly different between the 
two sample groups (PRL-3 vs. empty vector) using various significance 
thresholds to filter the data.  FC = Fold Change; FDR = False Discovery Rate. 
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Figure 10.2 Influence of PRL-3 transfection on global gene expression is 
independent of cell confluency 
A TaqMan Endogenous Control Array was used to examine the expression of 
16 classical endogenous control genes in HEK293 cells stably transfected with 
PRL-3 or with empty vector.  Cells were grown to confluencies of 20%, 40-
50%, and 80-90% prior to cell collection and RNA extraction.  Gene 
expression was then examined using qRT-PCR.  Visualization of the resulting 
cycle threshold (Ct) values revealed that stable transfection of the PRL-3 
containing vector leads to a significant decrease in expression (increase in Ct 
value) of most housekeeping genes, regardless of cell confluency. 
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Figure 10.3 PRL-3 transgene expression is influenced by cell 
density 
HEK293 cells stably transfected with PRL-3 or empty vector were 
grown to various stages of cell confluency, then RNA was extracted 
and PRL-3 expression was evaluated using qRT-PCR.  PRL-3 
transcript levels, which were found to be down-regulated in the PRL-3 
transfectants compared to the empty vector controls, declined to lower 
and lower levels as cell confluency (density) increased. 
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Figure 10.4 PRL-3 expression in H1299 transient transfectants 
The fold change differences in PRL-3 mRNA transcript levels in H1299 
cells transiently transfected with PRL-3 or with empty vector (n=1 each) 
were determined by qRT-PCR.  The PRL-3 transient transfectants 
successfully overexpressed PRL-3 at more than 30-fold higher levels than 
in the empty vector control lines. 
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10.3 Discussion 
HEK293 cells stably transfected with PRL-3 appear to undergo some form 
of transgene silencing over time, where the degree of silencing is tied to the 
density, or possibly the rate of proliferation, of the cells in culture.  The PRL-3 
transgene was under the control of the cytomegalovirus (CMV) immediate-early 
promoter on the pcDNA3 expression vector.  Due to its potent activity, the CMV 
promoter is one of the most commonly used promoters, in vitro and in vivo, for 
driving expression of transgenes in mammalian cells.  However, CMV promoter-
driven expression is strongly affected by cellular context and, thus, can be highly 
cell type specific (Mao et al., 2008; Radhakrishnan, Basma, Klinkebiel, Christman, 
& Cheng, 2008; Wiederkehr & Caroni, 1995).  It has been documented that, in 
some stably transfected cells, CMV promoter activity is vulnerable to silencing 
and is gradually suppressed over the course of time in culture (K. H. Choi, 
Basma, Singh, & Cheng, 2005; Norrman et al., 2010).  It is possible that this is 
the reason for the eventual down-regulation of PRL-3 in the HEK293 stable 
transfectants. 
The mechanisms involved in silencing the CMV and other transgene 
promoters are poorly understood, particularly in cultured mammalian cells, but 
DNA methylation (Brooks et al., 2004; K. H. Choi et al., 2005), histone 
hypoacetylation (K. H. Choi et al., 2005), and RNAi (Ketting & Plasterk, 2000) 
have all been implicated.  The specific mechanisms used can vary from cell type 
to cell type, but generally result in either gene inactivation by blocking 
transcription or inhibition of mRNA accumulation following transcription.  When 
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transcription is blocked, this is referred to as transcriptional gene silencing or 
TGS.  When transcription occurs, but mRNA accumulation is inhibited, it is 
known as post-transcriptional gene silencing or PTGS (Stam, Mol, & Kooter, 
1997).  Studies in developing tobacco plants have shown that PTGS can be 
released with synthesis of DNA in proliferating cells and again reactivated when 
proliferation is complete (Mitsuhara et al., 2002).  It is therefore plausible that the 
decline in PRL-3 expression with increasing cell confluency is related to a partial 
release of gene silencing when the cells are rapidly proliferating and a 
reactivation of gene silencing when proliferation slows as the cells approach 
confluency or begin to exceed the capacity of the medium to support growth.  
However, further studies would be required to determine the exact mechanisms 
of gene silencing in these cell lines and the factors by which they are controlled. 
Not only is PRL-3 expression reduced in the PRL-3 stable transfectants, 
but there appears to be a global down-regulation of transcription in these cell 
lines.  Again, the mechanisms for this are unclear.  They could be similar to those 
affecting PRL-3 expression, although the decreases in expression seen for other 
genes seem to be less dependent on cell density than those observed for PRL-3.  
The goal of the microarray analysis on the HEK293 stable transfectants was to 
elucidate the pathways in which the PRL enzymes act and to identify new 
candidates for possible PRL effectors and/or substrates, but there is clearly 
additional biology occurring in the PRL-3 stable transfectants that would interfere 
with this goal.  The use of transient transfectants instead may avoid any issues of 
transgene silencing over time because, unlike stable transfection, the transgene 
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is not integrated into the genome and its expression is not dependent on the site 
of integration or influenced by the surrounding chromosomal elements.  We show 
here, proof of concept that PRL-3 transcripts can be successfully overexpressed 
in transiently transfected H1299 cells compared to cells transfected only with 
pcDNA3 vector and that no apparent down-regulation of global transcription 
occurs in these transient lines.  In future studies, biological replicates of the 
H1299 transient transfectants should be generated, which could then be used to 
assess alterations in gene expression that occur more directly as a result of PRL-
3 overexpression. 
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CHAPTER 11. MICRORNA EXPRESSION IS NOT THE PRIMARY CAUSE OF 
DECREASED GLOBAL TRANSCRIPTION IN HEK293 CELLS STABLY 
TRANSFECTED WITH PRL-3 
11.1 Introduction 
MicroRNAs are now known to play key roles in the post-transcriptional 
regulation of gene expression through the destabilization of their mRNA targets 
or inhibition of protein translation (Eulalio et al., 2008).  Given their ability to 
regulate the expression levels of target mRNAs, I theorized that alterations in 
microRNA abundance might partially explain the profound effect we observed of 
stable PRL-3 transfection on global mRNA levels in HEK293 cells.  To begin to 
investigate this, TaqMan Low Density Human MicroRNA arrays were used to 
examine the differences in microRNA expression profiles between HEK293 cells 
stably transfected with PRL-3 and those transfected with empty vector. 
 
11.2 Results 
Triplicate biological replicates of HEK293 cells stably transfected with 
PRL-3 or with empty vector were assayed using TaqMan Human MicroRNA 
arrays and Partek Genomics Suite was used to compare the resulting miRNA 
expression profiles.  This analysis revealed that approximately 222 (33%) of the 
664 miRNAs on the TaqMan array were altered by more than 2-fold in the PRL-3
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 transfectants compared to the empty vector controls.  162 (73%) of these were 
down-regulated and only 60 were up-regulated.  Despite the large number of 
changes that were observed, no miRs met an initial significance threshold set at 
a fold change (FC) >2 with FDR < 5% and only two miRs (miR-509-5p and miR-
624*) met a cutoff of FC > 2 and FDR <10%.  Increasing the FDR cutoff to 30% 
generated a list of 35 significantly changing miRs, which are displayed in Table 
11.1.  Twenty-eight of these were increasing and 7 of these were decreasing in 
the PRL-3 transfectants. 
Ingenuity Pathway Analysis was next used to perform a direct comparison 
of the lists of miRNAs and mRNAs that were significantly changing in the PRL-3 
transfectants.  Of the greater than 2,000 mRNA transcripts most significantly (FC 
> 100; FDR < 10%) differentially expressed between the stable HEK293 PRL-3 
transfectants and empty vector controls, 54 were predicted, based on either 
experimental evidence or moderate to high confidence predictions, to be targets 
of at least one of 26 out of the 35 miRs that were also significantly (FC > 2; FDR 
< 30%) changing.  Due to its size, the table listing these predicted miR-mRNA 
interactions has been placed in the appendix as Table B. 
Although microRNAs can positively regulate their mRNA targets 
(Vasudevan, 2012), they are best known for their ability to function as negative 
regulators of gene expression; therefore the generated list of 26 miRs and 54 
mRNAs was scrutinized to look for negative correlations in miRNA and mRNA 
target expression.  We found that all of the 54 mRNAs were significantly down-
regulated in the PRL-3 transfectants compared to the empty vector samples, 
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therefore miRs that were significantly down-regulated tended to be moving in the 
same direction as their targets, while miRs that were significantly up-regulated 
were all inversely correlated to the expression of their targets. 
216 
 
 
 
 
Table 11.1 MicroRNAs displaying differential expression between 
HEK293 cells stably transfected with PRL-3 or empty vector 
A total of 664 microRNAs were examined for differential expression, 
using TaqMan Array Human microRNA cards.  Significance was 
determined based on a threshold of Fold Change > 2 and FDR < 30%.  
Data is sorted from lowest (best) to highest FDR. 
miR FDR 
Fold 
Change 
hsa-miR-509-5p 0.054 20.48 
hsa-miR-624* 0.091 4.91 
hsa-miR-98 0.103 -14.02 
hsa-miR-519a 0.118 15.14 
hsa-miR-375 0.120 25.84 
hsa-miR-346 0.121 10.80 
hsa-miR-190b 0.126 -4.25 
hsa-miR-642 0.129 24.04 
hsa-miR-129-3p 0.131 9.01 
hsa-miR-576-3p 0.132 21.15 
hsa-miR-671-3p 0.145 21.63 
hsa-miR-372 0.151 9.00 
hsa-miR-519e 0.166 4.19 
hsa-miR-19a* 0.172 -13.38 
hsa-miR-423-5p 0.176 10.95 
hsa-miR-33a* 0.180 12.96 
hsa-miR-526b* 0.192 -4.86 
hsa-miR-128 0.197 16.52 
hsa-miR-133a 0.211 6.17 
hsa-miR-210 0.214 -2.59 
hsa-miR-605 0.215 24.04 
hsa-miR-34b* 0.231 9.81 
hsa-miR-570 0.232 3.01 
hsa-miR-512-3p 0.232 3.03 
hsa-miR-219-1-3p 0.234 5.20 
hsa-miR-622 0.241 29.65 
hsa-miR-518d-3p 0.251 4.37 
hsa-miR-614 0.262 -6.31 
hsa-miR-672 0.265 5.63 
hsa-miR-517c 0.267 4.25 
hsa-miR-150 0.276 2.94 
hsa-miR-141 0.278 -4.22 
hsa-miR-487a 0.285 5.31 
hsa-miR-215 0.295 3.83 
hsa-miR-515-3p 0.296 5.12 
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11.3 Discussion 
Blocking translation was initially thought to be the predominant means by 
which miRNAs inhibit protein synthesis, however there is now much evidence 
supporting the idea that microRNAs can inhibit protein production by lowering 
mRNA levels (Bagga et al., 2005; Lim et al., 2005).  Although a topic of much 
debate, some researchers have recently provided evidence that down-regulation 
of mRNA expression may even be the primary mechanism by which miRNAs 
exert their effects (Baek et al., 2008; H. Guo, Ingolia, Weissman, & Bartel, 2010).  
HEK293 cells stably transfected with PRL-3 appear to have undergone silencing 
of the PRL-3 transgene over time.  However, not only is PRL-3 expression down-
regulated, but global mRNA levels in these cells are much lower than those in 
HEK293 cells transfected with empty vector.  To examine any changes in miRNA 
expression levels that might help to explain the large scale decreases in mRNA 
expression observed in the PRL-3 transfectants, I used TaqMan microRNA 
arrays to evaluate and compare the miRNA expression profiles of the PRL-3 and 
empty vector transfected HEK293 cell lines. 
Approximately 33% of the 664 microRNAs on the TaqMan arrays 
exhibited at least a 2-fold change in expression between the PRL-3 transfectants 
and the empty vector controls, however most (73%) of these had lower 
expression levels in the PRL-3 transfected lines than in the controls.  These 
results are not, therefore, consistent with the hypothesis that increased 
expression of miRNAs is causing a global down-regulation of mRNA expression 
levels. 
218 
 
 
 
 
Although miRNA up-regulation does not appear to be the major 
mechanism by which mRNA transcript levels are decreased in the PRL-3 
transfectants, some significant alterations in miRNA abundance in these lines do 
exist and all of the significantly up-regulated miRNAs show an inverse correlation 
of expression to their predicted and/or known targets.  It is important to note that 
the changes in miRNA expression are relatively small (< 30-fold increases) 
compared to the changes in expression of their target genes (100-300-fold 
decreases); however 34 (63%) of the 54 significantly altered mRNAs are targeted 
by multiple significantly up-regulated miRNAs, indicating the possibility that the 
degree of the change at the mRNA level could be due to the combined effects of 
multiple miRNAs acting in unison.  Nevertheless, the possibility of additional 
mechanisms contributing to decreased mRNA expression, even when the 
expression of miRs targeting those transcripts is increasing, cannot be ruled out. 
Other possible explanations for the widespread and high magnitude 
changes of mRNA expression, that could be examined in future studies, include 
increases in global DNA methylation, decreases in global histone acetylation, up-
regulation of siRNA expression, or altered phosphorylation of the C-terminal 
domain (CTD) of RNA polymerase II, leading to inhibition of its activity. 
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CHAPTER 12. CONCLUSIONS AND FUTURE DIRECTIONS 
Elucidation of the mechanisms governing tumor formation and metastasis 
is crucial to enhancing our understanding of the oncogenic process and to 
providing effective tools for cancer diagnosis, prognosis, and optimal patient 
therapy.  The results presented in this dissertation helped to define the basal 
gene expression of the PRL-1 and PRL-2 phosphatases in adult human tissues 
and provided a foundation for the recognition and interpretation of the changes in 
these expression patterns that are associated with cancer and/or other disease 
states.  We found that PRL-1 and PRL-2 are nearly ubiquitously expressed in 
normal human tissues and thus are likely to play an important role in maintaining 
normal tissue homeostasis.  This role may be tissue and/or cell-type specific, 
because each molecule is widely expressed in cell types from a variety of 
different molecular backgrounds and functions, including cells with different 
proliferation and differentiation potentials.  In human cancers, we showed that 
alterations of PRL-1 and PRL-2 expression are a common event, but that the 
nature of these alterations are also highly tissue-type specific.  In some tissues, 
such as the stomach and liver, PRL-1 and PRL-2 expression appear to have a 
tumor promoting effect, while in other tissue types, like the ovary and lung, 
expression of these molecules may normally serve a protective function.  The 
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frequent deregulation of these molecules in human neoplasms suggests that they 
may be useful markers for cancer diagnosis.  They may also serve as indicators 
of disease severity and/or as valuable therapeutic targets for disease treatment 
in some tumor types. 
To fully realize the potential of the PRL phosphatases as molecular targets 
for cancer therapy, researchers must first understand the mechanisms that 
govern their function, the signaling pathways and substrates on which they act, 
their normal biological roles, and the basis of their transforming activity.  In order 
to enhance our understanding of PRL-1-mediated signaling events, I performed a 
global, unbiased analysis of the changes in mRNA and miRNA expression that 
occur in response to stable PRL-1 overexpression in HEK293 cells and 
correlated these results to changes occurring at the protein level.  This analysis 
significantly expanded on the current knowledge surrounding PRL-1 signaling 
and allowed identification of several novel candidates for mediators of PRL-1 
function.  Future studies should focus on further validation and functional 
characterization of the identified targets (e.g. by perturbation of the potential 
targets to determine the effect on PRL-1-mediated cellular response).  In 
particular, the relationship between PRL-1 and SPARC, RhoGDIα, and Filamin A 
should be further examined.  Moreover, the role of PRL-1 in regulating the Rho 
GTPase signaling pathways should be explored in greater depth. 
Analysis of the PRL-2 and PRL-3 signaling pathways might also benefit 
from a broad, integrated, systems-level approach such as that taken here.  This 
would allow a direct comparison of the gene expression profiles of each of the 
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three PRL family members.  Although HEK293 cells stably transfected with PRL-
3, under the control of a CMV promoter, appear to undergo transgene silencing 
over time, we have shown that PRL-3 can be successfully overexpressed in a 
transiently transfected H1299 lung carcinoma cell line.  Using a transient 
transfection approach for all three PRL genes could provide a quick and 
straightforward method by which the effects of exogenous PRL expression could 
be examined over a time course, allowing separation of early events from those 
occurring further downstream.  Since PRL-mediated signaling events, particularly 
those for PRL-1, may be profoundly dependent on cellular context, a variety of 
cell types should ultimately be examined. 
Although additional studies will be required to clarify the biological function 
of the PRL phosphatases and the exact mechanisms by which they mediate their 
effects, as well as to establish their utility as targets for anti-cancer therapy, the 
results presented here provide novel insights into the biology of these enzymes 
that should open up new lines of investigation for future study. 
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Appendix A Literature Reports of PRL Expression in Normal Tissues 
Table A.1 Instances where positive PRL expression has been reported in the 
literature for normal tissues 
Tissue Molecule Species* Detection Methods Reference* 
Adipose Tissue (Fat) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human; Bat ISH; PCR Dumaual 2006; Yuan 2007 
Adrenal Gland (Adult) PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
  PRL-2 Human; Rat ISH; Northern Blot Dumaual 2006; Carter 1998 
Adrenal Gland (Developing) PRL-1 Mouse ISH Rundle 1999 
Appendix (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Bladder (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Bone/Cartilage (Developing) PRL-1 Mouse ISH Rundle 1999 
Bone Marrow (Adult) PRL-1 Human PCR Gjorloff-Wingren 2000 
  PRL-2 Human PCR Gjorloff-Wingren 2000 
Brain (Adult) PRL-1 Human; Rat ISH; Northern Blot Dumaual 2006; Diamond 1994, Takano 1996, Guo 2006 
  PRL-2 Human; Mouse, Rat; Bat ISH; Northern Blot; PCR Dumaual 2006; Carter 1998, Zhao 1996, Zeng 1998, Guo 2006; 
Yuan 2007 
Brain (Developing) PRL-1 Rat, Mouse; Human ISH; Northern Blot Takano 1996, Rundle 1999; Guo 2006 
  PRL-2 Human Northern Blot Zhao 1996 
  PRL-3 Human Northern Blot Guo 2006 
Breast (Adult) PRL-1 Human ISH; PCR Dumaual 2006; Guo 2003 
 PRL-2 Human ISH Dumaual 2006 
Cervix (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Colon (Adult) PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
  PRL-2 Human ISH; Northern Blot Dumaual 2006; Guo 2006, Montagna 1995, Zhao 1996 
  PRL-3 Human IHC** L. Peng 2004** 
Colon (Developing) PRL-1 Rat IHC Kong 2000 
Esophagus (Developing) PRL-1 Rat IHC Kong 2000 
Eye (Adult Retina) PRL-1 Human; Monkey ISH; IHC, Southern, Western Dumaual 2006; Yarovinsky 2000 
 PRL-2 Human ISH Dumaual 2006 
Heart (Adult) PRL-1 Human Northern Blot Guo 2006 
  
PRL-2 Human; Mouse, Rat; Bat ISH; Northern Blot; PCR Dumaual 2006; Carter 1998, Zhao 1996, Zeng 1998, Guo 2006; 
Yuan 2007 
  PRL-3 Human; Mouse ISH; Northern Blot Guo 2006; Zeng 1998, Matter 2001, Wu 2004 
Heart (Developing) PRL-3 Human; Rat IHC; Northern Blot Guo 2006 
Hyaline Cartilage (Adult) PRL-2 Human ISH Dumaual 2006 
Kidney (Adult) PRL-1 Human; Rat ISH; Northern Blot; IHC Dumaual 2006; Diamond 1994, Guo 2006; Kong 2000 
  PRL-2 Human; Mouse; Rat ISH; Northern Blot Dumaual 2006; Zhao 1996, Carter 1998, Zeng 1998 
Kidney (Developing) PRL-1 Human; Mouse; Rat Northern Blot; ISH; IHC Guo 2006; Rundle 1999; Kong 2000 
  PRL-2 Human Northern Blot Zhao 1996 
  PRL-3 Human Northern Blot Guo 2006 
Liver (Adult) PRL-1 Human; Rat ISH; Northern Blot; IHC Dumaual 2006; Diamond 1994, Haber 1995, Guo 2006; Diamond 
1996, Kong 2000 
  PRL-2 Human; Mouse ISH; Northern Blot Dumaual 2006; Zeng 1998 
  PRL-3 Human Northern Blot Wu 2004 
Liver (Developing) PRL-1 Rat; Mouse; Human ISH; IHC; Northern Blot; PCR Haber 1995, Rundle 1999; Guo 2006; Gjorloff-Wingren 2000 
  PRL-2 Human Northern Blot; PCR Zhao 1996, Guo 2006; Gjorloff-Wingren 2000 
  PRL-3 Human Northern Blot Guo 2006 
Lung (Adult) PRL-1 Human; Rat ISH; IHC Dumaual 2006; Kong 2000 
  PRL-2 Human; Mouse ISH; Northern Blot Dumaual 2006; Zeng 1998 
  PRL-3 Human; Mouse Northern Blot Guo 2006, Zeng 1998 
Lung (Developing) PRL-1 Human; Mouse; Rat Northern Blot; ISH; IHC Guo 2006; Rundle 1999; Kong 2000 
  PRL-2 Human Northern Blot Guo 2006, Zhao 1996 
  PRL-3 Human Northern Blot Guo 2006  
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Table A.1 Cont. 
Tissue Molecule Species* Detection Methods Reference* 
Lymph Node (Adult) PRL-1 Human ISH; PCR Dumaual 2006; Gjorloff-Wingren 2000 
  PRL-2 Human ISH; PCR Dumaual 2006; Gjorloff-Wingren 2000 
Ovary (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH; Northern Blot Dumaual 2006; Montagna 1995, Zhao 1996 
Pancreas (Adult) PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
  PRL-2 Human ISH; Northern Blot Dumaual 2006; Zhao 1996 
  PRL-3 Human Northern Blot Guo 2006, Matter 2001 
Parathyroid (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Placenta PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
 PRL-2 Human ISH Dumaual 2006 
Prostate (Adult) PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
  PRL-2 Human ISH; Northern Blot Dumaual 2006; Montagna 1995, Zhao 1996 
  PRL-3 Human Northern Blot Guo 2006 
Skeletal Muscle (Adult) PRL-1 Rat; Human Northern Blot; ISH Diamond 1994, Guo 2006; Dumaual 2006 
  PRL-2 Mouse; Human; Bat Northern Blot; ISH; PCR Zhao 1996, Zeng 1998, Guo 2006; Dumaual 2006; Yuan 2007 
  PRL-3 Human; Mouse Northern Blot Guo 2006, Matter 2001, Wu 2004, Zeng 1998 
Skin (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Small Intestine (Adult) PRL-1 Human; Rat ISH; Northern Blot; IHC Dumaual 2006; Guo 2006; Diamond 1996, Kong 2000 
  PRL-2 Human ISH; Northern Blot Dumaual 2006; Montagna 199, Zhao 1996 
  PRL-3 Human; Mouse IHC; Northern Blot Guo 2006; Zeng 2000 
Small Intestine (Developing) PRL-1 Mouse; Rat ISH; Northern Blot; IHC Rundle 1999; Diamond 1996; Kong  2000 
Spinal Cord (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
Spinal Cord (Developing) PRL-1 Mouse ISH Rundle 1999 
Spleen (Adult) PRL-1 Rat; Human Northern Blot; ISH; PCR Diamond  1994; Dumaual 2006; Gjorloff-Wingren  2000 
  PRL-2 Human Northern Blot; ISH; PCR Montagna  1995, Zhao  1996; Dumaual 2006; 
Gjorloff-Wingren 2000 
  PRL-3 Mouse Northern Blot Zeng  1998 
Spleen (Developing) PRL-1 Human Northern Blot Guo 1996 
  PRL-2 Human Northern Blot Guo 1996 
  PRL-3 Human Northern Blot Guo 1996 
Stomach (Adult) PRL-1 Human; Rat ISH; Northern Blot; IHC Dumaual 2006; Guo 2006; Kong 2000 
 PRL-2 Human ISH Dumaual 2006 
  PRL-3 Human IHC; Northern Blot Dai 2009; Guo 2006 
Stomach (Developing) PRL-1 Rat IHC Kong 2000 
Testis (Adult) PRL-1 Human ISH; Northern Blot Dumaual 2006; Guo 1996 
  PRL-2 Human; Mouse; Rat ISH; Northern Blot Dumaual 2006; Montagna 1995, Zhao 1996, Carter 1998, 
Zeng 1998 
  PRL-3 Mouse Northern Blot Zeng 1998 
Tongue (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Tonsil (Adult) PRL-1 Human PCR Gjorloff-Wingren 2000 
  PRL-2 Human PCR Gjorloff-Wingren 2000 
Thymus (Adult) PRL-1 Rat; Huma Northern Blot; PCR Diamond 1994; Gjorloff-Wingren 2000 
  PRL-2 Human Northern Blot; PCR Guo 2006, Montagna 1995, Zhao 1996; Gjorloff-Wingren 2000 
Thymus (Developing) PRL-1 Mouse ISH Rundle 1999 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Thyroid (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH; Northern Blot Dumaual 2006; Guo 2006 
Uterus (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
 PRL-3 Human Northern Blot Guo 2006 
*Ordered first by the specific detection method that was used and second by the date published. 
**Only 7.1% of samples gave positive results 
Abbreviations:  IHC, immunohistochemistry; ISH, in situ hybridization; PCR, polymerase chain reaction. 
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Table A.2 Reports in the literature where PRL expression was undetectable in 
normal tissues 
Tissue Molecule Species* Detection Methods Reference* 
Adrenal Gland (Adult) PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Bone Marrow (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Bladder (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Brain (Adult) PRL-3 Mouse; Human Northern Blot; ISH; IHC Zeng 1998, Guo 2006; Matter 2001; Kong  2007 
Brain (Developing) PRL-2 Human Northern Blot Guo 2006 
Colon (Adult) PRL-1 Human IHC Y. Wang 2007 
  PRL-2 Human IHC Y. Wang 2007 
  PRL-3 Human IHC; ISH; Northern Blot Bardelli 2003; Y. Wang 2007; Guo 2006 
Esophagus (Adult) PRL-1 Rat; Human IHC; Northern Blot Kong 2000; Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Fibrocartilage (Adult) PRL-1 Human ISH Dumaual 2006 
 PRL-2 Human ISH Dumaual 2006 
Heart (Adult) PRL-1 Human; Rat ISH; Northen Blot Dumaual 2006; Diamond 1994 
  PRL-3 Human; Rat IHC Guo  2006 
Heart (Developing) PRL-1 Mouse; Human ISH; Northern Blot Rundle 1999; Guo  2006 
  PRL-2 Human Northern Blot Guo  2006 
Hyaline Cartilage (Adult) PRL-1 Human  ISH Dumaual 2006 
Kidney (Adult) PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Mouse; Human Northern Blot Zeng 1998, Matter 2001, Guo 2006 
Kidney (Developing) PRL-2 Human Northern Blot Guo 2006 
Liver (Adult) PRL-1 Rat IHC Kong 2000 
  PRL-2 Human; Rat Northern Blot Zhao 1996, Carter 1998, Guo 2006 
  PRL-3 Mouse; Human Northern Blot Zeng 1998, Matter 2001, Guo 2006 
Lung (Adult) PRL-1 Rat; Human Northern Blot Diamond 1994; Guo 2006 
  PRL-2 Human Northern Blot Zhao 1996, Guo 2006 
  PRL-3 Human Northern Blot Matter 2001 
Lymph Node (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Ovary (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Pancreas (Adult) PRL-2 Human Northern Blot Guo 2006 
Placenta PRL-2 Human Northern Blot Zhao 1996, Guo 2006 
  PRL-3 Human Northern Blot Matter 2001, Guo 2006 
Prostate (Adult) PRL-2 Human Northern Blot Guo 2006 
Skeletal Muscle (Developing) PRL-1 Mouse ISH Rundle 1999 
Small Intestine (Adult) PRL-1 Rat Northern Blot Diamond 1994 
  PRL-2 Human Northern Blot Guo 2006 
Spinal Cord (Adult) PRL-3 Human Northern Blot Guo 2006 
Spleen (Adult) PRL-1 Human Northern Blot Guo  2006 
  PRL-2 Mouse; Human Northern Blot Zeng 1998, Guo  2006 
  PRL-3 Human Northern Blot Guo  2006 
Stomach (Adult) PRL-1 Rat Northern Blot Diamond 1994 
  PRL-2 Human Northern Blot Guo 2006 
Testis (Adult) PRL-2 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Thymus (Adult) PRL-1 Human Northern Blot Guo 2006 
 PRL-3 Human Northern Blot Guo 2006 
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Tissue Molecule Species* Detection Methods Reference* 
Thymus (Developing) PRL-1 Human Northern Blot Guo 2006 
Thyroid (Adult) PRL-1 Human Northern Blot Guo 2006 
  PRL-3 Human Northern Blot Guo 2006 
Uterus PRL-1 Human Northern Blot Guo 2006 
  PRL-2 Human Northern Blot Guo 2006 
*Ordered first by the specific detection method that was used and second by the date published. 
Abbreviations:  IHC, immunohistochemistry; ISH, in situ hybridization. 
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Appendix B Correlation of miRNA and mRNA Expression in HEK293 Cells Stably Transfected with PRL-3 
Table B Significant miRNAs and the significant mRNAs which they are predicted to target 
The Ingenuity Pathway Analysis tool was used to identify mRNAs that were significantly (Fold Change > 100; FDR < 10%) 
differentially expressed in HEK293 cells stably transfected with PRL-3 versus those transfected with empty vector and that 
were also known or predicted targets of miRNAs which were significantly (Fold Change > 2; FDR < 30%) differentially 
expressed in the same sample set.  The resulting list of predicted or known miRNA-mRNA interactions and the fold 
change differences in expression for each that were observed in the current study are shown. 
miR ID 
miR 
Fold Change 
Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-98 -14.02 TargetScan Human High (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-98 -14.02 TargetScan Human Moderate (predicted) 225421_at PM20D2 -117.803 
hsa-miR-98 -14.02 TargetScan Human High (predicted) 204286_s_at PMAIP1 -199.922 
hsa-miR-98 -14.02 
TarBase,TargetScan 
Human,miRecords 
Experimentally Observed, 
High (predicted) 201589_at SMC1A -214.353 
hsa-miR-526b* -4.86 TargetScan Human Moderate (predicted) 201891_s_at B2M -142.07 
hsa-miR-526b* -4.86 TargetScan Human Moderate (predicted) 208808_s_at HMGB2 -203.616 
hsa-miR-526b* -4.86 TargetScan Human High (predicted) 221891_x_at HSPA8 -307.422 
hsa-miR-526b* -4.86 TargetScan Human Moderate (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-526b* -4.86 TargetScan Human High (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-526b* -4.86 TargetScan Human High (predicted) 201417_at SOX4 -137.064 
hsa-miR-526b* -4.86 TargetScan Human Moderate (predicted) 201351_s_at YME1L1 -180.101 
hsa-miR-190b -4.25 TargetScan Human Moderate (predicted) 224585_x_at ACTG1 -162.754 
hsa-miR-190b -4.25 TargetScan Human Moderate (predicted) 205361_s_at PFDN4 -111.338 
hsa-miR-190b -4.25 TargetScan Human Moderate (predicted) 225421_at PM20D2 -117.803 
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miR ID 
miR 
Fold Change 
Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 208796_s_at CCNG1 -102.758 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 208905_at CYCS -128.101 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 200934_at DEK -150.128 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 224935_at EIF2S3 -166.898 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 212449_s_at LYPLA1 -196.579 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 200626_s_at MATR3 -124.303 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 218499_at MST4 -106.237 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 200738_s_at PGK1 -124.247 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 204286_s_at PMAIP1 -199.922 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 208319_s_at RBM3 -230.462 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 201427_s_at SEPP1 -174.877 
hsa-miR-141 -4.22 TargetScan Human Moderate (predicted) 217851_s_at SLMO2 -105.53 
hsa-miR-141 -4.22 TargetScan Human High (predicted) 212160_at XPOT -131.845 
hsa-miR-210 -2.59 TargetScan Human Moderate (predicted) 201312_s_at SH3BGRL -104.897 
hsa-miR-150 2.94 TargetScan Human High (predicted) 224372_at DCAF6 -158.764 
hsa-miR-150 2.94 TargetScan Human Moderate (predicted) 1555653_at HNRNPA3 -175.135 
hsa-miR-150 2.94 TargetScan Human Moderate (predicted) 221553_at MAGT1 -146.678 
hsa-miR-150 2.94 TargetScan Human High (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-150 2.94 TargetScan Human High (predicted) 208694_at PRKDC -110.014 
hsa-miR-150 2.94 TargetScan Human Moderate (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 208905_at CYCS -128.101 
hsa-miR-570 3.01 TargetScan Human High (predicted) 1555653_at HNRNPA3 -175.135 
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miR ID 
miR 
Fold Change 
Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-570 3.01 TargetScan Human High (predicted) 200914_x_at KTN1 -106.924 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 221553_at MAGT1 -146.678 
hsa-miR-570 3.01 TargetScan Human High (predicted) 201669_s_at MARCKS -203.708 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 226091_s_at MRFAP1 -115.33 
hsa-miR-570 3.01 TargetScan Human High (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 204286_s_at PMAIP1 -199.922 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 201589_at SMC1A -214.353 
hsa-miR-570 3.01 TargetScan Human High (predicted) 201273_s_at SRP9 -432.297 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 224587_at SUB1 -119.306 
hsa-miR-570 3.01 TargetScan Human Moderate (predicted) 221493_at TSPYL1 -101.53 
hsa-miR-512-3p 3.03 TargetScan Human Moderate (predicted) 224585_x_at ACTG1 -162.754 
hsa-miR-512-3p 3.03 TargetScan Human Moderate (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-512-3p 3.03 TargetScan Human Moderate (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-215 3.83 TargetScan Human Moderate (predicted) 209291_at ID4 -100.949 
hsa-miR-215 3.83 TargetScan Human Moderate (predicted) 221805_at NEFL -182.674 
hsa-miR-215 3.83 TargetScan Human High (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-517c 4.25 TargetScan Human Moderate (predicted) 200626_s_at MATR3 -124.303 
hsa-miR-518d-3p 4.37 TargetScan Human Moderate (predicted) 214039_s_at LAPTM4B -158.612 
hsa-miR-515-3p 5.12 TargetScan Human High (predicted) 210211_s_at HSP90AA1 -556.599 
hsa-miR-515-3p 5.12 TargetScan Human Moderate (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-515-3p 5.12 TargetScan Human Moderate (predicted) 201589_at SMC1A -214.353 
hsa-miR-515-3p 5.12 TargetScan Human Moderate (predicted) 201417_at SOX4 -137.064 
hsa-miR-515-3p 5.12 TargetScan Human High (predicted) 201273_s_at SRP9 -432.297 
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Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
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hsa-miR-219-1-3p 5.2 TargetScan Human Moderate (predicted) 217719_at EIF3L -170.601 
hsa-miR-219-1-3p 5.2 TargetScan Human High (predicted) 200914_x_at KTN1 -106.924 
hsa-miR-219-1-3p 5.2 TargetScan Human Moderate (predicted) 200650_s_at LDHA -145.996 
hsa-miR-219-1-3p 5.2 TargetScan Human Moderate (predicted) 200738_s_at PGK1 -124.247 
hsa-miR-219-1-3p 5.2 TargetScan Human High (predicted) 224587_at SUB1 -119.306 
hsa-miR-487a 5.31 TargetScan Human Moderate (predicted) 201443_s_at ATP6AP2 -150.744 
hsa-miR-487a 5.31 TargetScan Human Moderate (predicted) 218499_at MST4 -106.237 
hsa-miR-487a 5.31 TargetScan Human Moderate (predicted) 225421_at PM20D2 -117.803 
hsa-miR-133a 6.17 TargetScan Human High (predicted) 201443_s_at ATP6AP2 -150.744 
hsa-miR-133a 6.17 TargetScan Human High (predicted) 200084_at C11orf58 -100.286 
hsa-miR-133a 6.17 TargetScan Human Moderate (predicted) 1555653_at HNRNPA3 -175.135 
hsa-miR-133a 6.17 TargetScan Human High (predicted) 209291_at ID4 -100.949 
hsa-miR-133a 6.17 TargetScan Human High (predicted) 217851_s_at SLMO2 -105.53 
hsa-miR-133a 6.17 TargetScan Human High (predicted) 201417_at SOX4 -137.064 
hsa-miR-372 9 TargetScan Human High (predicted) 224372_at DCAF6 -158.764 
hsa-miR-372 9 TargetScan Human Moderate (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-372 9 TargetScan Human Moderate (predicted) 211942_x_at RPL13A -245.93 
hsa-miR-372 9 TargetScan Human Moderate (predicted) 201351_s_at YME1L1 -180.101 
hsa-miR-372 9 TargetScan Human Moderate (predicted) 212426_s_at YWHAQ -116.345 
hsa-miR-129-3p 9.01 TargetScan Human High (predicted) 1555653_at HNRNPA3 -175.135 
hsa-miR-129-3p 9.01 TargetScan Human Moderate (predicted) 201417_at SOX4 -137.064 
hsa-miR-129-3p 9.01 TargetScan Human Moderate (predicted) 201273_s_at SRP9 -432.297 
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miR 
Fold Change 
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Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-346 10.8 TargetScan Human Moderate (predicted) 212449_s_at LYPLA1 -196.579 
hsa-miR-346 10.8 TargetScan Human High (predicted) 200738_s_at PGK1 -124.247 
hsa-miR-519a 15.14 TargetScan Human Moderate (predicted) 200934_at DEK -150.128 
hsa-miR-519a 15.14 TargetScan Human Moderate (predicted) 221891_x_at HSPA8 -307.422 
hsa-miR-519a 15.14 TargetScan Human Moderate (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-519a 15.14 TargetScan Human Moderate (predicted) 201417_at SOX4 -137.064 
hsa-miR-128 16.52 TargetScan Human Moderate (predicted) 201443_s_at ATP6AP2 -150.744 
hsa-miR-128 16.52 TargetScan Human High (predicted) 208796_s_at CCNG1 -102.758 
hsa-miR-128 16.52 TargetScan Human High (predicted) 214039_s_at LAPTM4B -158.612 
hsa-miR-128 16.52 TargetScan Human High (predicted) 201669_s_at MARCKS -203.708 
hsa-miR-128 16.52 TargetScan Human Moderate (predicted) 200006_at PARK7 -131.528 
hsa-miR-128 16.52 TargetScan Human Moderate (predicted) 201273_s_at SRP9 -432.297 
hsa-miR-509-5p 20.48 TargetScan Human Moderate (predicted) 201016_at EIF1AX -329.726 
hsa-miR-509-5p 20.48 TargetScan Human Moderate (predicted) 201669_s_at MARCKS -203.708 
hsa-miR-509-5p 20.48 TargetScan Human Moderate (predicted) 212160_at XPOT -131.845 
hsa-miR-509-5p 20.48 TargetScan Human Moderate (predicted) 201351_s_at YME1L1 -180.101 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 208905_at CYCS -128.101 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 200934_at DEK -150.128 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 201016_at EIF1AX -329.726 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 209291_at ID4 -100.949 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 201669_s_at MARCKS -203.708 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 204286_s_at PMAIP1 -199.922 
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Table B Cont. 
miR ID 
miR 
Fold Change 
Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-576-3p 21.15 TargetScan Human High (predicted) 200603_at PRKAR1A -233.943 
hsa-miR-576-3p 21.15 TargetScan Human High (predicted) 222077_s_at RACGAP1 -107.434 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 217851_s_at SLMO2 -105.53 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 201589_at SMC1A -214.353 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 201417_at SOX4 -137.064 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 221493_at TSPYL1 -101.53 
hsa-miR-576-3p 21.15 TargetScan Human Moderate (predicted) 212426_s_at YWHAQ -116.345 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 208905_at CYCS -128.101 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 224935_at EIF2S3 -166.898 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 214039_s_at LAPTM4B -158.612 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 212449_s_at LYPLA1 -196.579 
hsa-miR-605 24.04 TargetScan Human High (predicted) 221553_at MAGT1 -146.678 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 225421_at PM20D2 -117.803 
hsa-miR-605 24.04 TargetScan Human High (predicted) 201589_at SMC1A -214.353 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 201273_s_at SRP9 -432.297 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 212320_at TUBB -171.879 
hsa-miR-605 24.04 TargetScan Human Moderate (predicted) 212160_at XPOT -131.845 
hsa-miR-642 24.04 TargetScan Human Moderate (predicted) 204102_s_at EEF2 -284.914 
hsa-miR-642 24.04 TargetScan Human Moderate (predicted) 212320_at TUBB -171.879 
hsa-miR-375 25.84 TargetScan Human Moderate (predicted) 200934_at DEK -150.128 
hsa-miR-375 25.84 TargetScan Human High (predicted) 213564_x_at LDHB -128.475 
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Table B Cont. 
miR ID 
miR 
Fold Change 
Target Prediction 
Database Prediction Confidence 
mRNA 
Probe ID 
mRNA 
Gene Symbol 
mRNA 
Fold Change 
hsa-miR-375 25.84 TargetScan Human Moderate (predicted) 225421_at PM20D2 -117.803 
hsa-miR-622 29.65 TargetScan Human Moderate (predicted) 208796_s_at CCNG1 -102.758 
hsa-miR-622 29.65 TargetScan Human High (predicted) 201016_at EIF1AX -329.726 
hsa-miR-622 29.65 TargetScan Human High (predicted) 201503_at G3BP1 -113.556 
hsa-miR-622 29.65 TargetScan Human Moderate (predicted) 208754_s_at NAP1L1 -115.477 
hsa-miR-622 29.65 TargetScan Human Moderate (predicted) 208319_s_at RBM3 -230.462 
hsa-miR-622 29.65 TargetScan Human High (predicted) 221452_s_at TMEM14B -120.017 
hsa-miR-622 29.65 TargetScan Human High (predicted) 223105_s_at TMEM14C -221.955 
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